DOH National Antibiotic Guidelines 2017

Cover Design
John Michael L. Roque
Layout Design
Adell R. Azuelo
Lora Alaine D. Raymundo
John Michael L. Roque
All rights reserved 2017
National Antibiotic Guidelines Committee

Pharmaceutical Division
Department of Health
Philippine Blood Center, Lung Center Compound, Quezon Avenue, Quezon City, 1100
ISBN - 978-621-95675-1-0
Any part of the book or its entirety may be reproduced or transmitted without any
alteration, in any form or by any means, with permission from DOH provided it is not
used for commercial purposes.
National Antibiotic
Guidelines
2017
Department of Health
Manila, Philippines
TABLE OF CONTENTS
MESSAGE OF THE SECRETARY OF HEALTH ................................................. i

ACKNOWLEDGMENTS ................................................................... ii
EDITORIAL TEAM ..................................................................................... iv
ACRONYMS AND ABBREVIATIONS ............................................................ v
INTRODUCTION TO THE NATIONAL ANTIBIOTIC GUIDELINES ..................... viii
BLOOD-BORNE INFECTIONS AND OTHER SYSTEMIC SYNDROMES ............. 1
BONE AND JOINT INFECTIONS IN PEDIATRICS ………………………................... 19
BONE AND JOINT INFECTIONS IN ADULTS ……………………………................... 26
CARDIOVASCULAR INFECTIONS ………….…...………………………..................... 33
CENTRAL NERVOUS SYSTEM INFECTIONS …………………………….................... 47
DENTAL AND ORAL INFECTIONS ……………………....………………...................... 55
GASTROINTESTINAL TRACT INFECTIONS ……………………………...................... 61
OCULAR INFECTIONS ………………………………………………………........................ 74
UPPER RESPIRATORY INFECTIONS ……………………….……………...................... 86
LOWER RESPIRATORY INFECTIONS ………………………….…………..................... 105
SKIN AND SOFT TISSUE INFECTIONS IN PEDIATRICS ……………….................. 124
SKIN AND SOFT TISSUE INFECTIONS IN ADULTS ……………………................... 150
URINARY TRACT INFECTIONS ……………………………….……………...................... 170
PUBLIC HEALTH PROGRAMS
FILARIASIS …………………………………………………………………………..…… 183
LEPROSY ……………………………………………………………………………….. 184
MALARIA ………………………………………………………………………….……. 186
SCHISTOSOMIASIS ………………….………………….…………….….……… 195
SEXUALLY TRANSMITTED INFECTIONS …………………….……… 196
TUBERCULOSIS ….…………………………………………………………… 219
SURGICAL PROPHYLAXIS …………………………………….……………........................ 230
i
ACKNOWLEDGMENTS
The participation and assistance of the following experts and reviewers of

this document are gratefully acknowledged:
Dr. Estrella B. Paje-Villar, former NAG Committee Chair
Dr. Ivan Olegario, former editor
DOH offices:
Disease Prevention and Control Bureau (DPCB)
Epidemiology Bureau (EB)
Food and Drug Administration (FDA)
Health Facility Development Bureau (HFDB)
Professional Associations:
Pediatric Infectious Disease Society of the Philippines
Pediatric Nephrology Society of the Philippines (PNSP)
Philippine Academy of Family Physicians (PAFP)
Philippine Academy of Ophthalmology (PAO)
Philippine Academy of Pediatric Pulmonologist (PAPP)
Philippine Coalition Against Tuberculosis (PhilCAT)
Philippine College of Chest Physicians (PCCP)
Philippine College of Physicians (PCP)
Philippine College of Surgeons (PCS)
Philippine Dental Association (PDA)
Philippine Dermatological Society (PDS)
Philippine Hospital Infection Control Society, Inc. (PHICS)
Philippine Neurological Association (PNA)
Philippine Obstetrical and Gynecological Society (POGS)
Philippine Orthopedic Association (POA)
Philippine Pediatric Society (PPS)
Philippine Pharmacists Association, Inc. (PPhA)
Philippine Society for Microbiology and Infectious Disease (PSMID)
Philippine Society of Nephrology (PSN)
Philippine Society of Newborn Medicine (PSNBM)
Philippine Society of Otolaryngology Head and Neck Surgery (PSO-HNS)
Philippine Society for Pediatric Gastroenterology, Hepatology and
Nutrition (PSPGHAN)
ii
Philippine Society of Pediatric Surgeons (PSPS)
Philippine Urological Association (PUA)
Hospitals:
Philippine Children’s Medical Center (PCMC)
Research Institute for Tropical Medicine (RITM)
San Lazaro Hospital (SLH)
The Medical City (TMC)
UP- Philippine General Hospital (UP-PGH)
Development Partners:
World Health Organization
iii
EDITORIAL TEAM
National Antibiotic Guidelines Committee
Chair
MEDIADORA C. SANIEL, MD, MBA-H, FPCP
Members
CELIA C. CARLOS, MD, FPPS, FPIDSP, FPSMID
CARMINA A. DELOS REYES, MD, FPPS, FPAPP
MARI ROSE A. DE LOS REYES, MD, FPCP
BENILDA B. GALVEZ, MD, FPCCP
MARY ANN D. LANSANG, MD, MMEDSC
CECILIA C. MARAMBA-LAZARTE, MD, MSCID, MSCCT
ROSALIND G. VIANZON, MD, MPH
CYNTHIA S. FABREGAS, MD, DPCOM
OLIVIA M. LIMUACO, RPh, PhD
YOLANDA R. ROBLES, RPh, PhD
VITO G. ROQUE, Jr. MD
Antimicrobial Resistance Program Secretariat
CORAZON I. FLORES, MD, MPH, CESO IV

ANNA MELISSA M. GUERRERO, MD, MPH (HTA)
IRENE V. FLORENTINO-FARIÑAS, RPH, MD, MNSA
MS. ANNE JULIENNE M. GENUINO, RPH
MS. NIÑA ISABELLE M. TOLENTINO, RPH
MS. LORA ALAINE D. RAYMUNDO, RPH
iv
ABBREVIATIONS AND ACRONYMS
ABECB Acute bacterial exacerbation of chronic bronchitis

ABP Acute bacterial prostatitis
ABRS Acute bacterial rhinosinusitis
ABSSSI Acute bacterial skin and skin structure infections
AL Artemether-lumefantrine
ALT Alanine aminotransferase
AOM Acute otitis media
ARSP Antimicrobial Resistance Surveillance Program
ART Antiretroviral therapy
ASB Asymptomatic bacteriuria
AUC Acute uncomplicated cystitis
BMI Body mass index
BUN Blood urea nitrogen
CAMRSA Community associated MRSA
CAP Community acquired pneumonia
CBP Chronic bacterial prostatitis
CHD Congenital heart disease
CMV Cytomegalovirus
CNS Central nervous system
CRP C-reactive protein
CRS Chronic rhinosinusitis
CSF Cerebrospinal fluid
CSOM Chronic suppurative otitis media
CT Computed tomography
CVC Central venous catheter
CVS Cardiovascular system
DAIR Debridement and retention of prosthesis
DEC Diethyl carbamazine
DFI Diabetic foot infections
DOT Duration of Therapy
EIA Enzyme immunoassay
ELISA Enzyme-linked immunosorbent assay
ENT Ears, nose and throat
EPTB Extra pulmonary tuberculosis
ESBL Extended spectrum ß-Lactamase
ESR Erythrocyte sedimentation rate
ETEC Entero-toxigenic Escherichia coli
FDC Fixed dose combination
v
FQ Fluoroquinolone
FTA-ABS Fluorescent treponemal antibody absorption test
GIT Gastro-intestinal tract
GABHS Group A Beta-hemolytic Streptococci
GAS Group A streptococcus
GCSF Granulocyte stimulating factor
GNB Gram-negative bacteria
GUT Genitourinary tract
HACEK Haemophilus sp., Aggregatibacter sp., Cardiobacterium hominis,
Eikinella corrodens, and Kingella sp.
HAI Hospital-associated Infections
HAP Hospital acquired pneumonia
HBIG Hepatitis B Immunoglobulin
HBeAg Hepatitis B envelope antigen
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
HCV Hepatitis C virus
HR Isoniazid + Rifampicin
HRZE/S Isoniazid + Rifampicin + Pyrazinamide +
Ethambutol/Streptomycin
HSV Herpes simplex virus
HIV Human immunodeficiency virus
ICT Immunochromatographic test
IDSA Infectious Diseases Society of America
IE Infective Endocarditis
I&D Incision and drainage
IRIS Immune reconstitution inflammatory syndrome
ISPD International Society for Peritoneal Dialysis
LBW Low birth weight
LP Lumbar puncture
MAP Mean arterial pressure
MDR-TB Multiple drug resistant tuberculosis
MDT Multidrug therapy
MIC Minimum inhibitory concentration
MMR Mumps, Measles, Rubella
MRI Magnetic resonance imaging
MSSA Methicillin-susceptible Staphylococcus aureus
MRSA Methicillin-resistant Staphylococcus aureus
MTB Mycobacterium tuberculosis
NAAT Nucleic acid amplification testing
NBE Nocturnal blood examinations
vi
NT Neutralization test
OC Oral contraceptive
OGTT Oral glucose tolerance test
PANDAS Pediatric Autoimmune Neuropsychiatric Disorder Associated
with Group A Streptococcus Infections
PCAP Pediatric community acquired pneumonia
PCR Polymerase chain reaction
PHN Post-herpetic neuralgia
PICC Peripherally inserted central catheter
PID Pelvic Inflammatory Disease
PLHIV People living with HIV
PMDT Programmatic Management for drug-resistant Tuberculosis
PT Prothrombin time
PVL Panton valentin leukocidin
PWID People who inject drugs
RHD Rheumatic Heart Disease
RPR Rapid plasma reagin
RSU Respiratory syncytial virus
SIRS Systemic inflammatory response syndrome
SLDs Second line drugs
SLE Systemic Lupus Erythematosus
SOFA Sequential organ failure assessment
STD Sexually Transmitted Disease
STI Sexually Transmitted Infections
TALF Treatment after lost to follow up
TB Tuberculosis
TMP-SMX Trimethoprim-sulfamethoxazole
TCA Trichloroacetic acid
TSS Toxic shock syndrome
TEE Transesophageal echo
TPHA Treponema pallidum haemagglutination
TTE Transthoracic echocardiogram
ULN Upper limit of normal
UTI Urinary tract infection
VAP Ventilator associated pneumonia
VDRL Venereal Disease Research Laboratory
VP Ventriculoperitoneal
VSD Ventricular septal defect
VZIG Varicella zoster immunoglobulin
VZV Varicella zoster virus
WHO World Health Organization
vii
INTRODUCTION
The National Antimicrobial Stewardship (AMS) Program, an integral

component of the Philippine Action Plan to Combat Antimicrobial Resistance (AMR),
gives structure and direction to healthcare facilities to adopt a proactive
multidisciplinary approach to promote rational antimicrobial use. One of the six core
elements of AMS is the development and implementation of policies, guidelines and
clinical pathways to improve antimicrobial prescribing and dispensing. Specifically, Core
Element 2 states that “all hospitals shall adopt or adapt to their local context the
National Antibiotic Guidelines” to optimize antimicrobial use and help improve the
quality of patient care and patient safety. Armed with enhanced knowledge provided by
the Guidelines, health practitioners at all levels of healthcare are then empowered to
appropriately treat common infectious disease syndromes seen among children and
adults (e.g. respiratory and urinary tract infections, diarrhea, skin and soft tissue
infections, tuberculosis) as well as other diseases for which much irrational antibiotic
use prevails in the country.
The challenging task of formulating the Guidelines was given by the

Department of Health to the National Antibiotic Guidelines Committee (NAGCOM), a
multidisciplinary group of experts in the fields of infectious diseases, epidemiology,
pharmacology and public health program management. It was decided from the outset
that there would be no need to reinvent the wheel. Divided into subgroups, the
NAGCOM reviewed existing evidence-based local and international guidelines and
relevant literature, with priority given to guidelines that utilized the GRADE (Grading of
Recommendations Assessment, Development and Evaluation) system. Adaptations of
available guidelines and treatment recommendations were made taking into
consideration the latest national Antimicrobial Resistance Surveillance Program
resistance rates, list of approved drugs in the National Formulary, quality of the
evidence, balance of potential benefits and harm, cost-effectiveness, availability of
diagnostic tests, feasibility and resource implications. Interim recommendations were
viii
discussed en banc and a consensus was usually reached. The interim guidelines were
then sent to the specialty/subspecialty societies for their inputs prior to finalizing the
Guidelines. Consultations with external technical experts and public health program
implementers were also done as needed.
The Guidelines in this handbook contain treatment recommendations for

infectious diseases grouped by organ systems and presented in a tabular format for ease
of use. Brief descriptions of disease categories with their etiologic agents, corresponding
antibiotic regimens (dose, route, frequency and duration) for pediatric and adult
patients, relevant comments and key references are presented. A section on surgical
prophylaxis, although not treatment-focused, has been added since antibiotic misuse to
prevent surgical site infections also needs urgent attention.
How should the Guidelines be used in health facilities? The AMS program
stipulates that hospitals should have facility-specific antibiotic guidelines. Depending on
local antibiotic susceptibilities, formulary options, costs, and available resources, the
AMS Committee of a health facility can adopt or adapt portions of the Guidelines. There
are several other ways by which the Guidelines, adopted or adapted, can be used in AMS
(http://icamr.doh.gov.ph) including: creation of clinical pathways, development of
educational modules (print and electronic) for healthcare professionals, implementation
of point-of-care interventions (e.g. dose optimization, de-escalation) and prospective
audit and feedback, and performance evaluation.
The Guidelines are not intended to supersede a healthcare provider’s sound

clinical judgment. Variations in a patient’s clinical presentation (such as presence of co-
morbidities), patient’s preferences and availability of resources may require judicious
adaptation of the Guidelines by individual users.
ix
GENERAL PRINCIPLES OF ANTIMICROBIAL THERAPY:
The fundamental questions to ask in anti-infective therapy are:

• WHAT am I treating? – The infectious disease/clinical syndrome and the likely or
proven pathogen [The MICROBIOLOGIC FACTORS]
• WHO am I treating? – The patient’s demographic, clinical, and behavioral
characteristics [The HOST-RELATED FACTORS]
• WHICH antimicrobial (or antibiotic combination) is most appropriate? [The DRUG-
RELATED FACTORS]
• HOW do I administer the appropriate antimicrobial(s)? – Dose, interval/frequency,
route of administration, duration of treatment, etc. [The DOSING REGIMEN
including duration of therapy]
A. FACTORS TO CONSIDER IN THE CHOICE OF ANTIMICROBIALS:

1. MICROBIOLOGIC FACTORS: the disease/clinical syndrome and the likely/proven
pathogen(s)
i. Site of infection – adequate concentration of the antibiotic at the site of
infection must be attained.
ii. Severity of infection: serious life-threatening infections (e.g., sepsis,
meningitis, endocarditis, etc.) require early empiric therapy after appropriate
specimens are obtained to determine the pathogen involved.
iii. Bacterial load (inoculum size), virulence, regrowth pattern and susceptibility
pattern of the pathogen.
iv. Infection at sequestered sites, which may not be reached by significant levels
of the principal antibiotic being used (e.g., nasopharyngeal carriage).
v. Prior antimicrobial therapy: exert selection pressure for micro-organisms
resistant to the antibiotic previously given to outgrow the rest of the
microflora, invade and cause infection.
vi. Local factors – e.g., presence of pus, devitalized tissue, foreign body, pH
changes, impaired penetration of antibiotic into the affected area.
2. HOST-RELATED FACTORS influence the efficacy and toxicities of antimicrobials

i. Age – a major factor that can influence gastric acidity, renal function and
hepatic function, as well as propensity to develop hypersensitivity.
ii. Genetic factors – e.g., glucose-6-phosphate dehydrogenase deficiency causes
hemolytic anemia and jaundice with the administration of primaquine,
sulfonamides, sulfones, nitrofurans, chloramphenicol, etc.; or aplastic
anemia from chloramphenicol as an idiosyncratic reaction.
iii. Hepatic and renal function – the ability of the patient to
metabolize/inactivate or excrete the antimicrobial is one of the most
important host factors, especially when high serum or tissue levels are
potentially toxic.
iv. Pregnancy and Nursing Status (See Appendix for Pregnancy Risk Categories
by the US FDA).
x
v. Host defense mechanisms, both humoral and cellular; immunocompetent vs.
immunocompromised host (e.g., HIV infection, recipients of cytotoxic drugs,
transplanted organs, burn patients, with vascular abnormalities, impaired
localized phagocytosis, etc.)
vi. Co-morbid conditions: HIV/AIDS, diabetes mellitus and other metabolic
disorders, atopy, pre-existing organ dysfunction, obesity, etc.
vii. Previous history of adverse drug reactions (e.g., allergy, intolerance, etc.).
3. DRUG-RELATED FACTORS
i. Pharmacodynamics – “what the drugs does to the pathogen and to the body”
– antimicrobial spectrum; bacteriostatic vs. bactericidal; concentration-
dependent vs. time-dependent bacterial killing.
ii. Pharmacokinetics – “what the body does to the drug” – includes the
processes of absorption, distribution, biotransformation/metabolism,
excretion; the relationship between the antimicrobial concentration at the
site of action and the minimum inhibitory concentration for the pathogen is
the major determinant of successful therapy; poor antimicrobial penetration
of the blood-brain barrier, intraocular tissues and prostate, but increased
with inflammation.
iii. Adverse effects: risk/benefit ratio.
iv. Drug interactions – could be pharmaceutical, pharmacodynamic or
pharmacokinetic in nature.
v. Cost/benefit ratio – the total cost of the regimen and not the unit cost of the
drug, should be considered.
vi. Others: ease and accuracy of dosing, stability, and acceptability.
B. ANTIBIOTIC COMBINATION THERAPY:
Antibiotic combinations provide a broader spectrum coverage than single agents; hence,
the physician is often tempted to use a combination of 2 or more for the sense of
security they provide. However, when inappropriately used, antibiotic combination can
lead to deleterious effects.
RATIONALE FOR ANTIBIOTIC COMBINED THERAPY:

i. Provide broad-spectrum empiric therapy in the initial therapy of critically ill
patients and neutropenic patients with severe life-threatening infections,
e.g. beta-lactam antibiotic plus aminoglycoside for sepsis in neonates.
ii. Treat polymicrobial infection (e.g., use of anti-aerobes and anti-anaerobes
for intraabdominal abscess, diabetic foot infection; however, newer
generation fluoroquinolones, carbapenems, or beta-lactam plus beta-
lactamase inhibitor combinations can be employed as monotherapy).
iii. Prevent/delay emergence of resistance (e.g., diseases due to Mycobacterium
tuberculosis, M. leprae, Pseudomonas aeruginosa, etc.).
xi
iv. Decrease dose-related toxicity (e.g. flucytosine plus amphotericin B in
cryptococcal meningitis).
v. Obtain enhanced inhibition/killing (synergism) (e.g., penicillin plus
aminoglycoside in enterococcal endocarditis and Streptococcus viridans
endocarditis; sulfamethoxazole plus trimethoprim, etc.).
C. GENERAL ADVERSE REACTIONS TO CHEMOTHERAPEUTIC AGENTS:

1. Hypersensitivity reaction – ranges from mild skin rash to severe anaphylactic
reactions; not dose-related.
2. Idiosyncratic reaction – may be genetic in origin; not dose-related.
3. Toxicity reactions – augmented reactions (dose-related); e.g., ototoxicity,
hepatotoxicity, nephrotoxicity, neurotoxicity, etc.
4. Biologic and metabolic reactions in the host (e.g., alteration of normal
microflora; superinfections).
5. Treatment failure/relapse.
6. Masking effect.
7. Adverse drug interactions with other drugs – e.g. metabolic enzyme
inhibition or induction, protein binding displacement, etc.
D. GENERAL STEPS IN APPROPRIATE ANTIMICROBIAL THERAPY:

1. Formulate a clinical diagnosis of microbial infection.
2. Obtain appropriate specimen for laboratory exam when applicable.
3. Formulate a specific microbiologic diagnosis.
4. Determine the need for empiric therapy.
5. Institute pharmacologic treatment considering MICROBIAL, HOST and DRUG
FACTORS and using EFFICACY, SAFETY, SUITABILITY and COST of the
antimicrobial options in the selection process, and following the “RULES OF
RIGHT”.
6. Institute adjunctive and non-pharmacologic therapy.
7. Adjust antimicrobial regimen according to the isolated pathogen and its
susceptibility pattern, correlated with the patient’s clinical response
(DIRECTED or TARGETED ANTIMICROBIAL THERAPY). Sound clinical
judgment/assessment remains the most important method to determine the
efficacy of the treatment.
E. CAUSES OF FAILURE IN ANTIMICROBIAL THERAPY:

a. DRUG FACTORS such as wrong choice of antimicrobial, wrong dose, route,
intervals and duration of administration; drug interactions; deterioration
during storage.
b. HOST FACTORS such as poor host defense, inadequate absorption,
distribution, impaired elimination, presence of foreign body, anatomic
defects, etc.
c. MICROBIAL FACTORS such as wrong microbiologic diagnosis, drug resistance,
superinfection, bacterial load, dual or mixed infection not detected, etc.
xii
F. MISUSE/ABUSE OF ANTIMICROBIALS:
1. Use in untreatable (viral) infection.
2. Empiric use on fever of undetermined origin.
3. Complete reliance on chemotherapy with omission of surgical drainage and
other non-pharmacologic therapy when necessary.
4. Inappropriate chemoprophylaxis.
5. Inappropriate antibiotic combination.
6. Inappropriate choice of antibiotic dosage, route, intervals and duration of
administration.
7. Lack of appropriate bacteriologic information when indicated.
8. Over-the-counter sale of antibiotics.
9. Recycling antibiotic prescription and/or self-medication.
10. Use of antimicrobials as growth promoters in farm animals, use in agriculture
and aquaculture.
G. FACTORS THAT LEAD TO INAPPROPRIATE USE OF ANTIMICROBIALS:

a. Good intention – to give the best treatment without regard to spectrum of
activity of the antibiotic and its cost.
b. Inappropriate dosing – e.g. beliefs that higher doses or more prolonged
administration is better.
c. Inappropriate chemoprophylaxis – timing and duration of surgical
prophylaxis and a variety of other prophylactic purposes in hospitalized
patients, which are not evidence-based.
d. Pressure from patients/parents to be treated with antimicrobials.
e. Time constraint – more time required to explain why antibiotic is not needed
than simply writing the prescription.
f. Use of multiple/broad-spectrum antibiotics to cover the possibility of
infection from numerous microorganisms as a substitute for appropriate
diagnostic evaluation.
g. Cost and availability of diagnostic test.
h. Inadequacy of knowledge of diagnostic procedures and management of
infectious diseases.
i. Malpractice considerations and fear of litigation.
j. Concern about increasing prevalence of antibiotic resistance.
k. Easy solution provided by pharmaceutical companies and aggressive
promotion.
H. UNWANTED CONSEQUENCES OF MISUSE/INAPPROPRIATE USE OF

ANTIMICROBIALS:
a. Adverse drug reactions.
b. Increased cost of therapy.
c. Increased length of hospital stay.
d. Emergence of drug-resistant organisms.
e. Predisposition to secondary infections, complications and even death.
xiii
BLOOD-BORNE INFECTIONS AND OTHER SYSTEMIC
SYNDROMES
I. SEPSIS IN CHILDREN
Systemic Inflammatory Response Syndrome (SIRS)

The presence of two or more of the following four criteria, one of which must be
abnormal temperature or white blood cell count:
1. Core temperature (rectal, bladder, oral, or central catheter probe) >38.5°C
(101.3°F) or <36°C (96.8°F)
2. Tachycardia or bradycardia
3. Mean RR >2 standard deviations for age or mechanical ventilation for an
acute process not related to an underlying neuromuscular disease or to
general anesthesia
4. Abnormal WBC count or >10% immature neutrophils
Sepsis: SIRS in the presence of or caused by suspected or proven infection
A. Neonate
POTENTIALLY SEPTIC NEONATE
Etiology: Asymptomatic neonates with documented maternal risk factors like

history of UTI during the last trimester, membranes ruptured >18h before delivery,
fever >38°C before delivery or during labor and/or foul-smelling or purulent
amniotic fluid
Preferred Regimen:
Ampicillin PLUS Gentamicin or Amikacin
Weight, Age Ampicillin Gentamicin Amikacin
≤2 kg, ≤7d old: 50mg/kg q12h 5mg/kg q48h 15mg/kg q48h
≤2 kg, 8-28d old: 50mg/kg q8h 5mg/kg q36h 15mg/kg q24h
>2kg, ≤7d old: 50mg/kg q8h 4mg/kg q24h 15mg/kg q24h
>2kg, 8-28d old: 50mg/kg q6h 4-5mg/kg q24h 17.5mg/kg q24h
Comments:
For infants who remain asymptomatic and whose initial blood cultures are
negative after 48-72 hours of incubation, antimicrobial therapy can be
discontinued. If no pathogen has been isolated but bacterial sepsis cannot be
excluded, a negative CRP test at 72 hours can help support decision to discontinue
antibiotics.
NEONATAL SEPSIS
Etiology: Gram-negative bacilli, Group B streptococci, S. pneumoniae, S. aureus
National Antibiotic Guidelines 1

SYNDROMES
Neonates with bacterial sepsis may present either with non-specific signs and
symptoms or focal signs of infection. The clinical criteria for the diagnosis of
bacterial sepsis by the Integrated Management of Childhood Illness (IMCI) and
WHO are as follows:
NEUROLOGIC: convulsions, drowsy or unconscious, decreased activity,
bulging fontanel
RESPIRATORY: respiratory rate >60 breaths/min, grunting, sever chest
indrawing, central cyanosis
CARDIAC: poor perfusion, rapid and weak pulse
GASTROINTESTINAL: jaundice, poor feeding, abdominal distention
DERMATOLOGIC: skin pustules, periumbilical erythema or purulence
MUSCULOSKELETAL: edema or erythema overlying bones or joints
OTHER: Temperature >37.7°C (99.9°F; or feels hot) or <35.5°C
(95.9°F; or feels cold)
Preferred Regimen:
1st line: 2nd line:
Cefotaxime Ceftazidime
≤2 kg, ≤7d old: 50mg/kg q12h ≤2 kg, ≤7d old: 50mg/kg q12h
≤2 kg, 8-28d old: 50mg/kg q8-12h ≤2 kg, 8-28d old: 50mg/kg q8-12h
>2kg, ≤7d old: 50mg/kg q12h >2kg, ≤7d old: 50mg/kg q12h
>2kg, 8-28d old: 50mg/kg q8h or >2kg, 8-28d old: 50mg/kg q8h
Ceftriaxone 50mg/kg q24h PLUS
PLUS Gentamicin
Gentamicin ≤2 kg, ≤7d old: 5mg/kg q48h
≤2 kg, ≤7d old: 5mg/kg q48h ≤2 kg, 8-28d old: 5mg/kg q36h
≤2 kg, 8-28d old: 5mg/kg q36h >2kg, ≤7d old: 4mg/kg q24h
>2kg, ≤7d old: 4mg/kg q24h >2kg, 8-28d old: 4-5mg/kg q24h or
>2kg, 8-28d old: 4-5mg/kg q24h or Amikacin
Amikacin ≤2 kg, ≤7d old: 15mg/kg q48h
≤2 kg, ≤7d old: 15 mg/kg q48h ≤2 kg, 8-28d old: 15mg/kg q24h
≤2 kg, 8-28d old: 15mg/kg q24h >2kg, ≤7d old: 15mg/kg q24h
>2kg, ≤7d old: 15mg/kg q24h >2kg, 8-28d old: 17.5mg/kg q24h
>2kg, 8-28d old: 17.5mg/kg q24h
WITH OR WITHOUT
Oxacillin
≤2 kg, ≤7d old: 25mg/kg q12h
≤2 kg, 8-28d old: 50mg/kg q8h
>2kg, ≤7d old: 50mg/kg q8h
>2kg, 8-28d old: 50mg/kg q6h or
Vancomycin (for MRSA)
Meningitis: 15mg/kg/dose
Bacteremia: 10mg/kg/dose
2 National Antibiotic Guidelines

SYNDROMES
Dosing Interval chart
Gestational Postnatal Interval
Age(weeks) (days) (hours)
≤29 0-14 18
>14 12
30 to 36 0-14 12
>14 8
37 to 44 0 to 7 12
>7 8
≥45 ALL 6
DOT: 7-10d or approximately 5-7d after clinical signs and symptoms of infection
have disappeared
Comments:
Precautions for ceftriaxone: Because of its extensive protein binding, ceftriaxone
can displace bilirubin from albumin-binding sites, with the potential risk of
inducing kernicterus. Thus, its use should be avoided in jaundiced neonates.
Likewise, neonates should not receive ceftriaxone intravenously if also receiving
intravenous calcium in any form, including parenteral nutrition, because of the risk
for precipitation of ceftriaxone-calcium salt.
Add Oxacillin or Vancomycin (MRSA) if with skin/soft tissue infections (refer to

the Skin and Soft Tissue Infections guidelines). Use Ceftazidime if Pseudomonas or
Burkholderia is suspected.
B. Child, Immunocompetent
CLINICAL SEPSIS WITHOUT FOCUS
Etiology: Preferred Regimen:

S. pneumoniae, Ceftriaxone 100mg/kg/d IV q12-24h (Max: 2-4 g/d) or
S. aureus (MSSA & Cefotaxime 200-225mg/kg/d q4-6h (Max: 8-12g/d)
MRSA), WITH OR WITHOUT
H. influenzae B, Oxacillin 150-200mg/kg/d q4-6h (Max: 4-12 g) or
Meningococci Vancomycin 40-60mg/kg/d q6h (for MRSA) (Max: 2-4g/d)
DOT: 10-14d or longer depending on established foci of infection
Comments:
Check on immunization status against Pneumococcus and H. influenzae B. Provide
coverage for S. aureus if with concomitant skin/soft tissue infections or previous
trauma. May use oxacillin only if culture-proven sensitive.

SYNDROMES
URINARY SOURCE (SEE UTI, COMPLICATED)

Enterobacteriaceae, Ceftriaxone 100mg/kg/d IV q12-24h (Max: 2-4g/d) or
P. aeruginosa, Cefotaxime 200-225 g/kg/d q4-6h (Max: 8-12g/d)
Enterococcus PLUS
Gentamicin 6-7.5mg/kg/d q8h or 5-7.5mg/kg/d qd or
Amikacin 15-22.5mg/kg/d q8-12h or 15-20mg/kg/d qd
INTRA-ABDOMINAL SOURCE
Etiology: Enterobacteriaceae, Bacteroides sp, Enterococci, P. aeruginosa
Preferred Regimen:
1st line: 2nd line:
Ampicillin 200-400mg/kg/d IV q8h Ampicillin-sulbactam 200 mg/kg/d
(Max: 6-12 g/d) q6h (ampicillin component) (Max: 8
PLUS g/d) or
Gentamicin 6-7.5mg/kg/d q8h or Piperacillin-tazobactam 300mg
5-7.5 mg/kg/d qd or (piperacillin component) (Max: 9-
Amikacin 15-22.5mg/kg/d q8-12h or 16g/d)
15-20 mg/kg/d qd WITH OR WITHOUT
PLUS Gentamicin 6-7.5mg/kg/d q8h or
Metronidazole 30-50mg/kg/d q6h 5-7.5mg/kg/d qd or
(Max: 1.5g/d) or Amikacin 15-22.5mg/kg/d q8-12h or
Clindamycin 20-40mg/kg/d IV q6-8h 15-20 mg/kg/d qd or
(Max: 1.8-2.7g/d) Ceftriaxone 100mg/kg/d IV q12-24h
(Max: 2-4 g/d) or
Cefotaxime 200-225mg/kg/d q4-6h
(Max: 8-12g/d)
PLUS
Metronidazole 30-50mg/kg/d q8h
(Max: 1.5g/d) or
Clindamycin 20-40 mg/kg/d IV q6-8h
(Max: 1.8-2.7 g/d)
POST-SPLENECTOMY/ FUNCTIONAL ASPLENIA

S. pneumoniae, Ceftriaxone 100mg/kg/d IV q12-24h (Max: 2-4 g/d)
H. influenzae, OR

SYNDROMES
N. meningitides Cefotaxime 200-225mg/kg/d q4-6h (Max: 8-12g/d)
HEALTHCARE-ASSOCIATED SEPSIS
Etiology: Gram-negative bacilli, S. aureus
Preferred Regimen:
Ceftazidime 150-200mg/kg/d q8h (Max: 6 g/d) or
Cefepime 100-150mg/kg/d q8h (Max: 4-6g/d) or
Piperacillin-tazobactam 300mg/kg/d q8h (piperacillin component) (Max: 9-16
g/d) or Meropenem 60-120mg/kg/d q8h (Max: 1.5-6g/d)
WITH OR WITHOUT
Amikacin 15-22.5mg/kg/d q8-12h or 15-20mg/kg/d qd
WITH OR WITHOUT
Vancomycin 40-60mg/kg/d q6h (Max: 2-4 g/d)
Comments:
Choice of empiric antibiotic therapy should be based on current antimicrobial
susceptibility pattern within an institution. For severe infections with
Pseudomonas and/or if antimicrobial resistance is suspected add aminoglycosides.
If with previous surgery, IV therapy or other instrumentation and staphylococcal
infection is suspected.
SEVERE SEPSIS AND SEPTIC SHOCK
Severe Sepsis: Sepsis plus one of the following: cardiovascular organ dysfunction,
acute respiratory distress syndrome or two or more other instances of organ
dysfunction as defined in the consensus statement
Septic Shock: Sepsis and cardiovascular organ dysfunction
Preferred Regimen:
Piperacillin-tazobactam 300mg/kg/d q8h (piperacillin component) (Max: 9-
16g/d) or Meropenem 60-120mg/kg/d q8h (Max: 1.5-6g/d) PLUS
Vancomycin
Neonates* Child
Meningitis: 15mg/kg/dose 40-60 mg/kg/d q6h
Bacteremia: 10mg/kg/dose (Max dose: 2-4 g/d)
*See previous Dosing Interval Chart in Neonatal Sepsis
DOT: 10-14d in the absence of a complication
Comments:
The initial assessment and treatment of the pediatric shock patient should include
stabilization of airway, breathing, and circulation (the ABC’s) plus early

SYNDROMES
administration of broad spectrum antibiotics. The choice of antimicrobial agents
depends on the predisposing risk factors, clinical situation, and the antibiotic
resistance patterns in the community and/or hospital settings. Modify antibiotic
regimen based on culture and sensitivity.
STAPHYLOCOCCAL TOXIC SHOCK SYNDROME
Clinical Findings:
Fever: Temperature ≥38.9°C (102°F)
Rash: Diffuse macular erythroderma
Desquamation: 1-2 weeks after onset of illness, on palms, soles, fingers, and toes
Hypotension
Involvement of ≥3 of the following organ systems:
• GIT: Vomiting or diarrhea at onset of illness
• Muscular: Severe myalgia or creatinine phosphokinase > 2x twice the upper
limit of normal
• Mucous membrane: Vaginal, oropharyngeal, or conjunctival hyperemia
• Renal: BUN or serum creatinine > 2x upper limit of normal or ≥5 wbc/hpf in
the absence of UTI
• Hepatic: Total bilirubin, AST, or ALT > 2x upper limit of normal for the
laboratory
• Hematologic: platelets <100,000/mm3
• CNS: disorientation or alterations in consciousness without focal neurologic
signs when fever and hypotension are absent
Negative results on the following tests, if obtained: Blood, throat, or cerebrospinal
fluid cultures (blood culture may be positive for S. aureus, Serologic tests for Rocky
Mountain spotted fever, leptospirosis, or measles)
Case Classification
Probable: A case with 5 of the 6 clinical findings as above
Confirmed: A case with all 6 of the clinical findings as above, including
desquamation, unless the patient dies before desquamation could occur
Preferred Regimen:
Oxacillin 150-200mg/kg/d IV q4-6h (Max: 4-12g/d) or
Cefazolin 75-100mg/kg/d IV q8h (Max: 3-6g/d) or
Vancomycin (for MRSA): 40-60 mg/kg/d IV q6h drip x 1h (Max: 2-4 g/d)
PLUS Clindamycin 30-40mg/kg/d IV q6-8h (Max: 1.8-2.7 g/d)
PLUS IVIG 150-400mg/kg x 5d or 1 dose of 1-2 g/kg
DOT: 10-14d in the absence of a complication
Comments:
Immediate aggressive fluid management; surgical debridement; anticipatory
management of multisystem organ failure. Intravenous immunoglobulin (IVIG) can

SYNDROMES
be considered in severe staphylococcal TSS unresponsive to other therapeutic
measures.
STREPTOCOCCAL TOXIC SHOCK SYNDROME
Clinical Criteria: Hypotension plus 2 or more of the following: renal impairment,

coagulopathy, hepatic involvement, adult respiratory distress syndrome,
generalized erythematous macular rash, and soft-tissue necrosis
Definite Case: Clinical criteria plus Group A streptococcus from a normally sterile
site
Probable Case: Clinical criteria plus Group A streptococcus from a nonsterile site
Preferred Regimen:
Penicillin G Na 200,000-300,000 U/kg/d IV q4-6h (Max: 12-24 MU/d) OR
Ceftriaxone 100mg/kg/d q12-24h (Max: 2-4 g/d)
PLUS Clindamycin 30-40mg/kg/d IV q6-8h (Max: 1.8-2.7 g/d)
PLUS IVIG 1g/kg on d1, followed by 0.5 g/kg on d2-3
Comments:
Immediate aggressive fluid management. Surgical debridement. Anticipatory
management of multisystem organ failure. Intravenous immunoglobulin (IVIG)
may be considered if refractory to several hours of aggressive therapy or in the
presence of undrainable focus or persistent oliguria with pulmonary edema.
Febrile Neutropenia in Children

Neutropenia is defined as an ANC of < 500 cells/mm3 or an ANC that is expected
to decrease to <500 cells/mm3 during the next 48h.
Etiology: Staph including MRSA, Streptococcus, Enterococci, P. aeruginosa and

other gram-negative bacilli, Fungi
Preferred Regimen:
Cefepime 150mg/kg/d div q8h or Piperacillin-tazobactam 300mg/kg/d div q6h or
Meropenem 60-120mg/kg/d div q8h (Max: 2-4g)
If antimicrobial resistant pathogens are suspected consider adding Amikacin 15-

20mg/kg/d qd. In cases of suspected catheter-related infection, or skin or soft-
tissue infection, pneumonia, or hemodynamic instability consider adding
Vancomycin 40-60mg/kg/d q6h (Max: 2-4g/day)
If with abdominal symptoms (pain or blood per rectum) or suspected C. difficile

infection consider adding Metronidazole IV: 22.5-40mg/kg/d q8h (Max: 1.5 g/d);
PO: 30-50mg/kg/d q8h (Max: 2.25 g/d).

SYNDROMES
Empirical antifungal coverage should be considered in high-risk patients who have
persistent fever after 4–7 days of a broad-spectrum antibacterial regimen and no
identified fever source. Treatment is continued until patient is afebrile and ANC
>500 cells/μl.
Comments:
Start empiric antibiotics as soon as possible after taking blood cultures and refer
to an ID specialist. Baseline laboratory tests to request for are:
• (CBC) count with differential leukocyte count and platelet count
• creatinine and BUN
• electrolytes
• hepatic transaminase enzymes
• bilirubin
• blood cultures, at least 2 sets of which are recommended, with a set
collected simultaneously from each lumen of an existing central venous
catheter (CVC), if present, and from a peripheral vein site; 2 blood culture
sets from separate venipunctures should be sent if no central catheter is
present.
• Culture of specimens from other sites of suspected infection should be
obtained as clinically indicated
• CXR for patients with respiratory signs and symptoms
GCSFs are not routinely recommended
II. SEPSIS IN ADULTS
Sepsis is defined as presence of suspected or documented infection associated

with life threatening organ dysfunction represented by a quick SOFA (Sequential
Organ Failure Assessment) score of 2 or more of the following: 1) respiratory rate
of 22/min or more; 2) altered mentation; 3) systolic BP of 100 mmHg or less.
Septic Shock is defined as sepsis plus need for vasopressor to increase MAP to >
65 mmHg and lactate >2mmol (18 mg/dL)
A. Sepsis, Non-Neutropenic
SOURCE IS UNCLEAR
Preferred Regimen:
1st line: 2nd line:
Piperacillin-tazobactam 4.5g IV q6-8h Meropenem 1g IV q8h PLUS
PLUS Vancomycin 25-30mg/kg loading Vancomycin 25-30mg/kg loading
dose then 1g IV q8h dose then 1g IV q8h

SYNDROMES
Comments:
Do source control, if possible. Intravenous antibiotics should be given as soon as
sepsis or septic shock is recognized and within the 1st hour. Initial fluid
resuscitation of crystalloid at 30ml/kg should be given in first 3 hours. Target MAP
to >65 mmHg in patients receiving vasopressors. Appropriate routine
microbiologic cultures (including blood) be obtained before starting antimicrobial
therapy in patients with suspected sepsis or septic shock if doing so results in no
substantial delay in the start of antimicrobials
SUSPECT INTRA-ABDOMINAL SOURCE
Etiology: Aerobic and anaerobic gram-negative bacilli
Preferred Regimen:
1st line: Piperacillin-tazobactam 4.5 g IV q8-6h
2nd line: Ceftriaxone 2g IV q12h PLUS Metronidazole 1g loading dose then 500mg
IV q6h or 1g IV q12h OR
Ciprofloxacin 400mg IV q12h or Levofloxacin 750mg IV q24h PLUS
Metronidazole 1g loading dose then 500mg IV q6h or 1g IV q12h
SUSPECT, URINARY TRACT INFECTION
Etiology: Aerobic Gram-negative bacilli (E. coli), Enterococcus species
Preferred Regimen:
1st line: 2nd line:
Piperacillin-tazobactam 4.5g IV q8-6h Ceftriaxone 1g IV q24h OR
Ertapenem 1g IV q24h
Comments:
Base recommendation on local/ hospital antibiogram results. Always assess for
risk factors for antibiotic resistance (e.g. ESBL production because of prior
fluoroquinolone use). Use Ertapenem if with risk for antibiotic resistance.
SUSPECT COMMUNITY-ACQUIRED PNEUMONIA (See treatment of high risk

pneumonia)
SUSPECT ILLICIT IV DRUG USE SOURCE

S. aureus Vancomycin 25-30mg/kg loading dose then 1g IV
q8h PLUS Piperacillin-tazobactam 4.5g IV q8-6h

SYNDROMES
SUSPECT MENINGOCOCCEMIA

N. meningitides Ceftriaxone 2g IV q12h
SEPTIC SHOCK, POST SPLENECTOMY
Preferred Regimen: Comments:

Ceftriaxone 2g IV q12h Increase dose if considering meningitis
STAPHYLOCOCCAL TOXIC SHOCK
Preferred Regimen: Comments:

Vancomycin 25-30mg/kg loading Note: Intravenous Immunoglobulin has
dose then 1g IV q8h PLUS the potential to neutralize super antigen
Clindamycin 900mg IV q8h PLUS and to mitigate subsequent tissue
IVIG 1g/kg d1 then 500mg/kg/d for damage
2-3d
STREPTOCOCCAL TOXIC SHOCK
Preferred Regimen:
1st line 2nd line
Penicillin G 24 MU/d IV in 4-6 div Ceftriaxone 2g IV q24h PLUS
doses PLUS Clindamycin 900mg IV q8h PLUS
Clindamycin 900mg IV q8h IVIG 1g/kg on d1 then 500mg/kg on d2-3
If with Penicillin allergy: Clindamycin 900mg IV q8h PLUS Vancomycin 25-
30mg/kg loading dose then 1g IV q8h. Also start IVIG 1g/kg on d1 then 500mg/kg
on d2-3 for patients unresponsive to vasopressor.
DOT is individualized; Min of 14d if with bacteremia.
B. Febrile Neutropenia in Adults
Defined as an oral temperature of >38.3°C or two consecutive readings of >38.0°C

for >1h and an absolute neutrophil count (ANC) of <500/μL, or <1000/μL and
expected to fall below 500/μL over the next 48h. Assess for risk (low or high risk)
of complication for severe disease at presentation of fever.
LOW RISK
Etiology: Gram positive organisms (predominantly coagulase negative

staphylococci and S. aureus), gram negative bacilli; fungal inf. uncommon

SYNDROMES
Preferred Regimen:
Ciprofloxacin 750mg PO bid or Levofloxacin 750mg PO qd PLUS
Amoxicillin clavulanic acid 625mg tid
Penicillin Allergy: Ciprofloxacin 750mg PO bid or Levofloxacin 750mg PO qd PLUS
Clindamycin 300mg PO q6h
DOT: Until patient is afebrile and absolute neutrophil count >500cells/μl
Comments:
Those with anticipated <7 days of neutropenia, no medical co-morbidities, and no
significant liver or renal dysfunction, able to take oral medications. Empiric
antibiotic Rx should be started as soon as possible after taking blood cultures. A
fluoroquinolone (FQ) should not be used in patients given a FQ-based antibacterial
prophylaxis. Instead an IV regimen as recommended for high risk patients should
be administered. GCSFs are not routinely recommended as an adjunct to antibiotic
Rx.
HIGH RISK
Etiology: Gram positive (staph, strep, enterococci) and gram-negative bacteria w/

GNB (e.g. P. aeruginosa) causing the more serious infections; fungi (esp. Candida
and Aspergillus)
Preferred Regimen:
Initial therapy for fever Monotherapy with:
Cefepime 2g IV q8h or Meropenem 1-2g IV q8h or
Piperacillin-tazobactam 4.5g IV q6h
PLUS Aminoglycoside or Fluoroquinolone or Vancomycin if with suspected
central line infection, severe mucositis, skin and soft tissue infection, pneumonia,
hypotension
PLUS Antifungal treatment if fever continues beyond 4-7d and no source is
identified
DOT should be dictated by particular organism and site:

Staphylococcus bacteremia should be treated for at least 2 weeks after negative
blood culture; prolonged (4-6 weeks) if disseminated or deep infection. Other
infections may be treated for 14 days. In patients with unexplained fever, initial
regimen should be continued until marrow recovery
Comments:
Those with profound neutropenia of <100 cells/μl and anticipated fever >7days
and/or significant medical comorbidities, hemodynamic instability, hepatic or
renal insufficiency, uncontrolled or progressive cancer, pneumonia or other
complex infections, mucositis grade 3 or 4, new onset neurologic/mental changes,

SYNDROMES
IV catheter infection, inpatient status at time of development of fever, and GI
symptoms. These patients should be admitted in the hospital.
Empiric antibiotic Rx should be started ASAP after blood cultures. Continue

treatment until patient is afebrile and absolute neutrophil count is >500 cells
(some >1000 cells). Modifications to the initial antibiotic regimen should be guided
by clinical and microbiologic data. Use of CSF is controversial; may be considered
in the presence of serious infectious complications such as progressive course,
pneumonia, and invasive fungal infection.
ANTIBACTERIAL PROPHYLAXIS
For high risk patients with expected duration of neutropenia of > 7 days and ANC
≤100 cells/mm3
Preferred Regimen:
1st line 2nd line
Levofloxacin 500-750mg PO/IV qd Ciprofloxacin 500-750mg PO or 400mg
IV q12h
Comments:
Not routinely recommended for low risk patients.
ANTICANDIDAL PROPHYLAXIS

Allogeneic hematopoietic stem cell Fluconazole 400mg IV/PO q24h OR
transplant (HSCT) recipients, acute Micafungin 150mg/d IV OR
leukemia undergoing intensive Itraconazole 200mg PO bid
remission - induction or salvage DOT: until recovery of neutropenia
therapy. For high risk patients with
expected duration of neutropenia of
>7d and ANC≤ 100 cells/mm3
ANTI-ASPERGILLUS PROPHYLAXIS

Patients undergoing chemotherapy Voriconazole 200mg PO/IV bid OR
for AML/MDS with neutropenia and Posaconazole 200mg PO tid for
allogeneic HSCT recipients patients ≥13 years of age
Comments:
Prophylaxis against aspergillus infection in pre-engraftment allogeneic or
autologous transplant recipients has not been shown to be efficacious

SYNDROMES
ANTIVIRAL PROPHYLAXIS

HSV seropositive patients undergoing Aciclovir 800mg PO bid OR
allogeneic HSCT or induction for acute Aciclovir 400mg PO tid-qid
leukemia
III. TYPHOID FEVER
UNCOMPLICATED TYPHOID FEVER
Preferred Regimen:
1st line 2nd line
PEDIATRICS
Amoxicillin 75-100mg/kg/d q8h x 14d Cefixime 15-20mg/kg/d q12h x 7-
(Max: 500mg 2 caps q6h) OR 10d (Max: 200mg 1 tab q12h) OR
Ampicillin 100-200mg/kg/d IV q6h x 14d Azithromycin 20mg/kg/d q24h x 5-
(Max: 12g/24h) OR 7d (Max: 500mg 1-2 tabs q24h) OR
Chloramphenicol 50-75mg/kg/d q6h x Ciprofloxacin 30mg/kg/d q12h x 7-
14-21d (Max: 500mg 2 caps q6h) OR 10d (Max: 500mg 1 tab q12h)
TMP-SMX 8mg/kg/d (TMP component)
q12h x 14d (Max: 160/800mg 1 tab
q12h)
ADULTS
Amoxicillin 1g q6h x 14d OR Cefixime 200mg PO q12h x 7- 10d
TMP-SMX 800/180mg I tab q12h x 14d OR
OR Chloramphenicol 1g PO q6h x 14d Azithromycin 500mg-1g PO qd x 5-
OR Ciprofloxacin 500mg 1 tab q12h x 7d
7-10d
Comments:
Based on ARSP 2015, Salmonella typhi remained susceptible to the 1st line agents
like ampicillin, chloramphenicol & TMP-SMX. The use of second line antibiotics
should be reserved for suspected or proven Multi-drug resistant typhoid fever
(MDRTF). MDRTF is defined as typhoid fever caused by Salmonella typhi strains
which are resistant to the first-line recommended drugs for treatment namely
chloramphenicol, ampicillin and TMP-SMX.
MDRTF should be suspected in any of the following situations:

• Failure to respond after 5-7 days treatment with a first line antibiotic;
• Household contact with a documented case or during an epidemic of
MDRTF; and/or

SYNDROMES
• Clinical deterioration or development of complications during conventional
antibiotic treatment
Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia,

thrombocytopenia and granulocytopenia) are known to occur after the
administration of chloramphenicol. An irreversible type of marrow depression
leading to aplastic anemia with a high rate of mortality may occur after short or
long-term use of chloramphenicol.
Ciprofloxacin is not recommended for pregnant women. It can be used among

children if the benefits outweigh the potential harms. High–dose parenteral
Ampicillin can be used if fluoroquinolone is not well tolerated.
Stepping down to an oral antibiotic may be done if patient is afebrile for 48hrs and
is able to tolerate oral medications. De-escalation to oral antibiotics should be
based on results of culture and sensitivity if available.
SEVERE/COMPLICATED TYPHOID FEVER

(Gastrointestinal bleeding, intestinal perforation, typhoid encephalopathy, etc.)
Preferred Regimen:
1st line Step down antibiotics
PEDIATRICS
Ceftriaxone 75mg/kg/d IV q24h x 10- Cefixime 15-20mg/kg q12h x 7-10d
14d (Max: 2-3g q24h) OR (Max: 200mg 1 tab q12h) OR
Ciprofloxacin 30mg/kg/d q12h x 7-10d Azithromycin 20mg/kg q24h x 5-7d
(Max: 500mg/dose q12h) OR (Max: 500mg 1-2 tabs q24h) OR
Azithromycin 20mg/kg/d IV q24h x 5- Ciprofloxacin 30mg/kg q12h x 7-
7d (Max: 1g q24h) 10d (Max: 500mg 1 tab q12h)
ADULTS
Ceftriaxone 1-2g IV x 10-14d OR Cefixime 200mg 1tab q12h x 7-10d
Ciprofloxacin 400mg IV q12h x 7-10d OR Azithromycin 500mg 1-2tabs
q24h x 5-7d OR
Ciprofloxacin 500mg 1tab q12h x
7-10d
CHRONIC CARRIER
Defined as asymptomatic shedding of typhoidal S. enterica for 1 year or more

SYNDROMES
Preferred Regimen:
1st line 2nd line
PEDIATRICS
Ciprofloxacin 30mg/kg/d q12h x 4 Ampicillin 100-200mg/kg/d IV q6h x
weeks (Max: 1-1.5g/d) 4 weeks (Max: 12g/d)
ADULTS
Ciprofloxacin 500-750mg q12h PO x
28d
NONTYPHOIDAL SALMONELLOSIS (Salmonella gastroenteritis)
Preferred Regimen:
1st line 2nd line
Cefotaxime 100-200 mg/kg/d IV q6h Ciprofloxacin 10-20 mg/kg/d q12h x
x 5-14d (Max: 8-12 g/d) OR 7-10d (Max:1-1.5g/d) OR
Ceftriaxone 75 mg/kg/d IV q24h x7d Chloramphenicol 50-75 mg/kg/d
(Max: 2-4 g/d) OR q6h x 7d (Max: 2-4 g/d)
Cefixime 15 mg/kg/d PO q12h x 7-10d
(Max: 400mg/d)
EXTRA-INTESTINAL INFECTIONS (bacteremia, meningitis, osteomyelitis)

N. meningitides Ceftriaxone 100 mg/kg/d IV q12-24h (Max: 2-
4g/d)
DOT: Bacteremia: 10-14d; Meningitis: 4 weeks; Osteomyelitis: 4-6 weeks
Comments:
Antibiotics are not generally recommended for the treatment of uncomplicated
Salmonella gastroenteritis because they may suppress normal intestinal flora and
prolong both the excretion of Salmonella and the remote risk for creating the
chronic carrier state. Indications for antibiotic treatment include any of the
following:
• Neonates and young infants (≤3 • Hemolytic anemia, including sickle
months old) cell disease, malaria, and
• HIV/AIDS bartonellosis
• Other immunodeficiencies and • Collagen vascular disease
chronic granulomatous disease • Inflammatory bowel disease
• Immunosuppressive and • Achlorhydria or use of antacid
corticosteroid therapies medications
• Malignancies, especially leukemia • Impaired intestinal motility
and lymphoma • Schistosomiasis, malaria
• Malnutrition

SYNDROMES
Based on ARSP 2015, nontyphoidal Salmonella is also susceptible to
chloramphenicol & ciprofloxacin. Antibiotics should be revised depending on the
susceptibility pattern.
IV. LEPTOSPIROSIS
Suspected leptospirosis case:

• Fever of at least 2d; AND
• Either residing in a flooded area or has high-risk exposure (wading in floods and
contaminated water, contact with animal fluids, swimming in flood water or
ingestion of contaminated water with or without cuts or wounds); AND,
• At least two of the following: myalgia, calf tenderness, conjunctival suffusion,
chills, abdominal pain, headache, jaundice or oliguria
MILD LEPTOSPIROSIS:
A suspected case of leptospirosis with:

• Stable vital signs • NO evidence of meningismus/ meningeal
• Anicteric sclerae irritation, sepsis/ septic shock, difficulty of
• Good urine output breathing, jaundice
• Can take oral medications
Preferred Regimen:
1st line 2nd line
<8 yo: Amoxicillin 50mg/kg q8h x 7d Azithromycin 1g loading dose then 10
(Max: 500mg q8h) mg/kg qd x 2d (Max: 500 mg/d)
≥8 yo: Doxycycline 2-4mg/kg/d bid x
7d (Max: 200mg/d)
Comments:
Precautions for doxycycline: children <8 years, pregnancy, interaction with birth
control pills, photosensitivity, diarrhea, GI upset and interaction if co-administered
with iron, supplements, statins, other antibiotics and laxatives. Take doxycycline
with food or after a meal.
MODERATE TO SEVERE LEPTOSPIROSIS:
A suspected case of leptospirosis with:

• Unstable vital signs • Meningismus/ meningeal irritation
• Jaundice/ icteric sclerae • Sepsis/ septic shock
• Abdominal pain • Altered mental states or difficulty of
• Nausea, vomiting and diarrhea breathing
• Oliguria/anuria • Hemoptysis

SYNDROMES
Preferred Regimen:
1st line 2nd line
Penicillin 250,000-400,000 U q4-6h Ampicillin 100 mg/kg q6h x 7d
x 7d (Max: 1.5 MU q6-8h) (Max: 0.5-1.0 g q6h) OR
Cefotaxime 100-150 mg/kg q6-8h x 7d
(Max: 1g q6h) OR
Ceftriaxone 80-100 mg/kg q24h x 7d
(Max: 2g q24h) OR
Azithromycin 500mg qd x 5d
Comments:
Step-down therapy can be instituted once patient is clinically stable and bale to
tolerate oral medication. Any oral antibiotic under mild leptospirosis can be
selected.
ANTIBIOTIC PROPHYLAXIS
Pre-exposure prophylaxis - not routinely recommended except for travelers,

soldiers, those engaged in water-related recreational and occupational activities
in highly endemic areas.
Post-exposure prophylaxis depends on type of risk.
Preferred Regimen:
1st line 2nd line
Doxycycline 4mg/kg x 1 dose Amoxicillin 50mg/kg/d q8h x 3-5d
(Max: 200mg regardless of age) (Max: 500mg q8h) OR
Azithromycin 10mg/kg x 1 dose
Take 100mg bid if 200 mg qd is not (Max: 500 mg)
tolerated. If children are exposed for more than
7d, the dose should be repeated after 1
week.
Comments:
The most effective preventive measure is avoidance of high-risk exposure. If
unavoidable, use protective measures such as boots, goggles, over-alls, and rubber
gloves. Antibiotic prophylaxis not 100% effective; protective measures should still
be used. Post-exposure doses may be repeated once weekly if with continued
exposure to risk factors (e.g. staying in a constantly flooded area)
REFERENCES:
• Ahmed NM, et al. Fever in children with chemotherapy –induced neutropenia. Available
at: http://www.uptodate.com/contents/fever-in-children-with-chemotherapy-induced-
neutropenia.

SYNDROMES
• American Academy of Pediatrics, In: Kimberlin DW, Brady MT, et al.eds. Red Book 2015
Report of the Committee on Infectious Diseases,30th ed. Elk Grove Village.2015
• Antimicrobial Resistance Surveillance Program. Manila: Department of Health; 2015
• Bradley JS, et al. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for
cardiopulmonary adverse events. Pediatrics.2009;123 (4): e609-e613.
• Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ. Feigin and Cherry’s Textbook of
Pediatric Infectious Diseases. Philadelphia: Elsevier Inc., 2014.
• Dellinger RP, et al. Surviving Sepsis Campaign: International Guidelines for Management of
Severe Sepsis and Septic Shock: 2012. Available at: www.ccmjournal.org.
• Emma Lappin et al. Gram positive toxic shock syndrome. The Lancet Infectious Dis. 9 (5):
May 2009.
• Freifeld A, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in
Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of
America. Clin Infect Dis. 2011 Feb 15;52(4): e56-93.
• Integrated Management of Childhood Illness Chart Booklet. Geneva: World Health
Organization; March 2014
• Kliegman RM, et al., eds. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA: Elsevier,
2016.
• Pediatric Infectious Diseases Society of the Philippines. PIDSP Core Group
Recommendation: Clinical Practice Guidelines on Childhood Leptospirosis 2015. Quezon
City: PIDSPI; 2015.
• Pediatric Infectious Diseases Society of the Philippines. Post-Disaster Interim Advice on the
Prevention of Leptospirosis in Children 2012. Quezon City: PIDSPI; 2012.

BONE AND JOINT INFECTIONS IN PEDIATRICS
A. OSTEOMYELITIS (HEMATOGENOUS)
Etiology:
Newborn to <4 months: S. aureus, Group B Streptococci, Enterobacteriaceae
4 months to adolescents: S. aureus, Group A Streptococci, Enterobacteriaceae
are uncommon
Salmonella sp. should be considered in developing countries or among patients
with sickle cell disease. Infections caused by Kingella kingae is increasingly
recognized in children under age 4 years.
1st line: 2nd line

Vancomycin Option 1: Clindamycin IV
Post Vancomycin dose Neonates
conceptual <1,200 0-4 10mg/kg/d in
age (weeks)* g BW weeks 2 doses
10-15mg/kg/d in 1 1,200- 0-7d 10mg/kg/d in
<26
dose 2,000 g old 2 doses
27-34 10-15mg/kg q18h** BW >7d 15mg/kg/d in
20-30mg/kg/d in 2 old 3 doses
35-41
doses** >2,000 0-7d 15mg/kg/d in
40-60mg/kg/d in 3-4 g BW old 3 doses
> 42
doses** >7d 20mg/kg/d
100-200mg/kg/d in old in 4 doses
7 days
4 doses Infants and older 25-
*Post conceptual age= gestational age + children 40mg/kg/d
weeks of life in 3-4 doses
**at 28 days of life, Vancomycin is (Max:
administered at 20 mg/kg/dose; interval
2.7g/d)
remains the same
PLUS Cefotaxime PLUS Cefotaxime+ or Ceftriaxone+
+see regimen under 1st line treatment
Neonates
<1,200g 0-4 100mg/kg/d in
Option 2: Vancomycin+ PLUS
BW weeks 2 doses
Ciprofloxacin 20-30mg/kg/d IV in 2-
1,200- 0-7d 100mg/kg/d in 3 doses (Max: 1.2 g/d)
2,000g old 2doses
BW >7d 150mg/kg/d in Option 3: Linezolid IV
old 3 doses <12y: 30mg/kg/d in 3 doses
>2,000g 0-7d 100mg/kg/d in >12y: 1200mg/d in 2 doses
BW old 2 doses PLUS Ciprofloxacin 20-30mg/kg/d in
>7d old 150- 2 or 3 doses (Max: 1.2 g/d)
200mg/kg/d in
3-4 doses Option 4: Cotrimoxazole 8-
Infants and older 100- 12mg/kg/d (trimethoprim
children 200mg/kg/d in

3-4 doses (Max: component) in 2 doses (Max:

12 g/d) 320mg/d) PLUS
OR Ceftriaxone Ciprofloxacin 20-30mg/kg/d in 2 or
Neonates 3 doses (Max: 1.2 g/d)
<1,200g 0-4 50mg/kg/d
BW weeks in 1 dose
1,200- 2,000g BW
>2,000g 0-7d
BW old
>7d old 75mg/kg/d in
1 doses
Infants and older 100-200
children mg/kg/d in 1-
2 doses
(max: 4 g/d)
DOT for neonates is not well-defined but 3 weeks is considered adequate. DOT for
other age groups is 3-6 weeks.
Comments:
Select antibiotics appropriate for the patient age. Revise quickly to specific therapy
according to culture results. Osteomyelitis of the long bones is more common in
children. Vertebral osteomyelitis is most common site in adults. Other bones are
less commonly involved.
The ARSP 2015 showed increased resistance of S. aureus to oxacillin at 62.6%. Start
empiric therapy with antibiotics against MRSA after collection of blood and joint
fluid for culture; review Gram stain of joint fluid.
When either Gram-positive or Gram-negative bacilli are possible pathogens,

vancomycin is typically used to cover MRSA and high-dose β-lactams are given to
cover Gram-negative organisms. Clindamycin is an alternative if there are no signs
of sepsis. If cultures grow MSSA, shift to oxacillin. In the primary regimens, use
cefotaxime only when Pseudomonas aeruginosa is deemed unlikely.
An antibiotic active against MRSA is recommended for the following:

• Patients who have failed initial recommended antibiotic treatment against
MSSA
• Those with markedly impaired host defences
• Those with SIRS and hypotension
Precautions for ceftriaxone: Because of its extensive protein binding, ceftriaxone

can displace bilirubin from albumin-binding sites, with the potential risk of
inducing kernicterus. Thus, its use should be avoided in jaundiced neonates.
Likewise, neonates should not receive ceftriaxone intravenously if also receiving

intravenous calcium in any form, including parenteral nutrition, because of the risk
for precipitation of ceftriaxone calcium salt.
B. OSTEOMYELITIS, CONTIGUOUS FOCUS
Etiology: S. aureus, Coagulase-negative staphylococci, Enterobacteriaceae,

Streptococcus sp., P. aeruginosa
Preferred Regimen:
1st line 2nd line
Clindamycin 25-40mg/kg/d in 3-4 If methicillin-resistant staphylococci:
doses IV (Max: 2.7 g/d) or Linezolid (Empiric)
Vancomycin 45-60mg/kg/d in 3-4 <12y: 30mg/kg/d IV in 3 doses
doses (Max: 4 g/d) >12y: 1200mg/d IV in 2 doses
PLUS PLUS
Ceftazidime 100-150mg/kg/d div in 3 Ceftazidime 100-150mg/kg/d div in 3
doses (Max: 6 g/d) or doses (Max: 6 g/d) or
Cefepime 100-150mg/kg/d in 2-3 Cefepime 100-150mg/kg/d in 2-3
doses (Max: 6 g/d) doses (Max: 6 g/d)
Specific therapy based on culture Methicillin-susceptible or

results: methicillin-resistant staphylococci
If susceptible gram-negative bacillus: (culture-proven):
Ciprofloxacin 20-30mg/kg/d in 2 or 3 Ciprofloxacin 20-30mg/kg/d IV in 2-3
doses (Max: 1.2 g/d) doses (Max: 1.2 g/d)
PLUS
If methicillin-sensitive staphylococci: Rifampin 10-20mg/kg/d in 1-2 doses
Oxacillin (Max: 600 mg/d)
Mild to moderate infections: 100-
150mg/kg/d in 4 doses (Max: 4 g/d)
Severe infections: 150-200mg/kg/d in
4-6 doses (Max: 12 g/d) OR
Cefazolin
Mild to moderate infections:
50mg/kg/d in 3 doses (Max: 3 g/d)
Severe infections: 100-150mg/kg/d in
3 doses (Max dose: 6 g/d)
DOT: not well defined but 6 weeks is generally recommended, longer if hardware
retained.
Comments:
The ARSP 2015 showed increased resistance of S. aureus to oxacillin at 62.6%. Start

fluid for culture; review Gram stain of joint fluid. Clindamycin is an alternative if
there are no signs of sepsis. If cultures grow MSSA, shift to oxacillin.
Involves long bone or post internal fixation of fracture. Empiric therapy is indicated
in septic patients. Otherwise, await culture results. It may be necessary to remove
hardware and use external fixation if there is persistent bone non-union.
Early hardware infection (symptoms <4 weeks):
• If hardware is removed, treat for 6 weeks.
• If hardware is retained, treat until bony fusion or hardware removal.
Late infection:
• Remove the hardware if possible, and treat for 6 weeks.
• If the hardware is retained, treat for 3-6 months or until the hardware
removed.
C. CHRONIC OSTEOMYELITIS
• Chronic osteomyelitis usually occurs in adults following trauma or surgery.

• It implies a long-standing infection and the presence of dead bone.
Etiology: S. aureus, Enterobacteriaceae, P. aeruginosa, Streptococci
Preferred Regimen:
Empiric therapy is not recommended. Treatment should be guided by valid
cultures and sensitivity studies
Optimal DOT: unknown. Prolonged course of therapy is typically recommended
but 6 weeks may be adequate if surgical debridement is performed. Consider
intermittent therapy or chronic suppressive therapy for relapses if surgical
debridement was unsuccessful or not feasible.
Comments:
Important therapeutic adjuncts include:
• Removal of orthopaedic hardware
• Surgical debridement (critical)
• Vascularized muscle flaps
• Distraction osteogenesis (IIizarov) techniques
D. SUPPURATIVE ARTHRITIS
INFANTS <3 MONTHS OLD
Etiology: S. aureus, Group B Streptococci, Enterobacteriaceae, N. gonorrhoeae

Preferred Regimen:
1st line: 2nd line
Vancomycin Clindamycin IV
Post Vancomycin Neonates
conceptual dose <1,200 0-4 10mg/kg/d
age (weeks)* g BW weeks in 2 doses
10-15mg/kg/d in 1 1,200- 0-7d 10mg/kg/d
<26
dose 2,000 g old in 2 doses
10-15mg/kg BW >7d 15mg/kg/d
27-34
q18h** old in 3 doses
20-30mg/kg/d in 2 >2,000 0-7d 15mg/kg/d
35-41
doses** g BW old in 3 doses
40-60mg/kg/d in 3- >7d 20mg/kg/d
> 42
4 doses** old in 4 doses
100-200mg/kg/d in Infants and older 25-
7 days
4 doses children 40mg/kg/d in
*Post conceptual age= gestational age + 3-4 doses
weeks of life (Max:
**at 28 days of life, Vancomycin is 2.7g/d)
administered at 20 mg/kg/dose; interval
remains the same
PLUS Cefotaxime+ OR Ceftriaxone+
+see regimen under 1st line treatment
PLUS Cefotaxime
Neonates
<1,200g 0-4 100mg/kg/d in
BW weeks 2 doses
1,200- 0-7d 100mg/kg/d in
2,000g old 2 doses
BW >7d 150mg/kg/d in
old 3 doses
>2,000g 0-7d 100mg/kg/d in
BW old 2 doses
>7d old 150-
200mg/kg/d in
3-4 doses
Infants and older 100-
children 200mg/kg/d in
3-4 doses (Max:
12 g/d)
or Ceftriaxone
Neonates
<1,200g 0-4 50mg/kg/d in
BW weeks 1 dose
1,200- 2,000g BW

>2,000g 0-7d
BW old
>7d 75mg/kg/d in
old 1 doses
DOT for neonates is not well-defined
but 3 weeks is considered adequate.
Comments:
In most neonates, no fever, toxemia or leucocytosis is present. Infants with septic
arthritis may present with fever and irritability; subtle symptoms such as pain with
diaper change may be the only sign. Pseudoparalysis can occur.
ARSP 2015 showed increased resistance of S. aureus to oxacillin at 62.6%. Start

Treatment of septic arthritis requires both adequate drainage of purulent joint

fluid and appropriate antimicrobial therapy. There is no need to inject
antimicrobial agents into joints because of their excellent penetration.
Modify regimen to treat specific pathogen based on results of blood or joint fluid
culture. Blood cultures are frequently positive. Adjacent bone is involved in 2/3 of
patients. See comments on Precautions for ceftriaxone. Clindamycin is an
alternative if with no signs of sepsis. If cultures grow MSSA, shift to oxacillin.
CHILDREN AGED 3 MONTHS TO 14 YEARS
Etiology: S. aureus (27%), S. pyogenes or S. pneumoniae (14%), H. influenzae (3%),

Gram-negative bacilli (6%), Others (including N. gonorrhoeae, N. meningitidis)
(14%), Unknown (36%)
Preferred Regimen:
1st line 2nd line
If Gram stain is negative OR if Gram Clindamycin 25-40mg/kg/d IV in 3-4
stain is positive for Gram positive doses (Max: 2.7 g/d) or
cocci: Linezolid
Vancomycin 40-60mg/kg/d in 3-4 <12y: 30mg/kg/d IV in 3 doses
doses (Max: 4 g/d) PLUS >12y: 1200mg/d IV in 2 doses
Cefotaxime 100-200mg/kg/d in 3-4 PLUS
doses (Max: 12g/d) or Cefotaxime 100-200mg/kg/d in 3-4
Ceftriaxone 100mg/kg/d in 1-2 doses doses (Max: 12 g/d) or
(Max: 4g/d) Ceftriaxone 100mg/kg/d in 1-2 doses
If Gram stain is positive for Gram- (Max: 4 g/d)
negative organisms:

Cefotaxime 100-200mg/kg/d in 3-4 DOT: 3-6 weeks. Minimum duration

doses (Max: 12 g/d) OR should be 3 weeks because some
Ceftriaxone 100mg/kg/d in 1-2 doses cases may actually have coincident
(Max: 4 g/d) bone infection.
DOT: After initial response, therapy is
usually completed with oral therapy
for a total of 2-3 weeks.
Comments:
Drainage of purulent joint fluid (needle aspiration sufficient in most cases,
repeated as needed for re-accumulated fluid) is a critical component of therapy.
ARSP 2015 showed increased resistance of S. aureus to oxacillin at 62.6%. Start
Beyond the neonatal period, infections with Enterobacteriaceae are rare

occurrences. No need to inject antimicrobial agents into joints because of their
excellent penetration. Mark decrease in H. influenzae since use of conjugate
vaccine. Septic arthritis due to Salmonella has no association with sickle cell
disease, unlike Salmonella osteomyelitis. Clindamycin is an alternative if with no
signs of sepsis. If cultures grow MSSA, shift to oxacillin.
REFERENCES:
• Bravo L, et al. Handbook of Pediatric Infectious Disease an Easy Guide 5th ed. Manila:
Philippine Pediatric Society.
• Feigin R, Cherry J, et al. Textbook of Pediatric Infectious Diseases, 6th ed. New York:
Elsevier; 2009
• The Sanford Guide to Antimicrobial Therapy 2014. Available at:
http://webedition.sanfordguide.com/.
• Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases
Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus
Infections in Adults and Children. Clin Infect Dis 2011:52; e18-55.
• MIMS Philippines 1/2016, 147th edition. Makati: MIMS; 2016.

BONE AND JOINT INFECTIONS IN ADULTS
I. BONE INFECTIONS
A. OSTEOMYELITIS (HEMATOGENOUS)
LONG BONES

S. aureus, MRSA likely: Vancomycin 15-20mg/kg IV q8-12h
Group A streptococci, MRSA unlikely: Oxacillin 2g IV q4h
Gram-negative bacilli If Gram-negative bacilli seen on Gram stain, ADD:
rarely Ceftazidime 2g IV q8h or Piperacillin-tazobactam 4.5g
IV q8h or Ceftriaxone 2g IV q24h
DOT: 4-6 weeks
Comments:
Not common in adults. Etiologic diagnosis is essential. Collect blood and bone
cultures before giving empiric antibiotic therapy. Adjust treatment based on
culture and sensitivity results. Surgical intervention, other than obtaining tissue
specimen, usually not required.
VERTEBRAL, INCLUDING DISC SPACE INFECTIONS AND OTHER SITES

S. aureus most MRSA likely: Vancomycin 15-20mg/kg IV q8-12h
common, streptococci, PLUS Ceftriaxone 2g IV q24h or Piperacillin-
Gram-negative bacilli tazobactam 4.5g IV q8h or Levofloxacin 750mg IV
q24h
MRSA unlikely: Oxacillin 2g IV q4h PLUS
Ceftriaxone 2g IV q24h or Piperacillin-tazobactam
4.5g IV q8h or Levofloxacin 750mg IV q24h
Optimal DOT is unknown; usually 6-12 weeks.
Comments:
Perform image-guided aspiration biopsy for histopathology or appropriate
cultures when etiologic diagnosis is not established by blood cultures. The MRI is
the optimal diagnostic imaging. Consider tuberculous etiology when course is
subacute and the following characteristic radiologic findings are seen:
• Destruction of 2 or more vertebrae and opposed endplates
• Spread along the anterior longitudinal ligament
• Disk infection with or without paraspinal mass or fluid collection
• Spondylitis without disc involvement
Do not start antibiotics until etiologic diagnosis is established EXCEPT in the
following situations: sepsis, hemodynamic instability, severe or progressive
neurological signs and symptoms.

B. OSTEOMYELITIS (CONTIGUOUS WITHOUT VASCULAR INSUFFICIENCY)
• Usually follows trauma, bone or joint surgery
FOOT BONE (CALCANEUS) FOLLOWING PUNCTURE WOUND
Etiology: P. aeruginosa
Preferred Regimen:
1st line 2nd line
Ciprofloxacin 750mg PO bid OR Ceftazidime 2g IV q8h OR
Levofloxacin 750mg PO q24h Piperacillin-tazobactam 4.5g IV q8h
Comments:
Obtain bone biopsy culture (gold standard). Adjust antibiotic based on
susceptibility results. Need debridement and removal of foreign body.
LONG BONE, POST-INTERNAL FIXATION OF FRACTURE

S. aureus, Vancomycin 15-20mg/kg IV q8-12h PLUS
Gram-negative bacilli, Ceftazidime 2g IV q8h or
P. aeruginosa Piperacillin-tazobactam 4.5g IV q8h
Comments:
Removal of internal fixation hardware is a must even without bone union because
of biofilm formation on metal implant. External fixation can be done to stabilize
fracture.
STERNUM, POST-SURGERY

S. aureus, Gram-negative bacilli less often Vancomycin 15-20mg/kg IV q8-12h
Comments:
Debridement is needed. If Gram-negative bacilli is likely, add appropriate
antibiotic based on local susceptibility profile.
SPINAL IMPLANT

S. aureus, Vancomycin 15-20mg/kg IV q8-12h PLUS
Gram-negative bacilli Ceftazidime 2g IV q8h or
Piperacillin-tazobactam 4.5g IV q8h

Comments:
Onset within 30d: early debridement, retention of implant, and definitive
antibiotic x 3 months
Late-onset (>30d): implant removal, debridement, and definitive antibiotic x 6
weeks
C. OSTEOMYELITIS (CONTIGUOUS WITH VASCULAR INSUFFICIENCY)
• Mostly seen in diabetics (See Diabetic Foot)

Usually polymicrobial Empiric treatment is not indicated unless acutely ill.
in etiology (aerobic Choose antibiotic treatment based on
and anaerobic) culture/sensitivity results
DOT (IV to oral): Approximately 6 weeks from the last
debridement
Comments:
Bone/tissue biopsy culture essential. Culture of swab of overlying ulcer unreliable.
Osteomyelitis more likely: ulcer >2cm², positive probe to bone, ESR>70, abnormal
x-ray. MRI – best imaging. Revascularize, if possible.
D. OSTEOMYELITIS (CHRONIC)
• Usually occurs by contiguous spread, present for weeks to months, associated

with dead bone

Staphylococci, Empiric treatment is not recommended. Antibiotics
Enterobacteriaceae, must be chosen based on culture/sensitivity results.
P. aeruginosa
Comments:
Surgical resection of necrotic or infected bone and removal of orthopaedic
hardware, together with antibiotic therapy, is standard of care. The optimal
treatment duration and route is uncertain; antibiotic treatment is usually
prolonged (usually 6 weeks). Treatment adjuncts include:
• Antibiotic-impregnated cement for local antibiotic delivery- allows higher
concentration of antibiotics without systemic toxic effects
• Hyperbaric oxygen
• Rifampin combined w/ another active agent vs chronic staphylococcal and
orthopedic implant infections

II. JOINT INFECTIONS
A. ACUTE BACTERIAL ARTHRITIS
• Joint fluid WBC count usually >50,000/mm³ but lower counts do not exclude
the diagnosis
Etiology: S. aureus and Strep. sp. predominate. Gram-negative bacilli in 5-20%
Comments:
Consider as an emergency. Collect blood and joint fluid for culture before starting
empiric antibiotic treatment. Empiric antibiotic choices should be based on joint
fluid Gram stain. Adjust treatment based on culture/sensitivity results. Joint
drainage is essential.
MONOARTICULAR

At risk for sexually Ceftriaxone 1g IV q24h
transmitted infection Treat presumptively for concomitant Chlamydia
(STI): N. gonorrhoeae infection: Azithromycin 1g PO x 1 dose
likely DOT (min): 7d
Not at risk for STI:
S. aureus, streptococci,
Gram-negative bacilli
Gram-positive cocci Vancomycin 15-20mg/kg IV q8-12h
Gram-negative cocci Ceftriaxone 1g IV q24h
Gram-negative Ceftazidime 2g IV q8h OR
bacilli Piperacillin-tazobactam 4.5g IV q6-8h
Vancomycin PLUS
Negative on Gram stain Ceftazidime OR Piperacillin-tazobactam
DOT: 2-4 weeks
Comments:
At risk for STI: May manifest as disseminated gonococcal infection, presenting
with the classic triad of dermatitis, tenosynovitis, and polyarthritis. Culture other
sites: urethra, cervix, and throat.
Not at risk for STI: Differentials for gram-stain negative arthritis include gout and
pseudo gout. Look for crystals in joint fluid. If occurring after articular injection,
treat based on joint fluid culture result. Empiric therapy is not recommended

POLYARTICULAR

N. gonorrhoeae, Acute If sexually active, Ceftriaxone 1g IV q24h
rheumatic fever,
Viruses
Comments:
Work up for other causes including reactive arthritis
B. SEPTIC BURSITIS
• Usually involves olecranon, prepatellar and postpatellar bursae

• Diagnosis is based on aspiration of fluid from the bursa for WBC count
(usually >1,000/mm³), Gram stain and culture/sensitivity.

S. aureus in > 80%
MSSA Oxacillin 2g IV q4h OR Cefazolin 2g IV q8h
MRSA Vancomycin 15-20mg/kg IV q8-12h
DOT: 14-21d
Comments:
Treatment includes antibiotics and daily aspiration of bursa until sterile. Some
cases may require bursectomy.
C. PROSTHETIC JOINT INFECTIONS
Definitive diagnosis: presence of a sinus tract communicating with the prosthesis

or purulence (without another etiology) surrounding the prosthesis
• Highly suggestive diagnosis: acute inflammation on histopathology
examination of periprosthetic tissue obtained at the time of debridement or
prosthesis removal. At least 3 and optimally 5-6 periprosthetic tissue
specimens or the prosthesis itself should be sent for aerobic/anaerobic
cultures.
• Other diagnostic evidence: growth of the same organism in at least 2 intra-
operative cultures or in a combination of pre-operative aspirate and intra-
operative cultures; or growth of S. aureus (or other virulent organism) in
tissue biopsy or synovial fluid.
Etiology: S. aureus (21-43%), Coagulase-negative staphylococci (17-39%),

Streptococci (7-12%), Gram-negative bacilli (5-12%), Enterococci (1-8%),
Anaerobes (2-6%), Propionibacterium acnes associated with shoulder arthroplasty
infection

Preferred Regimen:
Referral to specialist. Empiric therapy is not recommended. Treat based on
culture/ sensitivity results.
Comments:
Surgical strategies:
1. Debridement and retention of prosthesis (DAIR): within 30 days of
prosthesis implantation or symptoms <3 weeks, with a well-fixed
prosthesis, low-virulence organism, and absence of a sinus tract
2. 1-stage/direct exchange
3. 2-stage exchange
There is insufficient evidence to make a recommendation on the safety and
efficacy of antibacterial cement spacers. Antibiotic cement spacers are used to
deliver higher concentrations of local antibiotics without systemic side effects and
to prevent joint contractures

Methicillin- DAIR PLUS
susceptible S. aureus Oxacillin 2g IV q4h or Cefazolin 2g IV q8h PLUS
or epidermidis Rifampin 300mg PO bid x 2-6 weeks (coverage for
BIOFILM)
FOLLOWED BY Levofloxacin 750mg PO q24h or
Ciprofloxacin 750mg PO bid PLUS
Rifampin 300mg PO bid for 3 months (6 months for total
knee arthroplasty)
1-stage: IV  PO regimen as for DAIR for 3 months
2-stage: IV  PO regimen as above for 4-6 weeks
Methicillin-resistant DAIR PLUS
S. aureus or Vancomycin 15-20 mg/kg IV q8-12h PLUS
epidermidis Rifampin 300 mg po bid x 2-6 weeks
FOLLOWED BY Levofloxacin 750 mg PO q24h or
Ciprofloxacin 750 mg PO bid PLUS
Rifampin 300 mg PO bid for 3 months (6 months for
total knee arthroplasty)
1-stage: IV  PO regimen as for DAIR for 3 months
2-stage: IV  PO regimen as above for 4-6 weeks
Streptococci or P. DAIR PLUS
acnes Penicillin G 20-24MU IV q24 continuously (or in 6
divided doses) or Ceftriaxone 2g IV q24h x 4-6 weeks
1-/2-stage: as above x 4-6 weeks
Enterococci DAIR PLUS
(penicillin- Penicillin G 20-24MU IV q24 continuously (or in 6 div
susceptible) doses) or Ampicillin 2g IV q4h x 4-6 weeks

Enterococci DAIR PLUS

(penicillin-resistant) Vancomycin 15mg/kg IV q12h x 4-6 weeks
Enterobacteriaceae DAIR PLUS
IV B-lactam or fluoroquinolone based on susceptibility
results x 4-6 weeks
P. aeruginosa DAIR PLUS
Ceftazidime 2g IV q8h or Cefepime 2g IV q12h
Comments:
For Methicillin-susceptible/resistant S. aureus or epidermidis: confirm isolate
susceptibility to rifampin and fluoroquinolones
For Entercocci and P. aeruginosa: may add an aminoglycoside (optional)
REFERENCES:
• Antimicrobial Resistance Surveillance Program. Manila: Department of Health; 2015.
• Antibiotic Guidelines 2015-2016. Treatment Recommendations for Adult Inpatients.
• Baek-Nam K, et al. Oral antibiotic treatment of staphylococcal bone and joint infections in
adults. J Antimicrob Chemother 2014; 69: 309–322.
• Berbari EF et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice
Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults.
Clin Infect Dis Advanced Access. Published July 29, 2015.
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases
Society of America for the treatment of methicillin-resistant Staphylococcus aureus
infections in adults and children. Clin Infect Dis 2011; 52: e18.
• Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases, 8th ed. New
York: Elsevier; 2015.
• Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint
infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin
Infect Dis 2013;56: e1.
• Spellberg B, Lipsky B. Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults. Clin
Infect Dis 2012;54(3):393–407.
• Tande A, Patel R. Prosthetic Joint Infections. Clin Microbiol Rev 2014;302-345.
• Trampuz A, Zimmerli W. Diagnosis and Treatment of Implant-Associated Septic Arthritis
and Osteomyelitis. Curr Infect Dis Rep 2008; 10:394–403.

CARDIOVASCULAR INFECTIONS
I. INFECTIVE ENDOCARDITIS (IE)
DIAGNOSTIC CRITERIA (MODIFIED DUKE’S CRITERIA)

A. Pathological criteria (any one):
1. Histology or culture of a cardiac vegetation, an embolized vegetation, or
intracardiac abscess from the heart revealing microorganisms
2. Active endocarditis
B. Clinical Criteria:
Major criteria
1. Positive blood culture with typical IE microorganism, defined as one of the
following:
• Typical microorganism consistent with IE from 2 separate blood cultures
(viridans group streptococci, or S. bovis including nutritional variant strains,
or HACEK group, or S. aureus, or community-acquired enterococci, in the
absence of a primary focus)
• Microorganisms consistent with IE from persistently positive blood cultures
(at least two positive cultures of blood samples drawn >12 hours apart, or
all of 3 or a majority of 4 separate cultures of blood, with first and last
sample drawn > 1 hour apart)
• Coxiella burnetii detected by at least one positive blood culture or IgG
antibody titer for Q fever phase 1 antigen >1:800.
2. Evidence of endocardial involvement with positive echocardiogram defined as
oscillating intracardiac mass on valve or supporting structures, in the path of
regurgitant jets, or on implanted material in the absence of an alternative
anatomic explanation, or abscess, or new partial dehiscence of prosthetic valve
or new valvular regurgitation (worsening or changing of pre-existing murmur
not sufficient)
Minor criteria
1. Predisposing factor: known cardiac lesion, recreational drug injection
2. Fever >38°C
3. Embolism evidence: arterial emboli, pulmonary infarcts, Janeway lesions,
conjunctival/intracranial hemorrhages
4. Immunological problems: glomerulonephritis, Osler’s nodes, Roth spots,
rheumatoid factor
5. Microbiologic evidence: Positive blood culture (that doesn't meet a major
criterion) or serologic evidence of infection with organism consistent with IE but
not satisfying major criterion
Definitive (any one of these Possible (any one of these

combinations): combinations):
• 2 major clinical criteria • 1 major and 1 minor criteria
• 1 major and 3 minor criteria • 3 minor criteria are fulfilled
• 5 minor criteria
• 1 pathological criterion

A. Native Valve Infective Endocarditis
EMPIRIC THERAPY
Etiology: Streptococcus viridans (30-40%), Other streptococci (15-25%),

Enterococci (5-18%), Staphylococci (20-35%), Haemophilus sp., Aggregatibacter
sp., Cardiobacterium hominis, Eikenella corrodens, and Kingella species (HACEK)
(5%), Culture negative 10%
Preferred Regimen:
Community-acquired Healthcare-associated
PEDIATRICS
Ampicillin-sulbactam 200-300mg/kg Vancomycin 60 mg/kg/d IV q6h
IV q24h div 4 or 6 doses (Max: (Max: 2 g/d) for 6 weeks PLUS
12g/24h) x 4 weeks PLUS Gentamicin 3–6 mg/kg/d IV q8h
Gentamicin 3-6 mg/kg/d IV/IM q8h PLUS
Cefepime 100-150 mg/kg/d q8-12h
(Max: 6 g/d) or Ceftazidime 100-150
mg/kg/d IV q8h (Max: 2-4 g/d)
ADULTS
Ampicillin 12g/d IV q4h PLUS Vancomycin 15-20 mg/kg IV q8-12h
Gentamicin 1mg/kg IV q8h PLUS Gentamicin 1 mg/kg IV q8h
OR PLUS Cefepime 2g IV q8h or
Ceftazidime 2g IV q8h
Vancomycin 15-20mg/kg IV q8-12h (if
MRSA likely pathogen) PLUS
Ceftriaxone 2g IV q24h or
Gentamicin 1mg/kg IV q8h
Comments:
• At least 3 sets of blood cultures must be obtained.
• Transthoracic echocardiogram (TTE) must be done in all suspected cases.
• Transesophageal echo (TEE) must be done when TTE is negative if there is
ongoing suspicion of IE or concern about intracardiac complications.
PATHOGEN-SPECIFIC TREATMENT
Etiology: S. viridans or S. bovis (S. gallolyticus) with Penicillin G MIC ≤0.12 mcg/mL
Preferred Regimen:
PEDIATRICS ADULTS
Aqueous crystalline penicillin G Na Penicillin G 12-18MU/d IV q4h x 2
200,000-300,000 U/kg/d IV q4h weeks or Ceftriaxone 2g IV q24h x 2
(Max: 12-24 MU/d) x 4 weeks OR weeks

Ceftriaxone 100mg/kg/d IV/IM q12h PLUS

or 80mg/kg/d qd (Max: 2g q12h) x 4 Gentamicin 3mg/kg/d qd x 2 weeks or
wks Penicillin G 12-18MU/d IV q4h x 4
weeks or
Ceftriaxone 2g IV q24h x 4 weeks
If unable to tolerate Penicillin or
Ceftriaxone:
Vancomycin 15mg/kg IV q12h x 4 wks
Comments:
P: Suspect occult bowel pathology (e.g., tumor) when the etiologic agent is S.
bovis.
A: A 2-week combination regimen is reasonable with uncomplicated IE, rapid
treatment response and without renal disease. Treatment with vancomycin must
achieve trough concentration of 10-15 mcg/mL. Obtain the trough level before the
4th dose.
Etiology: S. viridans or S. bovis (S. gallolyticus) with Penicillin G MIC >0.12 to

≤0.5mcg/mL
Preferred Regimen:
PEDIATRICS ADULTS
Ampicillin 200-300mg/kg/d IV q4-6h Penicillin G 24MU/d IV q4h x 4 weeks
(Max: 12 g/d) x 4 weeks or PLUS Gentamicin 3mg/kg qd x 2 weeks
Ceftriaxone 100mg/kg/d IV/IM q12h OR
or 80mg/kg/d qd (Max: 2g q12h) x 4 Ceftriaxone 2g IV qd x 4 weeks
weeks If unable to tolerate Penicillin or
PLUS Ceftriaxone:
Gentamicin 3-6mg/kg/d IV q8h x 2wks Vancomycin 15 mg/kg IV q12h x 4 wks
Comments:
Check susceptibility to ceftriaxone.
Etiology: S. viridans or S. bovis (S. gallolyticus) with Penicillin G MIC >0.5 mcg/mL and
Enterococci susceptible to ampicillin/ Penicillin G, vancomycin, gentamicin (synergy
positive)
Preferred Regimen:
1st line 2nd line
Penicillin G 18-30 MU/d IV q4h or Ampicillin 12 g/d IV q4h
Ampicillin 12 g/d IV q4h x 4-6 weeks PLUS
PLUS Ceftriaxone 2 g IV q12h x 6 weeks
Gentamicin 1 mg/kg IV q8h x 4-6 weeks
DOT: 4 weeks if symptoms <3 months; 6 weeks if symptoms >3 months

Comments:
Alternative double B-lactam regimen may be used when unable to use
gentamicin (ex. creatinine clearance < 50 mL/min)
Etiology: Enterococci, penicillin-susceptible, aminoglycoside-resistant (gentamicin

MIC >500 mcg/mL), streptomycin susceptible
Preferred Regimen:
PEDIATRICS ADULTS
Ampicillin 200–300mg/kg/d IV div q4-6h Ampicillin 12g/d IV div q4h
(Max dose 12 g/d) PLUS PLUS
Ceftriaxone 100mg/kg/d IV/IM q12h or Ceftriaxone 2g IV q12h x 6 weeks
80mg/kg/day od (Max: 2 g q12h) x 6
weeks
Etiology: Enterococci, penicillin-resistant, aminoglycoside-sensitive
Preferred Regimen:
PEDIATRICS ADULTS
Vancomycin 60mg/kg/d IV q6h (Max: Vancomycin 15-20mg/kg IV q8-12h
2g/d) PLUS PLUS
Gentamicin 3-6mg/kg/d IV q8h x 6 wks Gentamicin 1mg/kg IV q8h x 6 wks
Comments:
Potential increased nephrotoxicity and ototoxicity with this combination. Dose
must be adjusted to achieve vancomycin target trough concentration of 15-20
mcg/mL. Refer to specialist.
Etiology: Enterococci, penicillin- and aminoglycoside-resistant or vancomycin-

resistant Refer to specialist.
Etiology: Methicillin-susceptible Staphylococcus aureus (MSSA)
Preferred Regimen:
PEDIATRICS ADULTS
Oxacillin 200mg/kg/d IV div 4–6 doses Oxacillin 2g IV q4h x 4-6 weeks OR
(Max: 12 g/d) x 6 weeks Cefazolin 2g IV q8h x 6 weeks
WITH or WITHOUT
Gentamicin 3-6mg/kg/d IV/IM q8h x 3-5d
Etiology: Methicillin-resistant S. aureus (MRSA)
Preferred Regimen:
P: Vancomycin 60mg/kg/d IV q6h (Max: 2 g/d)

A: Vancomycin 15-20mg/kg IV q8-12h x 6 weeks
Etiology: Haemophilus sp, Aggregatibacter sp, Cardiobacterium hominis, Eikenella

corrodens, and Kingella species (HACEK)
Preferred Regimen:
PEDIATRICS ADULTS
Ceftriaxone 100 mg/kg/d IV/IM q12h or Ceftriaxone 2g IV q24h x 4 weeks
80 mg/kg/d qd (Max: 2g q12h) x 4 weeks If beta-lactamase producing:
If beta-lactamase producing: Ampicillin-sulbactam 3g IV q6h x 4
Ampicillin-sulbactam 200-300mg/kg weeks
q24h IV div 4 or 6 doses x 4 weeks
B. PROSTHETIC VALVE IE
EMPIRIC THERAPY
Etiology:
Early (<2 months post-surgery): S. epidermidis and S. aureus mostly
Late (>2 months post-surgery): S. epidermidis, S. viridans, enterococci, S. aureus
Preferred Regimen:
PEDIATRICS ADULTS
Vancomycin 40-60mg/kg/d q6-8h Vancomycin 15-20mg/kg IV q8-12h
PLUS PLUS Gentamicin 1mg/kg IV q8h
Gentamicin 3–6mg/kg/d IV q8h PLUS PLUS Rifampin 600mg PO q24h
Rifampin 20mg/kg/d IV/PO div 3
doses x 6 weeks (Max: 900 mg/d)
DOT: 6 weeks
Comments:
Early surgical consultation is recommended. Surgical indications:
• Signs and symptoms of congestive heart failure due to valve dehiscence
• Intracardiac fistula and prosthetic valve dysfunction
• Persistent bacteremia despite 5-7 days of treatment
• Heart block, annular or aortic abscess
• Recurrent emboli
• Caused by fungal or highly resistant organisms
PATHOGEN-SPECIFIC TREATMENT
Etiology: Methicillin-susceptible S. aureus (MSSA)

Preferred Regimen:
PEDIATRICS ADULTS
Oxacillin 200mg/kg/d IV div 4–6 Oxacillin 2g IV q4h
doses x 6 weeks (Max: 12g/d) PLUS PLUS
Rifampin 20mg/kg q24h IV/PO div 3 Rifampin 300mg PO q8h x 6 weeks
doses x 6 weeks (Max: 900 mg/d) PLUS
PLUS Gentamicin 1mg/kg IV q8h x 2 weeks
Gentamicin 3-6 mg/kg/d IV/IM div 3
doses x 2 weeks
Etiology: Methicillin-resistant S. aureus (MRSA)
Preferred Regimen:
PEDIATRICS ADULTS
Vancomycin 40mg/kg/d IV div 2-3 Vancomycin 15-20mg/kg IV q8-12h
doses x 6 weeks PLUS PLUS
Rifampin 20mg/kg/d IV/PO div 3 Rifampin 300mg PO q8h x 6 weeks
doses x 6 weeks (Max: 900 mg/d) PLUS
PLUS Gentamicin 1mg/kg IV q8h x 2 weeks
Gentamicin 3-6mg/kg/d IV/IM div 3
doses x 2 weeks
DOT: 6 weeks
Etiology: Gram-negative enteric bacilli
Preferred Regimen (Pediatrics):

Ceftazidime 100-150mg/kg/d IV q8h x 6 weeks (Max: 2-4 g/d) or
Cefotaxime 200mg/kg/d IV q6h x 6 weeks (Max: 12 g/d) or
Ceftriaxone 100mg/kg/d IV q12h or 80 mg/kg/d IV q12-24h x 6 weeks (Max: 2
g/d) PLUS
Gentamicin 3-6mg/kg/d IV q8h
C. INFECTIVE ENDOCARDITIS (IE) PROPHYLAXIS
Summary Statements:
1. Only an extremely small number of cases of IE might be prevented by antibiotic
prophylaxis for dental procedures even if such prophylactic therapy were 100%
effective.
2. IE prophylaxis for dental procedures is reasonable only for patients with
underlying cardiac conditions associated with the highest risk of adverse
outcome from IE.
3. For patients with these underlying cardiac conditions, prophylaxis is reasonable
for all dental procedures that involve manipulation of the gingival tissue or the
periapical region of teeth, or perforation of the oral mucosa.

4. Prophylaxis is not recommended based solely on an increased lifetime risk of

acquisition of IE.
5. Administration of antibiotics solely to prevent endocarditis is not
recommended for patients who undergo a genitourinary or gastrointestinal
tract procedure.
CARDIAC CONDITIONS WITH THE HIGHEST RISK OF ADVERSE OUTCOME FROM IE

WHERE PROPHYLAXIS FOR DENTAL PROCEDURES IS REASONABLE
• Prosthetic cardiac valve or prosthetic material used for cardiac valve repair
• Previous IE
• Congenital heart disease (CHD)*
o Unrepaired cyanotic CHD, including palliative shunts and conduits
o Completely repaired congenital heart defect with prosthetic material or
device, whether placed by surgery or by catheter intervention, during the
first 6 months after the procedure**
o Repaired CHD with residual defects at the site or adjacent to the site of a
prosthetic patch or prosthetic device (which inhibit endothelialization)
• Cardiac transplantation recipients who develop cardiac valvulopathy
*Except for the conditions listed above, antibiotic prophylaxis is no longer recommended for
any other form of CHD.
**Prophylaxis is reasonable because endothelialization of prosthetic material occurs within 6
months after the procedure.
DENTAL PROCEDURES FOR WHICH IE PROPHYLAXIS IS REASONABLE FOR PATIENTS

WITH SPECIFIED CARDIAC CONDITIONS (SEE ABOVE STATEMENTS)
• All dental procedures that involve manipulation of gingival tissue or the
periapical region of teeth or perforation of the oral mucosa (biopsies, suture
removal, placement of orthodontic bands)
• The following procedures and events do NOT need prophylaxis:
o Routine anaesthetic injections through non- infected tissue
o Dental radiographs
o Placement of removable prosthodontic or orthodontic appliances
o Adjustment of orthodontic appliances
o Placement of orthodontic brackets
o Shedding of deciduous teeth
o Bleeding from trauma to the lips or oral mucosa.
RECOMMENDED REGIMEN FOR DENTAL PROPHYLAXIS

Regimen: Single dose 30-60 min.
Situation Agent
before procedure
ADULTS PEDIATRICS
Oral Amoxicillin 2g 50mg/kg
Unable to take Ampicillin OR 2g IM/IV 50mg/kg IM or IV

oral medication Cefazolin OR 1g IM/ IV 50mg/kg IM or IV

Ceftriaxone 1g IM/ IV 50mg/kg IM or IV

Allergic to Cephalexin* OR 2g 50mg/kg
penicillins or Clindamycin OR 500 mg 20mg/kg
ampicillin—oral Azithromycin OR 500 mg 15mg/kg
Clarithromycin 15mg/kg
Allergic to Cefazolin OR 1g IM/ IV 50mg/kg IM or IV
penicillins or Ceftriaxone† OR
ampicillin and Clindamycin 600mg IM/IV 20mg/kg IM or IV
unable to take
oral medication
*Or other first- or second-generation oral cephalosporin in equivalent adult or pediatric dosage.
†Cephalosporins should not be used in an individual with a history of anaphylaxis, angioedema,
or urticaria with penicillins or ampicillin.
INDICATIONS FOR SURGERY

1. Congestive heart failure*
• Congestive heart failure caused by severe aortic or mitral regurgitation or,
more rarely, by valve obstruction caused by vegetations
• Severe acute aortic or mitral regurgitation with echocardiographic signs of
elevated left ventricular end-diastolic pressure or significant pulmonary
hypertension
• Congestive heart failure as a result of prosthetic dehiscence or obstruction
2. Periannular extension (Most patients with abscess formation or fistulous tract
formation)
3. Systemic embolism†
• Recurrent emboli despite appropriate antibiotic therapy
• Large vegetations (>10 mm) after 1 or more clinical or silent embolic events
after initiation of antibiotic therapy
• Large vegetations and other predictors of a complicated course
• Very large vegetations (>15 mm) without embolic complications, especially
if valve-sparing surgery is likely (remains controversial)
4. Cerebrovascular complications‡
• Silent neurological complication or transient ischemic attack and other
surgical indications
• Ischemic stroke and other surgical indications, provided that cerebral
hemorrhage has been excluded and neurological complications are not
severe (e.g., coma)
5. Persistent sepsis
• Fever or positive blood cultures persisting for >5 to 7 days despite an
appropriate antibiotic regimen, assuming that vegetations or other lesions
requiring surgery persist and that extracardiac sources of sepsis have been
excluded
• Relapsing IE, especially when caused by organisms other than sensitive
streptococci or in patients with prosthetic valves

6. Difficult organisms
• Staphylococcus aureus IE involving a prosthetic valve and most cases
involving a left-sided native valve
• IE caused by other aggressive organisms (Brucella, Staphylococcus
lugdunensis)
• IE caused by multiresistant organisms (e.g. methicillin-resistant S. aureus or
vancomycin-resistant enterococci) and rare infections caused by Gram-
negative bacteria
• Pseudomonas aeruginosa IE
• Fungal IE
7. Prosthetic valve endocarditis
• Virtually all cases of early prosthetic valve endocarditis
• Virtually all cases of prosthetic valve endocarditis caused by S. aureus
• Late prosthetic valve endocarditis with heart failure caused by prosthetic
dehiscence or obstruction, or other indications for surgery
*Surgery should be performed immediately, irrespective of antibiotic therapy, in patients with
persistent pulmonary edema or cardiogenic shock. If congestive heart failure disappears with
medical therapy and there are no other surgical indications, intervention can be postponed to
allow a period of days or weeks of antibiotic treatment under careful clinical and
echocardiographic observation. In patients with well tolerated severe valvular regurgitation
or prosthetic dehiscence and no other reasons for surgery, conservative therapy under careful
clinical and echocardiographic observation is recommended with consideration of deferred
surgery after resolution of the infection, depending upon tolerance of the valve lesion.
†In all cases, surgery for the prevention of embolism must be performed very early since
embolic risk is highest during the first days of therapy.
‡Surgery is contraindicated for at least one month after intracranial hemorrhage unless
neurosurgical or endovascular intervention can be performed to reduce bleeding risk.
II. BACTERIAL PURULENT PERICARDITIS
Etiology: S. aureus, Group A Streptococcus, S. pneumoniae, Enterobacteriaceae
PEDIATRICS ADULTS
Vancomycin 60mg/kg/d q6h Vancomycin 15-20mg/kg IV q8-12h
(adjusted based on TDM) PLUS
PLUS Ceftriaxone 2g IV q24h or
Ceftriaxone 100mg/kg/d IV q12-24h Levofloxacin 750mg IV q24h or
(Max: 2 g q12h) Aminoglycoside (Gentamicin
5mg/kg/day or Amikacin 15 mg/kg/day)
Comments:
Initial antibiotic regimen should consist of 2 or more drugs, when etiologic agent
cannot be detected rapidly. Drainage usually necessary.
Etiology: Methicillin-resistant S. aureus is isolated and/or with history and clinical

features for MRSA infection; S. pneumoniae resistant to extended-spectrum
cephalosporins, or nosocomial infections

Preferred Regimen:
Vancomycin 60 mg/kg/d q6h (adjusted based on TDM)
DOT: Empirical and determined partly by the nature of concomitant infection.
Once a pathogen is isolated and the antimicrobial susceptibilities are known, the
most specific antimicrobial agent is continued IV for 3-4 weeks.
Etiology: Methicillin-sensitive S. aureus
Preferred Regimen:
Oxacillin 200mg/kg/day (Max: 4 - 12 g/d)
Etiology: S. pneumoniae (including penicillin-resistant strains), N. meningitidis, H.

influenzae type B (for children who may be inadequately immunized)
Preferred Regimen:
Cefotaxime 200-300 mg/kg/d IV q6-8h (Max: 12g/d) OR
Ceftriaxone 100 mg/kg/d IV q12-24h (Max: 2g q12h)
Comments:
An aminoglycoside should be added when:
1. purulent pericarditis occurs after surgery
2. in association with UTI
3. in the immunocompromised
III. ACUTE RHEUMATIC FEVER
PRIMARY PREVENTION: (See section on Streptococcal Tonsillopharyngitis)
Comments:
Therapy for acute rheumatic fever is symptomatic to control the inflammation,
decrease the fever, and keep cardiac failure in check.
SECONDARY PREVENTION (PREVENTION OF RECURRENT ATTACKS)
Preferred Regimen:
Benzathine penicillin G (every 3 For individuals allergic to penicillin
weeks*) Erythromycin 20mg/kg/d bid (Max: 250 mg
< 27 kg: 600,000 U IM bid) OR
> 27 kg: 1,200,00 U IM Azithromycin 5mg/kg qd (Max: 250 mg)
OR
Penicillin V 250mg PO bid

Comments:
Referral to a pediatric cardiologist is important. Prevention of recurrent episodes
of Group A Streptococcus (GAS) pharyngitis is the most effective method to
prevent severe RHD. An individual with a previous attack of rheumatic fever in
whom GAS pharyngitis develops is at high risk for a recurrent attack of rheumatic
fever.
Successful oral prophylaxis depends on patient adherence (compliance), and oral

agents are more appropriate for patients at low risk for rheumatic fever
recurrence.
Duration of Secondary Rheumatic Fever Prophylaxis Category

**Clinical or echocardiographic findings Duration of Last Attack
Rheumatic fever with carditis and 10 years or until 40 years of age
residual heart disease (persistent (whichever is longer)
valvular disease**)
Rheumatic fever with carditis but no 10 years or 21 years of age
residual heart disease (no valvular (whichever is longer)
disease**)
Rheumatic fever without carditis 5 years or 21 years of age
(whichever is longer)
IV. CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTION (CLABSI) IN

CHILDREN
Etiology: Coagulase-negative staphylococci (especially S. epidermidis), S. aureus,

Enterococcus spp., Escherichia coli, Klebsiella spp., Other enteric Gram-negative
bacteria
Preferred Regimen:
Vancomycin 60mg/kg/d q6h PLUS
Piperacillin-tazobactam 200-300mg/kg/day IV q8h PLUS
Aminoglycoside
Etiology: Candida spp.
Preferred Regimen:
Fluconazole 12mg/kg PO/IV as loading dose, then 6mg/kg/d is an acceptable
alternative if not critically ill and unlikely to have fluconazole-resistant Candida
spp.
DOT: up to 2 weeks after clearance of candidemia

Comments:
• Once the causative organism is identified, targeted therapy should be selected
based on susceptibility testing.
• If the catheter is retained, patients should receive 10-14 days of systemic
antibiotic therapy from the date of the first negative blood culture
• If the catheter is removed, patients should receive 10–14 days of appropriate
systemic therapy.
• A shorter 5- to 7-day treatment course is reasonable for CLABSI due to
coagulase-negative staphylococci if the catheter is removed and blood cultures
clear promptly.
V. CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTION IN ADULTS
Diagnosis: Fever AND: 1) positive percutaneous blood culture and same organism
cultured from central venous catheter (CVC) tip OR 2) positive blood cultures
simultaneously drawn with CVC positive at least 2 hours earlier than the
peripheral vein culture. Referral to specialist is recommended.
Infection prevention of long-term IV lines include components of both insertion
and maintenance bundles:
• Hand washing
• Maximal sterile barrier precautions during catheter insertion
• Use of >0.5% chlorhexidine prep with alcohol for skin antisepsis
(chlorhexidine–alcohol provides greater protection against short-term
catheter-related infections than povidone iodine–alcohol)
• Avoidance of femoral vessels
• Daily review of line necessity and replacement
• Disinfection of hubs
• Strict asepsis for dressing changes
• Standardized administration set changes
NON-TUNNELED central venous catheter (subclavian, internal jugular), peripherally

inserted central catheter (PICC): S. epidermidis, S. aureus (MSSA/MRSA)
TUNNEL TYPE indwelling venous catheters and ports (Broviac, Hickman, Groshong,),
dual lumen hemodialysis catheters (Permacath): S. epidermidis, S. aureus
(MSSA/MRSA), Candida sp.
Preferred Regimen:
Vancomycin 15-20mg/kg IV q8-12h
If S. aureus, remove catheter and treat for 2 weeks. Prolong to 4-6 weeks if
transesophageal echocardiogram positive for vegetation or if there are other
complications (e.g. septic thrombosis, osteomyelitis)
If S. epidermidis, may “save” catheter and treat for 10-14 days plus antibiotic lock
therapy (in the absence of complications)

For documented MSSA: Oxacillin 2 g IV q4h OR Cefazolin 2 g IV q8h

Comments:
If subcutaneous tunnel infected, remove catheter. Do not insert new catheter
over a guidewire.
IMPAIRED HOST (burn, neutropenic)
Etiology: S. epidermidis, S. aureus (MSSA/MRSA), Candida sp., Pseudomonas sp.,

Enterobacteriaceae, Corynebacterium jeikeium, Aspergillum, Rhizopus
Preferred Regimen:
Vancomycin 15-20mg/kg IV q8-12h
PLUS Cefepime 2g IV q8h or Ceftazidime 2g IV q8h
OR
Vancomycin 15-20mg/kg IV q8-12h PLUS Piperacillin-tazobactam 4.5g IV q6-8h
OR
Cefepime 2g IV q8h or Ceftazidime 2g IV q8h PLUS Amikacin 15 mg/kg qd
Comments:
Often w/ associated septic thrombophlebitis; biopsy of vein recommended to
rule out fungal etiology. If fungal, surgical drainage, ligation or removal often
indicated + antifungal Rx.
HYPERALIMENTATION
Etiology: S. epidermidis, S. aureus (MSSA/MRSA), Candida sp. Common
Preferred Regimen:
As above for staphylococcal infections
If Candida:
An echinocandin (e.g. anidulafungin 200 mg IV loading dose then 100 mg IV daily).
Fluconazole 12 mg/kg PO or IV as loading dose, then 6 mg/kg/d is an acceptable
alternative if not critically ill and unlikely to have fluconazole-resistant Candida sp.
DOT: up to 2 weeks after clearance of candidemia
Comments:
Remove venous catheter. Stop antimicrobial agents if possible. Ophthalmologic
consultation recommended when candidemia is suspected to detect early
ophthalmic involvement. Treat all patients with positive blood cultures for
Candida.
REFERENCES:
• Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis,
Antimicrobial Therapy, and Management of Complications: A Scientific Statement for

Healthcare Professionals from the American Heart Association. Circulation 2015; 132:1435-
1486.
• Ling ML, Apisarnthanarak A, Jaggi N, et al. APSIC guide for prevention of Central Line
Associated Bloodstream Infections (CLABSI). Antimicrob Resist Infect Control 2016; 5:16.
• Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and
management of intravascular catheter-related infection: 2009 Update by the Infectious
Diseases Society of America. Clin Infect Dis. Jul 1 2009; 49(1):1-45.
• O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular
catheter-related infections. Clin Infect Dis. 2011 May;52(9): e162–193. Epub 2011 Apr 1.
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of
Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis
2016;62: e1-50.
• Prendergast BD, Tornos P. Surgery for Infective Endocarditis. Circulation 2010; 121:1141-
1152.
• Wilson W, Taubert CA, Gewitz M, et al. Guidelines from the American Heart Association: A
Guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki
Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on
Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of
Care and Outcomes Research Interdisciplinary Working Group. Circulation
2007;116(15):1736-54.

CENTRAL NERVOUS SYSTEM INFECTIONS
I. COMMUNITY ACUTE BACTERIAL MENINGITIS
• Acute bacterial meningitis is an inflammatory disease of the leptomeninges,

the tissues surrounding the brain and spinal cord as proven by a positive
bacterial CSF culture, PCR, gram stain or antigen test; or suspected by clinical
characteristics and/or CSF markers of inflammation (an abnormal number of
white blood cells, elevated protein and low glucose levels)
• In children, common signs and symptoms include fever, irritability, poor
feeding, bulging fontanel and seizures. In neonates, signs and symptoms are
subtler and may resemble neonatal sepsis. There is no single or combination of
signs which are diagnostic of bacterial meningitis. If bacterial meningitis is
suspected, CSF analysis and culture should be performed to confirm the
diagnosis.
• In adults, the classic triad of acute bacterial meningitis consists of fever, nuchal
rigidity, and a change in mental status.
• Once suspected and awaiting laboratory results, empiric therapy should be
started right away to prevent complications and mortality.
< 2 MONTHS OLD

Etiology: Escherichia coli, Streptococcus pneumoniae, Klebsiella, Enterobacter,
Group B Streptococcus (rare)
Preferred Regimen:
Ampicillin or Cefotaxime IV/IM using the following dose:
Age 0-7 days Age >7 days
Body weight <2 kg 50mg/kg q12h 50mg/kg q8h
Body weight at least 2 kg 50mg/kg q8h 50mg/kg q6h
PLUS Amikacin 15mg/kg/d IV/IM q24h or Gentamicin 5mg/kg/d IV/IM q24h
Comments:
Adjust therapy based on culture. Early onset usually due to maternal transmission.
May use Ceftriaxone if Cefotaxime is not available and the neonate is not
jaundiced. Repeat lumbar tap in the neonate is necessary to verify sterilization of
the CSF in gram-negative meningitis. Duration of therapy is dependent on the
etiology of bacterial meningitis. Dexamethasone has no role in neonatal
meningitis. Antibiotic therapy should be started immediately after lumbar
puncture or, if this is delayed, after obtaining blood cultures.
> 2 MONTHS - 5 YRS

S. pneumoniae, Ceftriaxone 100mg/kg/d IV q12-24h (Max: 4 g/d)
H. influenzae, OR
N. meningitidis (less Chloramphenicol 100mg/kg/d IV q8h (Max: 4g/d)
common)

Comments:
Add vancomycin if penicillin- or cephalosporin-resistant H. influenzae is suspected.
Cefuroxime should not be used for the treatment of bacterial meningitis because
of delayed sterilization and a greater incidence of hearing loss. Dexamethasone is
of proven value for children with H. influenzae b meningitis in children less than 5
yrs. old at a dose of 0.15 mg/kg (max: 10 mg) q6h for 4 days. It should be started
along or shortly before the 1st antibiotic dose. The first dose should be
administered within 4 hours of starting antibiotic. Do not start dexamethasone
>12h after starting antibiotics.
Repeat lumbar puncture (LP) is recommended in patients with poor clinical

response despite 36 hours of appropriate antibiotic treatment, or those with
gram-negative meningitis. For H. influenzae and S. pneumoniae meningitis, if
patient is improving, repeat LP is not necessary.
Patients <10 yrs. with confirmed Hib meningitis should receive rifampin
prophylaxis to eradicate the carrier state. Recommended rifampicin dose for
prophylaxis:
<3yrs old: 10mg/kg/d x 4d;
>3-10 yrs.: 20mg/kg/d x 4d (Max: 600 mg)
>5 YRS - 18 YRS; 18 YRS-50 YRS

Etiology: S. pneumoniae, N. meningitidis
Preferred Regimen:
>5 yrs. - 18 yrs. 18 yrs.-50 yrs.
Ceftriaxone 100mg/kg/d IV q12h Ceftriaxone 2g IV q12h
(Max: 4 g/d) OR Chloramphenicol
100mg/kg/d IV q8h (Max: 4 g/d)
Comments:
Patients with confirmed meningococcal meningitis and not treated with
Ceftriaxone should receive either:
Rifampicin 10mg/kg/d x 2d (Max: 600 mg) OR
Ceftriaxone <15 yrs.: 125mg IM x 1 dose; >15 yrs.: 250mg IM x 1 dose OR
Ciprofloxacin 500mg PO x 1 dose
>50 YRS
S. pneumoniae, Ampicillin 2g IV q4h PLUS Ceftriaxone 2g IV
N. meningitidis, q12h
L. monocytogenes, aerobic For severe penicillin allergy:
Gram-negative bacilli Vancomycin 15-20mg/kg IV q8-12h

PLUS Aztreonam 2g IV q6-8h or

Ciprofloxacin 400mg IV q12h
DOT (regardless of age):
S. pneumoniae: 10-14d; H. influenzae B: 7-10d; N. meningitidis: 7d; Culture
negative: 10-14d; L. monocytogenes: 21d; Gram-negative enteric bacilli: 21d
ANATOMIC DEFECTS, NEUROSURGICAL COMPLICATIONS AND OPEN HEAD

TRAUMA
Etiology: S. aureus, S. epidermidis, Gram negative bacilli including Pseudomonas
Preferred Regimen:
PEDIATRICS ADULTS
Vancomycin 60mg/kg/d IV/IM div q6h Vancomycin 15-20mg/kg IV/IM q8-
PLUS Ceftazidime 150mg/kg/d div q8h 12h PLUS Ceftazidime 2g/d div q8h
DOT: 3-6 weeks
Comments:
For household contacts:
Hib meningitis: give same regimen as for patient
N. meningitides: give same regimen as for patient
For adults, dexamethasone should be started before or given with the first dose
of antibiotics at 0.15 mg/kg q6h IV x 2-4 days.
II. BRAIN ABSCESS
• Brain abscess is a focal collection of pus within the brain parenchyma. The
etiology may be trauma, direct spread of infection or hematogenous spread
from a distant site of infection.
• Imaging studies such as CT scan and MRI are necessary for diagnosis although
this cannot determine the etiology.
• Etiology and treatment depends on the source of infection.
IN THE PRESENCE OF DENTAL INFECTION:
Etiology: Streptococci (viridans and anaerobic), Fusobacterium, Bacteroides
Preferred Regimen:
PEDIATRICS ADULTS
Penicillin G 400,000U/kg/d IV/IM q6h Penicillin G 4MU IV/IM q4h PLUS
PLUS Ceftriaxone 100mg/kg/d IV/IM Ceftriaxone 2g IV q12h or
q12h (Max: 4 g/d) or Chloramphenicol 1g IV/IM q6h

Chloramphenicol 100mg/kg/d IV/IM q6h

DOT: unclear, usually 6-8 weeks.
Comments: Consult a neurosurgeon; aspiration of abscess is usually required if

lesion is >2.5 cm
IN THE PRESENCE OF CHRONIC OTITIS MEDIA, SINUSITIS, OR MASTOIDITIS
Preferred Regimen:
PEDIATRICS ADULTS
Ceftazidime 150mg/kg/d IV/IM q8h Ceftazidime 2g/d IV/IM q8h PLUS
PLUS Metronidazole 7.5mg/kg IV/IM Metronidazole 7.5mg/kg IV/IM q6h
q6h or 15mg/kg IV/IM q12h or 15mg/kg IV/IM q12h
IN THE PRESENCE OF HEAD TRAUMA:
Etiology: Streptococci (aerobic and anaerobic), H. influenzae, Gram-negative

enteric bacilli, Bacteroides sp, P. aeruginosa
Preferred Regimen:
PEDIATRICS ADULTS
Vancomycin 60mg/kg/d IV q6h Vancomycin 15-20mg/kg IV q8-12h
PLUS Ceftriaxone 100mg/kg/d IV/IM PLUS Ceftriaxone 2g IV q12h
q12h (Max: 4 g/d)
Comments:
If methicillin-sensitive S. aureus is documented, shift to oxacillin.
IN THE PRESENCE OF ENDOCARDITIS (NATIVE VALVE):
Etiology: S. aureus, aerobic streptococci, Gram-negative enteric bacilli
Preferred Regimen:
PEDIATRICS ADULTS
Ceftriaxone 100mg/kg/d IV/IM q12h Ceftriaxone 2g IV q12h PLUS
(Max: 4 g/d) PLUS Gentamicin 3-6mg/kg/d IV/IM q24h
Gentamicin 3-6mg/kg/d IV/IM q24h (If E. faecalis is documented, give q8h)
(If E. faecalis is documented, give q8h)
Comments:

IN THE PRESENCE OF ENDOCARDITIS (PROSTHETIC VALVE):
Etiology: S. viridans, S. aureus
Preferred Regimen:
PEDIATRICS ADULTS
Vancomycin 60mg/kg/d q6h IV PLUS Vancomycin 15-20mg/kg q8-12h PLUS
Gentamicin 3-6mg/kg/d IV/IM q24h Gentamicin 3-6mg/kg/day IV/IM q24h
(If E. faecalis is documented, give q8h) (If E. faecalis is documented, give q8h)
IN THE PRESENCE OF CONGENITAL HEART DISEASE:
Etiology: S. viridans, Haemophilus spp.
Preferred Regimen:
PEDIATRICS ADULTS
Ceftriaxone 100mg/kg/d IV/IM q12h Ceftriaxone 2g IV q12h PLUS
(Max: 4g/d) PLUS Metronidazole 7.5mg/kg IV q6h or 15
Metronidazole 7.5mg/kg IV q6h or 15 mg/kg IV q12h
mg/kg IV q12h
NO FOCUS
Etiology: S. pneumoniae, H. influenzae
Preferred Regimen:
1st line 2nd line
PEDIATRICS
Ceftriaxone 100mg/kg/d IV/IM q12h Penicillin G 400,000U/kg/d IV q6h
(Max: 4 g/d) PLUS PLUS
Metronidazole 7.5mg/kg/ IV q6h or 15 Chloramphenicol 100mg/kg/d IV
mg/kg IV q12h q6h
ADULTS
Ceftriaxone 2g IV q12h PLUS Penicillin G 4MU IV q4h
Metronidazole 7.5mg/kg IV q6h or 15 PLUS Chloramphenicol 1g IV q6h
mg/kg q12h
III. SPINAL ABSCESS
Etiology: S. aureus, Streptococci

Preferred Regimen:
PEDIATRICS ADULTS
Vancomycin 60mg/kg/d IV q6h Vancomycin 15-20mg/kg IV q8-12h

Comments:
IV. ENCEPHALITIS
• Encephalitis is an inflammation of the brain usually caused by viral infections.

The classic presentation is encephalopathy with diffuse or focal neurologic
symptoms, including the following: behavioral and personality changes, with
decreased level of consciousness, neck pain, stiffness, photophobia,
generalized or focal seizures.
• Findings of herpes simplex virus (HSV) infection in neonates may include the
following: herpetic skin lesions over the presenting surface from birth or with
breaks in the skin, oropharyngeal involvement, keratoconjunctivitis, seizure,
irritability, bulging fontanels. Severe signs include jaundice, hepatomegaly and
shock.
VIRAL INCLUDING, MEASLES, INFLUENZA, ENTEROVIRUSES, ARBOVIRUSES
Preferred Regimen: Supportive treatment
Comments:
Children should be immunized with measles vaccine at 9 months, and measles,
mumps, rubella (MMR), and varicella vaccines at 12 months. A booster of MMR is
given at 4-6 years old.
HERPES SIMPLEX
Preferred Regimen:
PEDIATRICS ADULTS
Aciclovir (<12 years): 20mg/kg IV Aciclovir 10 mg/kg IV infused over
infused over 1hour q8h 1hour q8h
DOT: 14-21 days
Comments: Early diagnosis and treatment is necessary.
V. FUNGAL MENINGITIS
• Candida may enter the central nervous system by hematogenous spread, at the
time of craniotomy, or through a ventricular shunt. Manifestations of Candida
meningitis may be similar to those of acute bacterial meningitis. Culture of the
CSF is the gold standard for diagnosis.
• Infection with the encapsulated yeast Cryptococcus neoformans can result in
harmless colonization of the airways, meningitis or disseminated disease,
especially in persons with defective cell-mediated immunity. Cryptococcal

meningitis is usually fatal without appropriate therapy, and death may occur
from 2 weeks to several years after symptom onset. The most common
symptoms include headache and altered mental status, personality changes,
confusion, lethargy, obtundation, and coma.
CANDIDA MENINGITIS
Preferred Regimen:
Amphotericin B deoxycholate 0.6-1 mg/kg/d IV over 2-6h
Start with test dose of 0.1 mg/kg/dose IV to a maximum dose of 1 mg over 20-60
min. If tolerated, initiate with 0.25 mg/kg over 2-6h, and increase by 0.25 mg/kg
daily.
DOT: several weeks until resolution of CSF, radiographic and clinical abnormalities
Comments:
BUN, creatinine and K+ should be monitored at least weekly. Removal of shunts is
recommended.
CRYPTOCOCCAL MENINGITIS (NON-AIDS)
Preferred Regimen:
Induction Phase Consolidation phase
Amphotericin B Fluconazole 200mg PO qd
deoxycholate 0.7-1 mg/kg/d DOT: 10-12 weeks after CSF culture is
IV over 2-6h negative
DOT: until patient is afebrile OR (for less severely ill)
and cultures are negative Fluconazole
(approximately 6 weeks) P: 6-12mg/kg/d qd
A: 400mg qd
DOT: 10-12 weeks after CSF culture is negative
Comments:
The ideal regimen includes flucytosine in the induction phase, but this drug is not
available in the Philippines. If CSF pressure >25 cm H20, repeat the lumbar tap to
drain fluid and control pressure.
CRYPTOCOCCAL MENINGITIS ASSOCIATED WITH HIV/AIDS
Preferred Regimen:
Induction Phase Consolidation phase Suppression (chronic
maintenance therapy)
Amphotericin B Fluconazole Fluconazole
deoxycholate 0.7-1 P: 6-12mg/kg/d IV qd P: 3mg/kg/d IV qd
mg/kg/d IV over 2-6h A: 400mg IV or po qd A: 200mg PO qd

PLUS Fluconazole DOT: at least 8 weeks DOT: at least 1 year

P: 6-12mg/kg/d IV qd
A: 800mg IV/PO qd
DOT: at least 2 weeks
Comments:
Induction: Defer ART to allow for 5 weeks of antifungal therapy. Repeat lumbar
tap daily until signs and symptoms of increased intracranial pressure consistently
improve.
Consolidation: Begin after successful induction therapy (defined as substantial
clinical improvement and negative CSF culture on repeat tap).
Suppression: May stop once CD4 > 100 cells/μL x at least 3 months and with
undetectable viral load.
REFERENCES:
• Baddour LM, Flynn PM, Fekete T. Infections of central nervous system shunts and other
devices. UptoDate 2016. Accessed at: www.uptodate.com/contents/infections-of-central-
nervous-system-shunts-and-other-devices.
• Bravo LC, Gatchalian SR, Gonzales ML, Maramba-Lazarte CC, Ong-Lim AT, Pagcatipunan
MR, delos Reyes CA. Hand book of Pediatric Infectious Diseases 2012, 5th edition. Section
of Infectious and Tropical Diseases, Manila 2012, pp 28-30.
• Centers for Disease Control and Prevention. 2013. Prevention and Control of
Meningococcal Disease. Recommendations of the Immunization Practices (ACIP). MMWR
2013; 62 (No.2).
• Chaudhuri, A., Martin PM, Kennedy PGE, Seaton RA, Portegies P, Bojar M, Steiner I for the
EFNS Task Force. 2008. EFNS guideline on the management of community meningitis:
report of an EFNS Task Force on acute bacterial meningitis in older children and adults.
Europ J Neurol 2008; 15: 649-659.
• Edwards MS, Baker CJ. Bacterial meningitis in the neonate: Treatment and outcome.
UptoDate 2016. Accessed from http://www.uptodate.com/contents/bacterial-meningitis-
in-the-neonate-treatment-and-outcome on January 13, 2016.
• Frazier JL, Ahn ES, Jallo GI, Management of Brain Abscesses in Children. Neurosurg. Focus
2008; 24:1-10.
• Furyk, J.S., O. Swann, and E. Molyneux. Systematic review: neonatal meningitis in the
developing world. Trop Med Int Health 2011;16(6): 672-679.
• Gilbert DN, Chambers HF, Eliopoulis GM, Saag MS, Pavia AT, Black DB, Freedman DO, Kim
K, Schwartz BS editors. Sanford Guide to Antimicrobial Therapy 2016
• Kaplan SL, Bacterial meningitis in children older than one month: Treatment and prognosis.
UptoDate 2016. Accessed from http://www.uptodate.com/contents/bacterial-meningitis-
in-children-older-than-one-month-treatment-and-prognosis on January 13, 2016.
• Maramba-Lazarte CC, Bunyi MAC, Gallardo EE, Lim JG, Lobo JJ, Aguilar CY. Etiology of
neonatal sepsis in five urban hospitals in the Philippines. PIDSP J 2011; 12(2): 75-85.

DENTAL AND ORAL INFECTIONS
I. DENTAL AND ORAL INFECTIONS
A. Buccal Cellulitis
• Seen in children <5 years old

• Usually with a history of a recent upper respiratory tract infection or sinusitis.
Etiology: H. influenzae, S. pneumoniae
Preferred Regimen:
1st line: 2nd line:
Ceftriaxone 50mg/kg IV q24h Amoxicillin-clavulanate 45 mg/kg/d
(amoxicillin component) PO div bid
DOT: 7-14d
Comments:
There has been a marked decrease in incidence in areas with universal H.
influenzae immunization. Manifests as marked cheek swelling with trismus and
systemic symptoms.
B. Herpes Simplex Virus Gingivostomatitis
This usually self-limiting disease may cause significant mouth discomfort, fever,
lymphadenopathy, and oropharyngeal vesicular eruptions leading to difficulty in
eating and drinking. This may lead to dehydration in young children and may
require hospitalization.
Etiology: Herpes simplex virus1 and 2
Preferred Regimen:
PEDIATRICS ADULTS
Aciclovir 15 mg/kg q8h x 5-7d Valaciclovir 2g PO q12h x 2 doses
DOT: 7d
Comments:
Treatment is generally not recommended in immunocompetent patients.
Paracetamol may be used as an analgesic, but aspirin should be avoided to prevent
Reye syndrome. One third would have recurrent lesions and are commonly
referred to as cold sores.

C. Oral candidiasis
Also called oral thrush, this condition is caused by an overgrowth of Candida. This
may be triggered by any condition which would depress the immune system
(diabetes, malignancy, immunodeficiency, AIDS, corticosteroids, radiation, etc.)
or intake of antibiotics
Etiology: Candida albicans
Preferred Regimen:
PEDIATRICS ADULTS
Nystatin oral suspension 100,000 Nystatin oral suspension 100,000
U/mL, 4mL qid OR Miconazole oral U/ml, 4mL qid OR Miconazole oral gel
gel 2%, apply to affected area qid 2%, apply to affected area qid OR
Fluconazole 100-200 mg PO qd
DOT: 7-14d
Comments:
Recurrent infections may be the first signs of HIV infection. Fluconazole is
preferred for moderate to severe disease.
II. ODONTOGENIC INFECTIONS
A. Dentoalveolar infection or peri-apical abscess
Abscesses may form because of extension of microorganisms through the root

apex. Radiographic evidence of bone destruction may take 10-14 days to develop.
Infections may spread through the tissues causing cellulitis and present with
fever, swollen face, pain and malaise.
Etiology: S. mutans, Actinomyces, Fusobacterium, Prevotella sp, Poryphoromonas

and other Anaerobes
Preferred Regimen:
1st line 2nd line
PEDIATRICS
Ampicillin-sulbactam 200-400 mg Clindamycin 10mg/kg PO q8h
IV q6h (ampicillin component) OR
Amoxicillin-clavulanate 45 mg/kg/d bid
(amoxicillin component)
ADULTS
Ampicillin-sulbactam 3g IV q6h OR Clindamycin 300mg PO q8h
Amoxicillin-clavulanate 875/125mg bid

DOT: about 7-14d, until local inflammation has resolved completely.
Comments:
Dental consult is needed because deep periodontal scaling or extraction of the
tooth is necessary to eliminate the infected pulp. Antibiotic treatment is only
necessary if any of the following are present: acute onset facial or oral swelling,
swelling inferior to the mandible, trismus, dysphagia, lymphadenopathy, fever
>38.3oC, or osteomyelitis. Initial IV therapy is preferred and may step down to oral
therapy once with clinical improvement in 3-5 days.
B. Acute gingivitis
Rarely requires systemic antimicrobial therapy. Antiseptic rinses are adequate in

most cases. In patients with rapidly advancing disease, severe pain or HIV
infection, systemic therapy may be necessary.
Etiology: Oral anaerobes, Spirochetes
Preferred Regimen: Chlorhexidine 0.12% oral rinse

PEDIATRICS ADULTS
Penicillin Penicillin VK 500mg PO q6h PLUS
<12 yrs.: 50-75mg/kg/d PO q6-8h Metronidazole 500mg PO q8h OR
12 yrs.: 250-500mg PO q6-8h PLUS Clindamycin 300mg PO/IV q8h OR
Metronidazole 30mg/kg/d in div Amoxicillin-clavulanate 875/125mg
doses q6h (Max: 4 g/d) bid
DOT: 7-10d, if systemic antibiotics are necessary
Comments:
Acute gingivitis in children may be induced by plaque, or associated with puberty,
blood dyscrasias, nutritional deficiency, or other infections such as herpes or fungi.
C. Acute necrotizing ulcerative gingivitis
Signs and symptoms includes foul breath, gingival pain, malaise, thick ropy saliva,
with or without fever. On examination of the oral cavity, the gingiva is edematous
and ulcerated with a pseudomembrane on the interdental papillae. The condition
is not contagious.
Etiology: Oral anaerobes, Spirochetes
Preferred Regimen:
Penicillin VK 500mg PO q6h PLUS Metronidazole 500mg PO q8h
OR Clindamycin 300mg PO/IV q8h OR Amoxicillin-clavulanate 875/125 mg bid
DOT: 10d

Comments:
Also called trench mouth or Vincent’s angina. Usually found in older adolescents
and adults. Antibiotic therapy should be followed within a few days by localized
gingival curettage by a dentist and oral rinses with 0.5% hydrogen peroxide or
0.12% chlorhexidine.
D. Juvenile periodontitis
This condition occurs in otherwise healthy children and is localized to the molar
and incisor regions. Deep gingival pocketing and bone resorption occur and may
cause tooth loss in this area.
Etiology: Aggregatibacter (Actinobacillus) actinomycetemcomitans,

Capnocytophaga
Preferred Regimen:
<8y old: >8y old:
Metronidazole 50mg/kg/d PO q8h Doxycycline 200mg PO
DOT: 7d
Comments:
Affects children 10-20 years old. Dental consult is necessary; it can usually be
controlled with root debridement and plaque control only. If condition does not
respond to conservative management then antibiotics should be started.
E. Periodontal abscess
This condition manifests as a red, fluctuant swelling of the gingiva, which is

extremely tender to palpation. The abscess is always in communication with a
periodontal pocket.
Etiology: Streptococcus mutans, Fusiform, Anaerobes
Preferred Regimen:
1st line 2nd line
PEDIATRICS
Amoxicillin-clavulanate 45 mg/kg/d Clindamycin 10mg/kg PO q8h
(amoxicillin component) bid
ADULTS
Amoxicillin-clavulanate 875/125mg bid Clindamycin 150-300mg PO q8h
DOT: 7d

Comments:
Dental consult is needed because drainage of loculated pus should be performed.
After abscess resolution, infected pulpal tissues should be removed by subgingival
scaling and root planing. Antibiotic treatment is only necessary if any of the
following are present: acute onset facial or oral swelling, swelling inferior to the
mandible, trismus, dysphagia, lymphadenopathy, fever >38.3oC, or osteomyelitis.
F. Pericoronitis
Microorganisms and debris may be impacted under the soft tissue overlying the
crown of the tooth in a third molar or any erupting permanent teeth. If the natural
drainage is blocked, this may lead to infection of adjacent soft tissues and fascial
spaces.
Etiology: Prevotella, Porphyromonas sp, Treponema denticola
Preferred Regimen:
Penicillin VK 500mg q6h OR Amoxicillin 500mg q8h
DOT: 7d
Comments:
Mainstays of treatment include saline gargle, maintenance of good oral hygiene,
pain management and local incision and drainage by a dentist. Antibiotic
treatment is only necessary for systemic signs such as fever and
lymphadenopathy.
G. Ludwig’s Angina
It is an aggressive, rapidly spreading, bilateral cellulitis of the submandibular

space which includes the sublingual space and the mylohyoid. The infection is life-
threatening due to the possibility of asphyxia and aspiration pneumonia. Patient
may present with fever, mouth pain, stiff neck, drooling and dysphagia. Typically,
there is no lymphadenopathy, but with tender, symmetric, “woody“induration.
Etiology: S. mutans, Actinomyces, Fusobacterium, Prevotella sp, Poryphoromonas

and other anaerobes
Preferred Regimen:
PEDIATRICS ADULTS
Ampicillin-sulbactam 200-400mg IV Ampicillin-sulbactam 3g IV q6h or
q6h (ampicillin component) or Penicillin G 2-4 MU IV q4-6h
Penicillin G 250,000- PLUS
400,000U/kg/day in 4 div doses PLUS Metronidazole 500mg IV q6-8h or
Clindamycin 600mg IV q6-8h

Metronidazole 22.5-40mg/kg/day IV
in 3 div doses or
Clindamycin 17-25mg/kg/d PO in 3-4
equally div doses
DOT: 2-3 weeks until clear evidence of clinical improvement is present, and fever
and leukocytosis have disappeared. If complications arise, longer courses may be
necessary.
Comments:
Mainstays of treatment include management of the airway, empiric antibiotics.
Surgery is necessary only if abscesses are identified by imaging. Antibiotic
treatment is only necessary for systemic signs such as fever and
lymphadenopathy. Immunocompromised patients may have MRSA or gram-
negative infections. Broad spectrum coverage is required for these patients.
REFERENCES:
• Antimicrobial Resistance Surveillance Laboratory, Department of Health. Antimicrobial
Resistance Surveillance Program 2015 Annual Report, Manila, Philippines 2016. Accessed
at http://arsp.com.ph/wp-content/uploads/2016/06/2015-ARSP-annual-report-
summary_1.pdf on September 7, 2016
MR, delos Reyes CA. Hand book of Pediatric Infectious Diseases 2012, 5th edition. Manila:
Section of Infectious and Tropical Diseases; 2012.
K, Schwartz BS editors. Sanford Guide to Antimicrobial Therapy 2016. VA: Antimicrobial
Therapy, Inc.; 2016.
• Simos C, Gonzalez BE. Infections of the Oral Cavity. Feign and Cherry’s Textbook of Pediatric
Infectious Diseases, 7th edition. Volume 1, Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ,
Hotez PJ. Elsevier, Philadelphia, 2014. pp 140-155.
• Levi ME, Eusterman VD. Oral Infections and Antibiotic Treatment. Otolaryngol Clin N Amer
2011; 44:57-78.
• Do DHN, Martin JT. Common Dental Infections in the Primary Care Setting. Am Fam
Physician 2008; 77(55): 797-802.
• Pari A, Ilango P, Subbareddy V, Katamreddy V, Parthasarthy H. Gingival diseases in
childhood—a review. Journal of clinical and diagnostic research 2014;8 (10): Ze01–4.
• Chow AW. Complications, diagnosis and treatment of odontogenic infections in UpToDate,
Calderwoood SB, Bloom A (Eds), UpToDate, Waltham, MA. (Accessed on February 23
2017.)
• Chow AW. Submandibular space infection (Ludwig’s Angina) in UpToDate, Calderwoood
SB, Bloom A (Eds), UpToDate, Waltham, MA. (Accessed on February 23 2017.)
• Chow AW. Epidemiology, pathogenesis and clinical manifestations of odontogenic
infections in UpToDate, Calderwoood SB, Bloom A (Eds), UpToDate, Waltham, MA.
(Accessed on February 23 2017.

GASTROINTESTINAL TRACT INFECTIONS
I. ACUTE DIARRHEA AND GASTROENTERITIS
A. Acute Diarrhea in Children
Acute diarrhea is defined as diarrhea lasting less than 14 days. Mainstay of

treatment is to give fluids, zinc supplements, and food.
Classification of dehydration status of children 2 months to 5 years of age (IMCI
2014):
• Severe dehydration (when 2 of the following signs are present)
- Lethargic or unconscious
- Sunken eyes
- Not able to drink or drinking poorly
- Skin pinch goes back very slowly
• Some dehydration (when 2 of the following signs are present)
- Restless, irritable
- Sunken eyes
- Drinks eagerly, thirsty
- Skin pinch goes back slowly
• No dehydration (when there are not enough signs to classify patient’s
status as some or severe)
Etiology:
Community and hospital-based based studies in children < 5 years (Saniel et al
1982-84, Lucero et al 1982-83, Carlos et al 1989):
Salmonella: 10-15%, ETEC: 9-15%, Rotavirus: 7-17%
Etiology of acute diarrheas in developing countries expressed in weighted

annual incidence per 100 child years (Nelson’s Textbook of Pediatrics, 20th
edition, 2015):
<12 months: Rotavirus: 2.1-10.1, Enterotoxigenic Escherichia coli (ETEC): 0.7-
3.6, Cryptosporidium: 0.7-5.4
12-23 months: Rotavirus: 1.6-12.4, ETEC: 0.7-2.8, Shigella: 0.5-8.5
24-59 months: Rotavirus: 0.3-3.5, Shigella: 0.2-3.1, Vibrio cholera 01: 0.2-1.8
Preferred Regimen:
IMCI protocol Neonate up to 2 months: Child 2 months to 5 years:
Suspected Ciprofloxacin 30mg/kg/d PO Ciprofloxacin 30 mg/kg/d
dysentery: div 2 doses x 3d div 2 doses x 3d
Suspected Erythromycin 250mg PO qid
cholera: _____ x 3d OR Tetracycline 250mg
PO qid x 3d

Recommendations of Feigin and Cherry:

Indication Preferred Regimen:
Suspected antibiotic-associated Metronidazole 30mg/kg/d IV or PO div 4
colitis presenting as severe doses x 10-14d OR
disease or with prolonged Vancomycin 40mg/kg/d PO div 4 doses
symptoms especially for patients with severe disease
Suspected nontyphoidal Ciprofloxacin 30mg/kg/d IV div 2 doses x
Salmonella in the setting of 10-14d OR Azithromycin 6mg/kg/d PO qd x
severe diarrhea in infants less 5d OR Ceftriaxone 75-100 mg/kg/d IV q24h
than 6 months of age, x 14d
malnourished and
immunocompromised children
Campylobacter Azithromycin 10mg/kg/d PO x 3d OR
Erythromycin 40mg/kg/d PO div 4 doses x
5d
Entamoeba histolytica Metronidazole 35-50mg/kg/d PO div 3
doses x 7-10d
Giardia Metronidazole 15mg/kg/d PO div 3 doses x
5-7d
Cyclospora Trimethoprim-sulfamethoxazole 10 mg
TMP/50mg SMX/kg/d PO div 2 doses x 7-
10d
Comments:
For children with severe dehydration living in an area with reported cases of
cholera, give antibiotic for cholera. For cases of acute diarrhea with dysentery
(blood in the stool), give ciprofloxacin for 3 days. For suspected antibiotic-
associated colitis, mild disease does not warrant antibiotic treatment since
symptoms resolve within 7-10 days after discontinuing precipitating antibiotics.
Probiotic treatment of children with C. difficile diarrhea has not been well studied.
Immunization of infants starting at 6 weeks of age with either of 2 available live

attenuated rotavirus vaccines is recommended to afford protection against severe
rotavirus disease. The monovalent human rotavirus vaccine is given as a 2-dose
series and the pentavalent human bovine rotavirus vaccine is given as a 3-dose
series. Oral vancomycin is not available locally.
B. Gastroenteritis (infectious diarrhea) In adults
MILD DIARRHEA (≤3 unformed stools/day; minimal associated symptomatology)
Preferred Regimen: Oral Hydration

MODERATE DIARRHEA (3 - 4 unformed stools/day; with or without systemic

symptoms)
Preferred Regimen: Oral or Parenteral Hydration
Comments:
Try to make specific diagnosis, especially in patients with severe diarrhea or
systemic symptoms.
SEVERE DIARRHEA (≥ 6 unformed stools/day ± fever, tenesmus, blood or fecal

leukocytes)
Etiologies: Bacterial: Shigella sp., Salmonella sp., C. jejuni, C. difficile (Toxin

positive) E. coli (enterotoxigenic, enteroaggregative, Shiga-toxin producing) K.
oxytoca (Toxin producer); Parasitic: Giardia lamblia, E. histolytica,
Cryptosporidium
Preferred Regimen:
Empiric therapy: Specific therapy:
Ciprofloxacin 500mg PO q12h OR Entamoeba histolytica:
Levofloxacin 500mg PO q24h x 3–5d Metronidazole 500-750mg PO tid x 7-
OR Azithromycin 500mg PO q24h for 10d OR Tinidazole 2g PO qd x 3d
3d (preferred for Campylobacter) Vibrio cholera:
OR Cotrimoxazole DS PO bid x 3–5d Doxycycline 300mg x 1 dose OR
Tetracycline 500mg qid X 3d OR
Cotrimoxazole DS PO bid X 3d
Shigella species:
Cotrimoxazole DS PO bid X 3d OR
Ciprofloxacin 500mg PO bid X 3d
C. Primary spontaneous bacterial peritonitis (SBP)
Characterized by a patient with cirrhosis, ascites, fever, and ≥ 250 neutrophils/μl

of ascitic fluid.
Etiology:
P: S. pneumoniae (30-50%; most common), E. coli (25-40%), Staphylococci (2-4%),
Group A Streptococcus, Enterococci, Klebsiella pneumoniae
A: Enterobacteriaceae, S. pneumoniae, Enterococcus sp., Anaerobes, Extended
spectrum β-lactamase (ESBL) positive Klebsiella sp. reported

Preferred Regimen:
PEDIATRICS ADULTS
S. pneumoniae: 1st line:
Cefotaxime 200mg/kg/d IV div 4 or 6 Cefotaxime 2g IV q8h (q4h, if life-
doses OR Ceftriaxone 100mg/kg/d IV threatening infection) OR
div 1-2 doses Ampicillin-sulbactam 3g IV q6h OR
If penicillin sensitive S. pneumoniae: Piperacillin-tazobactam 4.5g IV q6h
aqueous Penicillin G 200,000-300,000 (or 4-hour infusion of 4.5g q8h) OR
U/kg/d IV in 6 div doses x 10-14d Ceftriaxone 2g IV q24h OR
Gram-negative bacilli: Ertapenem 1g IV q24h
Cefotaxime 200mg/kg/d IV div 4 or 6
doses x 10d to 3 weeks OR 2nd line:
Ceftriaxone 100mg/kg/d IV div 1-2 If resistant E. coli, Klebsiella species
doses x 10d to 3 weeks WITH or (e.g., ESBL): Meropenem 1g IV q8h
WITHOUT DOT: Unclear. Treat at 5 days and
Gentamicin 3-7.5mg/kg/d IV div 3 perhaps longer if documented
doses OR Monotherapy with the bacteremia
following:
Piperacillin tazobactam 300mg/kg/d IV
div 3 doses (piperacillin component) or
Ampicillin-sulbactam 100-200mg/kg/d
div 4 doses (ampicillin component
Comments:
Perform analysis (check bleeding parameters first), Gram stain and culture of
peritoneal fluid to distinguish primary from secondary peritonitis. Ceftriaxone may
cause bile sludge in patients with jaundice or cirrhosis. Maintain fluid and
electrolyte balance. Do surgical consult. Start antimicrobials as soon as possible.
Generally managed medically. Duration of antibiotic therapy depends on clinical
course of the patient. Probiotics have no use in the adjunctive treatment.
Antibiotic Prophylaxis: Indications:

1. Patients with cirrhosis Variceal or upper GI bleeding
Norfloxacin 400mg PO q12h x
7d OR Ceftriaxone 1g IV qd x
7d
2. Prophylaxis of SBP • Low protein ascites (< 15 g/L)
Norfloxacin 400mg/d PO OR • Advanced liver failure (Child-Pugh score
Ciprofloxacin 500 mg/d PO > 9 points with serum bilirubin > 3
DOP for SBP: mg/dL) and/or renal dysfunction
Until liver transplantation, (serum creatinine > 1.2 mg/dL, BUN >
death, resolution of ascites or 25 mg/dL and/or serum sodium < 130
mEq/L)

improvement in liver function • Prior episode of SBP

to a compensated state.
D. Secondary peritonitis
Etiology: Usually polymicrobial consisting of anaerobes and facultative gram-

negative bacilli: Bacteroides fragilis group, Peptostreptococcus, E. coli, Klebsiella,
P. aeruginosa, Enterococcus
Preferred Regimen:
Metronidazole 22.5-40mg/kg/d IV div 3 doses PLUS Cefotaxime 200mg/kg/d IV
div 4 or 6 doses OR
Monotherapy with the following antibiotics:
Piperacillin tazobactam 300mg/kg/d IV div 3 doses (piperacillin component) OR
Meropenem 30-60mg/kg/d IV div 3 doses
DOT: Antibiotics are generally given for 5-10d but the primary basis for duration
of antibiotic treatment is the patient’s clinical course.
Comments:
Patient may require either immediate surgery to control the source of
contamination and to remove necrotic tissue, blood and intestinal contents from
the peritoneal cavity or a drainage procedure if a limited number of large
abscesses can be shown.
E. CAPD-associated peritonitis
Infectious complication of chronic ambulatory peritoneal dialysis (CAPD)
PEDIATRICS:

Gram-positive organisms, Vancomycin 45-60mg/kg/d IV or
coagulase negative intraperitoneal in 3-4 doses PLUS Gentamicin
staphylococci, S. aureus (30- 3-7.5mg/kg/d IV div 3 doses
45%), Enterobacteriaceae
(20-30%)
Ventriculo-peritoneal shunt Vancomycin 45-60mg/kg/d IV or
peritonitis: intraperitoneal div 3-4 doses
Coagulase-positive/negative PLUS for Gram-negative infections
Staphylococci Cefotaxime 200mg/kg/d IV div 4 or 6 doses
• Gram-negative bacilli OR
Ceftriaxone 100mg/kg/d IV div 1 or 2 doses
OR

Ceftazidime 200-300mg/kg/d div 3 doses OR

Meropenem 30-60mg/kg/d div 3 doses
DOT: generally, 10d but the primary basis for DOT is the patient’s clinical course.
ADULTS:

Gram-positive cocci For Gram-positive cocci:
(45%), Vancomycin added to the dialysis fluid.
Gram-negative bacilli For Gram-negative bacilli:
(15%), Cefepime 2g IV q8–12h OR
Mixture (1%), Ceftazidime 3g loading dose intraperitoneal (IP),
Fungi (2%), then 1-2g IP q24h or 2g IP q48h OR
M. tuberculosis (0.1%) Meropenem 1g IV q8h OR
Aztreonam 1–2g IV q6–8h OR
Ciprofloxacin 400mg IV q12h OR
Amikacin 15–20mg/kg IV q24h
Add an antifungal only if yeast seen on Gram stain.
Comments:
A positive Gram stain will help guide initial therapy. If polymicrobic gram-negative
flora is cultured, consider possibility of catheter-induced bowel perforation,
and/or concomitant underlying GI pathology (e.g., dead bowel). Infection almost
always limited to abdominal cavity; complicating bacteremia is rare. Hence,
usually treat by adding drugs to dialysis fluid; if bacteremia documented or likely,
treat via IV route.
The following are the recommendations based on the Consensus Guidelines for
Prevention and Treatment of Catheter-related infections and peritonitis in
pediatric patients receiving peritoneal dialysis (2012 update):
• Empiric diagnosis of PD-related peritonitis can be made if the effluent WBC
count > 100/mm3 and at least 50% of the WBCs are polymorphonuclear
leukocytes. Effluent should be centrifuged and sediment should be cultured.
• Antibiotics for the treatment of bacterial peritonitis should be administered by
the intraperitoneal route. Beta lactam antibiotics should be administered
continuously.
• Center-specific antibiotic susceptibility patterns should guide selection of
empiric antibiotic therapy although the ISPD recommends cefepime as empiric
treatment. Refer to a specialist for co-management.
Higher cure rate is achieved with VP shunt removal.

F. Hepatitis A
Etiology: Hepatitis A virus
Preferred Regimen:
PEDIATRICS ADULTS
No antiviral treatment is No antiviral treatment is recommended.
recommended Give supportive measures.
Comments:
P: Hepatitis A vaccine is given intramuscularly as a 2-dose series at a minimum age
of 12 months. A second dose is given at least 6 months from the first dose.
A: If within 2 weeks of exposure, Hepatitis A vaccination:
• Monovalent Hepatitis A vaccine
a. 720 ELISA units/ml IM - 2doses 1 month apart
b. 1440 ELISA units/ml IM single dose
• Booster dose between 6 & 12 months after initiation of primary course is
recommended to ensure long term antibody titers.
(Handbook on Adult Immunization for Filipinos, 2012)
A single dose of immunoglobulin 0.02 mL/kg IM is protective if administered

within 2 weeks of exposure, but is not locally available. Immunoglobulin might be
preferred over Hepatitis A vaccination among seronegative individuals with
significant underlying liver disease (Sanford Guide to Antimicrobial Therapy,
2016).
G. Hepatitis B
• Patients with Hepatitis B (HBV) are usually asymptomatic.

• When symptomatic, common complaints include: fatigue, nausea, anorexia,
myalgias, arthralgias, asthenia, weight loss (except where ascites).
• There is poor correlation between symptoms and disease stage or
transaminase elevation
Etiology: Hepatitis B virus
PEDIATRICS
Preferred Regimen: Refer to a specialist.
Comments:
Hepatitis B vaccine is given intramuscularly. The first dose is given at birth or within
the first 12 hours of life. The minimum interval between doses is 4 weeks. The final
dose is administered not earlier than age 24 weeks. Another dose is needed if the
last dose was given at age < 24 weeks.

For preterm infants, if born to HBsAg (-) mothers and medically stable, the first
dose of HBV may be given at 30 days of chronological age regardless of weight,
and this can be counted as part of the 3 dose primary series. Another dose of HBV
is needed for those < 2 kg whose 1st dose was received at birth.
For infants born to HBsAg (+) mothers, administer HBV and HBIG (0.5ml) within
12hours of life. HBIG should be administered not later than 7 days of age, if not
immediately available.
For infants born to mothers with unknown HBsAg status, if birth weight is >2 kg,
administer HBV within 12h of birth and determine mother’s HBsAg status as soon
as possible. If HBsAg (+), administer HBIG not later than 7 days of age. If with birth
weight of <2 kg, administer HBIG in addition to HBV within 12h of life.
Referral to a specialist is recommended for management of hepatitis cases.
ADULTS
Preferred Regimen: Refer to a specialist.
The following are key indicators for treatment: HBeAg status, HBV viral load (HBV
DNA), elevated liver enzymes (ALT level), cirrhosis. For HBeAg+ patients treatment
is typically deferred for 3-6 months to observe spontaneous seroconversion from
HBeAg+ to negative. [Sanford]
Comments:
Vaccination:
Recombinant Hepatitis B Vaccine (20μg/mL) IM 3 doses at 0,1,6 months
Combined Hepatitis A (720 ELISA units) & B (20 μg/mL recombinant) – 3 doses IM
at 0, 1, 6 months (Handbook on Adult Immunization for Filipinos, 2012)
H. Hepatitis C
• Usually asymptomatic (elevated transaminases).

• When symptomatic, common complaints include fatigue, nausea, anorexia,
myalgias, arthralgias, asthenia, weight loss (except where ascites).
• If symptomatic, usually abates in days to weeks; rarely associated with
hepatic failure.
• 75-85% of persons with acute infection progress to chronic HCV.

Hepatitis C virus Specialist referral RECOMMENDED.
Comments: No recommended prophylaxis; immune serum globulin not effective.

I. Liver Abscess
• Fever, right upper quadrant tenderness

• Findings consistent with single or multiple abscesses on abdominal ultrasound
or CT
PEDIATRICS

50% polymicrobial Ampicillin-sulbactam 100-200mg/kg/d IV div 4
S. aureus doses (ampicillin component) (Max: 8g) or
Streptococcus sp. Piperacillin-tazobactam 300mg/kg/d IV div 3
E. coli doses (piperacillin component) (Daily adult dose 9-
K. pneumoniae, 16 g) or
Salmonella Ceftriaxone 100mg/kg/d IV in 1-2 doses (daily
Anaerobic organisms adult dose: 2-4 g)
(Nelson’s Textbook of PLUS
Pedia, 2015) Metronidazole 30-50 mg/kg/d IV div 3 doses (daily
In developing countries, adult dose: 0.75-2.25 g) for 2-3 weeks then shift to
may consider E. oral to complete 4-6 weeks.
histolytica and Toxocara For hepatic abscess secondary to E. histolytica:
canis Metronidazole 30-50mg/kg/d IV div 3 doses x 10d
FOLLOWED BY
Intraluminal amoebicides such as Diloxanide (2nd
line agent) to cure luminal infection
ADULTS

Enterobacteriaceae Pending determination of bacterial versus
(esp. Klebsiella sp.) amoebic liver abscess:
Bacteroides sp. Metronidazole 30-40mg/kg/d div 3 doses IV q8h
Enterococcus sp. or 500mg PO q6-8h
E. histolytica PLUS
Fusobacterium Ceftriaxone 1-2g q24h IV or
necrophorum Piperacillin-tazobactam 4.5g IV q4-6h or
(Lemierre's) Ciprofloxacin 400mg IV q12h OR 750 mg PO or
Levofloxacin 750mg PO/IV q24h or
If amoeba serology is positive:
Metronidazole 750mg IV/PO tid x 10d

Comments:
If MRSA is suspected, start on anti-MRSA regimen (refer to section on treatment
of MRSA infections). Ceftriaxone may cause bile sludge in patients with jaundice
or cirrhosis. Serological tests for amebiasis should be done on all patients. For
anaerobic or mixed infections piperacillin-tazobactam, ertapenem (or other
carbapenem) are sufficiently active alone and metronidazole may be
discontinued.
J. Gallbladder infection

Acute acalculous Piperacillin tazobactam 300mg/kg/d IV div 3
cholecystitis is uncommon in doses (piperacillin component) OR
children and usually caused Ampicillin-sulbactam 100-200mg/kg/d div 4
by an infection secondary to doses (ampicillin component) OR
Groups A and B Streptococci, Cefotaxime 200mg/kg/d IV div 4-6 doses
Gram-negative bacilli (like WITH or WITHOUT
Salmonella) and Gentamicin 3.75mg/kg/d IV div 3 doses x 14-
Leptospirosis interrogans. 21d OR
Amikacin 15-22.5mg/kg/d div 3 doses x 14-21d
Antibiotic therapy should
cover for gut luminal flora
(E. coli, Klebsiella,
Enterococcus).
Comments:
Laparoscopic cholecystectomy is the most common surgical treatment for acute
calculous or acalculous cholecystitis in over 95% of pediatric cases. Other
treatment options when laparoscopic or open cholecystectomy is not feasible
include cholecystostomy.
II. COMPLICATED INTRA-ABDOMINAL INFECTIONS
• Complicated intra-abdominal infection extends beyond the hollow viscus of

origin into the peritoneal space and is associated with either abscess
formation or peritonitis.
• Contamination of peritoneal cavity by bowel flora due to bowel perforation,
ruptured appendix, ruptured diverticula, ischemic bowel, leaking surgical
anastomosis, intra-abdominal abscess or other like conditions.
• Common pathogens: Escherichia coli, Klebsiella pneumoniae, Pseudomonas
aeruginosa, Enterobacter cloacae, Acinetobacter baumannii
(Antibiotic management of complicated intra-abdominal infections in adults:
The Asian perspective, Annals of Medicine and Surgery, 2014)

A. Biliary complicated intra-abdominal infections
Clinical Setting: Preferred Regimen:

Community-acquired acute Cefazolin 1–2g IV q8h OR
cholecystitis of mild-to- Cefuroxime 1.5g IV q8h OR
moderate severity Ceftriaxone 1–2g IV q12–24h
Community-acquired acute 1st line: Piperacillin-tazobactam 4.5g IV q6h
cholecystitis of severe 2nd line: Metronidazole 500mg IV q8–12h
physiologic disturbance, PLUS Ciprofloxacin 400mg IV q12h or
advanced age, or Levofloxacin 750mg IV q24h or
immunocompromised state Cefepime 2g IV q8–12h
Acute cholangitis following 1st line: Meropenem 1g IV q8h
bilio-enteric anastamosis of 2nd line: Metronidazole 500mg IV q8–12h
any severity. PLUS Ciprofloxacin 400mg IV q12h or
Health care–associated Levofloxacin 750mg IV q24h or
biliary infection of any Cefepime 2g IV q8–12h
severity (IDSA, 2010).
Comments:
Obtain surgical consult for possible gallbladder removal. Patients undergoing
cholecystectomy for acute cholecystitis should have antimicrobial therapy
discontinued within 24 hours unless there is evidence of infection outside the wall
of the gallbladder (IDSA Complicated Intra-abdominal Infection Guidelines, CID
2010:50).
B. Extra-biliary complicated intra-abdominal infections

Mild-to-moderate 1st line:
severity: perforated or Cefoxitin 2g IV q6h OR
abscessed appendicitis and Ertapenem 1g IV q24h
other infections of mild-to- 2nd line:
moderate severity Metronidazole 500mg IV q8–12h
PLUS
Cefazolin 1–2g IV q8h or
Cefuroxime 1.5g IV q8h or
Ceftriaxone 1–2g IV q12–24h or
Cefotaxime 1–2g IV q6–8h or
Ciprofloxacin 400mg IV q12h or
Levofloxacin 750mg IV q24h
High risk or severity: 1st line:
severe physiologic Piperacillin-tazobactam 4.5g IV q6h OR
disturbance, advanced age, Meropenem 1g IV q8h

or immunocompromised 2nd line:

state Metronidazole 500mg IV q8–12h
PLUS
Cefepime 2g IV q8–12h or
Ceftazidime 2g IV q8h or
Ciprofloxacin 400mg IV q12h or
Levofloxacin 750mg IV q24h
Comments:
Antimicrobial therapy of established infection should be limited to 4–7 days,
unless it is difficult to achieve adequate source control. Longer durations of
therapy have not been associated with improved outcome. (IDSA Complicated
Intra-abdominal Infection Guidelines, CID 2010:50)
Duration of therapy is variable and clinical trial data, especially for severe disease
is sparse:
• Mild or moderate peritonitis: clinical trial found comparable clinical outcomes
in patients treated for 4 days vs those treated until vital signs and GI continuity
had returned (mean of 8 days). All patients had "source control". Normalization
of serum procalcitonin concentration may assist in customizing the duration of
therapy.
• Severe peritonitis: need source control and resolution of fever, leukocytosis and
ileus. Some centers continue antibiotics until the serum procalcitonin serum
concentration is <0.25 mg/ml or has decreased by 90% from its peak
concentration. (Sanford Guide to Antimicrobial Therapy 2016)
An appropriate source control procedure to drain infected foci, control ongoing
peritoneal contamination by diversion or resection, and restore anatomic and
physiological function to the extent feasible is recommended for nearly all patients
with intra-abdominal infection.
C. Acute pancreatitis
• Patients with necrotizing pancreatitis who develop gas in the area of necrosis,
rising inflammatory markers or persistent fever may be suspected of having
infected pancreatic necrosis and would be candidates for antibiotic therapy.
• Post-Necrotizing pancreatitis, infected pseudocyst or pancreatic abscess
Etiology: Enterobacteriaceae, Enterococcus sp., S. aureus, Staphylococcus

epidermidis, Anaerobes, Candida sp.
Preferred Regimen:
1st line 2nd line
Piperacillin-tazobactam 4.5g IV q4- Ciprofloxacin 400mg IV q12h OR
6h OR Meropenem 1g IV q8h Levofloxacin 750mg IV q24h

PLUS Metronidazole 500 mg IV q8–

12h
Comments:
Current consensus is that use of prophylactic antibiotics is not advisable in
pancreatitis, but that they should be employed when clinical factors point to
infected pancreatic necrosis. Those with necrosis involving 30% or more of the
pancreas are at greatest risk of developing infection.
REFERENCES:
• Carlos C, Saniel M. Etiology and epidemiology of diarrheas. Philipp J Microbiol Infect Dis
1990;19(2): 51-53.
• Cherry J, et al. Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 7th Edition.
Philadelphia: Elsevier; 2015.
• Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ. Feigin and Cherry's Textbook of
Pediatric Infectious Diseases. Philadelphia: Elsevier Inc., 2014.
• Integrated Management of Childhood Illness Chart Booklet. Geneva: World Health
Organization; March 2014
• Jalan R, et al. Bacterial infections in cirrhosis; A position statement based on the EASL
Special Conference 2013. J Hepatol 2014; 60:1310-1324.
• Kliegman RM, et al. Nelson’s Textbook of Pediatrics, 20th edition, 2015. Philadelphia:
Elsevier; 2015.
• Kliegman RM, Stanton B, St. Geme J, Schor N. Nelson Textbook of Pediatrics, 20th edition,
Philadelphia, Pennsylvania: Elsevier Inc, 2016.
• Kurup A, et al. Antibiotic management of complicated intra-abdominal infections in adults:
The Asian perspective, Annals of Medicine and Surgery 3 (2014) 85-91
• Lucero M, Saniel M, Geronimo J, Ang C, Leano F, Mate R, Trajano E, Sanvictores E, Forbes
Z, Tupasi T. Etiology of diarrhea in hospitalized children. Philipp J Microbiol Infect Dis 1984.
• Nagel JL, Rarus RE, Crowley AW, Alaniz C, Pogue JM. Retrospective analysis of azithromycin
versus fluoroquinolones for the treatment of legionella pneumonia. PT. 2014; 39:204-205.
• Philippine Foundation for Vaccination and the Philippine Society for Microbiology and
Infectious Diseases. Handbook on Adult Immunization for Filipinos 2012. Manila: Philippine
Foundation for Vaccination; 2012.
• Saniel M, Moriles R, Monzon O, Salazar N, Leano F, Trajano B, Sombrero L, Mat R,
Villanueva J, Geronimo J, Balis A. The relative importance of various enteropathogen in the
etiology of acute diarrhea: a hospital-based study in urban Philippines. SEAMIC Publication
(1987).
• Solomkin JS, et al. Diagnosis and Management of Complicated Intra-abdominal Infection in
Adults and Children: Guidelines by the Surgical Infection Society and the Infectious
Diseases Society of America. Clin Infect Dis. 2010;50(2):133-164.
• Warady BA, et al. Consensus guidelines for the prevention and treatment of catheter-
related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012
update. Perit Dial Int. 2012 Jun;32 Suppl 2: S32-86.

OCULAR INFECTIONS
I. EXTERNAL EYE INFECTIONS
A. Blepharitis

unclear, but may include P: Usually, topical antibiotic ointment of no
S. aureus and S. benefit
epidermidis as well as A: Topical antibiotics may provide symptomatic
associated seborrhea, relief.
rosacea, dry eye If associated acne rosacea: Doxycycline 100mg
PO bid x 2 weeks and then q24h
Comments:
Do lid margin care with baby shampoo and warm water q24h using a clean
washcloth, gauze pad, or cotton swab (50:50 mixture). Apply artificial tears if with
associated dry eyes. Avoid eyeliner, mascara, false eye lashes and eye lash
extensions.
Treatment involves patient education about disease chronicity and need for long
term commitment to lid hygiene with regular application of warm compresses,
gentle lid massage and lid washing. Topical antibiotic steroid combination during
the acute phase for around 2 to 4 weeks. Antibiotic alone to prevent recurrences
for 3 to 6 months.
B. Hordeolum (Stye)
• External hordeolum: External infection of the superficial sebaceous gland

(eyelash follicle)
• Internal hordeolum: Infection of the meibomian glands, and is also called
meibomianitis.
EXTERNAL HORDEOLUM: S. aureus
Preferred Regimen: No antibiotic
Comments:
Warm moist compress (40-45 degree Celsius) continuously using cotton, gauze or
face towel over the affected area for 10 to 15 minutes; may repeat as often as
necessary.
INTERNAL HORDEOLUM: S. aureus, including methicillin-sensitive and –resistant

strains

OCULAR INFECTIONS
Preferred Regimen:
PEDIATRICS ADULTS
Cloxacillin 100-150mg/kg/d PO For MSSA: Cloxacillin 250-500mg PO q6h
div q6h PLUS hot packs
For MRSA, community-associated:
Cotrimoxazole 800/160mg PO 2 tabs bid
For MRSA, hospital-acquired:
Linezolid 600mg PO bid
Comments:
Topical antibiotic ointment (erythromycin, tobramycin) or topical antibiotic-
steroid ointment (tobramycin-dexamethasone) 3 to 4 times a day. The decision to
use an antibiotic-steroid combination will depend on the judgment call of the
physician on the degree of inflammation involved. Incision and drainage if with
pointing abscess. Incision and curettage for chalazion. Can be acute, subacute, or
chronic. Rarely drain spontaneously and may need Incision and Drainage with
culture
II. ORBITAL CELLULITIS
A. Orbital Cellulitis in Children
Etiology: S. aureus, Streptococci Grp A B, hemolytic streptococcus or S. pyogenes,

S. pneumoniae, M. catarrhalis
uncommon causes: Aeromonas hydrophila, P. aeruginosa, Eikenella corrodens, H.
influenzae type B, Anaerobes (odontogenic source), Gram negative bacilli (post-
trauma)
Preferred Regimen:
1st line 2nd line
Vancomycin 45-60mg/kg/d IV in 4 div Linezolid
doses (Max: 4g/d) <12 y: 30 mg/kg/d IV in 3 doses
PLUS ≥12 y: 1200 mg/d IV in 2 doses
Ceftriaxone 100mg/kg/d IV/IM in 1-2 PLUS
doses (Max: 4g/d) Cefotaxime 100-200 mg/kg/d IV
If with odontogenic source, ADD: in 3-4 doses (Max: 2g/d)
Metronidazole 30mg/kg/d IV/PO in 4 div
doses (Max: 4g/d)
OR
Vancomycin 45-60 mg/kg/d IV in 4 div
doses (Max: 4g/d) PLUS
Piperacillin-Tazobactam 240-300 mg/kg/d
IV in 3-4 doses (piperacillin component)
(Max: 16g piperacillin/d)

OCULAR INFECTIONS
For children with serious allergy to PCN

and/or cephalosporins:
Vancomycin
PLUS Ciprofloxacin 20-30mg/kg/day in 2
div doses (Max: 1.5g PO qd/800mg IV qd)
or Levofloxacin
≥ 6 mos. to < 5 yrs.: 10mg/kg/dose q12h
≥ 5 years:10 mg/kg/dose q24h (Max:
500mg)
DOT: 7-14 days depending on clinical response
Comments:
Orbital cellulitis is serious and potentially life threatening. It is best to obtain
specimen for culture and sensitivity testing prior to treatment initiation. Surgical
consultation is recommended.
ARSP 2015 showed increased resistance of S. aureus to Oxacillin at 62.6%. Orbital

cellulitis is a serious infection with risk of cavernous sinus thrombosis. Antibiotics
with MRSA coverage should be promptly started. For confirmed MSSA, shift to
Oxacillin.
B. Orbital Cellulitis in Adults
Stage I: preseptal cellulitis, anterior lid swelling; CT normal.

Stage II: edema, chemosis, proptosis, limited extra-ocular motion; CT with
mucosal swelling but no fluid collection.
Stage III: occasional visual loss, CT subperiosteal abscess, globe displacement,
extraocular muscles involved.
Stage IV: ophthalmoplegia with visual loss; CT with proptosis, abscess formation
& periosteal rupture.
Etiology: S. pneumoniae, H. influenzae, M. catarrhalis, S. aureus, Anaerobes

(odontogenic source), Streptococcus sp. (Group A), Gram-negative bacilli (post-
trauma), Mucormycosis (in patients with diabetic ketoacidosis), Invasive
Aspergillus sp (severe neutropenia, HIV)
Preferred Regimen:
Stage 1: Amoxicillin-clavulanate 500mg PO tid x 10-14d
Stage II – IV:
If MRSA is not considered: If MRSA considered:

Piperacillin-Tazobactam 4.5g IV q8h Vancomycin 1g IV q12h PLUS
OR Ciprofloxacin 400mg IV q8-12h Ceftriaxone 1g IV q12h PLUS
PLUS Clindamycin 600mg IV q8h Metronidazole 1g IV q12h

OCULAR INFECTIONS
(if odontogenic source)

Option for MRSA if Vancomycin intolerant: Linezolid 600 mg IV q12h
DOT: 10-21 days depending on clinical response; 4-6 weeks if bone changes are
suggestive of osteomyelitis.
For serious allergy to penicillins and/or cephalosporins:

Vancomycin 1g IV q12h PLUS Ciprofloxacin 400mg IV q12h OR 500 to 750 mg PO
bid OR Levofloxacin 500 to 750 mg IV or PO qd
Comments:
Close consultation with ophthalmology and /or ENT is required. Surgical
debridement is warranted with abscesses or if medical management fails to lead
to an improvement in the first 24-36 hours.
III. DACRYOCYSTITIS (LACRIMAL SAC)
• Can be acute or chronic

• Due to obstruction of the lacrimal duct.
Etiology:
Acute dacryocystitis: Alpha –hemolytic streptococci, S. epidermidis, S. aureus
Chronic dacryocystitis: S. pneumoniae, H. influenzae, P. aeruginosa, S. viridans,
Enterobacteriaceae
Preferred Regimen:
PEDIATRICS ADULTS
Vancomycin 40mg/kg/d IV div 3- Mild infection limited to lacrimal sac and
4 doses PLUS lid: Cephalexin 500mg PO qid OR
Ceftazidime 100mg/kg/d IV div Amoxicillin-clavulanate 875mg PO bid OR
3 Cotrimoxazole 2 DS tablets PO bid
doses (if Gram-negative
dacryocystitis is entertained). With signs or symptoms of orbital cellulitis:
Vancomycin 15-20mg/kg/d IV q8-12h PLUS
Ceftriaxone 2g IV q24h or Cefepime 2g IV
q6h if pseudomonal infection is suspected
Documented MSSA infection:

Oxacillin 2g IV q6h OR Cefazolin 2g IV q8h
DOT: 7-14d
Comments:
Ophthalmologic consultation is needed and surgery may be required to do culture
studies (to detect MRSA). Empiric systemic antibiotic therapy is based on Gram

OCULAR INFECTIONS
stain of the aspirate, age of the child, severity of the infection, presence and type
of complications. Adjust therapy based on culture results.
Hospitalization may be considered in cases of suppurative bacterial infection with

associated lacrimal gland abscess. Oral agents may be used for less severe cases.
A. Canaliculitis (Lacrimal apparatus)
Etiology: Actinomyces, Staphylococci, Streptococci; rarely Arachnia

fusobacterium, Nocardia sp., Candida sp. (all rare)
Comments:
Apply hot packs to punctal area qid. Referral to ophthalmologist for removal of
granules and local irrigation with an antibiotic solution.
IV. CONJUNCTIVITIS
A. Conjunctivitis of the Newborn by day of onset post-delivery
1ST DAY POST-DELIVERY: CHEMICAL DUE TO SILVER NITRATE PROPHYLAXIS

Comments:
Chemical prophylaxis is rare since usual prophylaxis involves use of erythromycin
ointment 0.5% x 1 application OR tetracycline 1% ointment x 1 application
DAYS 2 TO 4: N. gonorrhoeae
Preferred Regimen:
Ceftriaxone 25-50mg/kg IV x 1 dose not to exceed 125mg.
Topical Gentamicin, Ciprofloxacin 6-8x/d
Comments:
Hyperpurulent discharge is observed. Irrigate conjunctiva with saline to remove
discharge as often as needed. Treat neonate for concomitant Chlamydia
trachomatis infection. Treat the mother and sexual partner. Topical treatment is
inadequate. Ophthalmologic consult is advised.
DAYS 3-10: Chlamydia trachomatis

Preferred Regimen:
1st line: Erythromycin base or ethylsuccinate syrup 12.5mg/kg q6h x 14d
2nd line: Azithromycin 20mg/kg PO q24h x 3d
Comments:
Diagnosed by antigen detection. Treat the mother and sexual partners. No topical
treatment is needed.

OCULAR INFECTIONS
DAYS 2-16: Herpes simplex types 1, 2

Preferred Regimen: Aciclovir 60mg/kg/d IV div q8h x 14d
Comments:
Topical anti-viral therapy under the direction of an ophthalmologist
B. Viral Conjunctivitis (Pink eye)
Etiology: Adenovirus 3 & 7 in children

Consider short course topical antibiotic-steroid drops one to two drops every 3 to
4 hours for 7 to 14 days in cases with severe inflammation, membranes or
epithelial defects.
Comments:
Highly contagious. If symptomatic, artificial tears may help. If with ocular pain and
photophobia, suspect keratitis (rare). Cold moist compresses as often as needed.
Although adenoviral conjunctivitis is self-limiting, topical antibiotic-steroid is given
to those with severe symptoms. marked swelling and with membrane formation
which can lead to permanent conjunctival scarring (these are cases that have to
be referred).
C. Bacterial (non-gonococcal) conjunctivitis

S. aureus, S. Eye drops: Levofloxacin OR Tobramycin OR
pneumoniae, Erythromycin OR Fusidic acid 1 drop tid - qid x 5-
S. viridans, 7d
H. influenzae, Eye drops: Tobramycin OR Levofloxacin 2 drops
Moraxella sp. qid x 5-7d
Comments:
Ointment is preferred over drops for children, those with poor compliance, and
those in whom it is difficult to administer eye medications. However, ointments
blur vision for 20 minutes after the dose is administered. Fluoroquinolones offer
the best spectrum of activity for empiric therapy. It is the preferred agent in
contact lens wearers. Remove discharge by irrigation with saline.
D. Gonococcal Conjunctivitis

N. gonorrhoeae A: Ceftriaxone 1g IV/IM x 1 dose PLUS
Azithromycin 1g PO x 1 dose for presumptive
Chlamydia co-infection PLUS

OCULAR INFECTIONS
Chlamydia trachomatis Topical Levofloxacin or Tobramycin or

(presumptive co- Erythromycin ointment qid x 2-3 weeks or until
infection) resolution of symptoms.
Comments:
Ophthalmology consult recommended because it can progress to corneal
perforation. Irrigate conjunctiva with saline to remove discharge as often as
needed. Test patient for HIV and syphilis. Treat sex partner.
V. KERATITIS
A. Herpes Keratitis

Herpes simplex 1 P and A:
and 2 Ganciclovir 0.15% or Aciclovir 3% ophthalmic
ointment, 5x/d until corneal ulcer heals, then tid x 7d
Comments:
Serious and often sight threatening so prompt ophthalmologic consultation is
essential for diagnosis, antimicrobial, and adjunctive therapy. 30% recur within 1y.
For those aged 12y and older with recurrent infections (>2x a year), Aciclovir 400
mg bid for 12 months may be given to prevent recurrences. Oral antiviral drugs
are not necessary.
B. Varicella zoster opthalmicus
Etiology: Varicella zoster virus
Preferred Regimen:
P: Aciclovir 10mg/kg IV (most effective within 72h from appearance of vesicles)
A: Famciclovir 500mg PO tid OR Valaciclovir 1g PO tid OR Aciclovir 800mg PO
5x/d x 10d
Apply tobramycin-dexamethasone ointment 2 to 3 times a day to lesions on the
eyelids until resolution of lid lesions.
C. Acute bacterial keratitis (no comorbidity)

S. aureus, S. pneumoniae, P: Gram-negative: Tobramycin eye drops
S. pyogenes, Haemophilus sp., 1-2 drops q4h

OCULAR INFECTIONS
Also for children: P. Gram-positive: Levofloxacin 0.5% eye

aeruginosa, Moraxella spp. drops
A: Gram-positive: Levofloxacin 0.5% eye
drops
Dry cornea / diabetes, Refer to ophthalmologist
immunosuppression:
S. aureus, S. epidermidis, S.
pneumoniae, S. pyogenes,
Enterobacteriaceae, Listeria sp.
Comments:
Obtain specimen for Gram stain and culture studies and adjust treatment
accordingly. Topical steroids are never used in isolation. NEVER patch the eye.
Bacterial keratitis can be a vision-threatening disease: prompt consultation with
an ophthalmologist is essential. Consider systemic antibiotic for large (>6 mm)
corneal ulcer, corneal perforation or scleritis due to Pseudomonas aeruginosa and
other Gram-negative enteric bacteria.
D. Bacterial keratitis secondary to contact lens use
Preferred Regimen:
PEDIATRICS ADULTS
Tobramycin 0.3% ophthalmic Ciprofloxacin 0.3% eye drops OR
solution 1-2 drops qh x 24h then taper Levofloxacin 0.5% eye drops OR
based on clinical response. Tobramycin 0.3% solution
Give 1 drop qh x 24-72h then taper
based on clinical response
Comments:
Referral to ophthalmologist is recommended. Discontinue contact lens use.
E. Fungal keratitis

Aspergillus, Fusarium, Candida Refer to ophthalmologist
Comments:
Obtain specimen for fungal wet mount and cultures. Empiric therapy is not
recommended for fungal keratitis. It is important to try to identify organism from
corneal scrapings. NEVER give topical steroid. NEVER patch the eye. Daily

OCULAR INFECTIONS
debridement is advised to enhance penetration of anti-fungal agents. Topical

cycloplegic (atropine sulfate 1%) one drop 3 times a day until free of pain.
F. Keratitis, Protozoan

Acanthamoeba sp. Refer to ophthalmologist
Comments:
Corneal infection usually associated with trauma or soft contact lens use. NEVER
patch the eye. Discontinue contact lens use. Topical broad-spectrum antibiotics to
prevent secondary bacterial infection. Avoid topical and subconjunctival steroids.
Topical cycloplegic (atropine sulfate 1%) one drop 3 times a day until free of pain.
G. Keratitis, Non-tuberculous Mycobacterial (Post-Lasik surgery)

Mycobacterium chelonae, Refer to ophthalmologist
M. abscessus, M.
massiliense
Comments:
Ophthalmologic consultation recommended. Prolonged course of therapy.
Treatment regimen is as for extrapulmonary tuberculosis (see National Antibiotic
Guidelines on Tuberculosis).
VI. ENDOPHTHALMITIS
A. Endophthalmitis, Hematogenous
Etiology: S. pneumoniae or other streptococci, N. meningitidis. S. aureus, K.

pnemoniae or other gram-negative organisms, Candida sp. (rare), Bacillus cereus
(heroin use)
(locally usually due to penetrating or perforating globe injury by pointed material
e.g. BBQ stick, walis tingting, wires)
Preferred Regimen: Refer to ophthalmologist
Comments: Intravitreal administration of antimicrobials is essential. Immediate

referral to vitreo-retinal surgeon.

OCULAR INFECTIONS
B. Endophthalmitis, Post-cataract surgery
Etiology:
Early, acute: S. epidermidis, S. aureus, Streptococcus sp., Enterococcus sp., Gram-
negative bacilli, Candida albicans
Low grade, chronic: Propionibacterium acnes, S. epidermidis, S. aureus (rare),
Fungi
Comments:
Immediate ophthalmologic consult is needed. If only light perception or worse,
perform immediate vitrectomy. May require removal of lens material.
C. Endophthalmitis, Candida
• Endogenous: occurs in ~15% of patients with candidemia

• Exogenous: occurs following ocular surgery or traumatic injury.

Candida sp.
Chorioretinitis without Fluconazole 800mg PO (12 mg/kg)
vitritis loading dose, then 400-800mg (6- 12 mg/kg
For fluconazole- qd) OR Voriconazole 400mg IV bid for 2
/voriconazole-susceptible doses loading dose (6 mg/kg), then 300 mg
isolates (4 mg/kg) IV/PO bid
For fluconazole- Refer to ophthalmologist

/voriconazole-resistant
isolates
With macular involvement Refer to ophthalmologist
Chorioretinitis with vitritis Refer to ophthalmologist

(Endophthalmitis)
Comments:
The extent of ocular infection (chorioretinitis with or without macular involvement
and with or without vitritis) should be determined by an ophthalmologist. For
fluconazole–susceptible isolates, fluconazole is preferred over voriconazole.
Vitrectomy should be considered to decrease the burden of organisms and to
allow the removal of fungal abscesses that are inaccessible to systemic antifungal
agents.

OCULAR INFECTIONS
D. Endophthalmitis, Post-traumatic
Etiology: Bacillus sp., S. epidermis, Gram-negative bacilli, Streptococci, Fungi
Comments:
Vitrectomy often necessary. Consider prophylactic administration of systemic +
intravitreal antibiotics in high risk injuries (soil contamination, >24h delay in
wound closure, intraocular foreign body).
VII. RETINITIS
A. Acute Retinal Necrosis
• Vision loss, usually in immunocompetent individuals, which progresses

rapidly with retinal necrosis, vasculitis and uveitis; frequently results in
retinal detachment.
• Begins unilaterally but may involve the other eye (up to 50% of cases).
Etiology: Varicella-zoster virus, Herpes simplex
Preferred Regimen:
Aciclovir 10–12mg/kg IV q8h x 7–10d until disease stabilizes, then oral therapy for
a min of 6 weeks with: Aciclovir 800mg PO 5x/d OR Valaciclovir 1g PO tid OR
Famciclovir 500mg PO tid
Comments:
Ophthalmology consult imperative.
B. Retinitis, Cytomegalovirus (HIV/AIDS)
Etiology: Cytomegalovirus (CMV)
Comments:
Watch for Immune Reconstitution Inflammatory Syndrome (IRIS) (e.g., Immune
Recovery Uveitis) in those on anti-retroviral therapy (ART). ART should not be
delayed owing to concern of IRIS.

OCULAR INFECTIONS
REFERENCES:
Available at: http://www.hopkinsmedicine.org/amp/guidelines/antibiotic_guidelines.pdf
• Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults
and Adolescents. Available at: http://aidsinfo.nih.gov/guidelines.
• Liu C, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the
Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children.
Clin Infect Dis 2011: 52;1–38.
• Pappas P, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update
by the Infectious Diseases Society of America. Clin Infect Dis 2016;62(4): e1–50.

UPPER RESPIRATORY TRACT INFECTION
I. PHARYNGITIS OR TONSILLITIS
A. Exudative or diffuse erythematous
• Associated cough, rhinorrhea, hoarseness and/or oral ulcers suggest a viral

etiology
• The Rapid Strep Test may be used to diagnose Group A Streptococcus (GAS)
pharyngitis.
• Complications of GAS pharyngitis include:
o Acute rheumatic fever (ARF) – follows Group A S. pyogenes infection, and is
rare after Group C/G infection. The rationale for therapy is to eradicate GAS
and prevent ARF. Benzathine penicillin G decreases the rate of ARF from
2.8% to 0.2% in trials. For prevention, start treatment within 9 days of
symptom onset.
o Post-streptococcal glomerulonephritis in children < 7 years old
o Pediatric autoimmune neuropsychiatric disorder associated with Group A
Streptococcus infection, or PANDAS
o Peritonsillar abscess and suppurative phlebitis are also potential
complications.
Etiology: Group A, C, G; streptococci; Fusobacterium (in studies)
Preferred Regimen:
1st line
PEDIATRICS ADULTS
Phenoxymethylpenicillin or Penicillin Phenoxymethylpenicillin or Penicillin
V 25-50mg/kg/d PO q6h x 10d OR V 500mg q12h or 250mg PO q6h x 10d
Amoxicillin trihydrate 50mg/kg/d PO OR
q8-12h (Max: 1g/d) x 10d Benzathine Penicillin G 1.2MU IM x
1dose
2nd line
PEDIATRICS ADULTS
Amoxicillin trihydrate 50mg/kg/d PO Amoxicillin trihydrate 500mg PO
q8-12h (Max: 1g/d) x 10d q12h x 10d
For penicillin allergy: The primary For penicillin allergy: The primary
choice is a macrolide, such as: choice is a macrolide, such as:
Erythromycin ethylsuccinate 40 Erythromycin ethylsuccinate 400mg
mg/kg/d PO q6h (Max: 1g/d) x 10d OR PO q6-12h x 10d OR
Clarithromycin 15mg/kg/d PO div Clarithromycin 250mg PO q12h x 10d
q12h x 10d OR OR Azithromycin 500mg x 1 dose and
Azithromycin 12 mg/kg PO qd x 5d then 250mg PO qd x 4d or 500mg PO
qd x 3d

Alternative to the macrolides for Alternative to the macrolides for

severe penicillin allergy: severe penicillin allergy:
Clindamycin 20-30mg/kg/d PO q8h Clindamycin 300-450mg PO q6-8h x
(Max: 1.8g/d) x 10d 10d
Comments:
Penicillin V should be given on an empty stomach because its absorption is
impaired by food. Take 1 hour before or 2 hours after a meal. In throat infections
caused by Epstein Barr virus (infectious mononucleosis), Amoxicillin or ampicillin
produces a non-allergic maculopapular rash, which does not preclude the future
use of penicillins. Cotrimoxazole, tetracyclines and fluoroquinolones are not
effective. Resistance of S. pyogenes to macrolides has been reported. ALERT! Co-
amoxiclav is not recommended.
B. Recurrent pharyngitis
• True Group A Streptococci (GAS) infection is difficult to distinguish from GAS

carriage with repeated viral pharyngitis.
• Tonsillectomy is not recommended to decrease streptococcal infection.
Etiology: Group A streptococci
Preferred Regimen:
1st line
PEDIATRICS ADULTS
Phenoxymethylpenicillin or Penicillin Phenoxymethylpenicillin or
V 25-50mg/kg/d PO q6h x 10d OR Penicillin V 500mg q12h or 250mg
Amoxicillin trihydrate 50mg/kg/d PO PO q6h x 10d OR
q8-12h (Max: 1g/d) x 10d Amoxicillin trihydrate 500mg PO
q12h x 10d
2nd line
PEDIATRICS ADULTS
Cefuroxime axetil 20mg/kg/d PO div Cefuroxime axetil 500mg-1g/d PO
q12h x 10d OR q12h x 10d OR
Co-amoxiclav Co-amoxiclav 500mg/125mg PO
<40kg: 25-45mg/kg/d PO div q8h q12h x 10d
(amoxicillin component) x 10d;
>40kg: 500mg PO q12h or 250mg PO
q8h. For more severe infections, may
increase dose to 500mg PO q8h.

For 3 months and older:

Dosing PNF preparations
Regimen
15-45 200mg amoxicillin/
mg/kg/d PO 28.5mg potassium
div q12h clavulanate/5mL
(amoxicillin (70mL);
component) 400mg amoxicillin/
x 10d 57mg potassium
clavulanate/5mL
(30mL, 70mL)
Comments:
GAS is able to enter the epithelial cells, and internalization is associated with the
presence of certain fibronectin-binding proteins. Because penicillin does not
effectively penetrate epithelial cells, this internalization may contribute to
persistence despite antibiotic therapy. In cases of persistent pharyngitis, antibiotic
options include cephalosporins, Co-amoxiclav, macrolides including azalides
(azithromycin), and clindamycin. However, there is varied expert opinion on
which therapy is most appropriate.
C. Peritonsillar abscess (Quinsy)
• Sometimes a serious complication of exudative pharyngitis

• Surgical drainage is required in treatment.
Etiology: Fusobacterium necrophorum (44%), Group A streptococci (33%), Group

C/G Streptococci (9%), Streptococcus anginosus group
Preferred Regimen:
1st line
PEDIATRICS ADULTS
Ampicillin-sulbactam 100mg/kg/d Ampicillin-Sulbactam 6-12g/d IV/IM
IV/IM q6h (ampicillin component) q6h (ampicillin component) (Max: 4g
Step down to: Co-amoxiclav sulbactam/d)
40mg/kg/d PO q8h (amoxicillin Step down to: Co-amoxiclav 750mg-
component) x 10d 1.5g /d PO q8h (amoxicillin
component) x 10d
2nd line
PEDIATRICS ADULTS
Ceftriaxone 50-75mg/kg/d IV q12- Ceftriaxone 2g IV q24h PLUS
24h PLUS Metronidazole 30mg/kg/d Metronidazole 500mg IV/PO q6-8h
(Max: 4 g/d) IV q6h

For penicillin allergy: For penicillin allergy:

Clindamycin 40mg/kg/d IV q6-8h Clindamycin 600-900mg IV q6-8h
Comments:
Fusobacterium is resistant to macrolides and are best avoided (not
recommended). There are some reports of beta lactamase production by oral
anaerobes.
D. Deep Neck Abscess/ Retropharyngeal Abscess
• Surgical drainage is required in treatment.
Etiology: Polymicrobial; S. aureus; Streptococcus spp.; Bacteroides spp.
Preferred Regimen:
1st line
PEDIATRICS ADULTS
Ampicillin-sulbactam 100mg /kg/d Ampicillin-sulbactam 6-12g (Max: 4
IV/IM q6h (ampicillin component) g/d) IV/IM q6h (ampicillin
Step down to: Co-amoxiclav component)
40mg/kg/d PO q8h (amoxicillin Step down to: Co-amoxiclav 750mg -
component) OR Cefuroxime Na 100- 1.5g/d PO q8h (amoxicillin
150mg/kg/d IV q8h component) OR Cefuroxime Na
750mg IV q8h
Step down to: Cefuroxime axetil 20-
30mg/kg/d PO q12h PLUS Step down to: Cefuroxime axetil
Metronidazole 30mg/kg/d (Max: 500mg PO bid PLUS Metronidazole
4g/d) IV q6h x at least 7d 500mg q8h IV x at least 7d
Step down to: Metronidazole 30- Step down to: Metronidazole 500mg
50mg/kg/d PO q8h PO q8h x at least 7d
2nd line
PEDIATRICS ADULTS
Ceftriaxone 50-75mg/kg/d IV q12- Ceftriaxone 2g IV q24h x 10-14d PLUS
24h x 7d PLUS Metronidazole Metronidazole 500mg IV q8h x at
30mg/kg/d (Max: 4g/d) IV q6h x at least 7d
least 7d
Comments:
If methicillin-resistant S. aureus (MRSA) is suspected (antibiotic therapy in the
preceding 90-day, current hospitalization for 5 days or more, high frequency of
antibiotic resistance in the community or in the specific hospital unit, presence of
risk factors for healthcare-associated pneumonia, immunosuppressive disease

and/or therapy, recent or prolonged hospitalization, exposure to antibiotics, or

stay in an intensive care unit), Clindamycin or vancomycin is recommended.
Community-acquired MRSA have been reported in children without identified risk

factors. These cases have a predominance of superficial infections, including
subcutaneous abscesses, cellulitis, and recurrent skin infections. Step down should
be guided by culture.
E. Membranous pharyngitis due to diphtheria
• Intensive surveillance and immediate notification to the Department of Health

is necessary.
• Supportive treatment is critical in management. Antibiotics are not the
mainstay of treatment.
• Ensure adequate airway. Perform cardiac assessment.
• Administer diphtheria toxoid before discharge.
• Culture contacts and treat accordingly.
• Observe standard and droplet precautions (respiratory droplet isolation) for
patients and carriers until 2 cultures from both the nose and throat collected
24 hours after completing antibiotics are negative for C. diphtheriae.
• Persons recovering from diphtheria should begin or complete active
immunization. Vaccine containing diphtheria toxoid is available in combination
with tetanus and pertussis. It is given at a dose of 0.5 mL IM. Routine pediatric
immunization should include 5 doses given on ages 6 weeks, 10 weeks, 14
weeks, 12 months (provided there is a minimum interval of 6 months from dose
3) and 4-6 years before school entry.
• Patients should be placed in isolation.
• Obtain nasal and pharyngeal cultures (special media.)
Etiology: C. diphtheriae (human to human), C. ulcerans and C. pseudotuberculosis

(animal to human, rare)
Preferred Regimen:
1st line
PEDIATRICS ADULTS
Penicillin G crystalline 100,000 to Penicillin G crystalline 50,000 U/kg
150,000 U/kg/d IV q6h or procaine (Max: 1.2 MU) IV q12h
penicillin 25,000 to 50,000 U/kg/d Step down to:
(Max: 1.2 MU) IM q12h Phenoxymethylpenicillin 250mg PO
Step down to: q6h x 14d
Phenoxymethylpenicillin 25-
50mg/kg/d PO q6h x 14d

2nd line
PEDIATRICS ADULTS
Erythromycin 40-50mg/kg/d (Max: Erythromycin 500mg qid x 14d
2g/d) IV q6h Step down to:
Step down to: Erythromycin ethylsuccinate 500mg
Erythromycin ethylsuccinate 40- PO q6h x 7-10d
50mg/kg/d (Max: 2g/d) PO q6h x 14d
Comments:
Antibiotics decrease toxin production, decrease spread of organisms. Penicillin is
superior to erythromycin. Eradication of the organism should be documented 24
hours after completing treatment by 2 consecutive negative cultures from
pharyngeal specimens taken 24 hours apart. If follow-up cultures are positive,
erythromycin should be given for an additional 10 days.
Treatment of carrier state:

Weight < 30 kg: benzathine penicillin G 600,000 U IM x 1 dose Weight >30 kg:
benzathine penicillin G 1.2 million U or oral erythromycin 40 to 50 mg/kg/d
F. Vesicular, ulcerative pharyngitis (viral)
• More common in patients aged < 3 years

• Associated signs and symptoms:
o Consistently present: Hoarseness, cough, colds, conjunctivitis, ulcerative
stomatitis.
o Mild or possibly absent: Systemic findings, pharyngeal erythema, sore
throat, difficulty swallowing, exudates, palatal petechiae.
o NO tender cervical lymph nodes
Etiology: Coxsackie A9, B1-5 Echo viruses (multiple types); Enterovirus 71; Herpes
simplex virus (HSV) 1, 2
Preferred Regimen:
For HSV 1 and 2 in immunocompromised host:
P: Aciclovir
Infants and children < 12y: 10mg/kg q8h x 7-14d as 1-3h IV infusion
> 12y: 5 mg/kg q8h x 7-14d as 1-3h IV infusion OR
Valaciclovir 12y: 4g/d q12h x 1d
A: Aciclovir 400mg PO 5x/d x 5d OR Valaciclovir 500mg bid x 7d
Recurrent herpes labialis:
P: Valaciclovir Children > 12 y: 4g/d q12h x 1d
A: Valaciclovir 500mg bid x 7d

Comments:
For vesicular pharyngitis suspected to be caused by coxsackie A9, B1-5, echo
viruses and enterovirus, antiviral therapy is not needed. Supportive therapy is
recommended. For mild infections in immunocompetent host, supportive therapy
is recommended.
G. Gonococcal pharyngitis
Etiology: N. gonorrhoeae
Preferred Regimen:
P: Ceftriaxone
<45 kg: 125mg IM x 1 dose;
>45 kg: 250mg IM x 1 dose
A: Ceftriaxone 250mg IM x 1 dose
Comments:
Spectinomycin, cefixime, cefpodoxime and cefuroxime are not effective for
pharyngeal gonococcal infections.
II. PARAPHARYNGEAL SPACE INFECTION; PERITONSILLAR ABSCESS
• May be due to poor dental hygiene, dental extractions, or foreign bodies (e.g.,
toothpicks, fish bones)
• Closely monitor the airway; a third of patients require intubation.
• Perform MRI or CT scan to identify the abscess. Perform surgical drainage.
• Complications include infection of the carotid (with possible rupture) and
jugular vein phlebitis
Etiology: Polymicrobial, including: Streptococcus sp. Anaerobes (which outnumber

aerobes 10:1)
Preferred Regimen:
1st line
PEDIATRICS ADULTS
Ampicillin-sulbactam 100mg/kg/d Clindamycin 600-900mg IV q8h or
q6h IV/IM (ampicillin component) Penicillin G 24 MU/d by continuous
Step down to: infusion or div q4-6h IV PLUS
Co-amoxiclav 40mg/kg/d PO div q8h Metronidazole 1g loading dose THEN
x 10d 0.5g IV q6h or 1g IV q12h.

2nd line
PEDIATRICS ADULTS
Ceftriaxone 50-75mg/kg/d IV q12- Ampicillin-sulbactam 3g IV q6h OR
24h PLUS Piperacillin-tazobactam 4.5g IV q6h
Metronidazole 30mg/kg/d (Max: 4 or 4h infusion of 3.375g q8h OR
g/d) IV/PO q6h 2nd or 3rd generation
cephalosporins, e.g., Ceftriaxone 1g
IV q24h PLUS Metronidazole 500mg
IV q8h x at least 7d
Comments: Clindamycin may be used in pediatric patients with penicillin allergy.
III. JUGULAR VEIN SUPPURATIVE PHLEBITIS (LEMIERRE’S SYNDROME)
• Pulmonary and systemic emboli are common.

• Erosion into the carotid artery can occur.
Etiology: Fusobacterium necrophorum in vast majority. Lemierre described

Fusobacterium in 1936; other anaerobes and Gram (+) cocci are less common
etiologies of suppurative phlebitis postpharyngitis.
Preferred Regimen (A):

1st line: Piperacillin-tazobactam 4.5g IV q8h OR
Metronidazole 500mg PO/IV q8h PLUS Ceftriaxone 2g IV qd
2nd line: Clindamycin 600-900mg IV q8h
Comments:
Avoid macrolides: fusobacterium resistance. Note: If not a complication of
pharyngitis, and if there is an internal jugular line, treat empirically for methicillin-
resistant Staphylococcus aureus using vancomycin.
IV. ACUTE EPIGLOTTITIS
• Requires urgent hospitalization. May present with life-threatening upper

airway obstruction, especially in pediatrics.
• Have tracheostomy set “at bedside.”
• Use of steroids is controversial and not recommended.
• H. influenzae Type b immunization is recommended, given IM at a minimum
age of 6 weeks with a minimum interval of 4 weeks in between doses.
o If given between 6 weeks to 6 months: Primary series of 3 doses, 1-2 months
apart. Booster dose at 12-15 months.
o If given between 7-11 months: Primary series of 2 doses, 1-2 months apart.
Booster dose at 18 months
o If given between 12-59 months, give only 1 dose.

Etiology: H. influenzae Type b; S. pneumoniae
Preferred Regimen:
P: 1st line: Ceftriaxone 50-100 mg/kg/d q12-24h IV x 7-10d
2nd line: Ampicillin-Sulbactam 100 mg/kg/d q6h IV x 10d
A: 1st line: Ceftriaxone 2g q24h IV infusion x 7-10d

2nd line: Levofloxacin 750mg IV q24h PLUS
Clindamycin 600-900mg q6-8h IV x 7-10d
Comments:
Levofloxacin is generally not recommended in patients < 18y. Avoid in patients
with history of QT prolongation or with drugs that prolong QT interval. Tendon
rupture can occur during or after therapy.
V. RHINOSINUSITIS
A. Acute bacterial rhinosinusitis (ABRS)
Etiology: S. pneumonia; H. influenzae; M. catarrhalis; S. aureus; Anaerobic

bacteria; Some other streptococcal species
Preferred Regimen:
1st line
PEDIATRICS ADULTS
Co-amoxiclav x 10-14d Co-amoxiclav x 10-14d
1-3 mos.: 30mg/kg/d div q12h high dose Amoxicillin 1g po tid OR
≥3 mos.: 20-40mg/kg/d div q8h or Co-amoxiclav 875mg/125mg PO
25-45mg/kg/d div q12h q12h x 5-7d
For bid dosing, use the following
formulations:
200/28.5mg or 400/57mg
2nd line
PEDIATRICS ADULTS
Co-amoxiclav Doxycycline 100mg bid x 5-7d
≥3 mos. AND <40 kg: 90 mg/kg/d For patients with severe penicillin
q12h using 600/42.9mg OR allergy (adult):
Cefuroxime 30mg/kg/d div q12h x Type 1: Doxycycline 100mg q12h PO
min 10d x 5-7d
For patients with severe penicillin Type 2: Cefuroxime 500mg bid x 5-7d
allergy (pediatric):
Type 1: Clarithromycin 15mg/kg/d
div q12h

Type 2: Cefuroxime30mg/kg/d div

q12h x min 10d
Comments:
Antibiotics for bacterial sinusitis are recommended if: 1) with high ever and
purulent nasal discharge or facial pain for > 3 days; 2) still symptomatic after 10
days with no antibiotic; or 3) symptoms worsen after a typical viral illness that
lasted 5 days and had initially improved.
The use of erythromycin and Clindamycin as single-drug therapy for ABRS is

controversial. On its own, erythromycin has poor coverage for Gram (-) bacteria
and may not cover for H. influenzae and M. catarrhalis if used empirically. The
same holds true for clindamycin; however, it makes up for this with the added
coverage against anaerobic bacteria. These considerations should be taken into
account when prescribing these antibiotics.
Avoid Trimethoprim-sulfamethoxazole because of increasing resistance.

Fluoroquinolones are generally not recommended as the serious side effects
(tendinopathy, peripheral neuropathy, and prolongation of QT interval) outweigh
the benefits.
B. Acute sinusitis (clinical failure after 3 days) in adults
Etiology: S. pneumonia; H. influenzae; M. catarrhalis; S. aureus; Anaerobic

bacteria; Some other streptococcal species; consider diagnostic tap/aspirate
Preferred Regimen:
1st line or mild/moderate disease: Cefuroxime axetil 500mg q12h PO x 7-10d
2nd line or severe disease: Levofloxacin 750mg qd PO x 5 d
C. Mucormycosis: diabetes mellitus with acute ketoacidosis; neutropenia;

deferoxamine therapy – adults only
Early diagnosis is key to treatment success. Symptoms suggestive of fungal

sinusitis (or lateral facial pain or numbness) should increase suspicion. Palatal
ulcers and/or black eschars and unilateral blindness in immunocompromised or
diabetic patients suggests mucor.
• Rapidly fatal without treatment.
• Diagnosis is by stain of tissue culture isolates, revealing wide ribbon-like,
non-septated hyphae with variation
• in diameter and right-angle branching.
• Diabetics are predisposed to mucormycosis due to microangiopathy and
ketoacidosis.

• Iron overload also predisposes to mucormycosis, as iron stimulates fungal

growth.
Etiology: Rhizopus sp. (mucor), Aspergillus
Preferred Regimen:
1st line: Amphotericin B 1-1.5mg/kg/d OR Liposomal Amphotericin B 5-
10mg/kg/d
2nd line: Posaconazole 400mg PO bid with meals. If NPO, 200mg qid
Comments:
Amphotericin B lipid complex monotherapy has a 20% success rate vs 69% for
other polyenes. Posaconazole (not in the PNDF and) is not included in the FDA-
approved indications for posaconazole. Complete or partial response rates with
Posaconazole salvage protocols is from 60% to 80%. Resistant to Voriconazole:
prolonged use of Voriconazole prophylaxis predisposes to mucormycosis
infections.
Total duration of therapy is based on response. Continue therapy until 1)

resolution of clinical signs and symptoms of infection, 2) resolution or stabilization
of radiographic abnormalities; AND 3) resolution of underlying
immunosuppression. Posaconazole may be used for secondary prophylaxis for
those on immunosuppressive therapy.
D. Acute sinusitis in adult hospitalized patients with nasotracheal or nasogastric

intubation
Etiology: Gram negative bacilli (Pseudomonas, Acinetobacter, E. coli common) in

47% of cases, Gram positive (Staphylococcus aureus) in 35%, Polymicrobial in 80%,
Yeasts 18%
Preferred Regimen:
1st line: Piperacillin-tazobactam 4.5g IV q6-8h OR Meropenem 1g IV q8h
Add Vancomycin if methicillin-resistant S. aureus is suspected.
2nd line:
Ceftazidime 2g IV q8h PLUS Vancomycin loading dose 25-30mg/kg IV followed by
15mg/kg IV q8h or q12h OR
Cefepime 2g IV q12h PLUS Vancomycin loading dose 25-30mg/kg IV followed by
15mg/kg q8h or q12h IV
Comments:
After 7 days of nasotracheal or nasogastric tubes, 95% have x-ray “sinusitis”
(fluid in sinuses), but on transnasal puncture only 38% culture positive. For

patients requiring mechanical ventilation with nasotracheal tube for > 1-week,
bacterial sinusitis occurs in < 10%. May need fluconazole if yeast cells seen on
Gram stain of sinus aspirate.
E. Chronic rhinosinusitis (CRS): Symptoms > 6 weeks
• Defined as drainage, blockage, facial pain or decreased sense of smell PLUS

mucopurulence on endoscopy or CT scan changes.
• Serum IgE levels may be tested if allergy is suspected
• Perform CT scan of the maxillary bone if an odontogenic source is suspected.
• Culture and sensitivity testing is important.
Etiology: Multifactorial, e.g., damage to the ostiomeatal complex during acute

bacterial disease; allergy with or without polyps; occult immunodeficiency; and/or
odontogenic disease (periodontitis in maxillary teeth)
Preferred Regimen: No persuasive evidence of benefit from antibiotics

P & A: Otolaryngology consultation is recommended.
Comments:
Treatment is usually with antibiotic therapy for 3 to 6 or up to 10 weeks with
appropriately selected agents, but the efficacy of this approach is controversial.
The benefit of antifungal agents for CRS is unproven and not currently
recommended.
Pediatric patients:
• Evaluate children for allergy.
• Adjuvant therapy includes nasal saline washes (twice daily per nostril),
antihistamines, anti-inflammatory agents, and topical (intranasal)
corticosteroids.
• Functional endoscopic sinus surgery can be considered for children with failed,
extensive, prolonged, and adequate medical management.
VI. LARYNGITIS
VIRAL (90 %)
Comments: Antibiotics are not indicated in viral laryngitis.
DIPHTHERIA IN DEVELOPING COUNTRIES (PEDIATRICS)
Comments: See the recommendations for membranous pharyngitis due to

diphtheria.

VII. OTITIS
A. Otitis externa
• Usually secondary to chronic seborrhea. Control seborrhea with dandruff

shampoo containing selenium sulphide OR ketoconazole shampoo plus
medium-potency steroid solution (e.g., triamcinolone 0.1%)
Etiology: Usually secondary to seborrhea (chronic)
Preferred Regimen:
P: Ofloxacin ear drops
< 1y: no recommendation
1-12y: 5 drops bid in the affected ear
> 12y: 10 drops bid
DOT: 7-10d or 3d after cessation of symptoms.
A: Ofloxacin ear drops 10 drops/d x 7d
Comments:
Treatment of choice should be based on factors such as patient allergy, risk of
ototoxicity, bacterial resistance, availability, cost, and dosing schedule. Do not use
neomycin drops if the tympanic membrane is punctured. For chronic otitis externa
(symptoms 6 weeks to >3 months), treatment involves debridement and
application of topical anti-inflammatory agents, e.g., corticosteroids.
B. Fungal otitis externa / otomycosis
Etiology: Aspergillus; Candida spp.; Actinomyces spp.; Phycomycetes
Preferred Regimen:
P: Clotrimazole 1% solution 2-3 drops q8-12h up to 10-14d OR Gentian violet may
be used and is well tolerated (as recommended by the WHO Integrated
Management of Childhood Illness [IMCI] guidelines).
A: Clotrimazole 1% solution 2-3 drops q8- 12h up to 10-14d
Comments:
Debridement and dry ear hygiene is crucial in otomycosis. Thorough cleaning with
removal of the matted fungal debris is warranted. Assess for perforation of
tympanic membrane, because antifungals are ototoxic. Clean the canal of detritus.
Place a wick if edema prevents drug delivery. A 1:1 white vinegar + rubbing alcohol
solution may be instilled in the external ear canal after swimming to restore proper
acidic pH to the ear canal and to dry residual water.

C. Necrotizing otitis externa
• Very high erythrocyte sedimentation rates are typical.

• Debridement is usually required.
• Rule out osteomyelitis with a CT or MRI scan. If bone is involved, treat for 4-6
weeks.
Etiology: P. aeruginosa in >95%; P. aeruginosa, Proteus mirabilis in pediatric

patients
Preferred Regimen:
P: 1st line: Ceftazidime 100-150mg/kg/d IV q8h
2nd line: Piperacillin-tazobactam 300mg/kg/d IV q8h
A: 1st line: Piperacillin-tazobactam 4.5g IV q6h
2nd line: Piperacillin-tazobactam 4.5g IV q6h +/- Gentamicin or Amikacin qd
Comments:
Duration of therapy is prolonged for at least 6 weeks and until clinical and
radiographical improvement has been achieved. Obtain cultures from the ear
canal or from surgical debridement. Treatment from other etiologies should be
guided by antibiotic susceptibility results. Do not use neomycin drops if the
tympanic membrane is punctured. Give analgesics for severe pain.
D. Acute diffuse otitis externa / swimmer’s ear
• May also be caused by occlusive devices (earphones); contact dermatitis; and

psoriasis
Etiology: S. epidermidis in 46%; S. aureus in 11%; Pseudomonas sp. in 11%;

Anaerobes in 2%; Candida in 8%
Preferred Regimen:
P: Ofloxacin ear drops
< 1y: no recommendation
1-12y: 5 drops twice a day in the affected ear
> 12y: 10 drops twice a day
DOT: 7-10d or 3d after cessation of symptoms.
A: Ofloxacin ear drops 10 drops 1-2x/d x 7d
Comments:
Ointments should not be used in the ear. Do not use neomycin drops if the
tympanic membrane is punctured. Perform surgical debridement. Avoid
submerging head in water x 7-10 days. A 1:1 white vinegar + rubbing alcohol

solution may be instilled in the external ear canal after swimming to restore proper
acidic pH to the ear canal and to dry residual water. For chronic otitis externa
(symptoms 6 weeks to > 3 months), treatment involves debridement and
application of topical anti-inflammatory agents, e.g., corticosteroids.
E. Acute otitis media (AOM)
Prevention includes immunization against invasive pneumococcal disease and

Haemophilus influenzae Type B.
• Pneumococcal conjugate vaccine is given IM in children aged at least 6
weeks. Primary vaccination involves 3 doses with an interval of 4 weeks in
between doses. Booster is given 6 months after the 3rd dose.
• influenzae Type b conjugate vaccine is given IM in children aged at least 6
weeks. Primary vaccination involves 3 doses with an interval of 4 weeks in
between doses. Booster is given at age 12-15 months, with an interval of 6
months after the 3rd dose.
Etiology:
Viruses cause up to 6% of middle ear infections. Bacterial pathogens account for
85% of middle ear infections: S. pneumoniae in 49%; H. influenzae in 29%; M.
catarrhalis in 28%. In children aged 6 months to 3 years, there may be 2 episodes
of AOM per year, and 63% are virus-positive.
Preferred Regimen:
No antibiotic use in the prior month
1st line
PEDIATRICS ADULTS
Amoxicillin 80-90mg/kg/d PO div Amoxicillin 1g q8h x 10 d (high dose)
q12h
DOT: <2y: 10 d; 2-5y: 7 d; >5y: 5-7d
2nd line
PEDIATRICS ADULTS
With anaphylaxis: No penicillin allergy
Clarithromycin 15mg/kg/d PO q12h Co-amoxiclav 875mg/125mg PO
No anaphylaxis: q12h x 10d
Cefuroxime axetil 30mg/kg/d q12h With penicillin allergy
DOT: <2y: 10 d; 2-5y: 7 d; >5y: 5-7d With anaphylaxis:
OR Ceftriaxone 50mg/kg/d IM/IV x Levofloxacin 750mg PO q24h x 5d
3d No anaphylaxis:
Cefuroxime axetil 500mg–1g/d PO
q12h x 7d OR Ceftriaxone 2g qd IV/IM
x 3d

Comments:
For patients above 2 years old with no fever and ear pain with a negative or
questionable exam, consider analgesic treatment without antimicrobials. There
may be favorable results in mostly afebrile patients with waiting for 48 hours
before deciding to use antibiotics.
For patients allergic to β-lactam drugs:

• If history unclear or rash, may give effective oral cephalosporin
• If IgE-mediated allergy (e.g., anaphylaxis), avoid cephalosporins
Trimethoprim-sulfamethoxazole has a high failure rate if etiology is drug-resistant

S. pneumoniae or H. influenzae. Up to 50% of S. pneumoniae are resistant to
macrolides and 0%-5% are resistant to penicillins. Spontaneous resolution
occurred in 90% of patients infected with M. catarrhalis, 50% with H. influenzae,
and 10% with S. pneumoniae (overall 80% resolve within 2-14 days). For severe
disease, appropriate duration of treatment is unclear, but 5 days may be
inadequate.
Additional comments for pediatric patients:

Co-amoxiclav and Ceftriaxone may be used as a first-line agent if at the onset, the
child presents with high fever >39oC and/or if with severe otalgia. If infection is
non-responsive to antimicrobial therapy, tympanocentesis or myringotomy may
be necessary. Placement of tympanostomy tube is an option for some.
Adenoidectomy at time of tympanostomy tubes decreases future hospitalization
for AOM. Persistent middle ear effusion for 2-3 months after therapy is expected
and does not require retreatment. Macrolide resistance of S. pneumoniae has
been reported. Clindamycin is not effective against H. influenzae and M.
catarrhalis.
F. Acute otitis media (clinical failure after 3 days)
Etiology: Drug-resistant S. pneumoniae
Preferred Regimen:
1st line:
Co-amoxiclav for ≥3 months and <40 kg: 90mg/kg/d q12h using 600/42.9 mg;
DOT: <2yrs: 10 d; >2 y: 5-7d OR
Cefuroxime 30mg/kg/d PO q12h; DOT: <2y OR severe symptoms regardless of
age: 10d; >2yrs with mild or moderate disease:5-7d OR
Ceftriaxone 50mg/kg/d IM x 3d
2nd line:
Mild penicillin allergy: Cefuroxime 15mg/kg/d div q12h or
Ceftriaxone 50mg/kg IM/IV x 3d
Severe penicillin allergy: Levofloxacin 750mg PO bid x 5d

Comments:
Clindamycin not active against H. influenzae or M. catarrhalis. S. pneumoniae
resistant to macrolides are usually also resistant to clindamycin. Definition of
failure: no change in ear pain, fever, bulging tympanic membrane or otorrhea after
3 days of therapy. Tympanocentesis will allow culture. Amoxicillin-clavulanate
high dose reported successful for penicillin-resistant S. pneumoniae acute otitis
media.
G. Chronic suppurative otitis media (CSOM)
• Aural toilet is an essential part of the treatment of CSOM in all patients.

• Surgery must be performed on all cases of CSOM with suppurative
complications.
Etiology:
Aerobic: P. aeruginosa; E. coli; S. aureus; S. pyogenes; Proteus mirabilis; Klebsiella
sp.;
Anaerobic: Bacteroides; Peptostreptococcus; Propionibacterium
Preferred Regimen: Daily ear cleansing and drying should be done. Give
quinolone ear drops tid for 5 days.
Comments:
Antibiotic treatment as in acute otitis media if there is acute exacerbation.
Systemic antibiotics should not be routinely given to patients with CSOM either
alone or in combination with topical antimicrobials. Do not use neomycin drops if
the tympanic membrane is ruptured.
H. Acute mastoiditis
• Usually a complication of acute otitis media. Obtain cultures.

• Diagnosis is by CT or MRI scan.
• Look for complications, such as osteomyelitis, suppurative lateral sinus
thrombophlebitis, purulent meningitis, or brain abscess.
• Consult an otorhinolaryngologist (ENT) for possible mastoidectomy.
Etiology: 1st episode: S. pneumoniae; S. pyogenes; S. aureus; H. influenzae; M.

catarrhalis; P. aeruginosa; If secondary to otitis media: S. aureus; P. aeruginosa;
S. pneumoniae
Preferred Regimen:
P: Ceftriaxone 100mg/kg/d IV q12h PLUS Oxacillin 150-200mg/kg/d IV q6h or
Vancomycin 45-60mg/kg/d IV q6h

A:
1st line: Obtain cultures, then empiric therapy for the first episode:
Ceftriaxone 2g IV qd OR Levofloxacin 750mg IV qd
2nd line: Acute exacerbation of chronic otitis media:
If Pseudomonas and Staphylococcus spp. are suspected, surgical debridement of
the auditory canal, then: Vancomycin (dose to achieve serum trough levels of
15-20 mcg/mL) PLUS Piperacillin-tazobactam 4.5g IV q8h
If caused by a multidrug-resistant Pseudomonas sp: Meropenem 1g IV q8h should
be given.
Comments:
Antibiotic treatment as in acute otitis media if there is acute exacerbation.
Systemic antibiotics should not be routinely given to patients with CSOM either
alone or in combination with topical antimicrobials. Do not use neomycin drops if
the tympanic membrane is ruptured.
I. Chronic or recurrent mastoiditis
Etiology: S. pneumoniae; S. pyogenes; S. aureus; H. influenzae; Moraxella

catarrhalis; P. aeruginosa; Fungi
Preferred Regimen:
P: Piperacillin-tazobactam 300mg/kg/d IV q6h PLUS Gentamicin 7.5mg/kg/d IV
q8h
If intracranial extension is suspected: Cefepime 150mg/kg/d IV q8h
A: Culture ear drainage. May need surgical debridement. Topical fluoroquinolone
ear drops. Consult with an otorhinolaryngologist (ENT) is recommended.
Comments:
Surgical debridement, obtain cultures. Treatment in pediatric group depends on
the patient’s response.
References
• Bartlett JG, ed. (2015) Johns Hopkins ABX Guide. Baltimore, MD: Johns Hopkins University
Hospital;
• Cherry JD, et al., eds. (2014). Feigin and Cherry's Textbook of Pediatric Infectious Diseases.
7th ed. Philadelphia, PA: Saunders.
• Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, et al. (2012). Infectious
Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis
in children and adults. Clinical Infectious Disease, 54: e72-e112.
• Harris AM, Hicks LA, Qaseem A. (2016). Appropriate antibiotic use for acute respiratory tract
infection in adults: advice for high-value care from the American College of Physicians and
the Centers for Disease Control and Prevention. Annals of Internal Medicine, 164:425-34.

• Kimberlin, DW et al., ed. (2015). Red Book: Report of the Committee on Infectious Diseases.
30th ed. Elk Grove Village, IL: American Academy of Pediatrics.
• Kliegman RM, et al., eds. (2016) Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA:
Elsevier.
• Libman, H, Brockmeyer, DM, Gold, HS. (2017) Should We Prescribe Antibiotics to This Patient
with Persistent Upper Respiratory Symptoms? Grand Rounds Discussion from Both Israel
Deaconess Medical Center. Annals of Internal Medicine, 166, 201-208. doi:10.7326/M16-
2766.
• Macfadyen CA, Acuin JM, Gamble CL. (2006). Systemic antibiotics versus topical treatments
for chronically discharging ears with underlying eardrum perforations. Cochrane Database
of Systematic Review. Issue 1. Art. No.: CD005608. DOI: 10.1002/14651858. CD005608
• Mandell LA, et al. (2015). Mandell, Douglas, and Bennett’s Principles and Practice of
Infectious Disease, 8th edition.
• Philippine Society of Otolaryngology – Head and Neck Surgery. (2006). Clinical Practice
Guideline for Sinusitis. Pasig City: Philippine Society of Otolaryngology – Head and Neck
Surgery.
• Research Institute for Tropical Medicine. Antimicrobial Resistance Surveillance Program:
2015 Data Summary Report. Retrieved from: http://arsp.com.ph/arsp-data-summary-
report-2015/
• Reveiz L, Cardona AF. (2013). Antibiotics for acute laryngitis in adults. Cochrane Database of
Systematic Review (3):CD004783. doi: 10.1002/14651858.CD004783.pub4.
• Rosenfeld RM et al. (2015). American Academy of Otolaryngology – Head and Neck Surgery.
Clinical Practice Guideline (Update): Adult Sinusitis. Head and Neck Surgery.152 (2S): S1-S39.
• Rosenfeld RM et al. (2016). Acute Sinusitis in Adults. The New England Journal of Medicine,
375:962-70. DOI: 10.1056/ NEJMcp1601749
• The Sanford Guide to Antimicrobial Therapy 2015. Available at: http://
webedition.sanfordguide.com/.

LOWER RESPIRATORY TRACT INFECTION
I. BRONCHIOLITIS/WHEEZY BRONCHITIS (EXPIRATORY WHEEZING)
• Respiratory syncytial virus (RSV) is the most important etiology; rapid diagnosis
uses antigen detection methods.
• In adults, RSV accounts for 10.6% of hospitalizations for pneumonia, 11.4% for
chronic obstructive pulmonary disease, 7.2% for asthma and 5.4% for
congestive heart failure in patients >65 years of age. RSV caused 11% of
clinically important respiratory illnesses in military recruits.
• There is a need for surveillance for etiologies of bronchiolitis and bronchitis.
Etiology: RSV in 50%; Parainfluenza in 25%; Human metapneumovirus
Preferred Regimen:
P (Infants/children <5yrs.): Ribavirin for severe disease (e.g., requiring mechanical
ventilation). Administer at a concentration of 20mg/mL in sterile water by small
particle aerosol generator (SPAG) 2 via continuous aerosol administration for over
18-20 hours daily for 3-5d. Aerosolized ribavirin is not available in the Philippines
A: Antibiotics are not indicated.
Comments:
Antibiotics not indicated in infants hospitalized with RSV bronchiolitis unless there
is evidence of secondary bacterial infection. The mainstay of therapy is supportive
care, which includes hydration, measurement of oxygen saturation and use of
supplemental oxygen if needed.
Ribavirin is not routinely recommended due to the high cost, toxicity, absence of
controlled data. Aerosolized ribavirin should only be administered with SPAG 2.
Palivizumab is a humanized mouse monoclonal antibody for the prevention of
bronchiolitis, reducing hospitalization rates by 39-82% among high risk infants
(e.g., those with congenital heart disease, chronic lung disease, or preterm birth
<32 weeks). It is given at a dose of 15mg/kg IM once every 30 days, for a maximum
of 5 months (Pediatrics 126: e116, 2010).
II. BRONCHIITIS
A. Acute Bronchitis
• A throat swab polymerase chain reaction test may be done to diagnose

Mycoplasma or Chlamydophila (formerly Chlamydia)
Etiology:
Infants or children < 2y: Adenovirus (most common)
Children 2-5y: Respiratory syncytial virus; Parainfluenza 3 virus; Human
metapneumovirus

Adolescent and adults: Usually viral M. pneumoniae in 5%; Chlamydophyla

pneumoniae in 5%
Preferred Regimen:
PEDIATRICS ADULTS
< 5yrs.: Antibiotics are indicated only Antibiotics are usually not indicated.
with associated sinusitis or heavy Antitussive +/- inhaled
growth on throat culture for S. bronchodilators.
pneumoniae, Group A Streptococci,
H. influenzae; or there is no
improvement in 1 week. Otherwise,
treatment is symptomatic.
Comments:
Purulent sputum alone not an indication for antibiotic therapy. Expect cough to
last for 2 weeks. If there is fever or rigors, get a chest x-ray. If Mycoplasma is
documented, prefer doxycycline over macrolides due to increasing macrolide
resistance. A throat swab polymerase chain reaction test may be done to diagnose
Mycoplasma or Chlamydophila (formerly Chlamydia).
B. Peritonsillar abscess (Quinsy) Persistent cough (>14 days), afebrile during

community outbreak:
Pertussis (whooping cough)

• Presents as 3 stages: 1) catarrhal (1-2 weeks); 2) paroxysmal coughing (2-4
weeks); and 3) convalescence (1-2 weeks).
• Diagnosis is made through polymerase chain reaction on nasopharyngeal
secretions or increased pertussis-toxin antibody titres.
Etiology: Bordetella pertussis and occasionally, B. parapertussis.

Differential diagnoses include the following:
1. Asthma
2. Gastroesophageal reflux
3. Post-nasal drip
4. Mycoplasma infection
5. Chlamydophila infection
Preferred Regimen:
PEDIATRICS ADULTS
Neonates younger than 1 month: Azithromycin 500mg PO on d1,
Azithromycin 10mg/kg/d q24h for 5d 250mg q24h on d2-5
OR OR

Erythromycin 40mg/kg/d in 4 div Erythromycin estolate 500mg PO qid

doses x 14d x14d OR
>2 mos.: Trimethoprim-sulfamethoxazole
Azithromycin 10mg/kg/d PO on d1 160/800mg PO bid x 14d
then 5mg/kg/d PO q24h x 4d OR OR
Clarithromycin 7.5mg/kg PO q12h x Clarithromycin 500mg PO bid x 7d
7d
(Max: 1g/d) OR
Erythromycin estolate 40mg/kg/d in
4 div doses OR
Erythromycin base 40mg/kg/d div
q6h x 7-14d (Max: 1-2g/d) OR
Trimethoprim-sulfamethoxazole
8/40mg/kg/d in 2 div doses/d x 14d
Comments:
Treatment may abort or eliminate pertussis in the catarrhal stage, but does not
shorten the paroxysmal stage. Treatment is aimed at eradication of
nasopharyngeal carriage. In the non-outbreak setting, the likelihood of pertussis
increased if post-tussive emesis or inspiratory whoop is present.
Pertussis prophylaxis of household contacts (adults and children):

Azithromycin 500mg PO x1 dose on d1, then 250mg q24h on d2–5 OR
Erythromycin 500mg PO qid 14d OR
Clarithromycin 500mg PO bid x 7d OR
Trimethoprim-sulfamethoxazole 160/800 mg 1 tablet PO bid x 14d
C. Acute bacterial exacerbation of chronic bronchitis (ABECB), adults
• Almost always in smokers with chronic obstructive pulmonary disease. Tobacco

use and air pollution contribute to ABECB.
• Severe ABECB is characterized by increased dyspnea, sputum
viscosity/purulence and sputum volume.
• Management of severe ABECB includes: (1) consider a chest x-ray, especially if
febrile and/or with low oxygen saturation; (2) inhaled anticholinergic
bronchodilator; (3) oral corticosteroid; taper over 2 weeks; (4) tobacco
cessation; and (5) non-invasive positive pressure ventilation.
Etiology: Viruses in 20%-50%, Chlamydophila pneumonia in 5%, Mycoplasma

pneumonia in <1%
The role of S. pneumoniae, H. influenzae, and Moraxella catarrhalis is
controversial.


Mild Moderate infections:
Amoxicillin 500mg tid OR Doxycycline 100mg PO bid OR Cefuroxime 500mg PO
bid
Severe infections:
Co-amoxiclav 875/125mg bid OR Azithromycin 500mg q24h x 3d OR
Clarithromycin 500mg PO bid OR Levofloxacin 500mg PO q24h
DOT: 5-10d
Comments:
The role of antimicrobial therapy is debated even for severe diseases, but a recent
study on over 80,000 patients show value of antimicrobial therapy in patients
hospitalized with severe disease. The GOLD COPD 2015 Update states: Antibiotics
should be given to patients with exacerbations of COPD who have: (1) three
cardinal symptoms. (increase in dyspnea, sputum volume, and sputum purulence;
(2) have two of the cardinal symptoms, if increased sputum purulence is one of
the two symptoms; or (3) require mechanical ventilation (invasive or non-invasive.
IV antibiotics should only be used if the patient cannot tolerate oral antibiotics.
D. Influenza
• Fever, cough, myalgia during influenza season

• Complications include influenza pneumonia and secondary bacterial
pneumonia due to community-acquired methicillin-resistant and susceptible
Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus
influenzae.
• Prevention includes annual vaccination.
Etiology: Influenza A and B
Preferred Regimen:
P: Oseltamivir
Infant 2 weeks-11 months: 3mg/kg bid x 5d
≤15kg: 30mg bid x 5d
>15kg to 23kg: 45mg bid x 5d
>23kg to 40kg: 60mg bid x 5d
>40kg: 75mg bid x 5d
A: Oseltamivir 75mg PO bid x 5d
Comments: Resistant to Amantadine and rimantidine (100%)
E. Acute bacterial exacerbation (bronchiectasis)
Etiology: H. influenzae; P. aeruginosa; S. pneumoniae (rarely)

Preferred Regimen:
A: Levofloxacin 500mg PO q24h x 7-10d
Prevention of exacerbation:
Erythromycin 500mg PO bid OR Azithromycin 250mg q24h x 1 year
Comments:
May be caused by obstruction, decreased immunoglobulins, cystic fibrosis,
dyskinetic cilia, tobacco, or prior severe or recurrent necrotizing bronchitis (e.g.,
pertussis). Higher rates of macrolide resistance in oropharyngeal flora may
potentially increase the risk of cardiovascular deaths from macrolide-induced QTc
prolongation, liver toxicity, or hearing loss Pre-treatment screening includes
baseline liver function tests, electrocardiogram, hearing test, and sputum culture
to exclude mycobacterial disease.
Etiology: Aspergillosis; Aspergillus fumigatus (most common); A. flavus and others.

Allergic bronchopulmonary aspergillosis (clinical manifestation: wheezing,
pulmonary infiltrates, bronchiectasis, and fibrosis). Airway colonization is associated
with increase blood eosinophils, increase lgE levels and isolation of Aspergillus spp.
or other dematiaceous species (Alternaria, Cladosporium, etc.)

Treatment of allergic bronchopulmonary aspergillosis: Itraconazole 200mg PO bid
x 16 weeks or longer.
Comments:
Itraconazole decreases the number of exacerbations requiring corticosteroids
with improved immunological markers improved lung function and exercise
tolerance. Acute asthma attacks associated with allergic bronchopulmonary
aspergillosis is treated with corticosteroids.
III. PNEUMONIAS AND INFECTIONS OF THE LUNG PARENCHYMA
A. Community-Acquired Pneumonia (CAP) in Neonates
Etiology: Gram (-) bacilli, Group B Streptococci
Preferred Regimen:
Ampicillin 100-200mg/kg/d IV div q6h OR
Penicillin G 100,000-250,000 U/kg/d div q4-6h IV infusion over 15-60 min
For severe infections: 250,000-400,000 U/kg/d div q4-6h IV infusion over 15-60
min PLUS
Aminoglycoside: Amikacin 15mg/kg/d IV qd or Gentamicin 5mg/kg/d IV qd

Comments:
Recommendation for immunization:
• Pneumococcal Conjugate Vaccine given IM, given at 6 weeks of age. Primary
vaccination includes 3 doses with an interval of 4 weeks in between doses, and
a booster, 6 months after the 3rd dose
• Hib Conjugate Vaccine given IM, given at 6 weeks of age. Primary vaccination
includes 3 doses with an interval of 4 weeks in between
B. Community-Acquired Pneumonia (CAP) in Infants and Children up to 5 years
Pediatric CAP (PCAP) classification:

• PCAP A/B (non-severe): No or mild dehydration; no malnutrition; no pallor;
awake; no signs of respiratory failure; respiratory rate of ≥50-≥60/min (3-
12mos.), ≥40-≤50/min (1-5yrs.), ≥30-≤35/min (>5 yrs.)
• PCAP C (severe): Moderate dehydration; moderate malnutrition; with pallor;
irritable (+ intercostal/subcostal retractions, head bobbing, cyanosis);
respiratory rate of >60-≤70/min (3-12 mos.), >50/min (1-5 y), >35/min (>5y);
NO grunting; NO apnea
• PCAP D (very severe): Severe dehydration; severe malnutrition; with pallor;
lethargic/ stuporous/in coma (+ supraclavicular/intercostal/subcostal
retractions, head bobbing, cyanosis, grunting, apnea; respiratory rate >70/min
(3-12 mos.), >50/min (1-5 y), >35/min (>5y).
Etiology: S. pneumoniae in 30%-50%, H. influenzae type b in 10%-30%, S. aureus, K.

pneumoniae, Non-typeable H. influenzae
Preferred Regimen:
PCAP A or B:
If with complete Hib vaccination: Amoxicillin 80-90mg/kg/d div q12h PO x 5d
If with no Hib vaccination or incomplete or unknown vaccination history:
Co-amoxiclav 80-90mg/kg/d PO (amoxicillin component) div q8h (4:1 preparations)
or div q12h (7:1 preparations)
For children >40 kg: 500/125mg PO q8h (Max: 2g/d of amoxicillin) OR
Cefuroxime 20-30mg/kg/d PO div q12h
If allergic to Amoxicillin, consider macrolide:
Azithromycin 10mg/kg qd PO x 3d or 10mg/kg/d PO on d1 then 5mg/kg/d PO on
d2-5 OR Clarithromycin 15mg/kg/d div PO q12h x 7d
If with non-response to initial treatment (48-72h), consider the following:
1. If started on Amoxicillin 80-90mg/kg/d, shift to Co-amoxiclav 90 mg/kg/d div
PO q12h (amoxicillin component).
2. If started on Co-amoxiclav 80-90mg/kg/d, admit for IV antibiotics.
3. May also consider adding an oral macrolide.
4. Consider other diagnosis.

PCAP C:
If with complete Hib vaccination:
Penicillin G 200,000 U/kg/d IV div q6h OR Ampicillin 200mg/kg/d IV div q6h
If with no Hib vaccination or incomplete or unknown vaccination history:
Ampicillin-sulbactam 100mg/kg/d IV div q6h OR Cefuroxime 100mg/kg/d IV div
q8h OR
Ceftriaxone 100mg/kg/d IV div q12h
PCAP D:
Refer to Specialist. Admit to critical care unit, refer to specialist for antibiotic
guidance.
Comments:
Equal efficacy between oral Amoxicillin and IV penicillin if feeding is tolerated.
Available Co-amoxiclav preparations in the formulary are the following:
4:1 500 mg amoxicillin (as trihydrate) + 125 mg potassium clavulanate per tablet
7:1 875 mg amoxicillin (as trihydrate) + 125 mg potassium clavulanate per tablet
200 mg amoxicillin (as trihydrate) + 28.5 mg clavulanate per 5mL
granules/powder for suspension, 70 mL
400 mg amoxicillin (as trihydrate) + 57 mg potassium clavulanate per 5mL
granules/powder for suspension, 70 mL
Switch from IV to oral form 2-3 days after initiation of treatment in patients who
are:
a. Responding to initial treatment
b. Able to feed, intact GI absorption
c. Free from pulmonary/ extrapulmonary complications
Although the total course of therapy is usually 7 to 10 days for uncomplicated
pneumonia, longer courses of 2 to 3 weeks may be required for more severe
disease (pleural empyema or pulmonary abscesses).
Etiology: Children (>5 years) and adolescents: S. pneumoniae, M. pneumoniae, C.

pneumoniae
Preferred Regimen:
Erythromycin 50mg/kg/d PO div q6-8h x 10-14d OR Clarithromycin suspension
15mg/kg/d div q12h x 10d OR Azithromycin 10mg/kg PO qd x 3d or 10 mg/kg/d PO
on d1 then 5mg/kg/d PO on d2-5
Comments:
Treatment choices when atypical pathogens are suspected. Clinical presentation
may be indistinguishable from viral pneumonia. Complaints are related to slowly
progressive systemic symptoms over 3 to 7 days, with malaise, pharyngitis, and
headache, followed by cough that is irritative and nonproductive (lasting for 2-4
weeks). Physical examination may show rales, rhonchi, and wheezes in the context
of a child who does not appear ill (“walking pneumonia”).

C. Community-Acquired Pneumonia (CAP) in Adults
LOW-RISK CAP:
• Stable vital signs (RR <30/min, PR<125/min, SBP>90mmHg, DBP>60mmHg,
Temp>36˚C or<40˚C)
• No altered mental state of acute onset
• No suspected aspiration
• No or stable co-morbid conditions
• Chest X ray: localized infiltrates; no evidence of pleural effusion
Etiology (Potential pathogens): S. pneumoniae, H. influenzae, C. pneumoniae, M.

catarrhalis Enteric Gram (-) bacilli (among those with co- morbid illness)
Preferred Regimen:
Without co-morbid illness: Amoxicillin 1g PO tid OR Azithromycin 500mg PO qd
OR
Clarithromycin 500mg PO bid
With stable co-morbid illness: Co-amoxiclav 1g PO bid OR
Cefuroxime axetil 500mg PO bid +/- Azithromycin 500mg PO qd OR
Clarithromycin 500mg PO bid
DOT: For S. pneumoniae: 5-7d or 3-5d if using Azithromycin
Comments:
The recommendation to use Amoxicillin as first-line drug for low-risk CAP in
patients with no co-morbid illness is based on the 2015 ARSP data. Among
noninvasive S. pneumoniae isolates, only 1% (n=246 non-invasive isolates) were
reported as penicillin-resistant using non- meningitis breakpoints.
Fluoroquinolones are not recommended as first line treatment option for low risk
CAP. It is recommended that they be reserved as potential second-line agents for
the treatment of pulmonary tuberculosis, particularly for multi-drug resistant
tuberculosis. Sputum gram stain and culture is not necessary.
MODERATE-RISK CAP:
• Unstable Vital Signs: RR>30/min, PR > 125/min, Temp < 36˚C or > 40˚C
• Altered mental state of acute onset
• Suspected aspiration
• Unstable/Decompensated comorbid condition: uncontrolled diabetes mellitus,
active malignancies, neurologic disease in evolution, congestive heart failure
class II-IV, unstable coronary artery disease, renal failure on dialysis,
uncompensated COPD, decompensated liver disease.
• Chest X-ray: multilobar infiltrates; pleural effusion

Etiology (Potential Pathogens): S. pneumoniae, H. influenzae, C. pneumoniae, M.

pneumoniae, M. catarrhalis, Enteric Gram (-) bacilli, Legionella pneumophila,
Anaerobes (among those with risk of aspiration)
Preferred Regimen:
Ampicillin-Sulbactam 1.5g IV q6h or Cefuroxime sodium 1.5g IV q8h or
Ceftriaxone 2g IV q24h PLUS Azithromycin 500mg PO qd or Clarithromycin
500mg PO bid or Levofloxacin 750mg PO qd
DOT: 7-10d may be adequate (or 3-5d for azalides). A longer duration of up to
28d may be given for S. aureus or P. aeruginosa if with concomitant bacteremia.
Comments:
For those at risk of aspiration, infections with anaerobes should be considered.
Because of increasing resistance of gram (-) bacilli to fluoroquinolones,
monotherapy with fluoroquinolone is not recommended. Azithromycin and
fluoroquinolones can cause prolongation of QT interval. Caution should be taken
especially in elderly with cardiovascular diseases. Shift from IV to oral therapy
once the patient is clinically improving. Choose antibiotics based on available
micro- biological data, or use an oral agent from the same drug class. Blood
culture, sputum gram stain and culture are necessary
HIGH-RISK CAP:
Any of the clinical feature of Moderate-risk CAP plus any of the following: severe
sepsis and septic shock or need for mechanical ventilation
Etiology (Potential Pathogens): S. pneumoniae, H. influenzae, C. pneumoniae, M.

pneumoniae, M. catarrhalis; Enteric Gram (-) bacilli; L. pneumophila, Anaerobes
(among those with risk of aspiration), S. aureus, P. aeruginosa
Preferred Regimen:
No risk for P. aeruginosa:
Ceftriaxone 2g IV q24h OR Ertapenem 1g IV q24h PLUS
Azithromycin 500mg IV qd OR Levofloxacin 750mg IV qd
Risk for P. aeruginosa:
Piperacillin-tazobactam 4.5g IV q6h or Cefepime 2g IV q8-12h or Meropenem 1g
IV q8h PLUS Azithromycin 500mg IV qd PLUS Gentamicin 5-7mg/kg IV qd or
Amikacin 15mg/kg IV qd
OR
Piperacillin-Tazobactam 4.5g IV q6h or Cefepime 2g IV q8-12h or Meropenem
1g IV q8h PLUS Levofloxacin 750mg IV qd or Ciprofloxacin 400mg IV q8-12h
If MRSA pneumonia is suspected, add:
Vancomycin 25-30mg/kg loading dose then 15-20mg/kg IV q8-12h OR Linezolid
600mg IV q12h

DOT for all regimens: 7-10 days may be adequate. A longer duration of up to 28
days may be given for S. aureus or P. aeruginosa if with concomitant bacteremia.
Comments:
Risk factors for P. aeruginosa infections:
1. History of chronic or prolonged (>7 days within the past month) use of broad-
spectrum antibiotic therapy.
2. Severe underlying bronchopulmonary disease
3. Malnutrition
4. Chronic use of steroids >15mg/d for at least 2 weeks
Empiric therapy for MRSA among hospitalized patients with severe CAP is
indicated in any of the following conditions:
1. requirement for intensive care unit
2. necrotizing or cavitary infiltrates
3. empyema.
Treatment should be modified according to culture/sensitivity results once
available. Use of Linezolid or Clindamycin monotherapy for MRSA bacteremia,
even if associated with a pulmonary source, is not recommended.
D. Empyema
ACUTE EMPYEMA
Etiology: S. aureus; S. pneumoniae; S. pyogenes; H. influenzae
Preferred Regimen:
1st line 2nd line
PEDIATRICS
Clindamycin 25-40mg/kg/d IV div q6-8h Clindamycin 600mg q8h IV
PLUS Ceftriaxone 50-100mg/kg/dose PLUS
q24h IV infusion over 10-30 min Ceftriaxone 2g q24h IV
ADULTS
Vancomycin 40mg/kg/d IV div q6h PLUS Vancomycin 15mg/kg IV q8-12h
Ampicillin-sulbactam 100mg/kg/d IV PLUS
div q6h Ampicillin-sulbactam 1.5g IV q6h
OR OR
Vancomycin 40mg/kg/d IV div q6h PLUS Vancomycin 15mg/kg IV q8-12h
Ceftriaxone 50-100mg/kg/dose IV q24h PLUS
PLUS Ceftriaxone 2g IV q24h PLUS
Metronidazole 30 mg/kg/d IV div q6h Metronidazole 500mg IV q6h
DOT: 2-4 weeks based on clinical response to drainage and antimicrobial therapy

Comments: Treatment includes systemic antibiotic and drainage. Treatment

should be guided by culture results.
CHRONIC EMPYEMA
Etiology: Mostly anaerobic organisms Mycobacterium tuberculosis
Preferred Regimen: Refer to specialist.
Comments: Rule out the possibility of tuberculosis.
E. Lung Abscess
Etiology: S. aureus; S. pneumoniae; Anaerobes of the upper respiratory tract
Preferred Regimen:
P:
1st line: Clindamycin 25-40mg/kg/d IV div q6-8h PLUS
Ceftriaxone 50-100mg/kg/dose q24h IV infusion over 10-30 min
2nd line: Vancomycin 40mg/kg/d IV div q6h PLUS Ceftriaxone 50-
100mg/kg/dose q24h IV infusion over 10-30 min PLUS Metronidazole 30mg/kg/d
IV div q6h
A:
Clindamycin 600mg IV q8h OR Ampicillin-sulbactam 3g IV q6h OR
Ceftriaxone 2g IV q24h PLUS Metronidazole 500mg IV q6h or 1g IV q12h OR
Piperacillin-tazobactam 4.5g IV q8h (for mixed infections with resistant Gram-
negative aerobes)
DOT: 4-6 weeks.
Comments: Do surgical intervention if with failure to improve after 7d of

appropriate antibiotics.
F. Pneumonia, anaerobic or aspiration with or without lung abscess
Etiology: Anaerobes; Gram positive cocci; Streptococcus melliri; Gram-negative

bacteria
Preferred Regimen:
1st line
PARENTERAL ORAL
Clindamycin 600mg IV q8h PLUS Clindamycin 300-450mg PO tid
Ceftriaxone 2g IV q24h for suspected OR
Gram-negative infection Amoxicillin-clavulanic acid 1g PO bid
OR Ampicillin-sulbactam 3g IV q6h

2nd line
PARENTERAL ORAL
Piperacillin-Tazobactam 4.5g IV q8h Co-amoxiclav 1g PO bid
OR
Ceftriaxone 2g q24h IV PLUS
Metronidazole 500mg IV q6h OR
DOT: Up to 3-4 weeks, depending on clinical response; longer (up to 2-3 months)
for lung abscess.
G. Pneumonia with concomitant/post-influenza
Patients with active influenza or with history of influenza within 2 weeks of

development of CAP
Etiology: S. aureus; S. pneumoniae
Preferred Regimen:
Refer to recommendations for moderate or high-risk CAP in adults and ADD:
Vancomycin 15 mg/kg IV q8-12h OR Linezolid 600mg IV q12h
Comments:
Use of Linezolid monotherapy for methicillin-resistant S. aureus bacteremia, even
if associated with a pulmonary source, is not recommended.
H. Hospital-acquired pneumonia (HAP) and Ventilator-associated pneumonia

(VAP) in PEDIATRICS
• HAP in children is pneumonia (diagnosed by a combination of clinical,

laboratory and imaging parameters) that occurs on or after the 3rd day of
admission to an inpatient location.
• VAP in children is pneumonia where the patient is on mechanical ventilation
for >2 calendar days on the date of event, with day of ventilator placement
being day 1 and the ventilator was in place on the date of the event or the day
before.
Etiology: S. aureus; S. pneumonia
Preferred Regimen:
Refer to recommendations for moderate or high-risk CAP in adults and ADD:
Vancomycin 40-60mg/kg/d IV q6-8h for documented MRSA infections OR
Linezolid 600mg IV q12h

Etiology: P. aeruginosa, A. baumanii, K. pneumoniae; Klebsiella spp., E. coli,

Enterobacter spp.; Proteus spp.; Serratia marcesens
Preferred Regimen:
Ceftazidime 100-150mg/kg/d q8h IV infused over 15-30 minutes PLUS
Aminoglycoside: Amikacin 15mg/kg/d IV qd or Gentamicin 5mg/kg/day IV qd
Comments:
Choice should be based on current antimicrobial susceptibility pattern in the
institution. The recommendations for empiric therapy here are based on national
antimicrobial resistance data. If S. aureus is suspected, add Vancomycin.
Etiology (Multi-drug resistant (MDR) pathogens): P. aeruginosa, K. pneumoniae

(extended spectrum beta-lactamase and carbapenemase-producing Klebsiella
strains), Acinetobacter spp., Stenotrophomonas maltophilia, Burkholderiacepacia,
Methicillin-resistant S. aureus
Preferred Regimen:
Piperacillin-Tazobactam 300mg/kg/d q6h OR
Meropenem 300mg/kg/d q6h (120mg/kg/d q8h if with meningitis) (Max: 2-4g/d)
OR Cefepime 100mg/kg/day q8h (150mg/kg/d q8h for Pseudomonas)
Comments:
For infections with MDR Gram (-) bacilli that are highly resistant to several classes
of antimicrobial agents, referral to a specialist is warranted.
Risk factors for MDR pathogens:

• Antimicrobial therapy in preceding 90 days
• Current hospitalization of 5 days or more
• High frequency of antibiotic resistance in the community or in the specific
hospital unit
• Presence of risk factors for HCAP:
1. Hospitalization for 2 days or more in the preceding 90 days
2. Residence in a nursing home or extended care facility
3. Home infusion therapy (including antibiotics)
4. Chronic dialysis within 30 days
5. Home wound care
6. Family member with MDR pathogen
7. Immunosuppressive disease and/ or therapy
Etiology: Viral and fungal pathogens in immunocompromised hosts (patients on

chronic immunosuppressants, solid organ and bone marrow transplant recipients)
Comments: Refer to a specialist.

I. Hospital-acquired pneumonia (HAP) and Ventilator-associated pneumonia

(VAP) in ADULTS
Risk Factors for multidrug-resistant (MDR) VAP/HAP, methicillin-resistant S.

aureus (MRSA) VAP/HAP, and Pseudomonas VAP/HAP:
• Prior IV antibiotic use within 90 days
Additional Risk factors for MDR VAP

• Septic shock
• ARDS Preceding VAP
• At least 5 days hospitalization before VAP onset
• Acute Renal Replacement therapy prior to VAP onset
High Risk for Mortality

• Need for ventilator support due to pneumonia
• Septic shock
EMPIRIC TREATMENT FOR HAP

HAP is defined as a pneumonia not incubating at the time of hospital admission and
occurring 48h or more after admission and not associated with ventilation
NOT AT HIGH RISK OF MORTALITY AND NO FACTORS INCREASING THE LIKELIHOOD

OF MRSA
Preferred Regimen:
Piperacillin-Tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h OR Meropenem 1g
IV q8h
Comments:
All hospitals should generate their own antibiogram and empiric treatment be
guided by the local distribution of pathogens and their antimicrobial
susceptibilities. Antibiotic therapy should be de- escalated or modified based on
the culture and susceptibility results. Do sputum GS/CS and blood culture to
determine etiology of HAP.
NOT AT HIGH RISK OF MORTALITY BUT WITH FACTORS INCREASING THE

LIKELIHOOD OF MRSA
Preferred Regimen:
Piperacillin-Tazobactam 4.5g IV q6h OR
Cefepime 2g IV q8h OR
Meropenem 1g IV q8h OR
Aztreonam 2g IV q8h PLUS Vancomycin loading dose of 25-30mg/kg then 15-
20mg/kg IV q8-12h with goal to target trough level to 15-20 mg/mL OR

Linezolid 600mg IV q12h
HIGH RISK OF MORTALITY AND WITH RISK FACTOR FOR MDR
Preferred Regimen:
Piperacillin-Tazobactam 4.5g IV q6h or Cefepime 2g IV q8h or Meropenem 1g IV
q8h or Aztreonam (for Penicillin Allergy) PLUS
Levofloxacin 750 mg IV qd or Amikacin 15-20 mg/kg IV qd PLUS
Vancomycin loading dose of 25-30 mg/kg then 15-20mg/kg IV q8-12h with goal to
target trough level to 15-20mg/mL or Linezolid 600mg IV q12h
DOT: 7 days may be longer depending on clinical radiologic and laboratory
improvement
EMPIRIC TREATMENT OF VAP

VAP is defined as pneumonia occurring >48h after endotracheal intubation and
associated with ventilation
Preferred Regimen:
Piperacillin-Tazobactam 4.5g IV q6h or Cefepime 2g IV q8h or Meropenem 1g IV
q8h or Aztreonam 2g IV q8h PLUS
Levofloxacin 750mg IV qd or Amikacin 15-20mg/kg IV q24h PLUS
Vancomycin loading dose of 25-30mg/kg then 15-20mg/kg IV q8-12h with goal to
target trough level to 15-20 mg/mL or Linezolid 600mg IV q12h
DOT: 7 days may be longer depending on clinical radiologic and laboratory
improvement
Comments:
In patients with suspected VAP, include coverage for S. aureus, Pseudomonas
aeruginosa and other gram negative bacilli in all empiric regimens (gram positive
coverage + β lactams-based gram-negative antibiotics with antipseudomonal
activity + non-β lactam based antibiotics with antipseudomonal activity). All
hospitals should generate their own antibiogram and empiric treatment be guided
by the local distribution of pathogens and their antimicrobial susceptibilities
Initial treatment should cover for MRSA, Pseudomonas aeruginosa and other gram
(-) bacilli. Therapy should be modified based on culture and susceptibility results
If culture results show carbapenem resistance or MDR where Colistin is to be used,

referral to ID physician is required. Use procalcitonin levels and clinical criteria to
guide discontinuation of therapy for both HAP and VAP
PATHOGEN-SPECIFIC TREATMENT FOR ADULT AND PEDIATRICS

Choice of antibiotic should be based on the results of susceptibility testing
Etiology: Methicillin-resistant S. aureus

Preferred Regimen:
P and A:
Vancomycin 40-60mg/kg/dq6h with goal to target trough level to 15-20mg/mL OR
Linezolid 30mg/kg/d IV/PO div q8h (up to 12 yrs) or 600mg IV/PO q12h (age>12 y)
Preferred Regimen:
P: 1st line: Ceftazidime 100-150mg/kg/d IV div q8h PLUS Amikacin 15mg/kg/d IV
or Gentamicin 5-7mg/kg/d IV qd OR Cefepime 150mg/kg/d div q6h
2nd line: Piperacillin-tazobactam 300mg/kg/d IV div q6h OR
Meropenem 60mg/kg/d IV div q8h (120mg/kg/d if with meningitis) (Max: 2-
4g/d) OR Ciprofloxacin 20-30mg/kg/day IV div q12h (Max: 1.2 g/d) PLUS
Amikacin 15mg/kg/d IV or Gentamicin 5-7mg/kg/d IV qd
A:
Piperacillin-Tazobactam 4.5g q6h by extended infusion OR
Ceftazidime 2g IV q8h OR Cefepime 2g IV q12h or q8h OR
Meropenem 1g IV q8h OR
Levofloxacin 750mg IV or Ciprofloxacin 400mg IV q8h PLUS Amikacin
15mg/kg/d IV or Gentamicin 5-7mg/kg/d IV qd OR
Aztreonam 2g IV q6h for beta-lactam allergy
Comments:
Choice of antibiotic should be based on upon the results of susceptibility testing.
Aminoglycoside monotherapy should be avoided. For patients with VAP/HAP due
to P. aeruginosa not in septic shock or at high risk for death and for whom the
results of antibiotic susceptibility testing are known, monotherapy with a beta-
lactam is preferred.
For patients with HAP/VAP due to P. aeruginosa in septic shock or at high risk of
death when results of antibiotic testing is available, use combination therapy using
2 antibiotics to which the isolate is susceptible. Use Meropenem only if organism
is resistant to all other beta-lactams.
Etiology: Acinetobacter species
Preferred Regimen:
P:
Meropenem 60mg/kg/d IV div q8h PLUS
Amikacin 15mg/kg/d IV div q8h or Gentamicin 5mg/kg/d IV qd
For carbapenem-resistant strains:
Ampicillin-sulbactam 100-200mg/kg/d IV div q6h (ampicillin component) or
Piperacillin-tazobactam 300mg/kg/d IV div q6-8h PLUS
Amikacin 15mg/kg/d IV or Gentamicin 5-7mg/kg/d IV qd

For MDR Acinetobacter:

Ciprofloxacin 20-30mg/kg/d IV div q12h
A: Meropenem 1g IV q8h PLUS Ampicillin-sulbactam 3g IV q6h
MDR strain sensitive only to colistin: Combine Colistin with Meropenem
Comments:
In patients with HAP/VAP caused by Acinetobacter species that is sensitive only to
polymyxins, use IV colistin plus Meropenem. Do not use adjunctive rifampicin in
patients caused by Acinetobacter species that is sensitive only to colistin. Do not
use Tigecycline in patients with HAP/VAP due to Acinetobacter species. The
combination of colistin and Meropenem is preferred than tigecycline. Refer to
Specialist, if use of Colistin is indicated
Etiology: Klebsiella pneumoniae
Preferred Regimen:
P: 1st line: Meropenem 60mg/kg/d IV div q8h OR Imipenem 60-100mg/kg/day IV
div q6h
2nd line: Ciprofloxacin 20-30mg/kg/d IV div q12h OR Piperacillin-tazobactam
300mg/kg/d IV div q8h
A:
Ceftriaxone 2g IV q24h OR Levofloxacin 750mg IV q24h OR
Piperacillin-Tazobactam 4.5g IV q8-6h
Regimen for ESBL-producing organisms: Ertapenem 1g IV q24h
Comments:
Consider patient specific factors such as allergies and co morbidities in choosing
an antibiotic. Consider prolonged infusion of carbapenem
Etiology: Carbapenem-resistant gram negatives
Preferred Regimen: Refer to Specialist
Etiology: Achromobacter
Preferred Regimen:
P: 1st line: Ceftazidime 100-150mg/kg/d IV div q8h PLUS Cotrimoxazole 8mg/kg/d
PO div q12h
2nd line: Piperacillin-Tazobactam 300mg/kg/d IV div q6-8h or Meropenem
60mg/kg/d IV div q8h PLUS Cotrimoxazole 8mg/kg/d PO div q12h
A: 1st line: Piperacillin-tazobactam 4.5g IV q8-6h OR Meropenem 1g q8h IV
2nd line: Cotrimoxazole 8-10mg/kg/d PO div q6h or q8h (TMP component)

Comments: For Meropenem, if with meningitis, increase dose to 120 mg/kg/day

div q8h
Etiology: Burkholderia cepacia
Preferred Regimen:
P:
1st line: Meropenem 60mg/kg/d IV div q8h PLUS Amikacin 15mg/kg/d IV or
Gentamicin 5-7 mg/kg/d IV qd
2nd line: Ceftazidime 100-150mg/kg/d IV div q8h or Piperacillin-Tazobactam
300mg/kg/d IV div q6-8h or Ciprofloxacin 20-30 mg/kg/d IV div q12h or
Cotrimoxazole 8mg/kg/d PO div q12h
PLUS Amikacin 15 mg/kg/d IV or Gentamicin 5-7 mg/kg/d IV qd
A:
1st line: Meropenem 1g IV q8h OR Ciprofloxacin 400mg IV q12h
2nd line: Cotrimoxazole 8-10 mg/kg/day PO div q6h or q8h (TMP Component)
Etiology: Burkholderia pseudomallei
Preferred Regimen:
P:
1st line: Ceftazidime 150 mg/kg/d IV div q8h OR Meropenem 60mg/kg/d div IV
q8h x 7-14d PLUS Cotrimoxazole 8 mg/kg/d PO div q12h (TMP component) x 12-
24 weeks.
Some eradication regimens use:
Amoxicillin-clavulanate 90 mg/kg/d PO div q8h (amoxicillin component) OR
Doxycycline 4mg/kg/d div q12h PLUS Cotrimoxazole 8 mg/kg/d PO div q12h (TMP
component) x 12-24 weeks
A:
1st line: Ceftazidime 2g IV q6h x 10-14d OR Meropenem 1g IV q8h x 10-14 d
Followed by oral therapy: Cotrimoxazole 6-8mg/kg bid (TMP component) plus
Folic acid 5mg qd OR Doxycycline 100mg bid OR Amoxicillin-clavulanate 625mg
PO tid (for pregnant or sulfa allergy)
DOT: 6 months for osteomyelitis and CNS infection, 3 months for other infections
Etiology: Escherichia coli
Preferred Regimen:
P:
1st line: Ceftriaxone 100 mg/kg/d IV div q12-24h PLUS Amikacin 15mg/kg/d IV or
Gentamicin 5mg/kg/d qd IV
2nd line: Meropenem 60mg/kg/d IV div q8h PLUS Amikacin 15mg/kg/d IV or
Gentamicin 5mg/kg/d IV qd

Pansensitive Strains:
A: Choices include: Piperacillin-Tazobactam, Cephalosporins, Fluoroquinolones or
Aminoglycosides
ESBL strains
A: Ertapenem 1g IV q24h
Etiology: Enterobacter
Preferred Regimen:
P: 1st line: Cefepime 100-150mg/kg/d div q8-12h OR Meropenem 60mg/kg/d IV
div q8h OR
PLUS Amikacin 15mg/kg/d IV or Gentamicin 5-7mg/kg/d IV qd
2nd line: Cotrimoxazole 8mg/kg/day PO div q12h OR Ciprofloxacin 20-30mg/kg/d
IV div q12h
PLUS Amikacin 15mg/kg/d IV OR Gentamicin 5-7mg/kg/d IV qd
A: Piperacillin-Tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h OR Meropenem
500mg-1g IV q8h
References
Available at: http://www.hopkinsmedicine.org/amp/ guidelines/antibiotic_guidelines.pdf
• Cherry JD, et al., eds. (2014). Feigin and Cherry's Textbook of Pediatric Infectious Diseases.
7th ed. Philadelphia, PA: Saunders.
• Kimberlin, DW et al., ed. (2015). Red Book: Report of the Committee on Infectious Diseases.
30th ed. Elk Grove Village, IL: American Academy of Pediatrics.
• Kliegman RM, et al., eds. (2016) Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA:
Elsevier.
• Management of Adults with Hospital-acquired and Ventilator associated Pneumonia; 2016
Clinical Practice Guideline by the Infectious Diseases Society of American Thoracic Society.
CID 2016:63
• Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases, 8 th ed. 2015.
• Mandell LA, et al. Clin Infect Dis. (2007) 44 (Supplement 2): S27-S72.
• Philippine Academy of Pediatric Pulmonologists, Inc. 2012 PAPP Update in the Evaluation
and Management of Pediatric Community- Acquired Pneumonia. Quezon City: Philippine
Academy of Pediatric Pulmonologists, Inc.
• Research Institute for Tropical Medicine. Antimicrobial Resistance Surveillance Program:
2015 Data Summary Report. Retrieved from: http://arsp.com.ph/arsp-data-summary-
report-2015/
• The Sanford Guide to Antimicrobial Therapy 2016. 46 th ed. Available at:
• Task Force: Diagnosis, Empiric Management and Prevention of Community-Acquired
Pneumonia in Immunocompetent Adults 2016 Update. Joint Statement of PSMID, PCCP,
PAFP and PCR. Manila: Philippine Society of Microbiology and Infectious Diseases.

SKIN AND SOFT TISSUE INFECTIONS IN PEDIATRIC PATIENTS
I. SKIN INFECTIONS
A. Skin abscess, boils, furuncles
Etiology: S. aureus: Methicillin sensitive (MSSA), Methicillin resistant (MRSA)

Community-associated MRSA is of increasing concern for effective management.
Preferred Regimen: Incision and drainage is the mainstay of therapy.

Note: needle aspiration is inadequate.
1st line
ORAL PARENTERAL
Cloxacillin 50-100mg/kg/d in 4 doses Oxacillin
(Max: 2g/d) Mild to moderate infections:
OR 100-150mg/kg/d IV/IM in 4 doses
Cephalexin (Max: 4 g/d)
Mild to moderate infections: Severe infections: 150-200mg/kg/d
25-50mg/kg/d in 3-4 doses IV/IM in 4-6 doses (Max: 12 g/d) OR
Severe infections: Cefazolin
75-100mg/kg/d in 3-4 doses (Max: Mild to moderate infections:
4g/d) 50mg/kg/d IV/IM in 3-4 doses
(Max: 3g/d)
Severe infections: 100-150mg IV/IM
in 3-4 doses (Max: 6g/d)
DOT: 5-10d
2nd line
ORAL PARENTERAL
Clindamycin 10-30mg/kg/d PO in 3-4 Clindamycin 25-40mg/kg/d IV in 3-4
doses (Max: 1.8g/d) OR doses (Max: 2.7g/d) OR
Cotrimoxazole 8-12mg/kg/d in 2 Vancomycin 40-60 mg/kg/d IV in 4
doses (TMP component) (Max: doses (Max: 4 g/d) OR
320mg/d) OR Linezolid
Doxycycline 2-4mg/kg/d in 1-2 doses Mild to moderate infections
(Max: 200mg/d) OR <12 yrs.: 30mg/kg/d in 3 doses
Linezolid ≥12 yrs.: 1200mg/d in 2 doses
Mild to moderate infections: Severe infections: Same
<12 yrs.: 30mg/kg/d in 3 doses DOT: 7-10d
≥12 yrs.: 1200mg/d in 2 doses
Severe infections: Same (Max: 1.2g/d)
DOT: 7-10d
Comments:
May treat patients with incision and drainage only and in outpatient setting if
there is no diabetes or immunosuppression, and boil or abscess is <5 cm in

diameter. Oral therapy PLUS I&D may be effective in abscess >5 cm in diameter
and in multiple abscesses.
Antibiotic therapy is recommended for abscesses with the following conditions:

severe or extensive disease (e.g., involving multiple sites of infection) or rapid
progression in presence of cellulitis; presence of systemic inflammatory response
syndrome (SIRS), such as temperature >38°C or <36°C, tachypnea >24 breaths per
minute, tachycardia >90 beats per minute, or white blood cell count >12,000 or
<4000 cells/μL; associated comorbidities or immunosuppression; extremes of age
abscess in areas difficult to drain (e.g., face, hand and genitalia), associated septic
phlebitis; lack of response to I&D alone.
If no response after 2-3 days with oral antibiotics, look for complications and
consider: Incision and drainage: culture abscess and blood. Empirical antibiotic
therapy using parenteral agents (in absence of specific culture and sensitivity data
select an agent with activity against MRSA) follow up culture and sensitivity
results. Systemic agents should be used in patients who are toxic, who have
extensive disease, or who have associated cellulitis. An antibiotic active against
MRSA is recommended for any of the following:

• Patients with carbuncles or abscesses who have failed initial recommended
antibiotic treatment against MSSA
• Those with markedly impaired host defenses, or
Doxycycline is not recommended for age <8 yrs.; bacteriostatic; limited recent
clinical experience.
B. Recurrent furunculosis
Etiology: S. aureus (MSSA and MRSA) infection presenting as recurrent

furunculosis (abscesses, boils) in an otherwise healthy host.
Preferred Regimen: Treat as for furuncles and boils

For decolonization:
If patient and physician wish to attempt decolonization. Patient should have no
active skin infections and is otherwise a healthy host. Need to culture multiple
sites, e.g., nose, throat, and inguinal area skin. Nares-only culture missed 48% of
colonized individuals. Avoid systemic antibiotics.
Mupirocin ointment in anterior nares and under fingernails bid x 7d PLUS
Chlorhexidine 4% shower daily x 7d
One report indicates that bleach baths (tub of warm water with ¼ cup of 6%
sodium hypochlorite (household bleach) for 15 minutes, is as effective as use of

chlorhexidine shower body washes. Only a modest positive effect in a prospective,

randomized single-blinded controlled trial.
Comments:
Some strains of MRSA, particularly the CA-MRSA, produce a toxin named Panton-
Valentin leukocidin (PVL) and are associated with severe infections. PVL is a
virulence factor of S. aureus which correlates with chronic recurrent furunculosis.
Topical decolonization is considered if patient has 2 or more episodes in 1 year or
other household members develop infection.
Intermittent bathing with chlorhexidine 4% or dilute bleach baths/6% sodium

hypochlorite (1/4 cup of bleach in a quarter-filled bathtub or 13 gallons water or
1 tsp bleach in 1 gallon of water) for 15 minutes 3x a week can be used to
significantly reduce skin load of S. aureus
Systemic antibiotics is recommended for the treatment of active infection ONLY

and is not routinely recommended for decolonization. Recommended intranasal
preparation of mupirocin is not available locally. Some local experts use topical
mupirocin for nasal decolonization.
C. Folliculitis
Etiology: S. aureus (most common), P. aeruginosa (from exposure to inadequately

chlorinated swimming pools, whirlpools and hot tubs), Aeromonas hydrophila
(following water exposure).
Preferred Regimen:
Usually self-limiting; no therapy indicated. Hot packs for comfort. Incision and
drainage is the mainstay of therapy.
1st line: Topical antibiotic therapy for mild cases of folliculitis. Could use
mupirocin ointment if staphylococcal etiology.
Oral agents:
Cloxacillin 50-100mg/kg/d in 4 doses (Max: 2g/d) OR
Cephalexin Mild to moderate infections: 25-50mg/kg/d in 3-4 doses;
Severe infections: 75-100mg/kg/d in 3-4 doses (Max: 4 g/d)
DOT: 7-10 days
Comments:
Folliculitis is infection of the hair follicle with purulent exudate in the epidermis.
Hot tub folliculitis is almost always caused by P. aeruginosa, is usually self-limited
and no treatment is indicated. Systemic therapy in cases of large and multiple
lesions should be treated with Penicillinase resistant antibiotics (Cloxacillin or
cephalexin).

D. Staphylococcal scalded skin syndrome
Etiology: Result of colonization of skin or mucosa by strain of S. aureus producing

an exfoliative toxin. Pathogen may be MSSA or MRSA.
Preferred Regimen:
1st line:
Oral Agent: Cloxacillin 50-100mg/kg/d in 4 doses (Max: 2g/d)
Parenteral Agents:
Oxacillin
Mild to moderate infections: 100-150mg/kg/d IM/IV in 4 doses (Max: 4g/d)
Severe infections: 150-200mg/kg/d in 4-6 doses (Max: 12g/d) OR
Cefazolin
Mild to moderate infections: 50mg/kg/d IM/IV in 3-4 doses (Max: 3g/d)
Severe infections: 100-150 mg in 3-4 doses (Max: 6 g/d)
DOT: 7-10d for MSSA
2nd line (if MRSA is suspected):

Oral agent:
Clindamycin PO 10-30mg in 3-4 doses (Max: 1.8 /d)
Parenteral agents:
Clindamycin 25-40mg/kg/d in 3-4 doses (Max: 2.7g/d) OR
Vancomycin 40-60mg/kg/d IV in 4doses (Max: 4g/d)
E. Impetigo and ecthyma
Etiology Preferred Regimen

Streptococcus sp. (Group A Mupirocin ointment 2% tid OR
causes honey crust impetigo) Fusidic acid 2% cream bid
(Group B, C, G are less DOT: 7-12d
common)
Methicillin-susceptible Cloxacillin 50-100mg/k/d in 4 doses
Staphylococcus aureus bullous (Max: 12 g/d) OR
impetigo: Cephalexin
25-50 mg/kg/d in 3-4 doses
Severe infections: 75-100mg/kg/d in 3-4
doses (Max: 4 g/d)
DOT: 7d
Suspected or confirmed Clindamycin 30-40mg/k/d in 3-4 doses
methicillin-resistant (Max: 1.8 g/d) OR
Staphylococcus aureus bullous Cotrimoxazole 8-12mg/kg/d in 2 doses
impetigo: (TMP component) (Max: 320mg/d) OR

Doxycycline 2-4mg/kg/d in 1-2 doses (Max:

200mg/d)
DOT: 7d
Comments:
Impetigo can be either bullous or nonbullous. Topicals can be used for patients
with limited number of lesions and appropriate for those with mild, localized areas
of impetigo, no more than 3 areas of impetigo or an area of infection <5 cm. Oral
antibiotics are indicated for patients with more extensive areas of infection (those
with multiple lesions) if infection is not resolving or is worsening, or those with
systemic symptoms; and those with non-bullous impetigo in multiple family
members, child care groups, or athletic teams.
Bullous impetigo is caused by strains of S. aureus that produce a toxin that cleaves
the dermal-epidermal junction to form fragile, thin roofed vesicopustules. These
lesions may rupture, creating crusted, erythematous erosions, often surrounded
by a collar of the roof’s remnants.
Nonbullous impetigo can be caused by β-hemolytic streptococci or S. aureus, or

both in combination. Impetigo begins as erythematous papules that rapidly evolve
into vesicles and pustules that rupture, with the dried discharge forming honey-
colored crusts on an erythematous base.

• Patients who have failed initial recommended antibiotic treatment against MSSA
• Those with markedly impaired host defenses
Echthyma is a consequence of neglected impetigo, and S. aureus and/or

streptococci may be the cause. Lesions begin as vesicles that rupture, resulting in
circular, erythematous ulcers with adherent crusts, often with surrounding
erythematous edema. Streptococcus pyogenes infection manifests as “honey
crust” lesions or “punched out” ulcers (ecthyma). Unlike impetigo, ecthyma heals
with scarring. Most frequently occurs in children in hot, humid environments.
Gram stain and culture of the pus or exudates from skin lesions of impetigo and
ecthyma are recommended to help identify whether S. aureus and/or a GABHS is
the cause. Oral therapy for ecthyma and impetigo should be a 7-day regimen with
an agent active against S. aureus unless cultures yield streptococci alone (when
oral penicillin is the recommended agent).
F. Erysipelas
Etiology: Streptococcus pyogenes (Groups A, B, C, G) is the major cause

Preferred Regimen:
1st line:
Penicillin is the drug of choice except in patients with penicillin allergy
Parenteral Agents:
Penicillin G
Mild to moderate infections: 100,000-150,000 U/kg/d in 4 doses (Max: 8 MU/d)
Severe infections: 200,000-300,000 U/kg/d in 6 doses (Max: 24 MU/d) OR
Cefazolin
Mild to moderate infections: 25-50mg/kg/d in 3 doses (Max: 3g/d)
Severe infections: 100-150mg/kg/d in 3 doses (Max: 6 g/d)
If penicillin or cephalosporin allergic, with Severe infections:

Erythromycin 20mg/kg/d IV in 4 doses (Max: 4g/d) (DOC) OR
Vancomycin 40-60mg/kg/d IV in 4 doses (Max: 4g/d)
Treat IV until afebrile; then may shift to oral agents as outpatient; oral agents are
used also as out-patient therapy for less ill patients.
Oral agents:
Penicillin VK 25-30mg/kg/d in 3-4 doses (Max: 2 g/d) OR
Amoxicillin 25-50mg/kg/d in 3 doses (Max: 1.5 g/d) OR
Cephalexin
Mild to moderate infections: 25-50mg/kg/d in 3-4 doses
Severe infections: 75-100mg/kg/d in 3-4 doses (daily adult dose: 4 g/d)
If penicillin allergic:
Azithromycin (Children ≥6 months): 10 mg/kg PO on d1 (Max: 500 mg/d) followed
by 5 mg/kg on d2-5 qd (Max: 250 mg/d) OR
Clindamycin 30-40 mg/kg/d PO in 3-4 doses (Max: 1.8 g/d)
DOT: 7-10 days or until the patient is afebrile for 3-5 days; 5 days for Azithromycin
For erysipelas involving the face:

1st line: Vancomycin 40-60 mg/kg/d IV in 4 divided doses (Max: 4 g/d)
2nd line: Linezolid
<12 yrs.: 30mg/kg/d in 3 doses; ≥12 yrs.: 1200mg/d in 2 doses
Severe infections: same
DOT: 7-10 days, longer if patient is bacteremic
Comments:
Erysipelas is an unusual type of streptococcal infection involving the skin and
sometimes the adjacent mucous membranes. It is an elevated erythematous
lesion, sometimes exhibiting blebs filled with yellowish fluid, which may crust over
after rupture. These infections cause rapidly spreading areas of erythema,

swelling, tenderness, and warmth, sometimes accompanied by lymphangitis and

inflammation of the regional lymph nodes.
The skin surface may resemble an orange peel (peau d’orange) due to superficial
cutaneous edema surrounding hair follicles and causing skin dimpling because the
follicles remain tethered to the underlying dermis. Usually, can clinically
distinguish between red indurated demarcated inflamed skin of erysipelas (S.
pyogenes) from the abscess of S. aureus. Dual infection is rare. Bedside ultrasound
may be helpful in detection of deep S. aureus abscess(es). If in doubt, treat for
both. Community-associated MRSA can mimic erysipelas; look for loculated
purulence.
Mixed infection (Strep. And Staph.) is rare. If S. aureus is present, need incision
and drainage. Sudden onset of rapidly spreading red edematous tender plaque-
like skin on the face in an otherwise healthy host. S. aureus erysipelas of the face
can mimic streptococcal erysipelas of an extremity. If erysipelas-like on the face,
must treat as if MRSA is present.
G. Cellulitis (purulent)
Etiology: Most cases of cellulitis are attributed to S. aureus.
Preferred Regimen:
1st line (empiric therapy to cover for S. aureus)
ORAL PARENTERAL
Cloxacillin 50-100 mg/kg/d PO in 4 Oxacillin
doses (Max: 2 g/d) Mild to moderate infections: 100-
150mg/kg/d IV/IM in 4 doses (Max: 4
g/d)
Severe infections: 150-200mg/kg/d
IV/IM in 4-6 doses (Max: 12 g/d) OR
Cefazolin
Mild to moderate infections: 50mg/
kg/d in 3 doses (Max: 3g/d)
Severe infections: 100-150mg in 3
doses (Max: 6g/d)
DOT: 7-10d is recommended but should be individualized on the basis of the
patient’s clinical response
2nd line (For suspected/confirmed MRSA):
ORAL PARENTERAL
Clindamycin 30-40mg/kg/d in 3-4 Clindamycin 25-40mg/kg/d IV in 3-4
doses (Max: 1.8g/d) OR doses Max: 2.7g/d) OR
Vancomycin 40-60mg/kg/d IV in 4

Cotrimoxazole 8-12mg/kg/d in 2 doses (Max: 4g/d) OR

doses (TMP component) (Max: Linezolid
320mg/d) OR Mild to moderate infections:
Doxycycline 2-4mg/kg/d in 1-2 <12 yrs.: 30mg/kg/d in 3 doses
doses (Max: 200mg/d) ≥12 yrs. and adults: 1200mg/d in 2
doses
Severe infections: same
DOT: 7-10 days is recommended but should be individualized on the basis of
the patient’s clinical response
Comments:
Cellulitis refers to infection involving the deeper dermis and subcutaneous fats.
For purulent cellulitis, (e.g., cellulitis associated with purulent drainage or exudate
in the absence of a drainable abscess), empirical therapy for S. aureus is
recommended and empirical therapy for infection due to β-hemolytic streptococci
is likely unnecessary.
• Patients with carbuncles or abscesses who have failed initial
recommended antibiotic treatment against MSSA
H. Cellulitis (non-purulent)
Etiology: Usually caused by beta-hemolytic streptococci (e.g. Group A, B, C, G

streptococci) and MSSA
Preferred Regimen:
1st line (empiric therapy to cover both Strep and Staph)
ORAL PARENTERAL
Cephalexin Cefazolin
Mild to moderate infections: Mild to moderate infections: 50mg/kg/d
25-50mg/kg/d in 3-4 doses in 3 doses (Max: 3g/d)
Severe infections: 75-100mg/kg/d in Severe infections: 100-150mg in 3 doses
3-4 doses (Max: 4g/d) OR (Max: 6g/d) OR
Amoxicillin-clavulanic acid Ampicillin-sulbactam
7:1 formulation: 25-45mg/kg/d in 2 Mild to moderate infections: 100-
doses (amoxicillin component) 200mg/kg/d in 4 doses (Max:4 g/d)
(Max: 1.75 g/d) Severe infections: 200mg/kg/d in 4
4:1 formulation: 20-40 mg/kg/d PO doses (ampicillin component) (Max: 8
in 3 doses (amoxicillin component) g/d)
(Max: 1.5g)


patient’s clinical response.
2nd line (For suspected/confirmed MRSA):
ORAL PARENTERAL
Clindamycin 30-40mg/kg/d in 3-4 Clindamycin 25-40 mg/kg/d IV in 3-4
doses (Max: 1.8 g/d) OR doses (Max: 2.7 g/d) OR
Cotrimoxazole 8-12 mg/kg/d in 2 Vancomycin 40-60 mg/kg/d IV in 4 doses
doses (TMP component) (Max: 4 g/d) OR
(Max: 320mg/d) Linezolid
PLUS Mild to moderate infections:
Amoxicillin 25-50 mg/kg/d in 3 doses <12 yrs.: 30 mg/kg/d in 3 doses
(Max: 1.5 g/d) OR ≥12 yrs. and adults: 1200 mg/d in 2
Doxycycline 2-4 mg/kg/d in 1-2 doses
doses (Max: 200 mg/d) Severe infections: same
PLUS
Amoxicillin 25-50 mg/kg/d in 3 doses
(Max: 1.5 g/d)
patient’s clinical response
Comments:
Non-purulent cellulitis is defined as cellulitis with intact skin and no evidence of
purulent discharge. Empirical coverage for CAMRSA is recommended in patients
who do not respond to B-lactam therapy and may be considered in those with
systemic toxicity.

MSSA
Trimethoprim-sulfamethoxazole and doxycycline should not be used as a single

agent in the initial treatment of cellulitis because their activity against β-hemolytic
streptococci is not well defined. If coverage for both β-hemolytic streptococci and
CA-MRSA is desired, may combine Cotrimoxazole or a tetracycline with a β-lactam
(e.g., amoxicillin).
I. Non-infected burns
Etiology: Wide spectrum of potential pathogens: e.g., gram-positive cocci, gram-

negative bacilli, and fungi.

Preferred Regimen:
1st line: Silver sulfadiazine cream (mixture of silver nitrate and sodium
sulfadiazine)
2nd line: Topical antimicrobials
Stage I (epidermis) and II A and B wounds (partial thickness, superficial and
deep):
Silver nitrate 0.5% solution
Anti-tetanus prophylaxis is indicated
Comments:
Silver sulfadiazine
Minor adverse effects: Sulfonamide allergy; Steven Johnson's Syndrome; Some
believe drug impairs re-epithelialization of the burn wound; silver is toxic to
keratinocytes and fibroblasts. Transient leukopenia; probably due to margination
of WBCs in the wound rather than bone marrow suppression. Resolves
spontaneously. Not facial burns for fear of eye irritation or injury.
Silver nitrate solution

Messy. Turns skin black. Activity vs Gram-negative bacteria less broad than silver
sulfadiazine cream. Hyponatremia and hypochloremia can occur Rarely,
Methemoglobinemia can occur.
J. Burns with secondary infections
Etiology: S. pyogenes; Enterobacter sp.; S. aureus; S. epidermidis; E. faecalis; E.

coli; P. aeruginosa; Fungi (rare) and Herpes virus (rare).
Preferred Regimen:
1st line 2nd line
Oxacillin Vancomycin 40-60mg/kg/d IV in 4
Mild to moderate infections: 100-150 doses (Max: 4g/d) PLUS
mg/kg/d IV/IM in 4 doses (Max: 4g/d) Meropenem 60-120mg/kg/d in 3 div
Severe infections: 150-200mg/kg/d doses (Max: 6g/d)
IV/IM in 4-6 doses (Max: 12g/d) OR
PLUS Vancomycin 40-60mg/kg/d IV in 4
Ceftazidime doses (Max: 4g/d) PLUS
Mild to moderate infections: 90- Cefepime
150mg IV/IM in 3 doses (Max: 3g/d) Mild to moderate infections: 100mg
Severe infections: 200-300mg IV/IM in 2 doses (Max: 4g/d)
in 3-4 doses (Max: 6g/d) Severe infections: 100-150mg in 2-3
doses (Max: 6g/d)

Comments:
Ideal care is in dedicated burn unit. Gram positive organisms prevail in the early
postburn period: Staph (CONS and S. aureus), Micrococcus, Strep, Pediococcus,
and Enterococcus. These then are replaced by fungi (Candida) and gram-negative
bacteria: P. aeruginosa, E. coli, Enterobacter cloacae, Klebsiella pneumonia and
Serratia marcescens. Acinetobacter are also found more often in patients with
more severe burns and comorbidities.
Gram positive cocci, including S. aureus and MRSA were the most common causes
of burn infections in patients with relatively small burns <30% of BSA. Gram
positive cocci and gram-negative bacteria esp. P. aeruginosa were common causes
in patients with extensive burns>30% of BSA. Other complications of concern in
critically ill burn patient: S. aureus toxic shock syndrome (TSS), suppurative
phlebitis, pneumonia.

MSSA
K. Puncture wound
Etiology: S. aureus, Streptococcus sp., mixed flora
Preferred Regimen:
1st line:
Oxacillin
Mild to moderate infections: 100- 150mg/kg/d IV/IM in 4 doses (Max: 4g/d)
Severe infections: 150-200mg/kg/d IV/IM in 4-6 doses (Max: 12g/d)
2nd line:
Clindamycin 25-40mg/kg/d in 3-4 doses (Max: 2.7g/d) PLUS
Amikacin 15 -22.5mg/kg/d in 1-3 doses (max 1.5g/d) PLUS
Ceftazidime
Mild to moderate infections: 90-150mg IV/IM in 3 doses (Max: 3 g/d)
Severe infections: 200-300mg IV/IM in 3 or 4 doses (Max: 6 g/d)
OR
Piperacillin-Tazobactam
Severe infections: 240-300mg/kg/d in 3-4 doses (piperacillin component) (Max:
16g/d)
Lower dose is recommended for patients <6 months of age: 150-300mg/kg/d in
3-4 doses (piperacillin component) (Max: 16 g/d)

Lower dose is recommended for patients <6 months of age: 150-300mg/kg/d in

3-4 doses (piperacillin component) (Max: 16g/d)
Comments:
Refer to WHO prevention and management of wound infection. Use clindamycin
instead of oxacillin if anaerobes or MRSA are suspected. Any evidence of deep
infection, especially if it persists or develops more than 72h after injury and
particularly in children, is a strong indication for exploration and addition of an
anti-pseudomonal agent. If P. aeruginosa infection is highly considered (e.g.
wound is associated with nail through rubber-soled footwear), add amikacin and
ceftazidime or piperacillin-tazobactam.
L. Wound infection, post-trauma
Etiology: Polymicrobic (microbial flora dependent on nature of the trauma): S.

aureus (MSSA, MRSA), Streptococcus sp. (aerobic and anaerobic),
Enterobacteriaceae, C. perfringens, C. tetani, Pseudomonas sp. (water exposure),
Aeromonas sp., Acinetobacter species
Preferred Regimen:
Uncomplicated, mild or moderate, afebrile patient
1st line 2nd line (For suspected/confirmed
MRSA):
Oral agents Doxycycline 2-4mg/kg/d in 1-2 doses
Cloxacillin 50-100mg/kg/d in 4 (Max: 200mg/d) OR
doses (Max: 2g/d) OR Linezolid
Cephalexin Mild to moderate infections:
Mild to moderate infections: <12 yrs.: 30mg/kg/d in 3 doses
25-50mg/kg/d in 3-4 doses ≥12 yrs. and adults: 1200mg/d in 2 doses
Severe infections: Severe infections: Same
75-100mg/kg/d in 3-4 doses
(Max: 4 g/d) If Gram-negative bacilli are suspected:
PLUS
Amoxicillin-clavulanic acid
Mild to moderate infections
7:1 formulation: 25-45mg/kg/d PO in 2
doses (amoxicillin component) (Max:
1.75g/d)
4:1 formulation: 20-40mg/kg/d PO in 3
doses (amoxicillin component) (Max: 1.5g)
OR
Ciprofloxacin 20-30mg/kg/d PO in 2 doses
(Max: 1.5g/d)

Complicated, severe, febrile patient

1st line 2nd line
Parenteral agents Parenteral agents
Piperacillin-Tazobactam Meropenem
Severe infections: 240-300mg in Severe infections: 60-120mg/kg/d in 3
3 doses (piperacillin doses (Max: 6g/d) PLUS
component) (Max: 16 g/d). Vancomycin 40-60mg/kg/d IV in 4 div
Lower doses are recommended doses (Max: 4g/d)
for patients <6months of age: OR
150-300mg/kg/d in 3-4 doses Linezolid
(piperacillin component) (Max: Mild to moderate infections:
16g/d) PLUS <12 yrs.: 30mg/kg/d IV in 3 doses
Vancomycin 40-60mg/kg/d IV in ≥12 yrs. and adults: 1200mg/d IV in 2
4 div doses (Max: 4g/d) doses
Severe infections: same PLUS
Ciprofloxacin 20-30mg/kg/d IV in 2 -3
doses (Max: 1.2g/d)
Comments:
Debridement of wound may be indicated. Obtain culture and sensitivity, check
gram stain. Give tetanus prophylaxis and vaccine if indicated.

• Patients who have failed initial recommended antibiotic treatment against MSSA
If S. aureus are erythromycin-resistant in vitro, may have inducible resistance to

clindamycin; make sure lab checks if using the latter. Ciprofloxacin has been used
most extensively in children and adolescents and appears to be well tolerated,
effective and does not appear to cause arthropathy.
M. Post-operative wound infection (non-GI tract, non-GU tract surgery)
Etiology: skin flora, S. aureus, Streptococcus sp. (Group A, B, C, G)
Preferred Regimen:
Mild to moderate infections (without sepsis; afebrile patients)
1st line 2nd line
Clindamycin 30-40mg/kg/d in 3-4 Linezolid
doses (Max: 1.8g/d) OR Mild to moderate infections:
Cotrimoxazole 8-12mg/kg/d in 2 <12 yrs.: 30mg/kg/d in 3 doses
doses (TMP component)

(Max: 320mg/d) ≥12 yrs. and adults: 1200mg/d in 2

doses
Mild to moderate infections: same
Severe infection: with sepsis; febrile patients
1st line 2nd line
Parenteral agents Vancomycin 45-60mg/kg/d IV in 3-4
Clindamycin 25-40mg/kg/d IV in 3-4 doses (Max: 4g/d) OR
doses (Max: 2.7g/d) Linezolid
<12 y: 30 mg/kg/d IV in 3 doses
≥12 y and adults: 1200 mg/d IV in 2
doses
Severe infections: same PLUS
Ciprofloxacin 20-30mg IV in 2-3 doses
(Max: 1.2g/d) PLUS
Metronidazole 30mg/kg/d in 3-4
doses (Max: 4 g/d)
Comments:
Surgical site infections require prompt and wide opening of the surgical incision.
Antimicrobial therapy is recommended for deep incisional surgical site infections
if systemic signs of sepsis are present, if source control is incomplete or in
immunocompromised patients. In patients who have had clean operations,
antimicrobial therapy should cover gram-positive organisms.

MSSA
• Those with markedly impaired host defenses or
• Those with SIRS and hypotension.
N. Post-operative wound infection (GI tract or GU tract surgery)
Etiology: skin flora, GI and vaginal flora, S. aureus (MSSA, MRSA), Coliform species:
e.g., E. coli, Bacteroides species: e.g., B. fragilis, Other anaerobic bacteria
Preferred Regimen:
Mild infections
1st line 2nd line
Amoxicillin-clavulanic acid Amoxicillin-clavulanic acid
Mild to moderate infections Mild to moderate infections
7:1 formulation: 25-45mg/kg/d PO 7:1 formulation: 25-45mg/kg/d PO in
in 2 doses (amoxicillin component) 2 doses (amoxicillin component)

(Max: 1.75g/d) (Max: 1.75g/d)

4:1 formulation: 20-40mg/kg/d PO 4:1 formulation: 20-40 mg/kg/d PO in
in 3 doses (amoxicillin component) 3 doses (amoxicillin component)
(Max: 1.5g) (Max: 1.5g)
If S. aureus (MRSA) is suspected If S. aureus (MRSA) is suspected PLUS:
PLUS: Clindamycin 30-40mg/kg/d in 3-4
Cotrimoxazole 8-12mg/kg/d in 2 doses (Max: 1.8g/d)
doses (TMP component)
(Max: 320mg/d)
Severe infection
1st line 2nd line
Piperacillin-Tazobactam IV Vancomycin 40-60mg/kg/d IV in 3-4
Severe infections: 240-300mg/kg/d doses (Max: 4g/d) PLUS
in 3 doses (piperacillin component) Meropenem 60-120mg/kg/d IV in 3
(daily adult dose: 16 g/d). Lower doses (Max: 6g/d)
doses are recommended for OR
patients <6 months of age: 150- Linezolid IV
300mg/kg/d in 3-4 doses (Max: <12 yrs.: 30mg/kg/d in 3 doses
16g/d) PLUS ≥12 yrs. and adults: 1200mg/d in 2
Vancomycin 40-60mg/kg/d IV in 3-4 doses
OR Meropenem 60-120mg/kg/d IV in 3
Ceftriaxone 100mg/kg/d IV in 1 or 2 doses (Max: 6g/d)
Metronidazole 30mg/kg/d IV in 3-4
Vancomycin 40-60mg/kg/d IV in 3-4
doses (Max: 4g/d)
OR
Cefotaxime 100-200mg/kg/d IV in 3-
4 doses (Max: 12g/d) PLUS
Metronidazole 30mg/kg/d IV in 3-4
Vancomycin 40-60mg/kg/d IV in 3-4
doses (Max: 4g/d)
Comments:
In patients who have had procedures on the GI or GU tract, antimicrobial therapy
should cover both gram-positive and gram-negative organisms. If with skin
incision, usually remove sutures to drain wound, obtain culture and sensitivity,
and pack wound.

• Patients with carbuncles or abscesses who have failed initial antibiotic

treatment
O. Wound infection, soil contaminated
Etiology: S. aureus, GABHS, gram negative enterics, Enterobacter cancerogenus,

Anaerobes, Nocardia asteroids, Nocardia otitidis-caviarum, M. fortuitum, M.
abscessus, Actinomyces, Aspergillus, Enterococcus
Preferred Regimen:
1st line 2nd line
Penicillin G Clindamycin 25-40mg/kg/d IV in 3-4
Mild to moderate infections: doses (Max: 2.7g/d)
100,000- 150,000U/kg/d in 4 doses PLUS
(Max: 8MU/d) Amikacin 15-22.5mg/kg IV/IM in 1-3
Severe infections: 200,000-300,000 doses (Max: 1.5g/d)
U/kg/d in 6 doses (Max: 24MU/d)
PLUS
Amikacin 15-22.5mg/kg IV/IM in 1-3
doses (Max: 1.5g/d)
II. CAT, DOG AND MAMMAL BITE
A. Bite wound from cat
Etiology: Pasteurella species, S. aureus, Bacteroides sp., Fusobacterium sp., EF-4,

Capnocytophaga sp., Group A Strep
Preferred Regimen:
1st line 2nd line
Oral agent Clindamycin
Amoxicillin-clavulanic acid 30-40 mg/kg/d PO in 3-4 doses (Max:
Mild to moderate infections 1.8g/d) or 25-40 mg/kg/d IV in 3-4
7:1 formulation: 25-45mg/kg/d PO doses (Max: 2.7g/d)
in 2 doses (amoxicillin component) OR
(Max: 1.75g/d) Metronidazole 30mg/kg/d in 3-4
4:1 formulation: 20-40mg/kg/d PO doses (Max: 4g/d) PLUS
in 3 doses (amoxicillin component) Cefuroxime axetil 20-30mg/kg/d PO
(Max: 1.5g) in 2 doses (Max: 1g/d) or
Parenteral agent Doxycycline 2-4mg/kg/d PO/IV in 1-2
Ampicillin/sulbactam doses (Max: 200mg/d)

Mild to moderate infections: 100-

200mg/kg/d in 4 doses (Max: 4g/d)
Severe infections: 200mg/kg/d in 4
doses (ampicillin component)
(Max: 8g/d)
Comments:
Cleaning, irrigation and debridement are most important. Preemptive early
antimicrobial therapy for 3-5 days is recommended for patients who are
immunocompromised; are asplenic; have advanced liver disease; have preexisting
or resultant edema of the affected area; have moderate to severe injuries,
especially to the hand or face; or have injuries that may have penetrated the
periosteum or joint capsule.
Culture and treat empirically. 80% get infected, P. multocida infection develops
within 24 h. Observe for osteomyelitis. P. multocida is resistant to dicloxacillin,
Cephalexin and clindamycin. Many strains appear susceptible to azithromycin but
no clinical data. Consider rabies and tetanus post-exposure prophylaxis and
vaccination.
B. Dog bite
Only 5% of dog bite wounds get infected. Treat only if the bite is severe or patient
presents with co-morbidity (e.g., diabetes).
Etiology: Pasteurella canis, Staphylococcus aureus, Bacteroides sp., Fusobacterium

sp., EF-4, Capnocytophaga sp.
Preferred Regimen:
1st line 2nd line
Amoxicillin-clavulanic acid 875/125mg Clindamycin 300mg PO qid
PO bid or 500/125mg PO tid
Ampicillin/sulbactam 3g IV q6h
Comments:
For rabies post-exposure prophylaxis and vaccination, refer to: DOH AO 2014-
0012.
(http://www.doh.gov.ph/sites/default/files/basic-page/ao2014-0012 pdf)

C. Human bite
Etiology: Viridans streptococcus (100%), Staphylococcus epidermidis (53%),

Corynebacterium sp. (41%), Staphylococcus aureus (29%), Eikenella sp. (15%),
Bacteroides sp. (82%), Peptostreptococcus sp. (26%)
Preferred Regimen:
1st line 2nd line
Oral agent Piperacillin-tazobactam
Amoxicillin-clavulanic acid Severe infections: 240-300mg/kg/d
Mild to moderate infections in 3 doses (piperacillin component)
7:1 formulation: 25-45mg/kg/d PO in 2 (daily adult dose: 16 g/d). Lower
doses (amoxicillin component) doses are recommended for
(Max: 1.75g/d) patients <6 months of age: 150-300
4:1 formulation: 20-40mg/kg/d PO in 3 mg/kg/d in 3-4 doses (Max: 16g/d)
doses (amoxicillin component) For penicillin allergy:
(Max: 1.5g) Clindamycin
30-40mg/kg/d PO in 3-4 doses
Parenteral agent (Max: 1.8g/d) or 25-40mg/kg/d IV in
Ampicillin/sulbactam 3-4 doses (Max: 2.7g/d)
Mild to moderate infections: OR
100-200mg/kg/d in 4 doses (Max: 4g/d) Metronidazole 30mg/kg/d in 3-4
Severe infections: 200mg/kg/d in 4 doses (Max: 4g/d)
doses (ampicillin component) (Max: PLUS
8g/d) Ciprofloxacin
20-30mg/kg/d PO in 2 doses
DOT: 5 days (Max: 1.5g/d) or 20-30mg/kg/d IV in
2-3 doses (Max: 1.2g/d)
Comments:
Cleaning, irrigation and debridement are most important. For clenched fist or hand
injuries, X-rays should be obtained. For bites inflicted by hospitalized patients,
consider aerobic Gram-negative bacilli.
Eikenella sp.:
Susceptible to fluoroquinolones and beta-lactam-beta lactamase inhibitor
combinations, e.g., ampicillin-sulbactam. Resistant to clindamycin,
nafcillin/oxacillin, metronidazole, cephalexin/ cefazolin, TMP/SMX and
erythromycin.
Clenched fist (and other hand) bite wounds pose risk for deep infections (e.g.,
bone, joint, tendon sheath) and require careful evaluation. X-ray would evaluate
for fracture or foreign body. Potential risk of transmitting blood-borne pathogens
if injury contaminated with another's blood. Review tetanus immunization status.

D. Rat bite
Etiology: Spirillum minus, Streptobacillus moniliformis
Preferred Regimen:
Prophylaxis
1st line 2nd line
Amoxicillin 25-50mg/kg/d in
Doxycycline 2-4mg/kg/d in 1-2 doses
3doses (Max: 1.5g/d) (Max: 200mg/d)
DOT: 3d
Rat bite fever
1st line 2nd line
Penicillin G Erythromycin
Mild to moderate infections: Mild to moderate infections:
100,000-150,000U/kg/d in 4 doses 50 mg/kg/d PO in 3-4 doses (Max: 2g/d)
(Max: 8MU/d) Severe infections:
Severe infections: 20mg/kg/d IV in 4 doses (Max: 4g/d)
200,000-300,000U/kg/d in 6 doses OR
(Max: 24MU/d) Clindamycin
OR 30-40mg/kg/d PO in 3-4 doses (Max:
Doxycycline 2-4mg/kg/d in 1-2 1.8g/d) or 25-40mg/kg/d IV in 3-4 doses
doses (Max: 200mg/d) (Max: 2.7g/d)
DOT: 10-14d
Comments:
Rabies post-exposure prophylaxis and vaccination is not indicated for rat bites.
E. Necrotizing fasciitis/gas gangrene
Etiology: S. aureus (CA-MRSA), Group A streptococci, Clostridium sp.: C,

perfringens (most common), C. septicum, C. tertium
Preferred Regimen:
1st line 2nd line
Vancomycin 40-60mg/kg/d IV in 4 Cefotaxime 100-200mg/kg/d in 3-4
doses (Max: 4 g/d) PLUS doses (Max: 12g/d) PLUS
Piperacillin-Tazobactam Clindamycin
Severe infections: 240-300mg/kg/d 30-40mg/kg/d PO in 3-4 doses (Max:
in 3-4 doses (piperacillin 1.8g/d) or 25-40mg/kg/d IV in 3-4
component) (Max: 16 g/d) Lower doses (Max: 2.7g/d)
dose is recommended for patients Penicillin PLUS clindamycin is
<6 months of age: 150-300 mg/kg/d recommended for treatment of
in 3-4 doses (Max: 16g/d) documented group A streptococcal

necrotizing fasciitis and clostridial

myonecrosis
Penicillin G
100,000-150,000 U/kg/d in 4 doses
(Max: 8MU/d)
Severe infections:
200,000-300,000 U/kg/d in 6 doses
(Max: 24MU/d) PLUS
Clindamycin 30-40 mg/kg/d PO in 3-4
doses (Max: 1.8g/d) or 25-40mg/kg/d
IV in 3-4 doses (Max: 2.7g/d)
DOT: 10d
Comments:
Incision for exploration, drainage and debridement (include aerobic and anaerobic
cultures if available in your setting) and resect all nonviable tissue. Infection
extends into the fascial plane between muscle and subcutaneous fat with resulting
necrotizing fasciitis. Historically, S. aureus was not associated with necrotizing
fasciitis, but CA-MRSA is now different and can cause the disease. Usually gas
gangrene is preceded by a traumatic wound or surgery with contamination by
Clostridial spores. Diagnosis is easily made by gram stain of necrotic tissue. X-ray,
CT scan may show gas in involved tissue. Hyperbaric oxygen (HBO) is not
recommended.
F. Pyomyositis
Etiology: S. aureus, Streptococcus sp. (Group A and others), Gram-negative bacilli

(rare), Anaerobic bacteria (rarely Clostridium species)
Preferred Regimen:
1st line 2nd line
Oxacillin Clindamycin 25-40mg/kg/d in 3-4
Mild to moderate infections: doses (Max: 2.7g/d)
100-150mg/kg/d IV/IM in 4 doses OR
(Max: 4g/d) Vancomycin 40-60mg/kg/d IV in 4
Severe infections: doses (Max: 4g/d) Individual doses ≥1
150-200mg/kg/d IV/IM in 4-6 doses g should be infused over 1.5-2 h
(Max: 12g/d) or 100-150mg/kg/d IV
div q4-6h (Max: 12g/d) DOT: 2-3 weeks
OR
Cefazolin
50mg/kg/d in 3 doses (Max: 3g/d)

Severe infections:
100-150mg/kg/d in 3 doses
(Max: 6g/d)
Comments:
Magnetic resonance imaging (MRI) is the recommended imaging modality for
establishing the diagnosis. Computed tomography (CT) scan and ultrasound
studies are also useful. Appropriate cultures (blood and abscess) should be
obtained.
MSSA
An agent active against enteric gram-negative bacilli should be added for infection
in immunocompromised patients or following open trauma to the muscles
(aminoglycosides).
G. Decubitus ulcer
Etiology: Streptococcus sp., S. aureus, Enterobacteriaceae, P. aeruginosa,

Anaerobic streptococci, B. fragilis
Preferred Regimen:
1st line 2nd line
Superficial infection: Clindamycin 25-40mg/kg/d IV in 3-4
Silver sulfadiazine 1% cream doses (Max: 2.7g/d)
PLUS
Severe local infection: Ceftazidime
Piperacillin-Tazobactam Mild to moderate infections: 90-
Severe infections: 240-300mg/kg/d in 150mg IV in 3 doses (Max: 3g/d)
3-4 doses (piperacillin component) Severe infections: 200-300mg IV in 3
(Max: 16g/d). Lower dose is or 4 doses (Max: 6g/d)
recommended for patients <6 OR
months of age: 150-300mg/kg/d in 3- Ciprofloxacin
4 doses (Max: 16g/d) 20-30mg/kg/d PO in 2 doses (Max:
1.5g/d) or 20-30mg/kg/d IV in 2-3
doses (Max: 1.2g/d)
Comments:
Debride necrotic tissue and use moist wound dressing. Remove pressure if
decubitus ulcer; elevate leg if venous stasis; evaluate for revascularization if
arterial insufficiency. Do not use povidone iodine or chlorhexidine, both may

damage granulation tissue and fibroblasts. Best method is surgically obtained

deep tissue specimen for histology and culture. If osteomyelitis is suspected, also
bone biopsy. Needle aspiration from the ulcer margin is acceptable.
H. Cat scratch disease
Etiology: Bartonella henselae
Preferred Regimen:
1st line 2nd line
Lymphadenitis in Lymphadenitis in
immunocompromised patient: immunocompetent patient:
Azithromycin No therapy, as the lymphadenitis
Children ≥6 months: 10mg/kg PO on d1 spontaneously resolves.
(Max: 500mg/d) followed by 5mg/kg
on d2-5 qd (Max: 250mg/d) OR Complete resolution may take 2-6
Rifampicin 20mg/kg/d in 1-2 doses months.
(Max: 600mg/d) OR
Cotrimoxazole 8-12mg/kg/d in 2 doses
(TMP component) (Max: 320mg/d)
DOT: 7-10d
Comments:
Self-limited regional lymphadenitis. Disease manifestations can include
involvement of the central nervous system, eyes and viscera (liver, and spleen).
The optimal duration of therapy is not known but may be several weeks for
systemic disease.
III. TINEA CORPORIS, TINEA CRURIS, TINEA PEDIS
A. Tinea corporis, Tinea cruris (jock itch), Tinea pedis (athlete’s foot)
Etiology: Trichophyton rubrum, T. mentagrophytes, Epidermophyton floccosum
Preferred Regimen:
1st line 2nd line
Terbinafine 1% cream for Tinea Topical:
corporis, Tinea cruris, and Imidazoles (clotrimazole, ketoconazole,
interdigital Tinea pedis, apply bid x etc.) apply bid x 2-4 weeks
1 week; for plantar Tinea pedis, Systemic:
apply bid x 2 weeks. Terbinafine
<20 kg: 62.5mg/d
20-40 kg: 125mg/d

>40 kg: 250mg/d

Fluconazole 3-6mg/kg once a week x 2-4
weeks
Comments:
Redder margins than centers create impression of a ring. Opposed to Tinea capitis,
these infections can often be cured with topical therapy alone. Systemic therapy
can be reserved for severe or refractory infection, recurrent infection, or in
immunocompromised patients. Serious but rare cases of hepatic failure have been
reported in patients receiving terbinafine and should not be used in those with
chronic or active liver disease.
B. Tinea versicolor (Pityriasis versicolor)
Etiology: Malassezia furfur
Preferred Regimen:
1st line 2nd line
Limited disease: Itraconazole 5-10mg/kg/d PO in 2
Ketoconazole 2% shampoo daily for 3 doses x 7d
days; can use 2-3 times a week for
maintenance/prevention
Selenium sulfide 2.5% shampoo, daily
application while bathing for 1 to 2
weeks, can use 2-3 times a week for
maintenance/prevention
Extensive disease:
Fluconazole 3-6mg/kg x 1 dose,
repeat in 14 days
Comments:
Fine, scaly rash with patches of discolored skin with sharp borders commonly
found on back, underarms, upper arms, chest, and neck. Skin may appear lighter
than surrounding healthy skin; in African Americans, either hypo or hyper-
pigmentation. Rule out erythrasma.
Akapulco lotion (Senna alata extract): a meta-analysis (Tababa EJL, Genuino RF,
and Salud-Gnilo CM, 2016 unpublished) showed that 50% Akapulco lotion was
superior to placebo for tinea versicolor (mycologic cure and decrease in clinical
activity). It appears to be as effective as 25% sodium thiosulfate and ketoconazole
cream, but larger randomized trials with good follow-up rates are needed to
confirm these findings.

C. Tinea capitis (ringworm)
Etiology: Trichophyton tonsurans, Microsporum canis (North America; other

species elsewhere)
Preferred Regimen:
1st line 2nd line
Terbinafine Itraconazole 5mg/kg/d x 4 weeks
P (age>2y); weight-based dosing Fluconazole 6mg/kg/d PO every week
<20 kg: 62.5mg PO in 1 dose x 2 x 8-12 weeks (Max: 150 mg PO every
weeks week for adults)
20-40 kg: 125mg PO in 1 dose x 2 Griseofulvin (microsize formulation)
weeks 10-20 mg/kg/d (child) until hair
>40 kg: 250mg PO in 1 dose x 2 weeks regrows.
Comments:
Itchy, red, raised, scaly patches often sharply defined. Durations of therapy are for
T. tonsurans; treat for approximately twice as long for M. canis. All agents have
similar cure rates (60-100%) in clinical studies. Serious but rare cases of hepatic
failure have been reported in patients receiving terbinafine and should not be
used in those with chronic or active liver disease.
D. Scabies
• Mite infestation of the skin that causes intense itching which is worse at night.
• Diagnosis is based on history and distribution of skin lesions. Sometimes, mites
or eggs from scrapings of burrows are visible.
• Pruritus may persist for 2 weeks after mites are gone.
• Antihistamines may help reduce itching.
• Secondary streptococcal infections can occur.
Etiology: Sarcoptes scabiei (mite)
Preferred Regimen:
Permethrin 5% cream
Apply to entire skin from chin down to and including toes and under fingernails
and toenails. May require 30 g. Leave on 8-14 h. Repeat in 1-2 weeks. Safe for
children age >2 months. Reapply to hands after handwashing.
Comments:
Treat close contacts. Wash and dry linens to prevent re-infection.

E. Varicella-zoster virus infections
Clinical syndromes:
• Chickenpox
• Shingles (single dermatomal or multiple dermatomes)
• Disseminated VZV disease/organ involvement
Etiology: Varicella-zoster virus
Preferred Regimen:
Immunocompetent host, chickenpox:
Child age 2-12 y
Mild to moderate disease: no treatment
For patients at increased risk of moderate or severe varicella; chronic cutaneous

or pulmonary diseases:
Aciclovir 80mg/kg/d PO in 4 doses (Max: 3200mg/d) (start within 24h of rash) OR
Valaciclovir 60mg/kg/d PO in 3 doses (Max: 1g/dose in 3 doses)
DOT: 5 days
Comments:
Aciclovir slowed development and reduced number of new lesions and reduced
duration of disease in children. Aciclovir decreased duration of fever, time to
healing, and symptoms.
Prevention, post-exposure prophylaxis Varicella-zoster immune globulin (VZIG)

(125 units/10 kg [22 lbs.] body weight IM up to a max of 625 units; minimum dose
is 125 units) is recommended for post-exposure prophylaxis in susceptible persons
at greater risk for complications (immunocompromised such as HIV, malignancies,
pregnancy, and steroid therapy) as soon as possible after exposure (<96 h). If VZIG
is not available, IGIV can be used. Although licensed IGIV preparations contain
anti-varicella antibodies, the titer of any specific lot of IGIV is uncertain because
IGIV is not tested routinely for IGIV anti-varicella anti-bodies. The recommended
IGIV dose for post-exposure prophylaxis to varicella is 400 mg/kg, administered
once IV. If varicella develops, initiate treatment quickly (<24h of rash) with
aciclovir. Some would treat presumptively with aciclovir in high-risk patients.
Susceptible children should receive vaccination.
REFERENCES
• Baldwin G., Colbourne M. Puncture wounds. In Pediatrics in Review. 1999; 20 (1): 21-23.
• Bravo, Gatchalian, Gonzales, Maramba-Lazarte, Ong-Lim, Pagcatipunan, delos Reyes.
Handbook of Pediatric Infectious Disease an Easy Guide 5th ed.
• Feigin R, Cherry J, et al. Textbook of Pediatric Infectious Diseases, 6th ed, 2009
• Gilbert DN, Chambers HF, Eliopoulos GM, Saag MS, Black, Freedman DO, Pavia AT,
Schwartz B. The Sanford Guide to Antimicrobial Therapy 2014, 44th edition.

Society of America for the Treatment of Methicillin- Resistant Staphylococcus aureus
Infections in Adults and Children CID 2011: 52 (1 February)
• MIMS Philippines 1/2016, 147th edition.
• Pennycook A, Makover R, O’Donnell AM. Puncture wounds of the foot: can infective
complications be avoided? J Royal Society Med 1994; 87:581-583.
• Red Book 2015, 30th edition. Report of the Committee on Infectious Diseases. Am Acad
Pediatr 2015;808-820.
• Stevens DL, Bisno AL, Cambers HF, et al. Practice Guidelines for the diagnosis and
management of skin and soft tissue infections: 2014 Update by Infectious Diseases Society
of America, IDAS Practice Guidelines for SSTIs CID: 1-43.
• Tababa EJL, Genuino RF, Salud-Gnilo. Senna alata (Akapulko) extract versus topical
antifungals for treatment of superficial fungal skin infections: A systemic review and meta-
analysis (Unpublished)
• Topical antibiotics: very few indications for use: BPJ; Issue 64, p27.
• Wolff, K., Goldsmith L., Katz, S., Gilchrest, B., Paller, A. and Lefell, D. (2008) Fitzpatrick’s
Dermatology in General Medicine. 7th Edition. USA: McGrawhill Hill.

SKIN AND SOFT TISSUE INFECTIONS IN ADULTS
I. ABSCESS
A. Skin abscess, boils, furuncles
• These include purulent skin lesions, such as boils, furuncles, carbuncles and
abscesses, e.g., acute bacterial skin and skin structure infection (ABSSSI).
• Community-associated MRSA is of increasing concern for effective
management.
• See also Recurrent Furunculosis (decolonization)
Etiology: S. aureus; Methicillin-sensitive (MSSA); Methicillin-resistant (MRSA)
Preferred Regimen: Incision and drainage is the mainstay of therapy.

Note: needle aspiration is inadequate.
1st line:
Outpatient setting, no diabetes or immunosuppression, boil or smaller abscess
(<2 cm in diameter):
Incision and drainage only are usually effective. Hot packs are helpful. No need
for antimicrobial therapy.
Outpatient, larger (>2 cm in diameter within an area of erythema of ≥5 cm) or

multiple abscesses, or systemic inflammatory response syndrome:
Incision and drainage PLUS one of the following:
Clindamycin 300-450mg (higher dose in obese patient, BMI>40) PO tid x 5-10d
OR Cotrimoxazole 160/800mg (1 DS tab; 2 DS tabs in obese patient, BMI>40)
PO bid x 5-10d OR Doxycycline 100 mg PO q12h x 5-10d (may also be effective
for community-acquired MRSA infections)
If no response after 2-3d, follow up exudate culture and sensitivity (C/S) results
and shift to culture-guided antibiotic therapy, or if C/S results not yet available,
shift to another first-line antibiotic.
Inpatient:
Incision and drainage: culture abscess and blood. Empirical antibiotic therapy
(in absence of specific culture and sensitivity data select an agent with activity
against MRSA): Clindamycin 600mg IV q8h for patients without signs and
symptoms of sepsis/ bacteremia OR Vancomycin 15mg/kg q12h (trough
concentrations of 5-10 μg/mL are adequate for infections of moderate severity;
for severe infections or if bacteremia is present, 15-20 mg/kg q8-12h targeting
troughs of 15-20 μg/mL recommended)

2nd line:
For documented MSSA infection, a beta-lactam is the preferred agent:
Oral agents: Cloxacillin 500mg PO qid or Cephalexin 500mg PO tid- qid
Parenteral agents: Oxacillin 1g IV q4h or Cefazolin 1g IV q8h
For MRSA infections: Linezolid 600 mg IV/PO q12h
Comments:
Avoid fluoroquinolones. For abscesses >2 cm in diameter, a large randomized
controlled trial of incision & drainage plus Cotrimoxazole vs incision & drainage
alone showed a higher rate of clinical cure among the former group (80.5% vs
73.6%, respectively). One double-strength (DS) tab of Cotrimoxazole bid as
effective as two DS tabs bid. Lower dosage range of Cotrimoxazole (1 DS instead
of 2 DS) and clindamycin (150-300 mg instead of 450 mg) found to be associated
with treatment failure in obese patients (BMI >40).
Another large double-blind randomized controlled trial was conducted for single
abscesses ≤5 cm where Clindamycin, Cotrimoxazole or placebo was added to
incision & drainage. There was a higher rate of clinical cure in the two groups with
antibiotics but the study did not break down treatment outcomes for those with
abscesses ≤2 cm vs 2–5 cm, and prescribed antibiotics for 10 days regardless of
abscess size. Use of antibiotics for a single abscess ≤ 2 cm should be weighed
against the fairly high proportion of adverse events.
NOTE: For data on the prevalence of MRSA in the Philippines and the increasing
resistance of MRSA to Cotrimoxazole, refer to the latest report (2016) of the
Antimicrobial Resistance Surveillance Program at: http://arsp.com.ph/wp-
content/uploads/2017/06/2016_annual_report_summary.pdf
B. Furunculosis, recurrent
Clinical setting for decolonization

• If the patient and physician wish to attempt decolonization, the patient should
have no active skin infections and is otherwise healthy.
• Need to culture multiple sites, e.g., nose, throat, and inguinal area skin. Nares-
only culture missed 48% of colonized individuals.
• Does not apply to people who inject drugs (PWID).
Etiology: S. aureus (MSSA and MRSA) presenting as recurrent furunculosis

(abscesses, boils) in an otherwise healthy host.
Preferred Regimen: Treat as for furuncles and boils

For decolonization: Avoid systemic antibiotics.
Mupirocin ointment in anterior nares and under fingernails bid x 5-7d PLUS
Chlorhexidine 4% shower qd x 5-7d.

Comments: There is no "gold standard" regimen for decolonization. Optimal

regimen and duration of treatment are uncertain. In a prospective randomized
trial of combined topical and systemic therapy, at 3 months, cultures were
negative for MRSA in 74% for treated vs. 32% of patients not treated.
II. BITES
A. Cat bite
• 80% of cat bites get infected. Culture and treat empirically. Pasteurella
multocida infection develops within 24h.
• Observe for osteomyelitis
Etiology: Pasteurella multocida; S. aureus
Preferred Regimen:
1st line: Amoxicillin/clavulanate 875/125mg PO bid or 500/125mg PO tid
2nd line: Cefuroxime axetil 500mg PO q12h OR Doxycycline 100mg PO bid
If culture is positive for only P. multocida, can switch to Penicillin G IV or
Penicillin VK PO.
Comments:
P. multocida is resistant to Dicloxacillin, Cephalexin and Clindamycin. In vitro
sensitivity to fluoroquinolones has been observed. Many strains appear
susceptible to Azithromycin but no clinical data.
B. Dog bite
• Only 5% of dog bite wounds get infected. Treat only if the bite is severe or
patient presents bad comorbidity, e.g., diabetes.
Etiology: Pasteurella canis, S. aureus, Bacteroides sp., Fusobacterium sp., EF-4

Capnocytophaga sp.
Preferred Regimen:
1st line: Amoxicillin/clavulanate 875/125mg PO bid or 500/125 mg PO tid OR
Ampicillin/sulbactam 3g IV q6h
2nd line: Clindamycin 300mg PO qid
Comments: For rabies post-exposure prophylaxis and vaccination, refer to: DOH
AO 2014-0012. Go to: http://www.doh.gov.ph/sites/default/files/basic-
page/ao2014-0012.pdf

C. Human bite
Etiology: Viridans streptococcus (100%); S. epidermidis (53%); Corynebacterium

sp. (41%); S. aureus (29%); Eikenella sp. (15%); Bacteroides sp. (82%);
Peptostreptococcus sp. (26%)
Preferred Regimen:
1st line 2nd line:
Early (wound not yet infected): A carbapenem can be used in place
Amoxicillin-Clavulanate 875/125 mg PO of Ampicillin-Sulbactam, Cefoxitin,
bid x 5d or Piperacillin-Tazobactam if
Later (signs of infection, usually 3-24 h): parenteral therapy is required.
Ampicillin-Sulbactam 1.5 to 3 g IV q6h
OR Piperacillin-Tazobactam (4.5 g q8h If the patient is penicillin allergic:
or 4-hr infusion of 3.375 g q8h). Clindamycin PLUS Ciprofloxacin OR
For serious infections, until MRSA is Levofloxacin
excluded: ADD Vancomycin 1g IV q12h
(or 1.5g q12h if wt. >100 kg)
Comments:
Cleaning, irrigation and debridement are most important. For bites inflicted by
hospitalized patients, consider aerobic Gram-negative bacilli. Review tetanus
status.
Eikenella sp.
• Susceptible to: fluoroquinolones and beta-lactam / beta-lactamase inhibitor
combinations: e.g., Ampicillin-Sulbactam.
• Resistant to: Clindamycin, Nafcillin/oxacillin, Metronidazole,
Cephalexin/Cefazolin, Cotrimoxazole and erythromycin.
Clenched fist (and other hand) bite wounds pose risk for deep infections (e.g.,
bone, joint, tendon sheath) and require careful evaluation.
• X-ray would evaluate for fracture or foreign body.
• Potential risk of transmitting blood-borne pathogens if injury contaminated
with another's blood.
D. Rat bite
Etiology: Spirillum minus (Asia); Streptobacillus moniliformis (USA)
Preferred Regimen:
1st line 2nd line
Prophylaxis: Amoxicillin- Prophylaxis:
clavulanate 875/125mg PO bid x 3d Doxycycline 100mg PO bid x 3d

Rat bite fever: Rat bite fever:

Penicillin G 2MU IV q4h OR Erythromycin 500mg PO qid OR
Doxycycline 100mg PO bid x 10-14d Clindamycin 300mg PO qid x 10-14d
Comments:
Rabies post-exposure prophylaxis and vaccination are not routinely indicated for
rat bites. Consider consultation with an expert for bites secondary to wild rodents.
III. MASTITIS
A. Postpartum Mastitis
• Postpartum mastitis occurs in approximately 10% of nursing mothers.

• Poor breastfeeding technique and incomplete emptying are contributing
factors.
• Risk factors (same for MRSA and MSSA) include: mother employed outside the
home, primiparity, advanced maternal age, breastfeeding difficulties
• May present with or without abscess.
• S. aureus is most common etiology but other pathogens are possible. If
possible, obtain culture before starting empiric therapy.
Etiology: S. aureus (MRSA or MSSA); S. pyogenes (Group A or B); E. coli; Bacteroides

species; Corynebacterium sp.; Coagulase-negative staphylococci (e.g., S.
lugdunensis)
Preferred Regimen:
If MRSA is not present: If MRSA is present or possible:
Outpatient
Cloxacillin 500mg PO qid OR Clindamycin 300mg PO qid OR
Cephalexin 500mg PO qid Cotrimoxazole 160/800mg 1-2 tabs PO bid
Inpatient
Oxacillin 2g IV q4h Vancomycin 30mg/kg/d IV in 2- 3 div doses
Comments:
If baby can latch on and the mother is comfortable, continue breast feeding during
the antibiotic therapy. Discontinue breastfeeding only if the breast is too painful
for breast feeding. On occasion, feeding can be temporarily interrupted, e.g.,
surgical I&D of an abscess. Breast feeding should resume once pain is tolerable.
Continued breast feeding does not pose a risk to the infant; discuss with
pediatrician age-specific risks to infant of drug exposure through breast milk.

B. Non-puerperal mastitis
Etiology: S. aureus; Bacteroides sp. (less often); Peptostreptococcus; Selected

coagulase-negative staphylococci; Corynebacterium sp.-rare; can cause distinctive
granulomatous inflammation.
Preferred Regimen:
1st line:
If MRSA is not present: If MRSA is present or possible:
Outpatient
Cloxacillin 500 mg PO qid OR Clindamycin 300 mg PO qid OR
Cephalexin 500 mg PO qid Cotrimoxazole 160/800 mg 1-2 tabs PO bid
Inpatient
Oxacillin 2 g IV q4h Vancomycin 1 g IV q12h; 1.5 g IV q12h if
patient weight >100 kg
If subareolar & odoriferous, most likely anaerobes:
ADD Metronidazole 500mg IV/PO tid
2nd line:
For granulomatous mastitis due to Corynebacterium sp:
Doxycycline 100mg PO bid x 3-4 weeks
Comments:
Consider inflammatory carcinoma in older women without clear abscess,
especially if microcalcification, or a breast mass is detected radiographically. If not
subareolar, probably Staphylococcus. Need pretreatment aerobic and anaerobic
cultures. Drainage, either by ultrasound guided needle aspiration or surgical,
indicated for abscess.
IV. BUIRNS
A. Infected burn wound, sepsis
• An Infected burn wound is characterized by bacteria in the wound and wound

eschar at high concentration (>105/g tissue).
• Invasive infection is characterized by pathogens at a sufficient concentration,
depth, and surface area to cause suppurative separation of eschar or graft loss,
invasion of adjacent unburned tissue, or sepsis syndrome.
• Treatment may require surgical debridement of infected necrotic tissue,
application of skin grafts and/or skin substitutes, and /or topical medications.
• Critically ill patients may have suspected burn wound sepsis. The ideal care is in
a dedicated burn unit.

Etiology: S. pyogenes; Enterobacter sp.; S. aureus; S. epidermidis; E. faecalis; E. coli;

P. aeruginosa; Fungi (rare) and Herpes virus (rare)
Preferred Regimen:
1st line 2nd line
Vancomycin loading dose of 25- Meropenem 1g IV q8h or
30mg/kg IV, then 15mg/kg IV q8-12h Cefepime 2g IV q8h PLUS
PLUS Piperacillin-Tazobactam 4.5g Vancomycin loading dose of 25-
q6h 30mg/kg IV, then 15mg/kg IV q8-12h
If with IgE-mediated allergy to beta
If Candida infection suspected: lactams:
ADD Fluconazole 6mg/kg IV qd Could use Aztreonam 2g IV q6h
If ESBL- or carbapenemase-
producing multi-drug resistant gram-
negative bacillus:
The only alternative is Colistin PLUS
Meropenem.
Comments:
Patients should undergo quantitative wound cultures, blood cultures, and then
empiric antimicrobial therapy while awaiting results. Other complications of
concern in critically ill burn patients include S. aureus toxic shock syndrome (TSS),
suppurative phlebitis, and pneumonia.
V. CELLULITIS
A. Diabetes mellitus and erysipelas
• Patients with diabetes mellitus peripheral neuropathy commonly suffer from

inflammation of the skin and subcutaneous tissue.
• The patient may have contiguous skin ulceration and/or atherosclerotic
peripheral vascular disease.
Etiology: Streptococcus. sp. (Group A, B, C, G); S. aureus; Enterobacteriaceae

Anaerobes (poor prognosis if present).

Preferred Regimen:
1st line 2nd line
Early or mild infection: For hospitalized patient with severe
Clindamycin 300-450mg (higher dose disease, forced to use broad-
in obese patient, BMI >40) PO tid x 5- spectrum therapy that targets both
10d or Cotrimoxazole 160/800 mg 1- S. aureus and Enterobacteriaceae:
2 tabs PO bid PLUS Piperacillin-Tazobactam 4.5g IV q8h
Penicillin VK 500mg PO qid or PLUS
Cephalexin 500mg PO qid Vancomycin 1g IV q12h or
Linezolid 600mg IV/PO bid
Can substitute Piperacillin-

tazobactam for carbapenem:
Ertapenem 1g IV q24h or
Meropenem 1g IV q8h
Comments:
Assess the adequacy of arterial blood supply. Surgical debridement for cultures
may be required to determine or assess for contiguous osteomyelitis and the
presence of necrotizing fasciitis. The likelihood of contiguous osteomyelitis is
increased if one can probe to the bone. The likelihood of contiguous osteomyelitis
is low if MRI is negative. Other alternatives to a carbapenem: Levofloxacin,
Piperacillin-Tazobactam.
B. Facial erysipelas
This is characterized by the sudden onset of rapidly spreading red edematous

tender plaque-like skin on the face in an otherwise healthy host.
Etiology: Streptococcus sp. (Groups A, B, C, G); S. aureus
Preferred Regimen:
1st line:
For severe infection:
Vancomycin 1g IV q12h PLUS Piperacillin-Tazobactam 4.5g IV q8h
If weight >100 kg, increase dose to 1.5g IV q12h
2nd line: Linezolid 600mg IV q12h
Comments:
S. aureus erysipelas of the face can mimic streptococcal erysipelas of an extremity.
If there are erysipelas-like lesions on the face, treat as if MRSA is present. The usual
duration of treatment is 7-10d, longer if the patient is bacteremic.

C. Acute bacterial skin and skin structure infections (ABSSSI)
• This section focuses on the treatment of uncomplicated cellulitis, erysipelas in

extremities and other ABSSSI in the non-diabetic patient.
• This is characterized by an acute onset of rapidly spreading red edematous,
tender plaque-like area of skin usually on the lower leg, often febrile. It may be
associated with lymphangitis or lymphadenitis.
• The portal of entry is frequently a fungal infection between the toes (Tinea
pedis).
• If the facial skin is involved, see Facial erysipelas.
• Erysipelas is characterized by red indurated demarcated inflamed skin (S.
pyogenes), and is distinguishable from abscesses due to S. aureus. Dual
infection is rare. Bedside ultrasound may be helpful in detecting deep S. aureus
abscess. If in doubt, treat for both. Community-associated MRSA can mimic
erysipelas; look for loculated purulence.
Etiology: S. pyogenes (Groups A, B, C, G); S. aureus (rare)
Preferred Regimen:
1st line:
Inpatient parenteral therapy: Penicillin G 1-2 MU IV q6h
If history of penicillin skin rash and nothing to suggest IgE-mediated allergic
reaction:
Cefazolin 1g IV q8h OR Ceftriaxone 2g IV qd
If history/evidence of past IgE-mediated allergic reaction (anaphylaxis), then
may be forced to use: Vancomycin 15mg/kg IV q12h
2nd line:
Linezolid 600mg IV/PO bid. Give IV until afebrile.
Stepdown to Penicillin VK 500mg PO qid ac and hs (outpatient) x 10d of total
therapy.
Outpatient therapy for less-ill patients:

Penicillin VK 500mg PO qid OR Amoxicillin 500 mg PO q8h
If history of Penicillin skin rash and nothing to suggest an IgE-mediated reaction

(anaphylaxis, angio-neurotic edema): Cephalexin 500mg PO bid x 10d
If documented past history of IgE-medicated allergic reaction to beta-lactam

antibiotics: Azithromycin 500mg PO x 1 dose then 250mg PO qd x 4d OR Linezolid
600 mg PO bid x 10d
If clinically unclear whether infection is due to S. pyogenes or S. aureus, get

cultures and start empiric therapy: Amoxicillin OR Penicillin VK OR Cephalexin

for S. pyogenes and Clindamycin for S. aureus (MRSA). See Comment re

Cotrimoxazole.
For suspected S. aureus (fluctuance or positive gram stain):

MSSA (outpatient): Cloxacillin 500mg PO qid
MSSA (inpatient): Oxacillin 2g IV q4h
MRSA (outpatient): Doxycycline 100mg PO bid OR Clindamycin 300-450mg PO bid
OR Cotrimoxazole DS 1 tab PO bid
MRSA (inpatient): Vancomycin 1g IV q12h
Comments:
Treatment also includes leg elevation to reduce local edema. Mixed infection
(Strep. and Staph.) is rare. If S. aureus is present, need incision and drainage. Usual
duration of therapy is 7-10d. Some treat until the patient is afebrile for 3-5d. Treat
Tinea pedis if present. Stasis dermatitis due to venous insufficiency can
masquerade as bacterial cellulitis/erysipelas; condition is often bilateral, chronic
and patient afebrile. Systemic antibiotics offer no additional benefit. Do not use a
fluoroquinolone, Cotrimoxazole or a Tetracycline for reasons of resistance and/or
clinical failures.
D. Purulent cellulitis
• This is associated with purulent drainage or exudate, in the absence of a

drainable abscess
Etiology: S. aureus: predominantly MRSA; also MSSA Rare: beta-hemolytic

streptococci
Preferred Regimen:
1st line:
Non-severe:
Clindamycin 300-450mg (higher dose in obese patient, BMI >40) PO tid x 5-10d
OR Cotrimoxazole 160/800mg (1 DS tab; 2 DS tabs in obese patient, BMI >40)
PO bid x 5-10d OR Doxycycline 100mg PO q12h x 5-10d may also be effective
for community acquired MRSA infections
Inpatient:
Empirical antibiotic therapy (in absence of specific culture and sensitivity data,
select an agent with activity against MRSA):
Clindamycin 600mg IV q8h for patients without signs and symptoms of
sepsis/bacteremia OR
Vancomycin 15 mg/kg q12h (trough concentrations of 5-10 μg/ mL are
adequate for infections of moderate severity; for Severe infections or if
bacteremia is present, 15-20 mg/kg q8-12h)

2nd line:
For MRSA infection:
Linezolid 600 mg PO q12h
Severe infections: Linezolid 600mg IV q12h
For documented MSSA infection, use a beta-lactam agent:
Oral agents: Cloxacillin 500 mg PO qid OR Cephalexin 500 mg PO tid-qid
Parenteral agents: Oxacillin 1g IV q4h OR Cefazolin 1g IV q8h
Comments:
Culture of blood, exudate, and/ or bullae is needed when there are signs of
systemic toxicity, extensive skin involvement, or underlying comorbidities. Empiric
therapy for infection due to beta-hemolytic streptococci may not be necessary
since MRSA is the dominant organism (59%). Others: MSSA (17%) and beta-
hemolytic streptococci (2.6%). I&D with culture of the exudate and blood is
beneficial.
E. Seawater, brackish water-associated, contaminated skin wounds
• Individuals at highest risk of life-threatening infection: cirrhosis due to alcohol

or chronic viral hepatitis, alcoholism, hemochromatosis, diabetes mellitus,
thalassemia major, chronic renal disease, and lymphoma
Etiology: Vibrio vulnificus; Vibrio alginolyticus; Vibrio damsel
Preferred Regimen:
1st line (Severe infections/sepsis or those at risk for life-threatening infections):
Vancomycin 15-20 mg/kg IV q 8-12h OR Piperacillin-Tazobactam 4.5 g IV q8h
2nd line: Ciprofloxacin 750mg PO bid or 400mg IV bid OR
Levofloxacin 750mg IV/PO qd
DOT: based on clinical response.
Comments:
Due to the potential severity of disease empiric therapy for wound and septic
patients should include drugs active against V. vulnificus when risk factors are
present (e.g. sepsis and septic shock in immunocompromised patients including
hematological disease, malignancy, and liver disease. Roughly 75% of patients
have bullous skin lesions.
VI. HERPES INFECTION
A. Herpes zoster, shingles
• Effective treatment of shingles is most evident in patients >50 y.

• Must begin treatment within 3d of onset of rash.

• Immunization results in 25-fold decrease in infection rate.

• There should be increasing recognition of increased risk of stroke in the 6
months after an episode of H. zoster. Oral antivirals during clinical infection
may have a protective effect.
Etiology: Herpes zoster virus (Varicella zoster virus)
Preferred Regimen:
1st line:
Immunocompetent:
Aciclovir 800mg PO 5x/d x 7-10d PLUS Prednisone in patients age >50 yrs. to
decrease discomfort during acute phase of infection. Does not decrease incidence
of post-herpetic neuralgia.
Day 1-7: 30mg PO bid
Day 8-14: 15mg PO bid
Day 15-21: 7.5mg PO bid
Immunocompromised:
Not severe: Aciclovir 800mg PO 5x/d x 7d
Severe (>1 dermatome, trigeminal nerve or disseminated):
Aciclovir 10-12mg/kg IV (infusion over 1hr) q8h x 7-14d
2nd line:
Immunocompetent: Valaciclovir 1g PO tid x 7d
Immunocompromised (not severe): Valaciclovir 1g PO tid x 7d
Comments:
Valaciclovir reduced post-herpetic neuralgia (PHN) more rapidly than aciclovir in
patients age >50 y. Toxicity of both drugs are similar. Prednisone added to
aciclovir (in patients aged >50 yrs.) improved quality of life measurements. The
role of antiviral drugs in the treatment of PHN is unproven. However, 8 out of 15
patients improved with IV aciclovir 10 mg/kg q8h x 14d followed by oral
valaciclovir 1 g 3x/d for 1 month.
Herpes zoster is a common manifestation of immune reconstitution following ART

in HIV-infected children. Treatment must be begun within 72 h. Aciclovir-resistant
VZV occurs in HIV-positive patients previously treated with aciclovir.
B. Varicella zoster virus
• Clinical syndromes include: chickenpox, shingles (single dermatomal or

multiple dermatomes) [see also Herpes zoster (shingles)], and disseminated
VZV disease/organ involvement.
• Emerging data suggests VZV may cause vasculopathy of cerebral, temporal, and
other arteries (suggested as possible cause of Giant Cell arteritis).

Etiology: Varicella-zoster virus (VZV)
Preferred Regimen:
1st line:
Immunocompetent host, chickenpox:
Aciclovir 800mg PO 5x/d x 5-7d (start within 24h of rash) OR
Valaciclovir 1g PO tid x 5d
Pregnancy (3rd trimester), pneumonia:
Aciclovir 800mg PO 5x/d or 10 mg/kg IV q8h x 5d
Immunocompromised:
Aciclovir 10-12mg/kg (500 mg/M2) IV (infused over 1 hour) q8h x 7d
2nd line: Valaciclovir 1g PO tid x 5d
Prevention, post-exposure prophylaxis:

Refer to PSMID-PFV Adult Immunization Schedule 2015. Available at:
www.philvaccine.org/vaccination-schedules/adult-immunization-schedule
Comments:
Varicella pneumonia is associated with a 41% mortality in pregnancy, but Aciclovir
decreases incidence and severity of varicella pneumonia. If a varicella-susceptible
mother is exposed and develops respiratory symptoms within 10d after exposure,
start Aciclovir.
C. Necrotizing fasciitis
• Infection causing necrosis extending to fascial plane(s): usually involving an

extremity, perianal area, genitals (“Fournier’s gangrene”)
• Necrosis manifests by a decrease in pain and dusky, cyanotic skin, often with
blood-filled bullae. Typically, gas is present in the involved tissue.
• May have associated toxic shock syndrome as defined by hypotension, nausea,
vomiting, diarrhea, renal failure, respiratory failure, and maybe erythroderma.
Etiology: Mixed aerobic-anaerobic bacteria [Type I]: most common, fast moving;
Group A Streptococcus (GAS, S. pyogenes) [Type II]—acute or subacute;
Clostridium perfringens, MRSA, Vibrio vulnificus, Klebsiella spp.
Preferred Regimen:
1st line:
If Type I necrotizing fasciitis is suspected:
Piperacillin-Tazobactam 4.5g IV q8h PLUS Vancomycin 15-20mg/kg IV q8-12h
If Type II necrotizing fasciitis or clostridial necrotizing fasciitis is suspected:
Penicillin G 4MU IV q4h PLUS Clindamycin 600-900mg IV q8h (to block toxin
production)

If MRSA is suspected:
Vancomycin 15-20mg/kg q8-12h (target trough concentrations 15-20μg/ mL)
2nd line:
For Type 1 necrotizing fasciitis:
Meropenem 1g IV q8h PLUS Vancomycin 15-20mg/kg q8-12h (target trough
concentrations 15-20μg/ mL)
Penicillin allergy manifested as skin rash only and unable to tolerate
carbapenem:
Cefepime 1-2g q8-12h PLUS Metronidazole 500mg IV q6h PLUS Vancomycin
if S. aureus suspected
Penicillin allergy manifested as anaphylaxis or angioneurotic edema:
Levofloxacin 750mg IV qd or Ciprofloxacin 400mg IV q12h PLUS
Metronidazole 500mg IV q6h PLUS Vancomycin if S. aureus suspected
For streptococcal (Type II) necrotizing fasciitis:
If with penicillin allergy: Vancomycin 1g IV q12h
For clostridial necrotizing fasciitis:
Susceptibility of C. tertium to Penicillin and Metronidazole is variable in published
studies; resistance to Clindamycin and third-generation cephalosporins is
common. Vancomycin and Meropenem expected to have activity in vitro.
For necrotizing fasciitis caused by MRSA: Linezolid 600mg IV q12h.
Comments:
X-ray, CT scan, or MRI may show gas in involved tissue. Urgent surgical
debridement and antibiotics are the mainstay of therapy. Early exploratory
surgery is recommended to establish diagnosis (include aerobic and anaerobic
cultures) and resect all non-viable tissue. IDSA Guidelines do not recommend
hyperbaric oxygen.
Type II necrotizing fasciitis: presents with and without TSS and/or rhabdomyolysis.
Some lots of intravenous immunoglobulin (IVIG) have antibodies against
streptococcal toxins. Use of IVIG is supported by a small controlled study and a
retrospective review. More data is needed.
D. Diabetic Foot Infections (DFI)
• This manifests in diabetic patients with any foot wound with: signs of
inflammation (redness, warmth, tenderness, swelling, or pain), purulent
secretions, or additional secondary signs (e.g., non-purulent secretions, friable
or discolored granulation tissue, undermining of wound edges, foul odor).
• The use of a validated classification system for DFI, e.g., IDSA classification, is
recommended.

Etiology: Aerobic gram-positive cocci, including MRSA, are most common. Aerobic
gram-negative bacilli and anaerobes are common secondary organisms.
Preferred Regimen:
1st line 2nd line
Mild to moderate DFI: Mild to moderate DFI:
Clindamycin 300mg PO/IV qid OR Levofloxacin 750mg PO/IV qd
Cotrimoxazole 160/800mg 1-2 tabs
PO bid x 1-2 weeks Severe DFI:
Meropenem 1g IV q8h PLUS
Severe DFI: Vancomycin 15-20mg/kg IV q8-12h x
Piperacillin-Tazobactam 4.5g IV q6- 2-3 weeks OR
8hr IV (for Gram-negative bacilli Ceftazidime 1-2g IV q8h (or
coverage, especially if P. aeruginosa is Cefepime) PLUS Metronidazole
suspected) PLUS Vancomycin (for 500mg IV q8h PLUS Vancomycin 15-
MRSA coverage) 15-20mg/kg IV q8- 20mg/kg IV q8-12h x 2-3 weeks
12h x 2-3 weeks
DOT may be as short as one week for osteomyelitis if all infected and necrotic bone
and soft tissue are resected and there is clinical improvement. This may be
extended for 4-6 weeks (or even longer) if there is residual infected bone following
debridement of necrotic bone.
Comments:
Management requires multi-specialty collaboration (for diabetes control,
infectious diseases, debridement and other surgical interventions by
orthopedic/vascular/general surgeons). Orthopedic consultation and
management is needed when osteomyelitis is being considered.
For moderate to severe infections, send specimens from deep tissue, obtained by
biopsy or curettage after the wound has been cleansed and debrided. Avoid swab
specimens. Plain x-ray of the affected foot and/or MRI may be necessary to
determine the extent and depth of infection. Surgical debridement is usually
necessary for moderate to severe DFI.
VII. WOUND INFECTION
A. Post-operative wound infections
• Non-gastrointestinal tract and non-genitourinary tract surgery (e.g., "clean"

surgery). Treatment regimen is determined by the severity of infection (may be
mild in afebrile patients, or severe in febrile patients).
• Gastrointestinal tract (including oropharyngeal and esophageal) and non-
genitourinary tract surgery (e.g., potential contamination by bowel or vaginal
flora). The patient is febrile, with neutrophilia.

Etiology:
Non-gastrointestinal tract, non-genitourinary tract surgery: skin flora, S. aureus,
Streptococcus sp. (Group A, B, C, G)
Gastrointestinal tract (GIT) or genitourinary tract (GUT) surgery: skin flora,
gastrointestinal and vaginal flora, S. aureus (MSSA, MRSA), coliform species (e.g.,
E. coli), Bacteroides sp (e.g., B. fragilis), and other anaerobic bacteria
Preferred Regimen:
1st line 2nd line
NON-GI TRACT, NON-GU TRACT SURGERY:
Mild infection (without sepsis; Mild infection (without sepsis;
afebrile), if antimicrobial needed: afebrile patient):
Clindamycin 300-450mg PO tid OR Clindamycin 300-450mg PO tid
PO bid Severe infection (sepsis; febrile
patient):
Severe infection (sepsis; febrile Linezolid 600mg IV q12h PLUS
patient): Vancomycin 1g IV q12h (1.5g Ciprofloxacin 400mg IV q12h or
q12h if weight >100 kg) Levofloxacin 750mg IV q24h PLUS
Metronidazole 500mg IV q6h
GI TRACT OR GU TRACT SURGERY:
Mild infection: Meropenem 1g q8h PLUS
Amoxicillin-Clavulanate 1000/62.5mg Vancomycin 1g IV q12h
extended release, 2 tabs PO bid Can substitute Linezolid for
If S. aureus suspected: Vancomycin in the primary regimen.
ADD Clindamycin 300-450mg PO OR
PO bid
Severe infection:
Piperacillin-Tazobactam 4.5 g IV q8h
OR Parenteral third-generation
cephalosporin PLUS Metronidazole
500mg IV q6h OR
Ertapenem 1 g IV q24h PLUS
Vancomycin 1 g IV q12h
FOR SUSPECTED MSSA OR MRSA POSTWOUND INFECTION (GRAM STAIN
SHOWS GRAM POSITIVE COCCI):
Oral: Clindamycin 300-450mg PO tid Oral: Minocycline 100mg PO q12h
OR Cotrimoxazole DS 1-2 tabs PO bid OR Doxycycline 100mg PO bid OR
IV: Vancomycin 1 g IV q12h Linezolid 600mg PO/IV q12h

Comments:
If the infection is on the skin incision, remove sutures to drain wound, obtain
culture and sensitivity, and pack the wound. See IDSA Guidelines for the
assessment and management of infected surgical wounds. In the absence of
systemic response, wounds with <5 cm erythema and no induration or necrosis
may be treated with opening and dressing changes only.
If S. aureus is Clindamycin-sensitive but Erythromycin-resistant, watch out for

inducible Clindamycin resistance. Based on a 2011 global survey of approximately
5,000 S. aureus isolates, 94% of MSSA were susceptible to Tetracycline and >98%
were susceptible to Minocycline. For MRSA, approximately. 85% were susceptible
to Tetracycline, and 88.3% (by Eucast breakpoint) or 97.2% (by CLSI breakpoint)
were susceptible to Minocycline. In the Philippines, the rate of resistance of S.
aureus to tetracycline was 9.1 % in 2014 and 7.1 % in 2015.
Open and drain the wound if S. aureus suspected on GIT or GUT Surgery.
B. Infected wound, post-trauma
• Non-gastrointestinal tract and non-genitourinary tract surgery (e.g., "clean"

surgery). Treatment regimen is determined by the severity of infection (may be
mild in afebrile patients, or severe in febrile patients).
• Gastrointestinal tract (including oropharyngeal and esophageal) and non-
genitourinary tract surgery (e.g., potential contamination by bowel or vaginal
flora). The patient is febrile, with neutrophilia.
Etiology: Polymicrobic (Microbial flora dependent on nature of the trauma):

S. aureus (MSSA, MRSA), Streptococcus sp. (aerobic and anaerobic),
Enterobacteriaceae, C. perfringens, C. tetani, Pseudomonas sp. (water exposure),
Aeromonas sp., Acinetobacter sp.; especially in soldiers infected in Afghanistan,
Iraq
Preferred Regimen:
Uncomplicated, mild or moderate, afebrile patient:
1st line: Clindamycin 300-450mg PO tid OR Cotrimoxazole DS 1-2 tabs PO bid
Regimen focuses on S. aureus/ Streptococcus sp. If Gram-negative bacilli are
suspected: add a fluoroquinolone. Surgical debridement may be indicated.
2nd line: Minocycline 100mg PO bid OR Linezolid 600mg PO bid
Complicated, severe, febrile patient:

1st line: Piperacillin-Tazobactam 4.5g q8h PLUS Vancomycin 1g IV q12h
2nd line: Meropenem 1g IV q8h PLUS
Vancomycin 1g IV q12h or Linezolid 600mg IV/PO q12h PLUS
Ciprofloxacin 400mg IV q12h or Levofloxacin IV 750mg IV q24h

Comments:
If S. aureus is erythromycin-resistant in vitro, inducible resistance to clindamycin
is also possible. Ensure that the microbial laboratory checks this if clindamycin is
being considered.
VIII. FUNGAL SKIN INFECTIONS
A. Cutaneous candidiasis
Etiology: Candida albicans Other Candida spp.

Clinical settings
Common types of candida skin infections include: intertrigo, diaper dermatitis,
erosion interdigitalis blastomycetica, perianal dermatitis, balanitis, and
paronychia
Preferred Regimen:
1st line: Topical therapy for 3-5d
Clotrimazole 1% cream; Miconazole 2% cream; Ketoconazole 2% cream applied
bid
2nd line: If topical treatment does not work:
Fluconazole 100-200mg PO q week until normal nail anatomy restored
Alternatives: Itraconazole 200mg PO bid x 1 week x 3 consecutive months OR
Terbinafine 250 mg PO od x 3 months
Comments:
Maintain dry skin surface (e.g., for intertrigo, diaper dermatitis) and control
hyperglycemia if present. Acute paronychia usually caused by mixed bacterial
infections and may require I&D if the abscess is present. Chronic paronychia may
require referral to hand surgeon if medical treatment is ineffective
B. Tinea corporis/cruris
Check for history of:

• Current and previous topical and/or systemic treatment
• Occupational exposure (e.g., veterinarian, lab worker, farmer, pet shop
workers)
• Environmental exposure (e.g., gardening, pets), contact sports, locker rooms,
gyms, affected family members)
Etiology: Certain spp. of dermatophytes of the following genera: Epidermophyton,

Microsporum and Trichophyton

Preferred Regimen:
1st line: Terbinafine 1% cream bid x 3-4 weeks (recommended) OR
Ketoconazole 2% cream qd or bid x 2-4 weeks OR
Clotrimazole 1% cream, powder, solution bid x 2-4 weeks
2nd line: Topical therapy ineffective or intolerant to topical medications, or with
extensive and/or disabling, multifocal or inflammatory disease, deeper infection
with hair follicle involvement: Terbinafine 250mg PO qd x 2-4 weeks OR
Itraconazole 200mg PO qd x 2-4 weeks or 200mg bid x 7d OR Fluconazole 50-
100mg PO qd or 150mg once weekly x 2-3 weeks
Comments:
Topical antifungals preferred for localized, uncomplicated noninflammatory
lesions. Avoid tight-fitting clothes/underwear. If secondary bacterial infection is
suspected, obtain bacterial cultures and start adequate antibiotic coverage.
A meta-analysis showed that 50% Akapulco lotion was superior to placebo for
Tinea versicolor (mycologic cure and decrease in clinical activity). It appears to be
as effective as 25% sodium thiosulfate and ketoconazole cream, but larger
randomized trials with good follow-up rates are needed to confirm these findings.
C. Tinea pedis
May manifest as:

• Inter-digital, especially common in the 3rd and 4th web spaces
• Moccasin-style: powdery plaques with mildly erythematous base on heels,
soles, and lateral aspects of the feet
• Vesicobullous: may have purulent exudate, usually on the instep
Etiology: Trichophyton rubrum, Trichophyton interdigitale, Trichophyton

mentagrophytes. Rare: Epidermophyton floccosum, Candida, Acremonium,
Fusarium
Preferred Regimen:
1st line: Terbinafine 1% cream qd x 2-4 weeks (recommended) OR
Ketoconazole 2% cream bid x 3-6 weeks OR Clotrimazole 1% bid x 2-4 weeks
2nd line: Terbinafine 250mg PO x 2 weeks Fluconazole 150mg PO q1wk x 4 weeks
Comments:
A randomized controlled trial showed faster response with topical terbinafine
compared to topical clotrimazole after 1 week of treatment (84.6% vs 55.8%,
respectively). Another RCT showed comparable efficacy between clotrimazole 1%
od and ketoconazole 2% bid, applied for 28d. Tinea pedia can trigger an “id”
reaction on the hands -multiple, very pruritic, minute deep-seated vesicles on the
fingers and palms. May progress to a chronic phase resembling hand eczema.

Topical or systemic corticosteroids: may be considered in cases of extensive or

severe inflammatory tinea pedis. Topical or systemic antibiotics: may be needed
in cases of secondary Gram-negative toe web infection.
References
• Antimicrobial Resistance Surveillance Program. Manila: Department of Health; 2015.
• Bartlett JG, Editor in Chief. Johns Hopkins ABX Guide (@2000 – 2016).
• Daum RS, Miller LG, Immergluck L, et al. A placebo-controlled trial of antibiotics for smaller
skin abscesses. New Engl J Med 2017; 376:2545-55.
• Lipsky BA, Berendt AR, Comia PB, et al. 2012 Infectious Diseases Society of America Clinical
Practice Guidelines for the Diagnosis and Treatment of Diabetic Foot Infections. Clin Inf
Diseases 2012; 4:132-73.
Society of America for the treatment of Methicillin resistant Staphylococcus aureus
infections in adults and children. Clin Inf Diseases 2011; 52:1-38.
• The Sanford Guide to Antimicrobial Therapy, 2016.
• Stevens DL, Bisno AL, Chambers HF, et al. Practice Guidelines for the Diagnosis and
Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases
Society of America. Clin Inf diseases 2014; 59: 147-59.

URINARY TRACT INFECTIONS
I. URINARY TRACT INFECTION IN CHILDREN
In children, Urinary Tract Infection (UTI) is defined by the presence of a single

pathogen in urine culture accompanied by clinical findings in the history, physical
examination and diagnostic evaluation. The following recommended
antimicrobial treatments for selected pathogen-specific conditions are based on
evidence of clinical effectiveness, cost effectiveness and local patterns of drug
resistance reported the past two years. Once the sensitivity pattern of a specific
pathogen has been obtained from the urine culture requested, antibiotic therapy
may be adjusted accordingly.
A. Acute Uncomplicated UTI
• Acute pyelonephritis: Condition that indicates renal parenchymal involvement

where infants and children may present with fever with any or all of the
following symptoms: abdominal, back, or flank pain; malaise; nausea;
vomiting; and, occasionally, diarrhea. Infants and children who have
bacteriuria and fever >38°C OR those presenting with fever <38°C with loin
pain/tenderness and bacteriuria should be worked up for acute pyelonephritis.
• Acute cystitis: condition that indicates urinary bladder involvement where
infants and children may present with any or all of the following symptoms of
dysuria, urgency, frequency, suprapubic pain, incontinence, and malodorous
urine. Patients usually have no systemic signs or symptoms.
Etiology: E. coli, Klebsiella, Enterobacter, Enterococcus, Group B Streptococcus
Preferred Regimen:
Infants <2 months:
Cefotaxime PLUS
Age Weight Dose
<7d 50mg/kg/dose q12h
>7d <1200g 50mg/kg/dose q12h
>7d >1200g 50mg/kg/dose 8h
>1 month 100-200 mg/kg/d q6h
Amikacin
Age Weight Dose
0-4 weeks <1200g 7.5mg/kg qd
<7d 1200 - 2000g 7.5mg/kg qd
<7d >2000g 7.5-10mg/kg qd
>7d 1200 - 2000g 7.5mg/kg qd
>7d >2000g 10 mg/kg qd
DOT: 10-14 days

Comments:
If there are signs of sepsis, treat as neonatal sepsis. Adjust therapy based on
culture. Early onset is usually due to maternal transmission. Use ceftriaxone if
cefotaxime is not available and the neonate is not jaundiced.
Etiology: E. coli, Klebsiella, Enterobacter, Citrobacter
Preferred Regimen:
Oral:
>2 months to 18 years
Amoxicillin-clavulanate:
<40 kg: 20-40mg/kg/d q8h (amoxicillin component) or 25-45mg/kg/d q12h
using the 20mg/5mL or 400mg/5mL
>40 kg: 500-875mg q8h (Max: 2g/d) OR
Cefuroxime >3mos - 12years: 20-30 mg/kg/d PO q12h
Adolescent:
Cefuroxime 250-500mg PO q12h OR
Nitrofurantoin (only for cystitis) 5-7mg/kg/d q6h (Max: 400 mg/d)
Parenteral:
Ampicillin-Sulbactam 100-200mg/kg/d q6h (ampicillin component) IM or IV
infusion over 10-15 min OR Cefuroxime 75-150mg/kg/d q8h (Max dose: 6
g/d). For those >40 kg, use adult dose.
DOT (IV/PO): 7-14d
Comments:
Oral therapy is equally effective to IV therapy. IV therapy is preferred for seriously
ill children and for those who cannot take oral therapy. Early antibiotic therapy is
necessary to prevent renal damage. Switch to oral therapy once patient has been
afebrile for 24h and able to take oral medications. Obtain renal ultrasound within
6 weeks for 1st UTI in children <6 months old. Cephalosporins are not useful if
Enterococcus is suspected.
Nitrofurantoin should NOT be used for pyelonephritis and renal sepsis due to
poor serum concentrations.
Clinical response is expected in 24-48 hours. Antibiotic coverage should be re-

assessed if still unwell in 24-48h. Request for a kidney and urinary bladder
ultrasound and if abnormal, refer to a pediatric nephrologist for further work-up.
According to a Cochrane review on antibiotics for lower urinary tract infection in

children (August 2012), “there are insufficient data to answer the question on
which type of antibiotic and which duration is most effective to treat symptomatic
lower UTI. This review found that 10-day antibiotic treatment is more likely to
eliminate bacteria from the urine than single-dose treatments.”

B. UTI, recurrent catheter related or with co-morbids
These patients require a referral to a pediatric infectious disease specialist,

pediatric nephrologist and pediatric urologist.
Etiology: Enterobacteriaceae, P. aeruginosa, Enterococcus
Preferred Regimen:
Ceftriaxone PLUS
Age Weight Dose
<7d 50mg/kg/dose q24h
>7d <2000g 50mg/kg/dose q24h
>7d >2000g 50-75mg/kg/dose
q24h
Infants & children: 50-100 mg/kg/dose q24h
AND/OR
Amikacin
Age Weight Dose
0-4 weeks <1200g 7.5mg/kg qd
<7d 1200 - 2000g 7.5mg/kg qd
<7d >2000g 7.5-10mg/kg qd
>7d 1200 - 2000g 7.5mg/kg qd
>7d >2000g 10 mg/kg qd
Infants and children: 15-22.5mg/kg/d as single daily dose or q8h (Max: 24 g/d)
DOT: 7-14 days depending on response.
Comments:
Use cefotaxime instead of ceftriaxone in jaundiced patients. If Pseudomonas is
suspected, use ceftazidime instead of cefotaxime. Adjust antibiotics depending on
results of culture. Cephalosporins are not active against Enterococcus.
C. Perinephric abscess

Enterobacteriaceae, Oxacillin 100-200mg/kg/d q6h PLUS
S. aureus Amikacin 15-22.5mg/kg/d x 1 dose or q8h (Max: 24
g/d)
Comments: Use Vancomycin if MRSA is suspected. Refer to specialist for drainage.

D. Hospital acquired UTI
Preferred Regimen:
Ceftazidime 30-50mg/kg IV q8h (Max: 6 g/d) OR
Amikacin 15mg/kg IV q24h (Max: 24g/d)
Comments:
Choice should be based on current antimicrobial susceptibility pattern in the
institution
E. Prophylaxis for Recurrent UTI
Preferred Regimen: Nitrofurantoin 1-2mg/kg/d (up to 100 mg/d) PO in 1-2 div

doses
Comment: Refer to an infectious disease specialist or nephrologist
II. URINARY TRACT INFECTION IN ADULTS
A. Uncomplicated UTI
Acute uncomplicated cystitis (AUC)

• Acute dysuria, frequency, urgency in a non-pregnant, otherwise healthy
premenopausal female
Etiology: E. coli (75-90%), S. saprophyticus (5-15%)
Preferred Regimen:
1st line: 2nd line:
Nitrofurantoin macrocrystals Cefuroxime 250mg bid x 7d OR
100mg qid x 5d OR Fosfomycin 3g Cefixime 200mg bid x 7d OR
x 1 dose sachet in 3-4 oz (or 90- Amoxicillin-clavulanate 625mg bid x
120ml) water 7d
Comments:
Empiric treatment is the most cost-effective approach; urinalysis and urine culture
not pre-requisites. Nitrofurantoin monohydrate/ macrocrystals (100mg bid) are
not locally available. Amoxicillin/ampicillin and cotrimoxazole are not
recommended for empiric treatment given the high prevalence of resistance to
these agents. Fluoroquinolones are considered as reserved drugs because of
propensity for collateral damage (e.g., selection for drug-resistant bacteria); but
are efficacious in 3-day regimens. The treatment is the same for otherwise healthy
elderly women with AUC.

Acute uncomplicated pyelonephritis

• Fever, flank pain, costovertebral angle tenderness, nausea/vomiting, with
or without signs or symptoms of cystitis in an otherwise healthy
premenopausal female
Etiology: As for AUC, E. coli is predominant, as well as other Enterobacteriaceae
Preferred Regimen:
Oral
1st line: Ciprofloxacin 500mg bid x 7-10d OR Levofloxacin 750mg qd x 5d
2nd line: Cefuroxime 500 mg bid x 14d OR Cefixime 400 mg qd x 14d OR
Amoxicillin-clavulanate 625 mg tid x 14d (when GS shows Gram+ cocci)
Parenteral
1st line:
Ceftriaxone 1-2g q24h Amikacin 15mg/kg q24h
Ciprofloxacin 400mg q12h Gentamicin 3-5mg/kg q24 h +/-
Levofloxacin 250-750mg q24h Ampicillin
2nd line: Ampicillin-sulbactam 1.5g q6h (when GS shows g+ cocci)

Reserved for multidrug-resistant organisms:
Ertapenem 1g q24h (if ESBL rate >10%)
Piperacillin-tazobactam 2.25-4.5g q6-8h
Comments:
Urine analysis, gram stain, culture and susceptibility tests should be done. Blood
cultures are not routinely done unless septic. Consider giving initial IV/IM dose of
antibiotic followed by oral regimen in patients not requiring hospitalization.
Indications for hospitalization/parenteral regimen:
1. signs of sepsis
2. inability to take oral medications/hydration
3. concern re compliance
4. presence of possible complicating conditions
Switch to oral regimen once afebrile for 24-48 hr. and able to take oral medicines.
Tailor antibiotic regimen once culture result available. Routine urologic evaluation
and imaging not recommended unless still febrile after 72 hr. Post-treatment urine
culture not recommended if clinically responding to treatment.
Asymptomatic bacteriuria (ASB)

presence of bacteria in the urine without signs and symptoms of UTI
Diagnosis:
• In women: 2 consecutive voided urine specimens with the same organism
in quantitative counts ≥100,000 cfu/mL

• In men: single, clean-catch voided urine with one bacterial species in a

quantitative count ≥100,000 cfu/mL
• In both men and women: a single catheterized urine specimen with one
bacterial species in a quantitative count ≥100 cfu/mL; pyuria, odor and
color of urine not relevant to decision to treat
Etiology: Similar to acute uncomplicated cystitis
Preferred Regimen:
No screening and treatment DO NOT TREAT ASB in:
recommended except in: • healthy adults
• pregnant women • non-pregnant women
• persons undergoing invasive • patients with diabetes mellitus
genitourinary tract procedures • elderly patients
(likely to cause mucosal bleeding) • persons with spinal cord injury
• persons with indwelling urinary
catheter
• persons with HIV
• persons with urologic
abnormalities
Comments:
Antibiotics do not decrease asymptomatic bacteriuria or prevent subsequent
development of UTI. The optimal screening test is a urine culture. If urine culture
not possible, significant pyuria (>10 wbc/hpf) or a positive gram stain of unspun
urine (>2 microorganisms/oif) in two consecutive midstream urine samples may
be used to screen for ASB. When indicated, treatment should be culture-guided.
A 7-day regimen is recommended.
B. RECURRENT UTI IN WOMEN
• ≥3 episodes of acute uncomplicated cystitis documented by urine culture

in 1 year or ≥ 2 episodes in a 6-mo. period
Etiology: Similar to cystitis
Preferred Regimen: Treat as acute episode for uncomplicated UTI
Prophylaxis:
TMP-SMX 40/200mg or Nitrofurantoin 50-100 mg at bedtime for 6-12 mos
(continuous prophylaxis) OR
TMP-SMX 40-80/200-400mg or Nitrofurantoin 50-100 mg x 1 dose (post-coital)
OR
TMP-SMX 320/1600mg x 1 dose at symptom onset

Others:
Lactobacilli is not recommended. Cranberry juice and products can be used. For
post-menopausal women, intra-vaginal estriol nightly x2 weeks then twice-weekly
for at least 8 months.
Comments:
Radiologic or imaging studies not routinely indicated. Screen for urologic
abnormalities in the ff:
• No response to treatment
• Gross hematuria/persistent microscopic hematuria
• Obstructive symptoms
• History of acute pyelonephritis
• History of or symptoms suggestive of urolithiasis
• History of childhood UTI
• Elevated serum creatinine
• Infection with urea-splitting bacteria (Proteus, Morganella, Providencia)
C. UTI IN PREGNANCY
ACUTE UNCOMPLICATED CYSTITIS IN PREGNANCY
Etiology: E. coli (70%), Other Enterobacteriaceae, Group B Streptococcus
Preferred Regimen:
Cefalexin 500mg qid x 7d Nitrofurantoin macrocrystals 100mg qid x 7d
Cefuroxime 500mg bid x 7d Fosfomycin 3g single-dose sachet
Cefixime 200mg bid x 7d Amoxicillin-clavulanate 625mg bid x 7d
Comments:
Start empiric antibiotic immediately, but pre-treatment urine must be submitted
for culture and susceptibility; adjust treatment accordingly. Document clearance
of bacteriuria with a repeat urine culture 1-2 weeks post-treatment. Avoid
amoxicillin-clavulanate in those at risk of pre-term labor because of potential for
neonatal necrotizing enterocolitis.
Use nitrofurantoin from the 2nd trimester to 32 weeks only, if possible, because of
potential for birth defects and hemolytic anemia. Avoid cotrimoxazole especially
during the first and third trimesters because of risk of teratogenicity and
kernicterus. Fluoroquinolones are contraindicated.
ACUTE PYELONEPHRITIS IN PREGNANCY
Etiology: Similar to acute cystitis in pregnancy

Preferred Regimen:
Parenteral:
1st line: Ceftriaxone 1-2 g q24 h OR Ceftazidime 2 g q8 h
2nd line: Ampicillin-sulbactam 1.5g q6h (when GS shows gram+ cocci)
Oral:
Cefalexin 500mg to complete 14d
Cefuroxime 500mg bid to complete 14d
Cefixime 200mg bid to complete 14d
Amoxicillin-clavulanate 625mg bid to complete 14d
Comments:
Urinalysis, gram stain and culture/susceptibility tests should be done. Blood
cultures are not routinely done unless septic. Ultrasound of KUB reserved for
failure to respond to treatment.
Indications for admission: pre-term labor and other indications as listed above for
acute uncomplicated pyelonephritis. Switch to oral regimen when afebrile x 48
hrs. and based on culture/susceptibility result. Recommended duration of
treatment is 14d. Test of cure with a urine culture post-treatment is essential.
Follow up with monthly urine culture until delivery.
ASYMPTOMATIC BACTERIURIA (ASB) IN PREGNANCY
Etiology: Similar to acute cystitis in pregnancy
Preferred Regimen:
Cefalexin 500mg qid x 7d Fosfomycin 3g single-dose sachet
Cefuroxime 500mg bid x 7d Amoxicillin-clavulanate 625mg bid x
Nitrofurantoin macrocrystals 100mg qid 7d
x 7d
Comments:
Treat ASB to reduce the risks of symptomatic UTI and low birth weight neonates
and preterm infants. Choice of regimen is based on culture/susceptibility test
result. Note caveats for use of nitrofurantoin and amoxicillin-clavulanate.
Screen all pregnant women for ASB once between the 9th and 17th week,
preferably during the 16th week. The standard urine culture/susceptibility is the
test of choice. Urinalysis is inadequate for ASB screening. Do follow-up urine
culture 1-week post-treatment and monitor every trimester till delivery.

D. COMPLICATED UTI
• Significant bacteriuria plus clinical symptoms occurring in the setting of:

- functional or anatomic abnormalities of the urinary tract,
- presence of an underlying disease that interferes with host defense
mechanisms
- any condition that increases the risk of acquiring [persistent] infection
and/or treatment failure.
• Cut-off for significant bacteriuria in cUTI is 100,000 cfu/mL; may be lower in
certain clinical situations, such as in catheterized patients.
Etiology: more varied and may include drug – resistant organisms (e.g., ESBL-
producing E. coli), P. aeruginosa and enterococci
Preferred Regimen:
Parenteral:
Amikacin 15mg/kg q24h Ertapenem 1g q24h
Gentamicin 3-5mg/kg q24h Meropenem 1g q8h
Piperacillin-tazobactam 2.25-4.5g q6-8h
Oral:
Ciprofloxacin 500-750mg bid
Levofloxacin 500-750mg qd
Amoxicillin-clavulanate 625mg tid or 1g bid
DOT: 7-14d
Comments:
Always obtain urine for gram stain, culture and susceptibility prior to start of
treatment, and adjust regimen as needed based on culture result. Ancillary
diagnostic tests such as imaging of the urinary tract (CT or ultrasound) are often
warranted. Start with parenteral broad-spectrum antibiotic for severely ill
patients, and then switch to an oral regimen/de-escalate when there is clinical
improvement. Repeat urine culture 1-2 weeks post -treatment. Referral to a
specialist often warranted
E. CATHETER-ASSOCIATED UTI (CAUTI)
Etiology: more varied and may include drug – resistant organisms (e.g., ESBL-
producing E. coli), P. aeruginosa and enterococci
Preferred Regimen:
Amikacin 15mg/kg IV q24h Piperacillin-tazobactam 4.g IV q8h
Ertapenem 1g IV q24h Ampicillin 1-2g IV q6h
Meropenem 1g IV q24h (for susceptible enterococcal infections)
Cefepime 1-2g IV q8-12h Levofloxacin 750mg IV/PO q24h
Ceftazidime 1-2g IV q8h

(for mild infections with no previous 3rd gen.

cephalosporin or fluoroquinolone use)
DOT: 7 days w/ prompt resolution of signs and symptoms; 10-14 days of
antibiotic treatment for patients with delayed response
Comments:
Pyuria, odorous or cloudy urine alone is not an indication for initiating antibiotics.
Whenever possible, remove indwelling catheter; if still needed, replace with a
new catheter and obtain urine for gram stain and culture/susceptibility test prior
to initiating treatment. DO NOT obtain urine for culture if asymptomatic. Choice
of empiric antibiotics is institution-specific depending on the local susceptibility
patterns and severity of illness.
F. CANDIDURIA
ASYMPTOMATIC CANDIDURIA

Candida sp. in urine almost always No treatment indicated
represents colonization; more often
in the elderly, female, diabetic, w/ Exceptions: When undergoing
indwelling urinary device, w/ prior urologic procedure, treat with oral
surgical procedure, and taking Fluconazole 400mg (6 mg/kg) pre-
antibiotics; colony count and and post-procedure. Treat also
presence of pyuria not helpful in those at risk for dissemination (e.g.,
differentiating colonization from neutropenic patients).
infection.
Comments: Elimination of risk factors (ex. indwelling urinary catheter) usually

adequate to clear candiduria.
SYMPTOMATIC CYSTITIS
Etiology: Most common etiologic agent: C. albicans
Preferred Regimen:
Fluconazole 200-400mg PO qd x 2 weeks
For fluconazole-resistant Candida (C. krusei or glabrata):
AmB deoxycholate 0.3-0.6mg/kg x 1-7d
Comments:
Do ultrasound or CT of kidneys if candiduria persists in immunocompromised
patients.

PYELONEPHRITIS
Etiology: Most common etiologic agent: C. albicans
Preferred Regimen:
Fluconazole 200 mg PO qd x 2 wks.
For fluconazole-resistant Candida (C. krusei or C. glabrata):
AmB deoxycholate 0.3-0.6 mg/kg x 2 wks.
Comments:
Consider surgical intervention to relieve obstruction if any (e.g., fungus ball). If
disseminated disease suspected, treat as if bloodstream infection is present.
G. BACTERIAL PROTATITIS
• Most cases of bacterial prostatitis are preceded by a urinary tract infection.

• Risk factors: urinary tract instrumentation, urethral stricture, or urethritis
(usually due to sexually transmitted pathogens)
ACUTE BACTERIAL PROSTATITIS (ABP) WITHOUT RISK OF STD
Etiology: Enterobacteriaceae, enterococcus, P. aeruginosa
Preferred Regimen:
1st line: Ciprofloxacin 500mg PO or 400mg IV bid OR
Levofloxacin 500-750 mg IV/PO qd
If enterococcus is suspected/documented:
Ampicillin 1-2g IV q4h; Vancomycin 15mg/kg q12 h
2nd line: TMP-SMX DS bid OR Piperacillin-tazobactam 4.5g IV q6-8h
DOT: 2 weeks; extend to 4 weeks if patient still symptomatic.
Comments:
Do CBC, blood cultures, urinalysis and urine culture. Caveat: E. coli resistance to
TMP-SMX is high so TMP-SMX cannot be 1st line empiric treatment despite its high
prostatic concentration.
ABP WITH RISK OF STD
Etiology: N. gonorrhoeae and C. trachomatis
Preferred Regimen:
Ceftriaxone 250mg IM x 1 dose PLUS
Doxycycline 100mg bid or Azithromycin 500 mg PO qd
DOT: 2 weeks

Comments: Fluoroquinolones not recommended for gonococcal infection.
ABP WITH RISK OF ANTIBIOTIC-RESISTANT PATHOGENS
Etiology: Fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas, ESBL

or AmpC beta lactamase-producing Enterobacteriaceae
Preferred Regimen:
1st line: Ertapenem 1g IV qd OR Meropenem 1g IV q8h (for Pseudomonas)
2nd line: Cefepime 2g IV q12h
Comments: Consider a 4-week regimen.
COMPLICATED ABP (E.g., bacteremia or suspected prostatic abscess)
Etiology: Enterobacteriaceae, enterococcus, P. aeruginosa
Preferred Regimen:
1st line: Ciprofloxacin 400 mg IV q12h OR Levofloxacin 750 mg IV q24h
2nd line: Ceftriaxone 1-2g IV q24h PLUS Levofloxacin 750 mg IV q24h OR
Ertapenem 1g IV q24h OR Piperacillin-tazobactam 4.5g IV q8 h
DOT: 4 weeks
Comments:
Obtain blood cultures. Consider genitourinary imaging. Drain abscess. Switch to
oral regimen once bacteremia has cleared and abscess is drained.
CHRONIC BACTERIAL PROSTATITIS (CBP)

• Prolonged urogenital symptoms (e.g., >3 mos.)
• Hallmark: relapsing UTI
Etiology: Enterobacteriaceae, enterococci, P. aeruginosa
Preferred Regimen:
1st line: Ciprofloxacin 400 mg IV q12h OR Levofloxacin 750 mg IV q24h
2nd line: TMP-SMX DS bid
DOT: 4-6 weeks
Comments:
If refractory, options are:
1. treat intermittently for symptomatic episodes;
2. suppressive treatment; or
3. prostatectomy if all other options have failed.

REFERENCES:
• Antimicrobial Resistance Surveillance Laboratory, Department of Health. Antimicrobial
Resistance Surveillance Program 2015 Annual Report, Manila, Philippines 2016. Accessed
at http://arsp.com.ph/wp-content/uploads/2016/06/2015-ARSP-annual-report-
summary_1.pdf on September 7, 2016
• Bay AG, Anacleto F. Clinical and Laboratory Profile of Urinary Tract Infection Among
Children at The Outpatient Clinic of A Tertiary Hospital. PIDSP Journal 2010;11(1):10-16.
MR, delos Reyes CA. Hand book of Pediatric Infectious Diseases 2012, 5th edition. Manila:
Section of Infectious and Tropical Diseases; 2012.
K, Schwartz BS editors. Sanford Guide to Antimicrobial Therapy 2016. VA: Antimicrobial
Therapy, Inc.; 2016.
• Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the
treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by
the Infectious Diseases Society of America and the European Society for Microbiology and
Infectious Diseases. Clin Infect Dis 2011; 52: e103 -e120.
• Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, Prevention, and Treatment of
Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice
Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010;50 (5): 625-
663
• Hsueh P, Hoban D, Carmeli Y, et al. Consensus review of the epidemiology and appropriate
antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. Journal
of Infection (2011) 63, 114 -123
• Lipsky BA, Byren I, Hoey CT. Treatment of Bacterial Prostatitis. Clin Infect Dis 2010; 50:1641.
• Maramba-Lazarte CC, Bunyi MAC, Gallardo EE, Lim JG, Lobo JJ, Aguilar CY. Etiology of
neonatal sepsis in five urban hospitals in the Philippines. PIDSP J 2011; 12(2): 75-85.
• National Institute for Health and Care Excellence. Urinary Tract infection in Children:
Diagnosis, Treatment and Long-term Management. NICE guideline 54 accessed on 7/13/15
at nice.org.uk/cg54
• NICE Clinical Guidelines 54, Urinary Tract Infection in Children: Diagnosis, Treatment and
Long-Term Management, 2007. Available at: http://guidance.nice.org.uk/cg54. Accessed
on July 13, 2015.
• Philippine Clinical Practice Guidelines on the Diagnosis and Management of Urinary Tract
Infections in Adults 2013 Update. Quezon City: Philippine Society of Microbiology and
Infectious Diseases; 2013.
• Research Institute of Tropical Medicine. Antimicrobial Resistance Surveillance Program
2014 Annual Report. Muntinlupa: Research Institute of Tropical Medicine; 2015.
• Roberts KB. Revised AAP Guideline on UTI in Febrile Infants and Young Children. Am Family
Phys 2012;86(10):940-946.
• Shaikh N, Hoberman. Urinary tract infections in infants older than one month and young
children: acute management, imaging and prognosis. UpToDate last updated August 25,
2016.

DOH PUBLIC HEALTH PROGRAMS (FILARIASIS)
FILARIASIS (Selective Treatment)
For patients (+) for microfilariae in nocturnal blood examination (NBE) or

Immunochromatographic test (ICT)
Etiology:
Roundworms of the Filarioidea type. Lymphatic filariasis is caused by the worms
Wuchereria bancrofti, Brugia malayi, and Brugia timori. These worms occupy the
lymphatic system, including the lymph nodes; in chronic cases, these worms lead
to the syndrome of elephantiasis.
Preferred Regimen:
Day 1: Diethylcarbamazine (DEC) 6mg/kg div 3 doses (after meals)
PLUS Albendazole 400mg
Day 2 to Day 12: DEC 6mg/kg div 3 doses
DEC is free and only available at the DOH Central office and government health
facilities in endemic areas.
Comments:
Tablets should be taken after meals. Total cumulative DEC dose of 72 mg/kg for
W. bancrofti infections.
Precautions:
• Treatment of pregnant women should be deferred until after delivery.
• Treatment is contraindicated in individuals with severe cardiac and kidney
diseases.
• Individual with asthma, seizure disorders or severe malnutrition should be
treated with caution. Do not initiate treatment when patient has asthma attack.
Treat asthma first before taking antifilarial drugs.
• If patient is less than 2 years of age, refer to specialist.
Adverse Reactions
• Localized: Pain, inflammation, and tenderness of nodules, adenitis,
lymphangitis due to death of adult filarial worms. Usually begins from 2-4 days
after the first dose of DEC.
• Systemic: Fever, headache, malaise, myalgia and hematuria occur due to death
of microfilariae. Usually begin from few to 48 hours after taking DEC and are
usually self-limited.
For more information regarding the mass drug administration of the program of
the DOH, please refer to the website, www.doh.gov.ph.
REFERENCES:
• Department of Health. Guidelines for the Implementation of the National Filariasis
Elimination Program, 2009. Manila: National Filariasis Elimination Program National
Center for Disease Prevention and Control; 2009

DOH PUBLIC HEALTH PROGRAMS (LEPROSY)
LEPROSY
a chronic disease caused by Mycobacterium leprae that affects the skin, peripheral
nerves, upper respiratory tract mucosa and eyes, is curable by multidrug therapy
(MDT). When untreated it can cause permanent and progressive damage to the
affected organs.
Preferred Regimen:
Monthly Treatment: Daily Treatment: Duration of Treatment
Day 1 Days 2-28
PEDIA Multibacillary (MB) Regimen (10-14 years old)
Rifampicin 450 mg Clofazimine 50 mg 12 blister packs to be taken
Clofazimine 150 mg qod monthly within a maximum
Dapsone 50 mg Dapsone 50 mg period of 18 months.
*Note: Lapses in taking MDT
should be <3 months
ADULT (MB) Regimen (15 years old and above)
Rifampicin 600 mg Clofazimine 50 mg 12 blister packs to be taken
Clofazimine 300 mg Dapsone 100 mg monthly within a maximum
Dapsone 100 mg period of 18 months.
should be < 3 month
CHILD PB Regimen (10-14 years old)
Rifampicin 450 mg Dapsone 50 mg 6 blister packs to be taken
Dapsone 50 mg monthly within a maximum
period of 9 months
should be < 1 month
ADULT PB Regimen (15 years old and above)
Rifampicin 450 mg Dapsone 50 mg 6 blister packs to be taken
Dapsone 50 mg monthly within a maximum
period of 9 months
should be < 1 month
Comments:
When it has been determined that a leprosy patient needs MDT, the following
steps must be taken:
Step 1: Determine which type of MDT is required: PB or MB.
Step 2: Determine which dose level is required: adult or pediatric.
Step 3: Before the start of treatment, provide the patient, his/her family members
or other treatment partner with orientation counseling to indicate:
• The need for regular treatment (e.g., Leprosy is a curable infection.
Regular intake of medication and monthly checkups are important).

DOH PUBLIC HEALTH PROGRAMS (LEPROSY)
• The possibility of complication of leprosy which may need other

treatment
• That the health center or clinic is always ready to see them if they have
any problems.
Step 4: Give the first dose of treatment and explain how to take treatment at
home. Treatment rapidly kills the leprosy bacilli and renders the patient
non-infectious.
Pediatric dose under 10 years of age:

Rifampicin: 10mg/kg BW once a month
Clofazimine: 1mg/kg BW daily and 6 mg/kg BW monthly
Dapsone: 2mg/kg BW daily
The standard child blister pack may be divided so that the appropriate dose is
given to children under 10 years old. Clofazimine can be spaced out as required.
(e.g. Rifampicin 300mg once a month (Day 1) + dapsone 25 mg per day (Day 2 -
28)
A patient with a high baseline average bacillary index (BI of +4 to +6) may need
more than 12 months of treatment. A poor response to treatment is defined as a
less than +1 reduction in average BI after 12 months of MBMDT. This decision may
only be taken by specialists at referral units. Lepra reactions may occur before,
during, and after treatment. These complications should be detected and treated
early. The treatment of leprosy should still be continued during lepra reactions.
REFERENCES:
• Department of Health. National Leprosy Control Programme Manual of Procedures,
2016. Manila: Department of Health; 2016.
• World Health Organization. Global Leprosy Strategy 2016–2020: Accelerating
towards a leprosy-free world. Operational Manual. Geneva: World Health
Organization; 2016.

DOH PUBLIC HEALTH PROGRAMS (MALARIA)
MALARIA
The objectives of antimalarial treatment are to prevent severe malaria and, for
patients residing in endemic areas, to interrupt transmission via anopheline
vectors, among others. The National Malaria Program aims to eliminate the
disease by 2030; thus, compliance to guidelines and treatment with highly
effective drugs are critical. Response to malaria treatment must be monitored
with daily blood film microscopy until the end of administration of the first line
drugs, then weekly until the 28th day after the start of treatment. The second line
drug is administered when asexual forms of the parasite are detected in blood
films during this specified period. Recurrence of asexual parasitemia with the first
line drugs must also be immediately reported to the Department of Health.
A. Plasmodium falciparum or P. malariae
UNCOMPLICATED
Preferred Regimen:
INFANTS:
<6 mos: Quinine 10mg salt/kg q8h X 7d PLUS Clindamycin 10mg/kg bid x 7d
6-11 months: Artemether–Lumefantrine (AL) (20mg/120mg) combination
(Coartem) On d1, 1 tab followed by 1 tab after 8h; then 1 tab bid for d2-3
CHILDREN AND ADULTS

1st line: Artemether–lumefantrine (AL) (20mg/120mg per tab) combination
Weight Day 1 Day 2 and 3
5 to <15 kg 1 tab followed by 1 tab after 8h 1 tab bid
15 to <25 kg 2 tabs followed by 2 tabs after 8h 2 tab bid
25 to <35 kg 3 tabs followed by 3 tabs after 8h 3 tab bid
>35 kg &adults 4 tabs followed by 4 tabs after 8h 4 tab bid
PLUS Primaquine (15 mg/tab) 0.25mg base/kg on d1 (pediatric and adult).
For adults >60 kg: 3 tabs
2nd line:
P: Quinine sulfate 10mg salt/kg q8h x 7d PLUS Clindamycin 10mg/kg bid x 7d
A: Quinine sulfate 10mg salt/kg q8h x 7d PLUS Clindamycin 10mg/kg bid x 7d OR
Tetracycline 3mg/kg body weight od x 7d OR
Doxycycline 250mg qid x 7d AND
Primaquine (15mg/tab) 0.25mg-base/ kg on d1 (pediatric and adult).
For adults >60kg: 3 tab.

Comments:
Advise patients to take AL with milk or fat-containing food (gata or coconut milk,
buko or suman sa latik, and cookies), particularly on the second and third days of
treatment.
Considering that lumefantrine is highly lipophilic, its absorption is enhanced by co-

administration of fat. Low blood levels with resultant treatment failure could
potentially result from inadequate fat intake. Repeat administration of the first
dosage in the event of vomiting within one hour of administration.
Do not give AL to infants less than 6 months or less than 5 kg. Do not give
primaquine to infants below 1 year old. Obtain past medical and family histories
of G6PD deficiency before administration of primaquine. The normal G6P level for
adults is 5.5 to 20.5 units/gram of hemoglobin. If the G6PD status cannot be
documented when required withhold primaquine administration. Do not give
primaquine to patients with G6PD deficiency.
Closely monitor infants for side effects such as methemoglobinemia, hemolytic

anemia, hemoglobinuria in G6PD deficiency neutropenia, and renal dysfunction.
Precautions when using doxycycline:

• Avoid during pregnancy unless benefit outweighs risks; consider alternatives.
• Skin, nail, eye, tooth or gum discoloration may occur.
• Diarrhea may occur.
• It may reduce the efficacy of oral contraceptive pills. Consider other
contraceptive options.
• May cause photosensitivity. Avoid sun exposure.
• May cause increased intracranial pressure. Watch out for headache, blurred
vision, or changes in vision.
• May cause autoimmune reactions. Watch out for fever, rash, joint pain, or
tiredness.
SEVERE
1st line
Pediatrics Adults
For children < 20 kg: 3mg/kg bw per Artesunate IV or IM 2.4mg/kg/dose.
dose IV or IM Artesunate powder Give 3 IV/IM doses 12 hours apart.
dissolved in 5% NaHCO3. Diluted in Shift to oral artemether-
5mL D5W IV drip or IM (anterior lumefantrine once patient can
thigh; WHO 2015) tolerate oral medicines AND
Primaquine (15 mg/tab) 0.25 mg-
base/kg on Day 1 if patient can

tolerate oral medicines (pediatric and

adult). For adults > 60 kg: 3 tab.
2nd line
Pediatrics Adults
Parenteral quinine dihydrochloride Parenteral Quinine Dihydrochloride
Infusion Infusion
≤7y: 10 mg salt/kg in IV drip for 4h as 20 mg salt/kg in 500 mL D5W or 0.9
loading dose, then 10 mg salt/kg IV NaCl for 4h IV drip (total dose not to
drip q12h as maintenance dose exceed 2,000 mg), then 10 mg salt/ kg
8y-16y: 15 mg salt/kg IV drip for 4h in in 0.9NaCl or D5W IV drip for 4h q8h
10mL/kg D5W or 0.9 NaCl (infusion as maintenance dose
rate must not exceed 5mg/kg/h) as
loading dose, then 10 mg salt/kg IV Shift to oral artemether-
drip for 4h q8h as maintenance dose lumefantrine once patient can
PLUS Clindamycin 10mg/kg bid x 7 d tolerate
PLUS Clindamycin 10 mg/kg bw bid x
7d
OR Tetracycline 3 mg/kg bw od x 7d
OR Doxycycline 250 mg qid x 7d
2nd line for (for pre-referral to hospital)
Artesunate suppository (pediatric) 10 mg/kg
Comments:
Concomitant management of complications of severe P. falciparum malaria should
be done, e.g., hyperpyrexia, convulsions, hypoglycemia, severe anemia,
pulmonary edema and respiratory failure, acute renal failure, bleeding. See above
for “Precautions when using doxycycline”
Artesunate suppository is a last-resort drug, and is not recommended for older

children and adults. If referral is impossible, continue the application of AS using
one to two thirds of the initial dose as maintenance dose until the patient can
tolerate oral medication at which point, treatment with AL and Primaquine
according to schedule for uncomplicated P. falciparum in adults.
CONGENITAL AND NEONATAL MALARIA
Preferred Regimen: Chloroquine 10mg/kg on d1- 2, and 5 mg/kg on d3
B. Plasmodium vivax or P. ovale
UNCOMPLICATED

Preferred Regimen:
1st line: Chloroquine 10mg/kg on d1-2, then 5mg/kg on d3 (pediatric and adult)
PLUS
Primaquine 0.25mg base/kg/day x1 dose for d1-14 (pediatric and adult)
2nd line:
P: Artemether–lumefantrine (20mg/120 mg) combination
5 to < 15 kg 1 tab followed by 1 tab after 8h 1 tab bid
15 to < 25 kg 2 tabs followed by 2 tabs after 8h 2 tab bid
PLUS Primaquine tablet 0.25mg-base/kg starting on d1 (pediatric and adult)
A: Artemether–Lumefantrine (20mg/120mg) combination on d1, 4 tabs followed

by 4 tabs after 8h, then 4 tabs bid for d2-3 PLUS Primaquine tablet 0.25mg-
base/kg on d1-14 (pediatric and adult)
Comments:
Primaquine should be taken with meals (causes abdominal discomfort taken on
an empty stomach). Do not give primaquine to patients with G6PD-deficiency.
Patients with mild deficiency may receive a dose of 0.75 mg/kg once a week for 8
weeks.
RELAPSE (laboratory confirmed) (relapse refers to recurrence of parasitemia due to

hypnozoites of P. vivax)
Preferred Regimen:
Chloroquine 10mg/kg BW for d1-2, and 5 mg/kg BW on d3 OR
Artemether–Lumefantrine for 3 days (see regimen for uncomplicated vivax
malaria)
PLUS Primaquine 0.75mg/kg/d on d1-14 (Max: 30–45 mg/d) (do not give if patient
is G6PD deficient)
Comments:
Chloroquine and primaquine-tolerant vivax is known to exist in nearby countries
particularly in East Timor, Indonesia Papua New Guinea, Myanmar and Thailand.
If recurrence of parasitemia is within 28 days after the start of chloroquine, the
patient is treated with AL.
Relapse must be distinguished from recrudescence. Relapse is associated with P.

vivax or P. ovale and refers to infections resulting from activation of hypnozoites.
Its occurrence within 28 days of an initial infection/diagnosis is unlikely.
Recrudescence refers to persistence or re-appearance of parasitemia in a patient

within 28 days of the initial diagnosis it is an indication of treatment failure. It is

counted as the same case.
SEVERE
Preferred Regimen:
P:
1st line: For children <20kg – 3mg/kg bw per dose IV or IM Artesunate powder
dissolved in 5% NaHCO3. Diluted in 5ml D5W IV drip or IM (anterior thigh; WHO
2015)
2nd line: Parenteral Quinine dihydrochloride Infusion
<7y: 10 mg salt/kg in IV drip for 4h as loading dose, then 10 mg salt/kg IV drip q12h
as maintenance dose
8y-16y: 15 mg salt/kg IV drip for 4h in 10mL/kg D5W or 0.9 NaCl (infusion rate
must not exceed 5mg/kg/h) as loading dose, then 10 mg salt/kg IV drip for 4h q8h
as maintenance dose.
PLUS Clindamycin 10 mg/kg bid x 7 d
A: Artesunate IV or IM 2.4 mg/kg/dose. Give for at least 24 hours. Shift to oral
artemether-lumefantrine once patient can tolerate oral medicines, to complete
three days of treatment
IF PATIENT CAN TOLERATE ORAL MEDICATIONS, SHIFT TO:

P: Artemether–Lumefantrine (20 mg/120 mg) combination
PLUS Primaquine tablet 0.25 mg-base/kg starting on day 1 (pediatric and adult)
A: Artemether–Lumefantrine (20 mg/120 mg) combination on day 1, 4 tabs

followed by 4 tabs after 8h, then 4 tabs bid for days 2 and 3 PLUS Primaquine
tablet 0.25 mg-base/kg starting on d1 (pediatric and adult)
Comment: Management is similar to that of severe falciparum malaria.
C. Plasmodium knowlesi
Preferred Regimen:

A: Artemether–Lumefantrine (20 mg/120 mg) combination on day 1, 4 tabs

followed by 4 tabs after 8h, then 4 tabs bid for days 2 and 3
Comments:
Definite diagnosis for P. knowlesi is by PCR. By microscopy, it is usually mistaken
for P. malariae or even P. vivax; and infrequently, P. falciparum.
D. Mixed Infections
Plasmodium falciparum and P. vivax with/ without P. malariae
Preferred Regimen:
PLUS Primaquine tablet 0.25 mg-base/kg starting on days 1-14 (pediatric and
adult)

base/kg starting on d1-14 (pediatric and adult)
Plasmodium falciparum and P. vivax with/ without P. malariae
Preferred Regimen:

PLUS Primaquine tablet 0.25 mg-base/kg on day 1

base/kg starting on d1

Plasmodium vivax and P. malariae
Preferred Regimen:
P and A: Chloroquine tablet 10 mg/kg on d1-2, then 5 mg/kg body weight on d3
PLUS Primaquine 0.25 mg base/kg/d (taken as a single dose) for d1-14
PREGNANT AND LACTATING WOMEN

A. Plasmodium falciparum
UNCOMPLICATED
Preferred Regimen:
PREGNANT: Quinine sulphate 10mg/kg q8h x 7d PLUS
Clindamycin 10mg/kg bid x 7d
LACTATING: ADD Primaquine 0.25mg/kg, single dose on day 1 to the above
regimen
Comments:
Withhold primaquine during the entire period of pregnancy, but give it 2 weeks
after delivery in a single dose: 0.25mg/kg until G6PD status is ascertained. For
lactating mothers, antimalarials such as chloroquine, quinine and primaquine are
secreted in the breast milk in amounts that are not harmful to the infant and in
insufficient amounts to provide protection against malaria.
SEVERE
Preferred Regimen:
PREGNANT: Quinine dihydrochloride 20 mg/kg infused over 4h (in 500 mL 5%
dextrose water or 0.9% saline) as loading dose and 10 mg/kg q8h infused over 2-4
hours as maintenance dose. If patient can already tolerate oral meds, shift to oral
quinine sulphate (10 mg/kg q8h) to complete 7 days at the same dose PLUS
Clindamycin 10 mg/kg IV bid; shift to oral clindamycin as soon as patient tolerates
it at the same dose to complete 7 days.
LACTATING: ADD Primaquine 0.25 mg/kg, single dose after 7 days of clindamycin,
to the above regimen.
Comments:
If Quinine Plus is not available, give AL only if the patient is on the 2nd and 3rd
trimester according to the guidelines for uncomplicated P. falciparum. While AL is
contraindicated during the first trimester, give it as the last resort for pregnant
women during the 1st trimester with patient’s informed consent when Quinine is
not available. Withhold Primaquine during the entire period of pregnancy, but
must give it 2 weeks after delivery in single dose at 0.75 mg per kg body weight.

B. Plasmodium vivax
ACUTE
Preferred Regimen:
PREGNANT: Chloroquine tab 10mg/kg on d1-2, and 0.5 mg/kg on d3
LACTATING: ADD Primaquine 0.25mg/kg, single dose on d1 to the above
regimen
Comments:
after delivery at 0.25 mg/kg/day for 14 days. For breastfeeding women, give
primaquine only if their infant is confirmed to be non-G6PD-deficient. See
www.doh.gov.ph/newbornscreening for a list of newborn screening coordinators.
RELAPSE
Preferred Regimen:
PREGNANT: Chloroquine 150mg base/tab 2 tabs per week for 8 weeks
LACTATING: ADD Primaquine 0.25mg/kg body weight per day (mmax:30-45 mg/
day) beginning d1-14 to the above regimen
Comments:
after delivery at 0.5-0.75 mg/kg/ day (maximum of 30-45 mg/d) for 14 days.
C. Plasmodium ovale
Preferred Regimen:
PREGNANT: Chloroquine tab 10mg/kg on d1-2, and 0.5 mg/kg on d3
LACTATING: ADD Primaquine 0.25mg/kg body weight per day beginning day 1 to
14 to the above regimen.
Comments:
after delivery at 0.5 mg/kg/day for 14 days.
D. Plasmodium malariae
Preferred Regimen:
PREGNANT: Chloroquine tab 10mg/kg on d1-2, and 5 mg/kg on d3
LACTATING: Chloroquine tab 10mg/kg on d1-2, and 0.75 mg/kg on day 3 PLUS
Primaquine 0.25mg/kg X 1 dose on d 1 to the above regimen

Comments:
after delivery in a single dose of 0.75 mg/kg.
E. Mixed Infections
Preferred Regimen:
PREGNANT: Quinine sulphate 10mg/kg q8h x 7d PLUS Clindamycin 10mg/kg bid
x 7d
LACTATING: ADD Primaquine 0.25mg/kg, x 1 dose on d1 to the above regimen
Use Artemether–Lumefantrine (20mg/120mg) combination only if quinine +

clindamycin is not available, and if the patient is on the second or third trimester.
The following is the recommended dosage schedule:

<35 kg:3 tabs on d1 and 8 h after, 3 tabs bid on d2-3 > 35 kg: 4 tabs on day 1 and
8 h after, 4 tabs bid on d2-3
PLUS Primaquine
PREGNANT: withhold until delivery
Post-partum/lactating women: 0.25 mg/kg/day on days 1-14
CHEMOPROPHYLAXIS
• Chemoprophylaxis may be given to any individuals (Filipinos and foreigners
alike) traveling to an endemic area within the country.
• However, chemoprophylaxis alone does not give 100% protection against
infection with the Plasmodium parasite, even if chemoprophylaxis
requirements were strictly complied with. Personal protective measures are
just as important.
REFERENCES
• Department of Health. (2014). National Malaria Control Program: Manual of Operations,
5th edition.
• World Health Organization. (2015). Guidelines for the Treatment of Malaria, 3rd edition.
Geneva: WHO

DOH PUBLIC HEALTH PROGRAMS (SCHISTOSOMIASIS)
SCHISTOSOMIASIS (Selective Treatment (Passive or Active Surveillance))

Supported by a positive result on kato katz for Schistosoma japonicum ova by stool
exam and or rectal imprint
Etiology: Schistomes, the most common in the Philippines being S. japonicum.
Preferred Regimen: Praziquantel 40 mg/kg/d div 2-3 doses x 1d

Dose is increased to 60 mg/kg in neuroschistosomiasis. Praziquantel is free and
only available at the DOH Central office and government health facilities in
endemic areas.
Comments:
This regimen may also be given for hepato-intestinal schistosomiasis and
pulmonary schistosomiasis. Praziquantel should be given on a full stomach. Follow
up treatment of confirmed cases 1 month later because praziquantel does not kill
developing worms.
Observe patients for 1 to 3 hours for possible adverse reactions, such as headache,
dizziness, abdominal discomfort, and less commonly, nausea, vomiting, diarrhea,
fever and urticaria. Instruct them afterwards to watch out for these reactions for
24 hours. Supportive treatment may be given to relieve adverse reactions as
appropriate.
Indications of hospital referral:

• Presence of complications, such as periportal fibrosis, splenomegaly with
hypersplenism, development of portosystemic collateral blood vessels, cor
pulmonale, or glomerulonephritis
• CNS schistosomiasis (patients with seizures, focal neurologic deficit, or signs of
increased intracranial pressure or diffuse encephalitis).
For more information regarding the mass drug administration of the program of
the DOH, please refer to the website, www.doh.gov.ph.
REFERENCES:
• Department of Health. Clinical Practice Guidelines for the Diagnosis, Treatment and
Prevention of Schistosoma japonicum Infections in the Philippines: 2013 Update.

DOH PUBLIC HEALTH PROGRAMS
(SEXUALLY TRANSMITTED INFECTIONS)
I. Pelvic Infections
A. Pelvic Inflammatory Disease
Pelvic inflammatory disease (PID) comprises a spectrum of inflammatory

disorders of the upper female genital tract, including any combination of
endometritis, salpingitis, tubo-ovarian abscess, and pelvic peritonitis.
Etiology: N. gonorrhoeae; C. trachomatis; Bacteroides; Enterobacteriaceae; G.

vaginalis; H. influenzae; Enteric Gram-negative rods; S. agalactiae;
Cytomegalovirus (CMV); M. hominis; U. urealyticum; M. genitalium
Preferred Regimen:
PARENTERAL REGIMEN OUTPATIENT REGIMEN
(if with uncertain diagnosis, presence Recommended IM/PO Regimen
of tubo-ovarian abscess, pregnancy, Ceftriaxone 250mg IM/IV x 1 dose
HIV infection, fever >38.5˚C, nausea OR
and vomiting precluding use of oral
medications, lack of improvement Cefotaxime 0.5-1.0g IM x 1 dose PLUS
after 48h of oral antibiotic) Doxycycline 100mg PO bid x 14d
1st line: WITH or WITHOUT
Cefoxitin 2g IV q6 PLUS Metronidazole 500mg PO bid x 14d
Doxycycline 100mg PO q12h x 14d
OR
Clindamycin 900mg IV q8h PLUS

Gentamicin 2mg/kg IV/IM loading
dose, followed by 1.5mg/kg q8h
maintenance dose. Single daily dosing
(3–5mg/kg) can be used
THEN Doxycycline 100mg PO q12h x
14d
2nd line:
Ampicillin-sulbactam 3g IV q6h PLUS
Comments:
Presumptive treatment should be initiated in sexually active young women and
other women at risk for STDs if:
• with pelvic or lower abdominal pain
• no cause for the illness other than PID can be identified

• one or more of the following minimum clinical criteria are present on pelvic
exam: cervical motion tenderness, uterine tenderness or adnexal tenderness
Screen for trichomoniasis, bacterial vaginosis, and syphilis. For inpatient regimens,
continue treatment until satisfactory response for at least 24 h before switching
to outpatient regimen.
Women who do not respond to IM/oral therapy within 72 hours should be re-
evaluated to confirm the diagnosis and should be given intravenous therapy. The
recommended 3rd generation cephalosporins are limited in their coverage of
anaerobes. Metronidazole should be considered with third-generation
cephalosporins.
B. Tubo-ovarian Abscess
• late manifestation of PID; Useful clinical features that suggest the presence of
a pelvic abscess are pain, persistent fever, adnexal tenderness (for >7 days) and
an erythrocyte sedimentation rate greater than 30 mm/hr.
Etiology:
Sexually active: E. coli; Bacteroides fragilis; Other Bacteroides spp.;
Peptostreptococcus; Peptococcus; aerobic streptococci
Non-sexually active: E. coli, α-hemolytic streptococci; anaerobes
Preferred Regimen:
Cefoxitin 2g IV q6h PLUS Continuing oral therapy should
Doxycycline 100mg PO q12h x 14d OR consist of: Doxycycline 100mg PO bid
OR
Clindamycin 900mg IV q8h PLUS Clindamycin 450mg PO qid x 14d
dose, followed by 1.5 mg/kg q8h
(3–5 mg/kg) can be substituted PLUS
Doxycycline 100mg PO bid x 14d
DOT (IV/PO): at least 21 days.
Comments:
Ultrasonography of the pelvis is valuable in confirming the presence of an abscess.
An abscess larger than 10 cm has a 60% chance, a 7- to 9-cm abscess has a 35%
chance, and a 4- to 6-cm abscess has a 20% chance of requiring surgical
intervention.

Patient with tubo-ovarian abscess should have at least 24 hours of inpatient

treatment that includes anaerobic coverage. Clinical response should be noted in
72 hours and pelvic ultrasound should be repeated to note any further increase in
the size of the abscess.
C. Perihepatitis or Fitz-Hugh-Curtis syndrome
Classic manifestation is severe right upper abdominal pain (lasts about 48 h) that
often radiates to the shoulder.
Etiology: N. gonorrhoeae, C. trachomatis
Preferred Regimen: TREATMENT SIMILAR AS WITH PID

1st line: Recommended IM/PO Regimen
Cefoxitin 2g IV q6h PLUS Ceftriaxone 250mg IM once OR
Doxycycline 100mg PO q12h x 14d Cefotaxime PLUS
WITH or WITHOUT Doxycycline 100mg PO bid x 14d
Metronidazole 500mg PO bid x 14d WITH or WITHOUT
OR Metronidazole 500mg PO bid x 14d
Clindamycin 900mg IV q8h PLUS
dose, followed by 1.5 mg/kg q8h
(3–5 mg/kg) can be used.
Continuing oral therapy should consist

of:
OR Clindamycin 450mg PO qid x 14d
2nd line:
Ampicillin-sulbactam 3g IV q6h PLUS
Comments:
The diagnosis is made by having a high index of suspicion. Perihepatitis frequently
mimics cholelithiasis, hepatitis, pleuritis, subphrenic abscess, perforated peptic
ulcer, nephrolithiasis, appendicitis, ectopic pregnancy, abdominal trauma, and
pancreatitis.

D. Oophoritis
• inflammation of the substance of the ovaries, the oocytes in particular
Etiology: Mumps virus, Cytomegalovirus
Preferred Regimen: Treatment is palliative

Paracetamol Ibuprofen
P: 10-15 mg/kg/dose PO q4-6h P: 5-10mg/kg/dose PO q6-8h
A: 500 mg/dose PO q4h A: 400-800mg/dose PO q6-q8h
Comments:
The presence of an enlarged, tender, boggy, smooth, mobile ovary in a child with
mumps or one of the exanthems suggests oophoritis.
E. Epididymitis
Clinical syndrome consisting of pain, swelling, and inflammation of the epididymis

that lasts <6 weeks
Etiology:
Age ≤ 35 years: N. gonorrhoeae, C. trachomatis, Enterobacteriaceae (occasional)
Age > 35 years: Enterobacteriaceae
Preferred Regimen:
1st line: All: Bed rest, scrotal elevation, and analgesics.
Age ≤35 years: Ceftriaxone 250mg IM x 1 dose PLUS Doxycycline 100mg PO bid x
10d (for cases likely caused by chlamydia and gonorrhea)
Add Levofloxacin 500mg PO qd or Ofloxacin 300mg PO bid x 10d if patient is a
man who practices insertive anal sex since he will also be at risk for enteric
organisms, OR give as single agent if no risk for chlamydia and gonorrhea
Age >35 years: Levofloxacin 750mg IV/PO qd x 10-14d
2nd line:
Age ≤ 35 years: Levofloxacin 500mg PO qd x 10d
Age > 35 years: Ampicillin-sulbactam 3g IV q6h OR Ceftriaxone 2g IV q24h OR
Piperacillin-tazobactam 4.5g IV q6h or 4-hr infusion of 2.25g q8h
Comments:
All suspected cases of acute epididymitis should be evaluated for objective
evidence of inflammation by one of the following point-of-care tests.
• Gram or methylene blue or gentian violet (MB/GV) stain of urethral
secretions demonstrating ≥2 WBC/oif
• Positive leukocyte esterase test on first-void urine.

• ≥10 WBC/hpf on a spun first void urine
Men who have acute epididymitis confirmed or suspected to be caused by N.

gonorrhoeae or C. trachomatis should be advised to abstain from sexual
intercourse until they and their partners have been adequately treated and
symptoms have resolved. All men with acute epididymitis should be tested for
other STDs, including HIV. Tests should be done for C. trachomatis and for N.
gonorrhoeae by NAAT. Urine is the preferred specimen for NAAT testing in men.
F. Pelvic Vein Suppurative (Septic) Thrombophlebitis
Infection of ovarian or deep pelvic veins; usually postpartum (either vaginal or C-

section delivery); can complicate postpartum endometritis or pelvic inflammatory
disease.
Etiology: Bacteroides sp., Prevotella bivia, other anaerobes, Streptococcus sp.

(Group A, B), Enterobacteriaceae
Preferred Regimen:
If low prevalence of MDR GNB:
Piperacillin-tazobactam 2.25g IV q6h or 4.5 gm IV q8h OR
Ceftriaxone 2g IV qd PLUS Metronidazole 500mg IV q8h
If high prevalence (≥ 20%) of MDR GNB: Meropenem 1g IV q8h
Comments:
Diagnosis: CT scan or MRI. Treatment is a combination of effective antibiotics and
anticoagulation (Coumadin x 6 weeks). No clear role for surgery on infected veins.
Discontinue antibiotic(s) when WBC and differentials are normal and patient is
afebrile for 48 hrs. Carbapenem ensures adequate therapy versus ESBL producing
aerobic GNB.
G. Septic Abortion
Etiology: Bacteroides sp., especially Prevotella bivia; Streptococcus sp. (Groups A,

B); Enterobacteriaceae; Chlamydia trachomatis; Ureaplasma urealyticum (less
common); C. perfringens;
Preferred Regimen:
1st line 2nd line
Cefoxitin 2g IV q6–8h OR Meropenem 1g IV q8h OR
Ampicillin-sulbactam 3g IV q6h OR Ertapenem 1g IV q24h OR
High Dose Penicillin 5 MU IV q6h

PLUS Doxycycline 100mg PO q12h x Piperacillin-tazobactam 4.5g IV q6h

7d (or 4-hr infusion of 2.25g q8h)
PLUS Doxycycline 100mg PO q12h x
7d
OR
Clindamycin 450–900mg IV q8h PLUS
(Ceftriaxone 2g IV q24h or
Gentamicin 5mg/kg qd)
Comments:
Curettage, supportive therapy, and intensive cardiovascular monitoring.
Laparotomy is indicated, and hysterectomy should be considered if there is
deterioration or no response. Clindamycin + Ceftriaxone is preferred to ensure
activity versus Group B Strep (one-third of isolates are Clindamycin resistant).
H. Amnionitis/ chorioamnionitis
Etiology: Group B Streptococci; Escherichia coli; Mycoplasma; Pathogenic

anaerobes (e.g., Prevotella bivia).
Preferred Regimen:
1st line 2nd line
Cefoxitin 2g IV q6–8h OR Meropenem 1g IV q8h OR
Ampicillin-sulbactam 3g IV q6h OR Ertapenem 1g IV q24h OR
Clindamycin 450–900mg IV q8h PLUS Piperacillin-tazobactam 4.5g IV q6h
Ceftriaxone 2g IV q24h or Gentamicin (or 4-hr infusion of 2.25g q8h)
5mg/kg qd PLUS Doxycycline 100mg PO q12h
Comments:
For vaginal delivery: Ampicillin plus gentamicin.
For Cesarean section: should include anaerobic coverage such as clindamycin or
metronidazole to decrease the risk of post-partum endometritis. Clindamycin +
Ceftriaxone is preferred to ensure activity versus Group B Strep (one-third of
isolates are Clindamycin resistant).
I. Balanitis
Etiology: Candida sp. (40%), Streptococcus sp. (GBS), Gardnerella sp., Other
bacteria (e.g., anaerobes)
Preferred Regimen:
For Candida:

Mild cases: Topical azoles such as Clotrimazole or Miconazole 3-7d

Unresponsive and more severe cases: Fluconazole 150mg PO x 1 dose OR
Itraconazole 200mg PO bid x 1d
For anaerobes or Gardnerella: Metronidazole 2g x 1 dose
Comments: Group A streptococcal balanitis has been reported after oral sex.
J. Bartholinitis and Bartholin abscess
Etiology: N. gonorrhoeae, C. trachomatis, Anaerobes and facultative organisms
Preferred Regimen:
Incise and drain. Do not aspirate because it is likely to cause recurrences.
Recurrent infection: marsupialization or fistulization. Antibiotic coverage for N.
gonorrhoeae, C. trachomatis and anaerobes for at least 2weeks (see
recommendations for N. gonorrhoeae, C. trachomatis)
Comments: Risk factors similar to other sexually transmitted diseases.
II. Urethritis and Cervicitis
A. Urethritis
Characterized by urethral inflammation which may due to infectious or non-

infectious causes. Symptoms, when present, may include dysuria, urethral
pruritus, mucoid, mucopurulent or purulent discharge When diagnostic work-up
has not yet been done and cause is not known. The following are the
recommendations:
Etiology: N. gonorrhoeae; C. trachomatis; M. genitalium; T. vaginalis; Ureaplasma;
Preferred Regimen:
PEDIATRICS ADULTS
<45kgs and <8years of age: 1st line:
Ceftriaxone 125mg IM x 1 dose PLUS Ceftriaxone 250mg IM x 1 dose PLUS
Erythromycin base OR (Azithromycin 1g PO x 1 dose OR
ethylsuccinate 50mg/kg/d PO in 4 Doxycycline 100mg PO q12h x 7d)
div doses (Max: 2g/day) x 14d
2nd line: (if ceftriaxone is not
>45kgs but <8years of age: available)
Ceftriaxone 250mg IM x 1 dose PLUS Cefixime 400mg PO x 1 dose PLUS
Azithromycin 1g PO x 1 dose Azithromycin 1g PO x 1 dose

>45kgs and >8years of age: Other Second line Regimen:

Ceftriaxone 250mg IM x 1 dose PLUS Cefotaxime 500mg IM
EITHER Azithromycin 1g PO x 1 dose
OR Doxycycline 100mg PO bid x 7d Alternatives to Azithromycin or
Doxycycline:
Erythromycin base 500mg PO qid x 7d
OR Erythromycin ethylsuccinate PO
800mg qid x 7d OR
Levofloxacin 500mg PO qd x 7d OR
Ofloxacin 400mg PO bid x 7d
Comments:
If symptoms are present and no evidence of urethral inflammation, NAAT testing
for Chlamydia and gonorrhea might identify the infection. Use combination
therapy even if NAAT is negative for Chlamydia.
B. Nongonococcal Urethritis
Confirmed in symptomatic men when staining of urethral secretions without

Gram-negative or purple diplococci
Etiology: C. trachomatis; M. genitalium; T. vaginalis; Ureaplasma;
Preferred Regimen:
1st line 2nd line
Azithromycin 1g PO x 1 dose OR Erythromycin base 500mg PO qid x 7d
Doxycycline 100mg PO bid x 7d OR
Erythromycin ethylsuccinate 800mg
PO qid x 7d OR
Levofloxacin 500mg PO od x 7d OR
Ofloxacin 300mg PO bid x 7d
PERSISTENT AND RECURRENT NGU

Azithromycin 1g PO x 1 dose if initially treated with Doxycycline
Treat for T. vaginalis with Metronidazole 2g PO x 1 dose.
(Alternative Regimen: Metronidazole 500mg PO bid x 7d)
Comments:
Azithromycin should be administered to men initially treated with doxycycline. To
minimize transmission and reinfection, men treated for NGU should be instructed

to abstain from sexual intercourse until they and their partner(s) have been
adequately treated (e.g., for 7 days after single-dose therapy or until completion
of a 7-day regimen and symptoms resolved). Men who receive a diagnosis of NGU
should be tested for HIV and syphilis.
C. Cervicitis
Diagnostic signs: 1) a purulent or mucopurulent endocervical exudate visible in

the endocervical canal or on an endocervical swab specimen, and 2) sustained
endocervical bleeding easily induced by gentle passage of a cotton swab through
the cervical os.
Etiology: C. trachomatis; N. gonorrhoeae; M. genitalium
Preferred Regimen:
Azithromycin 1g PO x 1 dose OR Doxycycline 100mg PO bid x 7d
Consider concurrent treatment for gonococcal infection if patient is at risk for
gonorrhea or lives in a community where the prevalence of gonorrhea is high.
Comments:
Women with a new episode of cervicitis should be assessed for signs of PID and
should be tested for C. trachomatis and N. gonorrhoeae. Treatment of cervicitis in
pregnant women does not differ from not pregnant women. Women treated for
cervicitis should be instructed to abstain from sexual intercourse until they and
their partner(s) have been adequately treated.
D. Chlamydial Infections
Etiology: C. trachomatis
Preferred Regimen:
1st line
PEDIATRICS ADULTS
<45 kg: Azithromycin 1g PO x 1 dose OR
Erythromycin 50mg/kg/d q6h x14d Doxycycline 100mg PO bid x 7d
≥45 kg but who are aged <8 Years: Pregnant Women:
Azithromycin 1g PO x 1 dose Azithromycin 1g PO x 1 dose
Aged ≥8 years:
Azithromycin 1g PO x 1 dose OR

2nd line
PEDIATRICS ADULTS
<45 kg: Erythromycin base 500mg PO qid x 7d
Azithromycin 20mg/kg/d PO qd x OR
3d Erythromycin ethylsuccinate 800mg
PO qid x 7d OR Levofloxacin 500mg PO
qd x 7d OR Ofloxacin 300mg PO bid x
7d
Pregnant Women:
Amoxicillin 500mg PO tid x 7d OR
OR
OR Erythromycin ethylsuccinate
800mg PO qid x 7d OR
Erythromycin ethylsuccinate 400mg
PO qid x 14d
Comments:
Diagnostic test (not routinely recommended): NAAT, Tissue culture, and Direct
Fluorescent Antibody Test.
Specimen:
Women: first-catch urine or swab specimens from the endocervix or vagina
Men: first-catch urine or urethral swab
Infants and Children: nasopharyngeal swab (if pneumonia); swabs from inner
eyelid (if conjunctivitis)
Doxycycline and quinolones should not be given to pregnant women. Data are
limited on the effectiveness and optimal dose of azithromycin for the treatment
of chlamydial infection in infants and children who weigh <45 kg. Onsite, directly
observed single dose therapy with azithromycin should be available for persons
whose adherence is a concern.
E. Gonococcal Infections
Etiology: N. gonorrhoeae
UNCOMPLICATED INFECTIONS OF THE CERVIX, URETHRA, AND RECTUM;

UNCOMPLICATED INFECTIONS OF THE PHARYNX (MORE DIFFICULT TO ERADICATE
THAN UROGENITAL OR ANORECTAL SITES)

Preferred Regimen:
1st line
PEDIATRICS ADULTS
Ceftriaxone 25–50 mg/kg IV/IM x 1 Ceftriaxone 250mg IM x 1 dose PLUS
dose (Max: 125mg IM) Azithromycin 1g PO x 1 dose
2nd line
PEDIATRICS ADULTS
Cefixime 8 mg/kg/d PLUS Cefixime 400mg PO x 1 dose PLUS
Azithromycin 10-12mg/kg/d Azithromycin 1g PO x 1 dose
GONOCOCCAL CONJUNCTIVITIS
Preferred Regimen:
P: Cefixime 8 mg/kg/d PLUS Azithromycin 10-12mg/kg/d
A: Ceftriaxone 1g IM x 1 dose PLUS Azithromycin 1g PO x 1 dose
DISSEMINATED INFECTION
Preferred Regimen:
P: Ceftriaxone 50 mg/kg IV/IM (max: 1g) qd x 7d
A: 1st line: Ceftriaxone 1g IV/IM q24h PLUS Azithromycin 1g PO x 1 dose
2nd line: Cefotaxime 1g IV q8h PLUS Azithromycin 1g PO x 1 dose
OPHTHALMIA NEONATORUM
Preferred Regimen (P):

Ceftriaxone 25-50mg/kg IV/IM x 1 dose (Max: 125mg) OR
Spectinomycin 25mg/kg IM x 1 dose (Max: 75 mg)
DISSEMINATED GONOCOCCAL INFECTION (DGI) AND GONOCOCCAL SCALP

ABSCESSES IN NEONATES
Preferred Regimen:
Ceftriaxone 25–50mg/kg/d IV/IM x 1 dose x 7d OR
Cefotaxime 25mg/kg IV/IM q12h x 7d
if meningitis is documented: DOT: 10-14d
Comments:
Gram’s stain and Culture – endocervical (women) or urethral (men) swab
specimens NAAT - endocervical swabs, vaginal swabs, urethral swabs (men), and
urine (from both men and women). Because of the emerging resistance data for
gonococcal infections and reduced effectiveness of some medicines, good practice

dictates that the choice of treatment depends on reliable local data on

antimicrobial susceptibility. Oral cephalosporins are no longer recommended
except if ceftriaxone is not available; then consider Cefixime but with test of cure
one week later. Medication for gonococcal infection should be provided on site
and directly observed.
No data exist regarding the use of dual therapy for treating children with
gonococcal infection. Persons treated for gonorrhea should be instructed to
abstain from sexual activity for 7 days after treatment and until all sex partners
are adequately treated. All persons who receive a diagnosis of gonorrhoea should
be tested for other STDs, including chlamydia, syphilis, and HIV.
Fluoroquinolones are not recommended for gonococcal urethritis. For Gonococcal

meningitis and endocarditis, increase Ceftriaxone to 1–2 g IV every 12–24 hours.
Gonococcal ophthalmia is strongly suspected when intracellular gram-negative
diplococci are identified on Gram stain of conjunctival exudate.
DGI might present as sepsis, arthritis, or meningitis and is a rare complication of

neonatal gonococcal infection. Positive Gram-stained smears of exudate, CSF, or
joint aspirate provide a presumptive basis for initiating treatment for N.
gonorrhoeae. Complete immunization for hepatitis B and HPV.
III. Vaginal Discharge
A. Bacterial Vaginosis
A polymicrobial clinical syndrome resulting from replacement of the normal

hydrogen peroxide producing Lactobacillus sp. in the vagina with high
concentrations of anaerobic bacteria.
Etiology: Prevotella sp.; Porphyromonas; Peptostreptococci; Mobiluncus sp.; G.

vaginalis; Ureaplasm; Mycoplasma; Numerous fastidious anaerobes
Preferred Regimen:
P: <45 kg: Metronidazole 15mg/kg/d PO div q12h x 7d
A: 1st line: Metronidazole 500mg PO bid x 7d
2nd line: Clindamycin 300mg PO bid x 7d
Comments:
Gram stain is used to determine the relative concentration of lactobacilli (e.g., long
Gram-positive rods), Gram-negative and Gram-variable rods and cocci (e.g., G.
vaginalis, Prevotella, Porphyromonas, and peptostreptococci), and curved gram-
negative rods (e.g., Mobiluncus) characteristic of BV.

Amsel’s Diagnostic criteria:

at least 3 of the following symptoms or signs must be present:
- homogeneous, thin, white discharge that smoothly coats the vaginal walls;
- clue cells on microscopic examination
- pH of vaginal fluid >4.5
- a fishy odor of vaginal discharge before or after addition of 10% KOH (Whiff
test).
B. Vaginitis, Prepubertal
Etiology: Group A Streptococci; E. coli; Herpes simplex virus; N. gonorrhoeae; C.

trachomatis; T. vaginalis; Enteric bacteria including Shigella species
Preferred Regimen:
<45kgs, < 8 years of age:
Ceftriaxone 125mg IM x 1 dose PLUS Erythromycin 50mg/kg/d div q6h x 14d
>45kgs but <8years of age:
Ceftriaxone 250mg IM x 1 dose PLUS Azithromycin 1g PO x 1 dose
>45kgs and > 8 years of age:
Ceftriaxone 250mg IM x 1 dose PLUS EITHER Azithromycin 1g PO x 1 dose OR
C. Trichomoniasis
Most infected persons have minimal or no symptoms. Some infected men have
symptoms of urethritis, epididymitis, or prostatitis, and some infected women
have vaginal discharge that might be diffuse, malodorous, or yellow-green with
or without vulvar irritation.
Etiology: T. vaginalis
Preferred Regimen:
1st line 2nd line
Metronidazole 2g PO x 1 dose Metronidazole 500mg PO bid x 7d
Pregnant women:
Metronidazole 2g PO x 1 dose
Women with HIV Infection:
Metronidazole 500mg PO bid x 7d
Comments: Diagnostic Tests: Wet-mount microscopy NAAT, Trichomonas Rapid

Test (dipstick). Treatment of partner is recommended. If single dose
metronidazole regimen fails, give 2g orally for 5 days.

D. Candidiasis
Typical symptoms include pruritus, vaginal soreness, dyspareunia, external

dysuria, and abnormal (thick, curdy) vaginal discharge.
Etiology: T. vaginalis
Preferred Regimen:
1st line 2nd line
Clotrimazole 1% cream 5g Fluconazole 150mg PO x 1 dose
intravaginally qd x 7–14d OR
Miconazole 1,200mg vaginal
suppository, 1 supp x 1d
Comments:
Diagnostic Tests: Wet preparation (saline, 10% KOH) or Gram stain of vaginal
discharge which demonstrates budding yeasts, hyphae, or pseudohyphae. Culture.
A diagnosis of Candida vaginitis is suggested clinically by the presence of external
dysuria and vulvar pruritus, pain, swelling, and redness.
IV. Genital, Anal, or Perianal Ulcers
A. Chancroid
Painful genital ulcer plus tender suppurative inguinal adenopathy suggests the
diagnosis of chancroid
Etiology: H. ducreyi
Preferred Regimen:
Azithromycin 1g PO x 1 dose OR Ceftriaxone 250mg IM x 1 dose OR
Ciprofloxacin 500mg PO bid x 3d OR Erythromycin base 500mg PO tid x 7d
Comments:
Criteria for probable diagnosis:
i. one or more painful genital ulcers
ii. regional lymphadenopathy
iii. no evidence of T. pallidum infection by darkfield examination of ulcer
exudate or by a serologic test for syphilis performed at least 7 days after
onset of ulcers
iv. Negative HSV PCR test or HSV culture performed on the ulcer exudate

Sex partners of patients who have chancroid should be examined and treated if
they had sexual contact with the patient within 10 days prior to patient’s onset of
symptoms.
B. Genital HSV Infections
Etiology: HSV1 and HSV2
FIRST CLINICAL EPISODE
Preferred Regimen:
Aciclovir 400mg PO bid x 7-10d OR Aciclovir 200mg PO 5x/d x 7-10d OR
Valaciclovir 1g PO bid x 7-10d OR Famciclovir 250mg PO tid x 7-10d
For children < 45 kg:
Aciclovir 80mg/kg/d PO div q6-8h (Max: 1.2g/day) x 7-10d
Valaciclovir 40mg/kg/d div q12h x 7-10d
Comments: Diagnosis: Viral culture, PCR, HSV serology. Extend treatment if

healing is incomplete after 10 days.
RECURRENT GENITAL HERPES
Preferred Regimen:
Suppressive Therapy (A):
Aciclovir 400mg PO bid OR Valaciclovir 500mg PO qd OR Valaciclovir 1g PO qd OR
Famciclovir 250mg PO bid
Pregnant Women: Aciclovir 400mg PO tid OR Valaciclovir 500mg PO bid
HIV-infected Adults: Aciclovir 400–800mg PO bid- tid OR Valaciclovir 500mg PO
bid OR Famciclovir 500mg PO bid
Episodic Therapy (A):

Aciclovir 400mg PO tid x 5d OR Aciclovir 800mg PO bid x 5d OR
Aciclovir 800mg PO tid x 2d OR Valaciclovir 500mg PO bid x 3d OR
Valaciclovir 1g PO qd x 5d OR Famciclovir 125 mg PO bid x 5d OR
Famciclovir 1g PO bid x 1d OR Famciclovir 500mg x1 dose, then 250mg bid x 2d
HIV-infected Adults: Aciclovir 400mg PO tid x 5-10d OR Valaciclovir 1g PO bid x 5-
10d OR Famciclovir 500mg PO bid x 5-10d
Comments:
Suppressive therapy reduces:
1. frequency of recurrences by 70%–80%
2. risk of disease transmission.

Safety and efficacy have been documented among patients receiving daily therapy
with aciclovir for as long as 6 years and with valaciclovir or famciclovir for 1 year.
Valaciclovir 500mg qd is less effective than other regimen in those with ≥10
recurrences per year. Treatment is recommended starting at 36 weeks of
gestation. Effective episodic treatment of recurrent herpes requires initiation of
therapy within 1 day of lesion onset or during the prodrome.
SEVERE DISEASE
Preferred Regimen: Aciclovir 5–10mg/kg IV q8h x 2-7d or until clinical

improvement is observed, followed by oral antiviral therapy to complete at least
10 days.
Comments: HSV encephalitis requires 21 days of intravenous therapy. Impaired

renal function warrants dose adjustment.
NEONATAL HERPES
Preferred Regimen: Aciclovir 20mg/kg IV q8h x 14d if disease is limited to the skin
and mucous membranes, or for 21 days for disseminated disease and involving the
central nervous system.
C. Granuloma Inguinale (Donovanosis)
Characterized by painless, slowly progressive ulcerative lesions on the genitals or

perineum without regional lymphadenopathy;
Etiology: Klebsiella granulomatis (formerly known as Calymmatobacterium

granulomatis)
Preferred Regimen:
1st line 2nd line
Azithromycin 1g PO q week OR 500 Doxycycline 100mg PO bid for at least 3
mg qd for at least 3 weeks and until weeks and until all lesions have
all lesions have completely healed completely healed OR
Ciprofloxacin 750mg PO bid orally for at
least 3 weeks and until all lesions have
completely healed OR
Erythromycin base 500mg PO qid for at
least 3 weeks and until all lesions have
completely healed OR

Trimethoprim-sulfamethoxazole one
double-strength (160 mg/800mg) tablet
PO bid for at least 3 weeks and until all
lesions have completely healed.
Comments: Gentamicin 1 mg/kg IV q8h can be added if improvement is not

evident within the first few days of therapy.
D. Lymphogranuloma Venereum
Etiology: C. trachomatis serovars L1, L2, L3

Preferred Regimen:
1st line: Doxycycline 100mg PO bid x 21d
2nd line: Erythromycin base 500mg PO qid x 21d
Comments:
Persons with a clinical syndrome consistent with LGV, including proctocolitis or
genital ulcer disease with lymphadenopathy, should be presumptively treated for
LGV. Special diagnostic tests: culture, immunofluorescent test, NAAT (if available)
E. Syphilis
Etiology: Treponema pallidum
PRIMARY SYPHILIS
Clinical Presentation: presence of chance
Preferred Regimen:
PEDIATRICS ADULTS
Benzathine penicillin G 1st line: Benzathine penicillin G 2.4MU IM x 1
50,000 U/kg IM, up to the dose
adult dose of 2.4 MU x 1 2nd line: Doxycycline 100mg PO bid x 14d OR
dose Tetracycline 500mg qid x 14d OR
Ceftriaxone 1g IV/IM q24h x 10-14d OR
Azithromycin 2g PO x 1 dose
SECONDARY SYPHILIS
Clinical Presentation; Fever, puplosquamous rash often involving palms of hands and
soles of feet

Preferred Regimen:
PEDIATRICS ADULTS
Ceftriaxone 1g IV/IM q24h x10-14d OR
Comments (For Primary and Secondary Syphilis):

Diagnostic tests:
• Definitive diagnosis: Darkfield examinations
• Presumptive diagnosis: Nontreponemal tests (VDRL or RPR) Treponemal
tests (FTA-ABS or TPHA, EIAs, immunoblots).
Test all patients with syphilis for HIV
For primary and secondary syphilis, clinical and serologic evaluation should be
performed at 6 and 12 months after treatment. Failure of nontreponemal test
titers to decline fourfold within 6–12 months after therapy for primary or
secondary syphilis might be indicative of treatment failure. Infants and children
aged ≥1 month with primary and secondary syphilis should be evaluated for sexual
abuse. Doxycycline and tetracycline cannot be given to pregnant women.
LATENT SYPHILIS (EARLY LATENT SYPHILIS)

a. Early Latent Syphilis - latent syphilis of less than one-year duration
Preferred Regimen:
PEDIATRICS ADULTS
Ceftriaxone 1g IV/IM q24h x10-14d OR
Comments:
Characterized by serore activity without other evidence of primary, secondary, or
tertiary disease. Quantitative nontreponemal serologic tests should be repeated
at 6, 12, and 24 months.
A CSF examination should be performed if

1. a sustained (>2 weeks) fourfold increase or greater in titer is observed,

2. an initially high titer (≥1:32) fails to decline at least fourfold within 12–24
months of therapy
3. signs or symptoms attributable to syphilis develop,
b. Late Latent Syphilis - Latent syphilis of less than unknown duration
Preferred Regimen:
PEDIATRICS ADULTS
Benzathine penicillin G 50,000 U/kg 1st line: Benzathine penicillin G 7.2
IM, up to the adult dose of 2.4 MU, MU total, administered as 3 doses of
administered as 3 doses at 1-week 2.4 MU IM each buttock at 1-week
intervals (total 150,000 units/ kg up intervals
to the adult total dose of 7.2 MU) 2nd line: Doxycycline 100mg PO bid x
30d OR Tetracycline 500mg PO qid x
30d
TERTIARY SYPHILIS
Preferred Regimen (A): Benzathine penicillin G 7.2 MU total, administered as 3

doses of 2.4 MU IM each at 1-week interval
Comments:
Tertiary syphilis refers to gummas and cardiovascular syphilis but not to
neurosyphilis. Pregnant women and those who are allergic to penicillin should be
desensitized and treated with penicillin.
NEUROSYPHILIS
Preferred Regimen (A): Aqueous crystalline penicillin G 18–24 MU/d,

administered as 3–4 MU IV q4h or continuous infusion x 10-14d
Comments:
Diagnosis of neurosyphilis depends on a combination of CSF cell count or protein
and a reactive CSF-VDRL in the presence of reactive serologic test results and
neurologic signs and symptoms. In a person with neurologic signs or symptoms, a
reactive CSF-VDRL is considered diagnostic of neurosyphilis.
CONGENITAL SYPHILIS
Preferred Regimen:
Proven or Highly Probable Congenital Syphilis

Aqueous crystalline penicillin G 100,000–150,000 U/kg/d, administered as 50,000

U/kg/ dose IV q12h during the first 7 days of life and q8h thereafter for a total of
10 – 15d OR Procaine penicillin G 50,000 U/ kg/dose IM x 1 dose for 10-15d
Possible Congenital Syphilis:

Aqueous crystalline penicillin G 100,000–150,000 U/kg/d, administered as 50,000
U/kg/ dose IV q12h during the first 7d of life and q8h thereafter for a total of 10d
OR Procaine penicillin G 50,000 U/ kg/dose IM x 1 dose for 10d OR Benzathine
penicillin G 50,000 U/kg IM x 1 dose
Congenital Syphilis less likely:

Benzathine penicillin G 50,000 units/kg IM x 1 dose OR Do not treat but do close
serologic follow-up every 2–3 months for 6 months for infants whose mother’s
nontreponemal titers decreased at least fourfold after appropriate therapy for
early syphilis or remained stable for low-titer, latent syphilis (e.g., VDRL <1:2; RPR
<1:4).
Congenital Syphilis unlikely:

No treatment is required, but infants with reactive nontreponemal tests should be
followed serologically to ensure the nontreponemal test returns to negative.
Benzathine penicillin G 50,000 U/kg as a single IM injection might be considered,
particularly if follow-up is uncertain and the neonate has a reactive
nontreponemal test.
Comments:
Proven or Highly Probable Congenital Syphilis
Any neonate with:
1. PE consistent with congenital syphilis; OR
2. nontreponemal serologic titer fourfold higher than the mother’s titer; OR
3. positive darkfield test or PCR of lesions or body fluid(s).
Possible Congenital Syphilis:

Any neonate who has a normal physical examination and a serum quantitative
nontreponemal serologic titer equal to or less than fourfold the maternal titer and
one of the following:
1. mother was not treated, inadequately treated, or has no documentation of
having received treatment; OR
2. mother was treated with erythromycin or an inappropriate regimen (e.g.
nonpenicillin G) OR
3. mother received recommended treatment <4 weeks before delivery.

Congenital Syphilis less likely:

Any neonate who has a normal physical examination and a serum quantitative
nontreponemal serologic titer equal to or less than fourfold the maternal titer and
both of the following are true:
1. mother was treated during pregnancy, treatment was appropriate for the
stage of infection, and treatment was administered >4 weeks before
delivery, and
2. mother has no evidence of reinfection or relapse
Congenital Syphilis unlikely:

Any neonate who has a normal physical examination and a nontreponemal
serologic titer equal to or less than fourfold the maternal titer and both of the
following are true:
1. mother’s treatment was adequate before pregnancy and
2. mother’s nontreponemal serologic titer remained low and stable before and
during pregnancy and at delivery (VDRL <1:2; RPR <1:4).
SYPHYLIS IN PREGNANCY
Preferred Regimen: Penicillin is the only drug recommended for treatment of

pregnant women with syphilis. Give the same dose as in non-pregnant women
appropriate for the stage of syphilis.
Comments: All pregnant women should be screened for syphilis early in

pregnancy. Pregnant women allergic to penicillin should be desensitized and
treated with penicillin
V. Anogenital Warts
A. HPV and genital warts
Etiology: Human papillomavirus
Preferred Regimen:
A. Patient-Applied: Imiquimod 5% (or 3.75%) cream
B. Provider–Administered: Cryotherapy with liquid nitrogen or cryoprobe OR
Surgical removal either by tangential scissor excision, tangential shave excision,
curettage, laser, or electrosurgery (electrocautery or electrocoagulation) OR
Trichloroacetic acid (TCA)
Comments:
The aim of treatment is removal of the wart and amelioration of symptoms.
Treatment of anogenital warts should be guided by wart size, number, and

anatomic site; patient preference; cost of treatment; convenience; adverse

effects; and provider experience. Therapeutic methods are effective in 22 to 94%
in clearing exophytic genital warts, however recurrence rate is high, at least 25%
within 3 months.
B. Molluscum contagiosum
Preferred Regimen:
Curettage OR Cryotherapy with liquid nitrogen OR Electrodessication OR Chemical
agents (podophyllin, tretinoin, cantharidin, 25% to 50% trichloroacetic acid, silver
nitrate, tincture of iodine or potassium hydroxide) OR Imiquimod
Comments:
Physical destruction is the most effective and rapid means of curing molluscum
contagiosum. Genital lesions should be treated to prevent spread to sexual
contacts. Lesions in healthy individuals are self-limited and may not necessitate
treatment. Genital lesions have a potential carcinogenicity, neutropenia and
potential permanent as well as nephrotoxicity.
VI. Ectoparasitic Infections
A. Pediculosis Pubis
Persons with pubic lice usually seek medical attention because of pruritus or
because of lice or nits on pubic hair.
Etiology: Pubic Lice
Preferred Regimen:
Permethrin 1% cream rinse applied to affected areas and washed off after 10
minutes
B. Scabies
Etiology: Sarcoptes scabiei
Preferred Regimen:
Permethrin 5% cream applied to all areas of the body from the neck down and
washed off after 8–14h OR Ivermectin 200ug/kg PO, repeated in 2 weeks
Comments:
Infants and young children should be treated with permethrin. Infants and young
children aged <10 years should not be treated with lindane. Bedding and clothing

should be decontaminated (e.g., either machine-washed, machine-dried using the

hot cycle, or dry cleaned) or removed from body contact for at least 72hours.
Persons with scabies should be advised to keep fingernails closely trimmed to
reduce injury from excessive scratching.
References
John Hopkins Medicine
• Carlos C. Antimicrobial Resistance Surveillance Program 2014 Report
• CDC Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep
June 5, 2015: Vol. 64. No. 3
• CDC. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep
2010;59(No. RR-12).
• Feigin RD, et.al, Textbook of Pediatric Infectious Diseases. 7th edition, Philadelphia:
Saunders Elsevier; 2014
• Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases: 2-
Volume Set, 8th Edition
• Red Book, 30th Edition. 2015 Report on the Committee of Infectious Diseases
• The Sanford Guide to Antimicrobial Therapy 2014, 44th Edition Sanford Guide 2015.
Web Edition. (http://webedition.sanfordguide.com)
• WHO guidelines for the treatment of Treponema pallidum (syphilis) 29 August 2016
• WHO guidelines for the treatment of Chlamydia trachomatis 29 August 2016
• WHO guidelines for the treatment of Neisseria gonorrhoeae 28 August 2016

DOH PUBLIC HEALTH PROGRAMS (TUBERCULOSIS)
TUBERCULOSIS (TB)
The available anti-TB drugs are:
• First Line anti-TB drugs: Rifampicin (R), Isoniazid (H), Ethambutol (E),
Pyrazinamide (Z), and Streptomycin (S)
• Second line anti-TB drugs: Levofloxacin (Lfx), Moxifloxacin (Mfx), Kanamycin
(Km), Capreomycin (Cm), Prothionamide (Pto), Cycloserine (Cs), Linezolid (Lzd),
Clofazimine (Cfz), Bedaquiline (Bdq), Para-aminosalicylic Acid (PAS) and
Imipenem (Imp). These drugs will only be used in certified PMDT centers.
Anti-TB drugs in fixed-dose combination (FDC) preparation.

• Adult FDC tablet: Contains isoniazid 75 mg and rifampicin 150mg, +/-
pyrazinamide 400 mg, +/-ethambutol 275 mg per tablet.
• Pediatric FDC dispersible tablet: Contains isoniazid 50 mg and rifampicin 75 mg,
+/- pyrazinamide 150 mg per tablet. Give the entire daily dose once a day.
Single-drug formulations (SDF) are still recommended for the following situations:
adverse reactions or at risk for adverse reactions; co-morbid conditions requiring
dose adjustments (especially liver, kidney diseases); or expected to have
significant drug interactions. However, local availability of SDFs is poor.
A. CATEGORY I
Etiology:
Pulmonary TB, New (no treatment or had undergone previous treatment for less
than a month; whether bacteriologically confirmed or clinically diagnosed)
Miliary TB without dissemination or with dissemination not involving meningitis,
bones, joints
Extrapulmonary TB (EPTB), New (whether bacteriologically confirmed or clinically
diagnosed) EXCEPT CNS, bones, joints
Preferred Regimen:
PEDIATRICS (<15Y):
Intensive phase (2 mos. HRZE) Continuation phase
BODY
(No. of tablets) (4 mos. HR)
WEIGHT
HRZ E (100 mg) HR
4-7 kg 1 1 1
8 – 11 kg 2 2 2
12 – 15 kg 3 3 3
16-24 kg 4 4 4
25 + kg Adult dose and preparations

ADULTS:
BODY WEIGHT (No. of tablets) (4 mos. HR)
HRZE HR
30 - 37 kg 2 2
38 – 54 kg 3 3
55 – 70 kg 4 4
> 70 kg 5 5
Drug Dosage per kg body weight (if using single-drug formulations)

PEDIATRICS ADULTS
ANTI-TB Drug Dose (mg/kg Max dose/d Dose (mg/kg Max
BW) (mg) BW) dose/d(mg)
Isoniazid 10 (10 – 15) 300 5 (4 – 6) 400
Rifampicin 15 (10 – 20) 600 10 (8 – 12) 600
Pyrazinamide 30 (20 – 40) 2,000 25 (20 – 30) 2,000
Ethambutol 20 (15 – 25) 1,200 15 (15 – 20) 1,200
Comments:
ALL children being treated for TB should be weighed at least once every month to
allow for adjustment of dosage(s). All patients should be weighed monthly for
possible dose adjustments.
Anti-TB treatment shall be done through a patient-centered, Directly-Observed

Treatment (DOT) to foster adherence. Anti-TB treatment regimen shall be based
on anatomical site and bacteriologic status including drug resistance and history
of prior treatment, as well as the presence of co-morbid conditions.
A patient’s anti-TB regimen shall be comprised of at least four (4) first-line drugs.
Fixed dose combination (FDC) should be used even for children. Single drug
formulation should be used for specific subsets of patients such as those with
hypersensitivity reactions to rifampicin and other anti-TB drugs: drug reactions;
hepatic or renal impairment.
Refer to Table below on Summary of treatment regimens for EPTB.

B. CATEGORY IA
Etiology: Extra-pulmonary TB (EPTB), New: CNS, bones or joints
Preferred Regimen:
PEDIATRICS (<15Y):
HRZ E (100 mg) HR
4 - 7 kg 1 1 1
8 – 11 kg 2 2 2
12 – 15 kg 3 3 3
16 - 24 kg 4 4 4
ADULTS:
HRZE HR
30 - 37 kg 2 2
38 – 54 kg 3 3
55 – 70 kg 4 4
> 70 kg 5 5
Comments:
Referral to relevant specialties is recommended for EPTB. Use of corticosteroids
as adjunctive therapy is recommended ONLY for patients with TB meningitis
and/or TB pericarditis.
• TB meningitis: Dexamethasone 0.4mg/kg/24h with a reducing course over
6-8 weeks
• TB pericarditis: Prednisolone 60 mg for the first 4 weeks, 30 mg for weeks 5-
8, 15 mg for weeks 9-10 and 5 mg for week 11.
Refer to Table below on Summary of treatment regimens for EPTB.
C. CATEGORY II 2HRZES/ 1HRZE/5HRE

Etiology: PTB or EPTB, previously treated drug-susceptible TB (whether
bacteriologically confirmed or clinically diagnosed)
• Relapse
• Treatment After Failure
• Treatment After Lost to Follow-up (TALF)
• Previous Treatment Outcome Unknown
• Other

Preferred Regimen:
PEDIATRICS (<15Y):
Intensive phase (2HRZES* + Continuation phase
BODY
1HRZE) (No. of tablets) (5HRE)
WEIGHT
HRZ E (100 mg) HRE+
4 - 7 kg 1 1 1
8 – 11 kg 2 2 2
12 – 15 kg 3 3 3
16 - 24 kg 4 4 4
*Add streptomycin 15 mg/kg BW/d during the first 2 months of the intensive phase, not to
exceed 1 g/d.
ADULTS:
BODY
WEIGHT
HRZES* HRZE HRE
30 - 37 kg 2 2 2
38 – 54 kg 3 3 3
55 – 70 kg 4 4 4
> 70 kg 5 5 5
*Add streptomycin 15 mg/kg BW/d during the first 2 months of the intensive phase, not to
exceed 1 g/d.
Comments:
All retreatment patients are considered as Presumptive DR-TB and should
therefore be tested using Xpert MTB/ Rif Test before initiating Category II
treatment regimen (except if there is no sputum specimen, or there is no access
to Xpert services).
Category II regimen should only be given among SUSCEPTIBLE retreatment cases.

They should immediately be referred to the nearest MDR-TB facility (or other
private or government facility with Xpert/MTB/Rif service) for Rifampicin
susceptibility testing (Xpert). For patients with BW <50 kgs and those >60 yrs. old,
consider streptomycin dosing of 500-700mg or 10mg/kg/d.
Xpert MTB/Rif test shall be done first and result be made available before
starting on any second-line drugs.

D. CATEGORY IIA 2HRZES/ 1HRZE/9HRE
Etiology: EPTB, previously treated drug-susceptible TB (whether bacteriologically

confirmed or clinically diagnosed) - CNS, bones or joints.
Preferred Regimen:
PEDIATRICS (<15Y):
BODY
WEIGHT
HRZ E (100 mg) HRE+
4 - 7 kg 1 1 1
8 – 11 kg 2 2 2
12 – 15 kg 3 3 3
16 - 24 kg 4 4 4
*Add streptomycin 30 mg/kg BW/d during the first 2 months of the intensive
phase, not to exceed 1 g/d.
ADULTS:
BODY
WEIGHT
HRZES* HRZE HRE
30 - 37 kg 2 2 2
38 – 54 kg 3 3 3
55 – 70 kg 4 4 4
> 70 kg 5 5 5
*Add streptomycin 30 mg/kg BW/d during the first 2 months of the intensive
phase, not to exceed 1 g/d.
Comments:
Pre-treatment recommendations for patients starting Category II regimens:
1. Baseline history and PE for any risk factors for hepatic, renal and ocular toxicity;
sexual history; occupational history; personal/ social personal (including
smoking and alcohol use)
2. Those with risk behavior for HIV or coming from Category A/B HIV areas should
be offered PICT
3. Baseline ALT/crea at the minimum for >60y/o and those with risk factors for
liver or kidney disease
4. Screening for DM (using FBS, RBS or OGTT) for all TB patients
5. Baseline visual acuity and color perception for all TB patients

E. Standard Regimen Drug Resistant (SRDR)
Etiology: Rifampicin-resistant TB or Multidrug-resistant TB (MDR-TB)
Preferred Regimen:
Shorter Treatment Regimen: Moxifloxacin-Kanamycin-Prothionamide-
Clofazimine-Pyrazinamide-Ethambutol-Isoniazid high dose (MfxKmPtoCfzEZH)
• Strictly provided to MDR/RR-TB only.
• Treatment duration for 9-11 months.
Conventional Treatment Regimen:

• Provided to patients who do not qualify for the Shorter Treatment
• Treatment duration for 20-24 months.
Comments:
Since second-line drugs (SLDs) come in single dose formulations, DOT shall be
done throughout the treatment duration to ensure adherence. Refer to the
treatment centers/ satellite treatment centers for DR-TB management.
F. XDR-TB Regimen
Preferred Regimen:
Treatment shall be individualized based on DST result and history of previous
treatment and managed only by PMDT center.
INDIVIDUAL CONDITIONS/SPECIAL SITUATIONS
A. PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV)
Preferred Regimen:
In HIV-related TB, the priority is to treat TB. Standard TB regimen for HIV-
associated TB is the same as the general population.
ARV should be initiated after the 2nd week of TB treatment. For patients with TB
meningitis, ARV should be given after the Intensive Phase of TB treatment.
Cotrimoxazole prophylaxis (sulfamethoxazole 800mg/ trimethoprim 160 mg
daily) for Pneumocystis jiroveci pneumonia regardless of CD4 count.
Comments:
All newly diagnosed PLHIV should be screened for active TB. All PLHIV with cough
of any duration, fever, night sweats, or loss of weight shall undergo sputum
collection for Xpert testing. PLHIV without these symptoms should undergo chest
x-ray or clinical assessment to rule out EPTB.

Should there be cutaneous reactions observed in HIV-infected individuals, it is

important to note that RIF should be reintroduced last.
Efavirenz is the preferred NNRTI for PLHIV on TB treatment. Avoid the use of
nevirapine because of drug-drug interactions. Pyridoxine (Vitamin B6) at 10-25
mg/d.
B. DIABETIS MELLITUS
Preferred Regimen: Same as general population
Comments:
Glucose control should be optimal, referral to specialist is recommended for
difficult to control diabetes
C. NEW MILIARY TB AND MILIARY TB WITH DISSEMINATION
Preferred Regimen: Treat as Category I: 2HRZE/4HR
Comments:
In the absence of meningitis or bone and joint involvement, the effective
treatment regimen for NEW miliary TB cases is Category I.
D. PREGNANCY
Preferred Regimen:
Standard TB regimen for pregnant is the same as the general population. Pregnant
patients taking Isoniazid should be given Pyridoxine (Vitamin B6) at 10-25 mg/d.
Comments:
Always ascertain whether or not a woman is pregnant before she starts TB
treatment. First line anti-TB drugs are safe for pregnant women, EXCEPT
streptomycin (an ABSOLUTE contraindication).
E. BREASTFEEDING/LACTATING WOMEN
Preferred Regimen:
Standard TB regimen for breastfeeding/Lactating women is the same as the
general population. Breastfeeding/Lactating women should be given Pyridoxine
(Vitamin B6) at 10-25mg/d. Supplemental Pyridoxine should be given at 5-10
mg/d to the infant who is taking isoniazid or whose breastfeeding mother is taking
isoniazid.

Comments:
Breastfeeding woman afflicted with TB should receive a full course of TB
treatment. In lactating mothers on TB treatment, most anti-TB drugs will be found
in breast milk in concentrations equal to only a small fraction of the therapeutic
dose in infants.
F. ORAL CONTRACEPTIVES
Preferred Regimen: Category I: Category I: 2HRZE/4HR
Comments:
Rifampicin interacts with oral contraceptive (OC) medications with a risk of
decreased protective efficacy against pregnancy. Advise a woman receiving OC
while on Rif treatment that she has the following options:
1. Take an OC pill containing a higher dose of estrogen (50 u) following
consultation with a clinician
2. Use another form of contraception
G. LIVER DISEASE / HISTORY OF LIVER DISEASE
Preferred Regimen:
Treatment should be interrupted and generally modified or alternative regimen
used for those with alanine aminotransferase (ALT) elevation >3x the upper limit
of normal (ULN) in the presence of hepatitis symptoms/or jaundice. If ALT is
elevated 5x the ULN, treatment should be interrupted even in the absence of
symptoms. Refer to the appropriate specialist.
H. CHRONIC LIVER DISEASE
Preferred Regimen (For compensated liver cirrhosis):

2HRSE/6HR, 2HSE/10HE, 9HRE
Comments:
Patients undergoing prolonged ethambutol treatment should undergo regular
ophthalmologic screening (visual acuity and red/green color discrimination). For
decompensated liver cirrhosis: Refer to a specialist because use of possible SLDs is
warranted. The more advanced the liver disease, the fewer number of hepatotoxic
drugs should be used.
I. ACUTE VIRAL HEPATITIS
Preferred Regimen:
It is possible to defer TB treatment until acute hepatitis has been resolved. When
it is necessary to treat TB during acute hepatitis, the safest option is the

combination of streptomycin and ethambutol for 3 months. Once the hepatitis has
resolved, a Continuation Phase of 6 months HR is given (3SE/6HR). If the hepatitis
has not been resolved, SE should be continued for a total of 12 months (12SE).
Refer all patients to a specialist.
J. KNOWN CHRONIC KIDNEY DISEASE
Preferred Regimen:
2HRZE/4HR modified in dosage and frequency based on creatinine clearance.
Thrice weekly instead of daily pyrazinamide and ethambutol is recommended.
Comments:
Please refer to the Table below on Dose Adjustments for Patients with Kidney
Disease. Anti-TB medications should be administered immediately AFTER
hemodialysis or ANYTIME during peritoneal dialysis. SDFs are preferred over FDCs
to facilitate proper dose adjustments. Same adjustments are made for those
receiving second line drugs.
K. RENAL FAILURE (with reduced renal function or receiving hemodialysis)
Preferred Regimen:
H: 300 mg od; or 900 mg 3x per week
R: 600 mg od; or 600 mg 3x per week
Z: 25-35 mg/kg/dose 3x per week (NOT daily)
E: 15-25 mg/kg/dose 3x per week (NOT daily)
S: 12-15 mg/kg/dose 2 or 3x per week
Comments:
Noting the recommendations cited, it is possible to give a 4-drug FDC (HRZE) 3x
per week and then give a 2-drug FDC (HR) for the rest of the week during the
Intensive Phase. Continuation Phase may proceed with 4HR. Otherwise, another
safe option is 2HRZ/4HR. It is recommended that anti-TB medications be taken
after hemodialysis.
Summary of treatment regimens for Extra-pulmonary TB
Site Regimen Recommendation/

Level of Evidence
Central Nervous System 2 HRZE / 10 HR STRONG recommendation,
High quality evidence
Bone and Joints 2 HRZE / 10 HR STRONG recommendation,
Moderate quality evidence
Lymph node 2 HRZE / 4 HR STRONG recommendation,

Pericardium 2 HRZE / 4 HR STRONG recommendation,

Low quality evidence
Pleura 2 HRZE / 4 HR STRONG recommendation,
Liver 2 HRZE / 4 HR STRONG recommendation,
Gastrointestinal, 2 HRZE / 4 HR STRONG recommendation,
Peritoneum Moderate quality evidence
Kidney and Genitourinary 2 HRZE / 4 HR STRONG recommendation,
tract Low quality evidence
Dose Adjustments for Patients with Kidney Disease
Reference Dose Adjustment

dose
Anti TB Drug (normal GFR ≥ GFR ≤ Peritoneal
renal 30 30 Hemodialysis Dialysis
function) ml/min ml/min
Isoniazid 5 (4-6) None After dialysis None
mg/kg/d
(max 300
mg/d)
Rifampicin 10 (8-12) None After dialysis None
mg/kg/d
(max 600
mg/d)
Pyrazinamide 25 (20-30) None 25-35 25-35 mg/kg, 25-35
mg/ mg/kg, 3x/week, mg/kg,
kg/d (max 3x/week after 3x/week
2 g/d) dialysis
Ethambutol 15 (15-20) GFR > 15-25 15-25 mg/kg, 15-25
mg/ 70 mg/kg, 3x/week, mg/kg,
kg/d (max ml/min: 3x/week after 3x/week
1.2 g/d) None dialysis
GFR <
70
ml/min:
15-25
mg/kg,
3x/week

REFERENCES
• WHO Treatment of Tuberculosis Guidelines, 4th edition. Geneva, Switzerland: WHO, 2010.
• National Tuberculosis Control Program Manual of Procedures, 5 th edition. Sta. Cruz,
Manila: DOH, 2014.
• CPG for the Diagnosis, Treatment, Prevention and Control of Tuberculosis in Adult Filipinos
– 2016 Update. Manila: Philippine Coalition Against Tuberculosis (PhilCAT); 2016.

SURGICAL PROPHYLAXIS
ANTIBIOTIC PROPHYLAXIS TO PREVENT SURGICAL INFECTIONS GENERAL

COMMENTS:
I. Adults:
A. Surgical prophylaxis is recommended only when the potential benefits exceed
the risks and the anticipated costs.
B. The antibiotic chosen must cover the expected pathogens for the operative site
and take into account local resistance patterns.
C. Effective prophylaxis requires antimicrobial serum and tissue concentrations
above the minimum inhibitory concentration (MIC) for the probable organisms
associated with the specific procedure at the time of incision and throughout
the duration of the procedure.
1. Timing is crucial. Intravenous antimicrobial must be started within 60
minutes before surgical incision. Exceptions: Vancomycin and
fluoroquinolones require 1- to 2-hour infusion times; hence, dose is started
2 hours before surgical incision. Rapid infusion of vancomycin may result
in hypotension and other signs and symptoms of histamine release (red
man syndrome).
2. A single dose of antimicrobial with a long enough half-life to achieve
activity throughout the operation is sufficient for prophylaxis under most
circumstances. Post-procedure doses are generally not needed.
3. For procedures lasting more than two half-lives of the prophylactic agent,
or when there is excessive blood loss (>1,500 mL), intraoperative
supplementary dose(s) may be required. Re-dosing interval is measured
from time of the preoperative dose.
D. The use of vancomycin is discouraged but may be justifiable in centers where
rates of post-operative infection with methicillin-resistant Staphylococcus
aureus (MRSA) are high, or in patients with known MRSA colonization or at high
risk for this (e.g., hemodialysis patients). It is also an alternative when patients
have a history of an immediate type of allergic reaction to beta-lactams
(anaphylaxis, laryngeal edema, bronchospasm, hypotension, local swelling,
urticaria or pruritic rash occurring immediately after a beta-lactam dose) or
exfoliative dermatitis (e.g., Stevens-Johnson syndrome).
1. Unlike beta-lactams, vancomycin has no activity against gram-negative
organisms. When gram-negative bacteria are a concern (as shown by local
surveillance data), adding a second agent with appropriate in vitro activity
may be necessary. This can be done by adding cefazolin to vancomycin in
the non-allergic patient. In patients intolerant of or allergic to beta-
lactams, use vancomycin with another gram-negative antibiotic (e.g.,
aminoglycoside, fluoroquinolone, or aztreonam).
E. For patients currently given therapeutic antibiotic(s) for infection remote to
surgery site and when the antibiotic regimen is appropriate also for prophylaxis,
a dose should be given within an hour prior to incision.

F. The risks of pre-surgical prophylaxis include Clostridium difficile infection and

allergic reactions. Improper antimicrobial prophylaxis leads to excessive
surgical wound infection rate (up to 52% in most studies), prolonged hospital
stay, increased morbidity and mortality, and increased health care cost.
II. Pediatric Patients:

A. The principles mirror those for antibiotic prophylaxis in adults. However, data
in the pediatric population are limited and recommendations have largely been
extrapolated from studies in adults. For CLEAN SURGERIES, no prophylaxis is
recommended as a general rule. Exception: procedures where there are severe
consequences of infection (e.g. prosthetic implants, cardiac procedures).
B. Recommendations are generally the same as for adults except for dosing.
C. Fluoroquinolones should not be used because of the potential for toxicity.
RECOMMENDED ANTIBIOTIC PROPHYLAXIS REGIMEN BY SURGICAL PROCEDURE
A. Cardiovascular Surgery
Surgery: Regimen:
• Reconstruction of abdominal Cefazolin 2g x 1 dose for <120kg or
aorta 3g IV >120kg OR
• Leg vascular procedures that Cefuroxime 1.5g IV x 1 dose
involve a groin incision
• Any vascular procedure with If allergic to beta-lactams:
insertion of prosthesis/foreign Vancomycin <90kg: 1g IV x 1 dose;
body >90kg: 1.5g IV x 1 dose
• Lower extremity amputation for Consider intranasal mupirocin the
ischemia evening before surgery, on the day of
• Cardiac surgery surgery, and bid for 5 days post-surgery
• Permanent pacemakers in patients with positive nasal culture
• Heart transplant for S. aureus.
• Implanted cardiac defibrillators
Comments:
Single infusion just before surgery is as effective as multiple doses. Prophylaxis
beyond 24 hours is not recommended No prophylaxis is needed for cardiac
catheterization, carotid and brachiocephalic procedures without insertion of
prosthetic grafts, and intravascular central line insertion (tunneled/untunneled).
For prosthetic heart valves, it is recommended to stop prophylaxis either after
removal of the retrosternal drainage catheters or just give a 2nd dose after coming
off bypass. Vancomycin may be preferred in hospitals with increased frequency of
MRSA, in high-risk patients, and those colonized with MRSA.

B. Gastroduodenal/Biliary Surgery
Surgery: Regimen:
Gastroduodenal, includes Cefazolin 2g IV (3g if wt. >120kg) OR
percutaneous endoscopic gastrostomy Cefoxitin 2 g IV OR
(high risk only), Ceftriaxone (2g IV) x 1 dose
pancreaticoduodenectomy
(Whipple procedure)
Low risk, laparoscopic cholecystectomy No prophylaxis
Biliary, includes high risk laparoscopic Cefazolin 2g IV (3g if wt.> 120 kg)
cholecystectomy, open OR Cefoxitin 2 g IV
cholecystectomy
Endoscopic retrograde If without obstruction: No
cholangiopancreatography Prophylaxis
If with obstruction:
Ciprofloxacin 500-750mg PO or
400mg IV 2h prior to procedure
OR Piperacillin-tazobactam 4.5g IV
1h prior to procedure
Comments:
Gastroduodenal (PEG placement) high-risk conditions include: marked obesity,
obstruction, decreased gastric acid or decreased motility, gastric bleeding, cancer.
Ceftriaxone is recommended for centers where there is increasing resistance of
Enterobacteriaceae to 1st and 2nd generation cephalosporins. Avoid using
ceftriaxone in neonates. Biliary high-risk factors include: age >70 years, diabetes,
immune-suppression, acute cholecystitis, pregnancy, non-functioning gallbladder,
obstructive jaundice or common duct stones, anticipated bile spillage or
procedure duration >2h.
C. Colorectal surgery
Regimen:
Parenteral:
Cefazolin 2g IV (3g if wt.>120kg) PLUS Metronidazole 0.5g IV OR
Cefoxitin 2g IV OR
Ceftriaxone 2g IV PLUS Metronidazole 0.5 g IV OR
Ampicillin-Sulbactam 3g IV
If with beta-lactam allergy:
Clindamycin 900mg IV PLUS Gentamicin 5mg/kg IV OR
Aztreonam 2g IV OR
Ciprofloxacin 400mg IV
Oral (At 1 pm, 2 pm and 11 pm of preop day):
Neomycin 1g PLUS Erythromycin base 1g PO

Small bowel surgery

without obstruction Cefazolin 2g IV (3 g if wt.>120 kg)
with obstruction As for colorectal parenteral regimen
Appendectomy for uncomplicated Cefoxitin 2g IV OR
appendicitis Cefazolin 2g IV (3g if wt.>120 kg) PLUS
Metronidazole 0.5g IV
Comments:
Prevention of surgical site infection includes a combination of:
• Mechanical bowel preparation
• Oral antibiotic
• IV antibiotic
Cefazolin and Metronidazole can be given together in same IV bag. Need to repeat
cefazolin dose 4 hours after the initial pre-op dose.
On the pre-operative day:
1. Do bowel preparation at 10am using 4L polyethylene glycol electrolyte
solution PO over 2h.
2. Clear liquid diet only.
3. NPO after midnight.
D. Head and Neck Surgery
Regimen:
Cefazolin 2g IV x 1 dose PLUS Metronidazole 0.5 g IV
OR Clindamycin 600-900mg IV x 1 dose ± Gentamicin 5mg/kg IV x 1 dose
Comments:
The efficacy of prophylaxis is best established for head and neck cancer surgery.
Wound infection rates can still be high though even with prophylaxis. Clean,
uncontaminated head and neck surgery, such as thyroidectomy, does not require
prophylaxis except when there is placement of prosthetic material. Prophylaxis is
not indicated for tonsillectomy and functional endoscopic sinus procedures.
E. Neurosurgical Procedures
Surgery: Regimen:
Clean, non-implant; e.g. 1st line: Cefazolin 2g IV (3 g if wt.>120kg)
elective craniotomy 2nd line: Vancomycin ≤90 kg: 1g IV; >90 kg: 1.5g
IV OR Clindamycin 900mg IV once
Clean, contaminated Clindamycin 900mg IV x 1 dose OR
(cross sinuses, or Ampicillin-sulbactam 3g IV OR
naso/oropharynx) Cefuroxime 1.5g IV PLUS Metronidazole 0.5g IV

CSF shunt surgery, 1st line: Cefazolin 1-2g IV once OR

intrathecal 2nd line: Vancomycin ≤90 kg: 1g IV; >90 kg: 1.5g
pumps IV
OR Clindamycin 900mg IV once
Comments:
Vancomycin may be preferred in hospitals with increased frequency of MRSA, in
high-risk patients, and those colonized with MRSA.
F. Obstetric/Gynecologic Surgery
Surgery: Regimen:
Vaginal or abdominal 1st line: Cefazolin 2g IV OR Cefoxitin 2g IV OR
hysterectomy Ampicillin-sulbactam 3g IV
2nd line: Clindamycin 900mg IV PLUS
Gentamicin 5mg/kg IV x 1 dose
Caesarean section for 1st line: Cefazolin 2g IV
premature 2nd line: Clindamycin 900mg IV PLUS
rupture of membranes Gentamicin 5mg/kg IV x 1 dose
or active labor Administer before skin incision.
Episiotomy for vaginal Antibiotic prophylaxis is NOT recommended for
birth uncomplicated vaginal birth with or without an
episiotomy
G. Ophthalmic Surgery
Regimen:
Topical neomycin-polymyxin B–gramicidin OR fluoroquinolone given as 1 drop
q5-15 min x 5 doses within the hour before start of procedure.
Optional at the end of procedure:
Cefazolin 100mg by subconjunctival injection OR
Cefazolin 1-2.5mg intracameral OR
Cefuroxime 1mg intracameral
Comments:
Most available data involve cataract procedures.
H. Orthopedic Surgery
Surgery: Regimen:
Total joint replacement 1st line: Cefazolin 2g IV pre-op
(TJR), spinal 2nd line: Vancomycin ≤90 kg: 1g IV; >90 kg: 1.5g
IV OR Clindamycin 900mg IV

procedures, hip fracture Consider intranasal mupirocin if colonized with S.

repair, aureus.
implantation of internal
fixation devices (screws,
nails, plates, wires)
Clean operations of Prophylaxis not indicated
hands, feet and
arthroscopy w/o
implantation of
foreign materials
Comments:
Stop prophylaxis within 24h of surgery. For TJR (other than hip), finish the initial
antibiotic infusion before the tourniquet is inflated. Antibiotic-impregnated bone
cement in addition to intravenous antibiotic is commonly practiced for joint
replacements. Vancomycin may be preferred in hospitals with increased
frequency of MRSA, in high-risk patients, and those colonized with MRSA
I. Thoracic Surgery
Surgery: Regimen:
Noncardiac procedures, Cefazolin 2g IV x 1 dose OR
including lobectomy, Ampicillin-sulbactam 3g IV x 1 dose OR
pneumonectomy, lung Clindamycin 900mg IV x 1 dose
resection, and thoracotomy
Video-assisted thoracoscopic
surgery
J. Urologic Surgery/ Procedure
Surgery: Regimen:
Cystoscopy • Prophylaxis generally not necessary if urine is
sterile. May give a fluoroquinolone or
cotrimoxazole for those with potentially adverse
host factors (e.g., advanced age,
immunocompromised state, anatomic
abnormalities, etc.)
• Treat patients with UTI based on urine c/s prior
to procedure
Cystoscopy with Ciprofloxacin 500mg PO OR
manipulation Levofloxacin 500mg PO
Transrectal prostate Ciprofloxacin 500mg PO 12h prior to biopsy and
biopsy repeated 12h after 1st dose

Comments:
Cystoscopy: Modify antimicrobial to target urinary pathogens based on local
resistance patterns. Increasing cotrimoxazole and/or fluoroquinolone (FQ)
resistance among enteric gram-negative bacteria has been a concern.
Cystoscopy with manipulation: Procedures include ureteroscopy, biopsy,
fulguration, TURP, etc. Treat UTI with targeted therapy before procedure if
possible.
Transrectal prostate biopsy: Screening stool culture pre-procedure for
colonization with fluoroquinolone-resistant organisms is increasingly used to
guide the choice of prophylaxis, which should ideally be based on susceptibility of
prevailing organisms.
K. Others
Surgery: Regimen:
Breast surgery, Cefazolin 1-2g IV x 1 dose OR
herniorrhaphy Ampicillin-sulbactam 3g IV x 1 dose OR
Clindamycin 900mg IV x 1 dose
Recommended Doses for PEDIATRIC PATIENTS (beyond the Newborn Period) and
REDOSING INTERVALS for Commonly Used Antimicrobials for Surgical Prophylaxis
Antibiotic Dose for Pediatrics Half-Life in Redosing

Adults with Interval (From
Normal Renal Initiation of
Function Preoperative
(hours)* Dose) (hours) **
Ampicillin- 50mg/kg 0.8-1.3 2
Sulbactam (ampicillin
component)
Ampicillin 50mg/kg 1-1.9 2
Aztreonam 30mg/kg 1.3-2.4 4
Cefazolin 30mg/kg 1.2-2.2 4
Cefuroxime 50mg/kg 1-2 4
Cefoxitin 40mg/kg 0.7-1.1 2
Ceftriaxone 50-75mg/kg 5.4-10.9 NA
Ciprofloxacin 10mg/kg 3-7 NA
Clindamycin 10mg/kg 2-4 6
Fluconazole 6mg/kg 30 NA

Gentamicin*** 2.5mg/kg based 2-3 NA

on dosing weight
Metronidazole 15mg/kg 6-8 NA
Piperacillin- Infants 2-9 mos: 0.7-1.2 2
Tazobactam 80mg/kg
(piperacillin Children >9 mos
component) and <40kg:
100mg/kg
Vancomycin 15mg/kg 4-8 NA
Oral Antibiotics for Colorectal Surgery in Conjunction with Mechanical Bowel
Preparation
Erythromycin base 20mg/kg 0.8-3 NA
Metronidazole 15mg/kg 6-10 NA
Neomycin 15mg/kg 2-3 NA
* The maximum pediatric dose should not exceed the usual adult dose. Pediatric patients
weighing more than 40 kg should receive weight-based doses unless the dose or daily dose
exceeds the recommended adult dose.
** For antimicrobials with a short half-life (e.g., cefazolin or cefoxitin) used for long procedures,
redosing during surgery is recommended at an interval of approximately two times the half-life
of the agent in patients with normal renal function. Recommended redosing intervals marked as
“not applicable” (NA) are based on typical case length; for unusually long procedures, redosing
may be needed.
*** In general, gentamicin for surgical antibiotic prophylaxis should be limited to a single dose
given preoperatively. Dosing is based on the patient’s actual body weight. If actual body weight
is more than 20% above ideal body weight (IBW), the dosing weight (DW) can be determined as
follows: DW = IBW + 0.4 (actual wt. – IBW)
References:
• Anderson DJ, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery.
Infect Control Hospital Epidemiol 2014; 35(6): 605-627.
Available at: http://www.hopkinsmedicine.org/amp/guidelines/antibiotic_guidelines.pdf
• Bratzler DW, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. Am
J Health Syst Pharm 70:195, 2013.
• Berrios-Torres SI, Umscheid CA, Bratzler DW, et al; Healthcare Infection Control Practices
Advisory Committee. Centers for Disease Control and Prevention guideline for the
prevention of surgical site infection, 2017. JAMA Surg. Published online May 3, 2017.
doi:10.1001/jamasurg.2017.0904.
K, Schwartz BS editors. Sanford Guide to Antimicrobial Therapy 2016.
• Katzung BG, Masters SB, Trever AJ editors. Basic and Clinical Pharmacology, 13th edition
Mc Graw Hill 2015:883

• Research Institute for Tropical Medicine. Antimicrobial Resistance Surveillance Program

2015 Annual Report
• Scottish Intercollegiate Guidelines Network (SIGN). Antibiotic prophylaxis in surgery.
Edinburgh: SIGN; 2008.
• Wolf JS Jr1, et al. Best practice policy statement on urologic surgery antimicrobial
prophylaxis. J Urol. 2008 Apr;179(4):1379-90.
• World Health Organization 2016 Global Guidelines on the Prevention of Surgical Site
Infections. Available at: www.who.int/gpsc/ssi-prevention-guidelines/en/. Accessed 14
November 2016. www.who.int/gpsc/ssi-prevention-guidelines/en/. Accessed 14
November 2016.
• WHO recommendations for prevention and treatment of maternal peripartum infections.
Geneva: World Health Organization; 2015

DOH National Antibiotic Guidelines 2017

Uploaded by

Copyright:

Available Formats

DOH National Antibiotic Guidelines 2017

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

DOH National Antibiotic Guidelines 2017

Uploaded by

Copyright:

Available Formats

Cover Design

John Michael L. Roque

All rights reserved 2017

National Antibiotic Guidelines Committee

MESSAGE OF THE SECRETARY OF HEALTH ................................................. i

The participation and assistance of the following experts and reviewers of

National Antibiotic Guidelines Committee

Antimicrobial Resistance Program Secretariat

CORAZON I. FLORES, MD, MPH, CESO IV

ABECB Acute bacterial exacerbation of chronic bronchitis

The National Antimicrobial Stewardship (AMS) Program, an integral

The challenging task of formulating the Guidelines was given by the

The Guidelines in this handbook contain treatment recommendations for

The Guidelines are not intended to supersede a healthcare provider’s sound

The fundamental questions to ask in anti-infective therapy are:

A. FACTORS TO CONSIDER IN THE CHOICE OF ANTIMICROBIALS:

2. HOST-RELATED FACTORS influence the efficacy and toxicities of antimicrobials

B. ANTIBIOTIC COMBINATION THERAPY:

RATIONALE FOR ANTIBIOTIC COMBINED THERAPY:

C. GENERAL ADVERSE REACTIONS TO CHEMOTHERAPEUTIC AGENTS:

D. GENERAL STEPS IN APPROPRIATE ANTIMICROBIAL THERAPY:

E. CAUSES OF FAILURE IN ANTIMICROBIAL THERAPY:

G. FACTORS THAT LEAD TO INAPPROPRIATE USE OF ANTIMICROBIALS:

H. UNWANTED CONSEQUENCES OF MISUSE/INAPPROPRIATE USE OF

Systemic Inflammatory Response Syndrome (SIRS)

Sepsis: SIRS in the presence of or caused by suspected or proven infection

POTENTIALLY SEPTIC NEONATE

Etiology: Asymptomatic neonates with documented maternal risk factors like

Etiology: Gram-negative bacilli, Group B streptococci, S. pneumoniae, S. aureus

National Antibiotic Guidelines 1

2 National Antibiotic Guidelines

Add Oxacillin or Vancomycin (MRSA) if with skin/soft tissue infections (refer to

CLINICAL SEPSIS WITHOUT FOCUS

Etiology: Preferred Regimen:

National Antibiotic Guidelines 3

Etiology: Preferred Regimen:

Etiology: Enterobacteriaceae, Bacteroides sp, Enterococci, P. aeruginosa

POST-SPLENECTOMY/ FUNCTIONAL ASPLENIA

Etiology: Preferred Regimen:

4 National Antibiotic Guidelines

Etiology: Gram-negative bacilli, S. aureus

SEVERE SEPSIS AND SEPTIC SHOCK

National Antibiotic Guidelines 5

STAPHYLOCOCCAL TOXIC SHOCK SYNDROME

6 National Antibiotic Guidelines

STREPTOCOCCAL TOXIC SHOCK SYNDROME

Clinical Criteria: Hypotension plus 2 or more of the following: renal impairment,

Febrile Neutropenia in Children

Etiology: Staph including MRSA, Streptococcus, Enterococci, P. aeruginosa and

If antimicrobial resistant pathogens are suspected consider adding Amikacin 15-

If with abdominal symptoms (pain or blood per rectum) or suspected C. difficile

National Antibiotic Guidelines 7

II. SEPSIS IN ADULTS

Sepsis is defined as presence of suspected or documented infection associated

8 National Antibiotic Guidelines

SUSPECT INTRA-ABDOMINAL SOURCE

Etiology: Aerobic and anaerobic gram-negative bacilli

SUSPECT, URINARY TRACT INFECTION

Etiology: Aerobic Gram-negative bacilli (E. coli), Enterococcus species

SUSPECT COMMUNITY-ACQUIRED PNEUMONIA (See treatment of high risk